Page last updated: 2024-12-09

mercaptopurine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

purine-6-thiol : A thiol that is the tautomer of mercaptopurine. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2724350
CHEMBL ID1200751
CHEBI ID31822
SCHEMBL ID141410
SCHEMBL ID157654
MeSH IDM0023263
PubMed CID667490
CHEMBL ID1425
CHEBI ID2208
CHEBI ID50667
CHEBI ID94796
SCHEMBL ID3893
SCHEMBL ID2790086
SCHEMBL ID12683725
MeSH IDM0023263

Synonyms (324)

Synonym
AC-4229
purine-6-thiol, monohydrate
mercaptopurine (usp)
mercaptopurine hydrate (jp17)
purixan (tn)
6112-76-1
purinethol (tn)
D00161
6-mercaptopurine monohydrate
1,7-dihydro-6h-purin-6-thion, monohydrat [czech]
mercaptopurine hydrate
6h-purin-6-thion, monohydrat [czech]
purin-6-thiol, monohydrat [czech]
1,7-dihydro-6h-purine-6-thione monohydrate
6h-purine-6-thione, 1,7-dihydro-, monohydrate
ccris 5819
purine-6-thiol monohydrate
6-merkaptopurin, monohydrat [czech]
ai3-25013
6-mercaptopurine hydrate
6-mercaptopurine monohydrate, 98%
7h-purine-6-thiol hydrate
1,7-dihydro-6h-purine-6-thione hydrate
CHEBI:31822 ,
mercaptopurine monohydrate
1,7-dihydro-6h-purine-6-thione--water (1/1)
M-2690
MLS001335962
MLS001335961
smr000875320
nsc-759614
KUC107850AP
CHEMBL1200751
ksc-09-277a
A833061
AKOS009158932
6,7-dihydro-3h-purine-6-thione hydrate
EN300-61518
6-thiohypoxanthine monohydrate
6-purinethiol monohydrate
6-mercaptopurine, monohydrate
HMS2233O12
S4504
1,7-dihydro-6h-purine-6-thione hydrate (1:1)
ec 612-090-4
6h-purin-6-thion, monohydrat
purin-6-thiol, monohydrat
6-merkaptopurin, monohydrat
1,7-dihydro-6h-purin-6-thion, monohydrat
unii-e7wed276i5
mercaptopurine [usp:inn:ban:jan]
e7wed276i5 ,
purixan
FT-0621176
AB16826
AKOS015896904
AKOS016339563
HMS3369M01
mercaptopurine [usp-rs]
mercaptopurinum [who-ip latin]
mercaptopurine [vandf]
6h-purine-6-thione, 1,2,3,9-tetrahydro-, hydrate (1:1)
7h-purine-6-thiol monohydrate
mercaptopurine [mart.]
6-mercaptopurine monohydrate [mi]
mercaptopurine hydrate [jan]
mercaptopurine monohydrate [ep monograph]
mercaptopurine [who-ip]
mercaptopurine [usp monograph]
mercaptopurine [orange book]
mercaptopurine [who-dd]
mercaptopurine [ep impurity]
SCHEMBL141410
SCHEMBL157654
KS-5286
6-mercapto-purine monohydrate
WFFQYWAAEWLHJC-UHFFFAOYSA-N
9h-purine-6-thiol hydrate
6-mercaptopurine mono-hydrate
mercaptopurin monohydrat
AKOS024306763
6-mercaptopurinemonohydrate
mfcd03854445
3,7-dihydropurine-6-thione;hydrate
6-mercaptopurine (6-mp) monohydrate
mercaptopurine, united states pharmacopeia (usp) reference standard
mercaptopurine, pharmaceutical secondary standard; certified reference material
6-mercaptopurin-mono-hydrat
Z2569252111
3,7-dihydro-6h-purine-6-thione hydrate
mercaptopurine impurity standard, british pharmacopoeia (bp) reference standard
mercaptopurine, british pharmacopoeia (bp) reference standard
CS-8139
3-bromo-5-methyladamantane-1-carboxylicacid
SY036772
mfcd01461928
HY-13677A
leukerin monohydrate
1h-purine-6(7h)-thione hydrate
6-mercaptopurine,(s)
Q27114691
CCG-266359
mercaptopurine hydrate;6-mp hydrate
AC8105
1,4,5,7-tetrahydropurine-6-thione;hydrate
6112-76-1 (hydrate)
mercaptopurine impurity standard
STK727062
BB 0241023
AB00641894-04
AKOS008901311
KBIO1_000493
DIVK1C_000493
NCI60_041653
NCIMECH_000025 ,
mercaptopurine, 6-
mercaptopurinum [inn-latin]
mercaptopurina [inn-spanish]
ccris 2761
hsdb 3235
9h-purine-6(1h)-thione
einecs 200-037-4
mercaptopurine (anhydrous)
1h-purine, 6-mercapto-
mercaptopurine (van)
mercaptopurin [german]
merkaptopuryna [polish]
purine-6(1h)-thione
6-merkaptopurin [czech]
7-mercapto-1,4,6-tetrazaindene
purimethol
wln: t56 bm dn fn hnj ish
purinethol
purine, 6-mercapto-
nsc-755
u-4748
nsc 755
purine-6-thiol
1,9-dihydro-6h-purine-6-thione
AG-670/31547064 ,
SPECTRUM_000921
IDI1_000493
1,7-dihydro-6h-purine-6-thione
CHEBI:2208 ,
6-thiohypoxanthine
purine antimetabolite: inhibits nucleic acid replication
7h-purine-6-thiol
CMAP_000033
MLS001304953
leupurin
6-thiopurine
3h-purine-6-thiol
7-mercapto-1,3,4,6-tetrazaindene
1,9-dihydropurine-6-thione
mercaleukim
6-mercaptopurin
NSC755 ,
6-thioxopurine
6h-purine-6-thione, 1,7-dihydro-
6-mp
9h-purin-6-yl hydrosulfide
ismipur
6-purinethiol
leukerin
hypoxanthine, thio-
puri-nethol
nci-c04886
mercapurin
mercaleukin
mern
6 mp
purinethiol
mercaptopurine (inn)
D04931
mercaptopurine anhydrous
mercaptopurine
6-mercaptopurine ,
C01756
C02380
50-44-2
DB01033
NCGC00094717-02
NCGC00094717-01
NCGC00094717-03
KBIO2_007499
KBIO3_001481
KBIOGR_001493
KBIO2_002363
KBIOSS_002366
KBIO2_004931
KBIO2_001401
KBIOSS_001401
KBIO2_003969
KBIO3_002842
KBIOGR_002363
KBIO2_006537
NINDS_000493
SPECTRUM2_000060
SPECTRUM4_000857
SPBIO_000219
SPECTRUM3_000491
SPECTRUM1500387
BSPBIO_001981
SPECTRUM5_000950
MLS001304020
6 mercaptopurine
6 thiohypoxanthine
6 mercaptopurine monohydrate
mercaptopurinum
mercaptopurina
CHEBI:50667 ,
6 thiopurine
smr000544948
MLS001066623
9h-purine-6-thiol
HMS2091B20
AC-11464
AKOS000170222
AKOS000275858
CHEMBL1425
3,7-dihydropurine-6-thione
HMS501I15
AKOS016903205
M0063 ,
HMS1920L07
NCGC00091641-02
NCGC00091641-04
NCGC00188973-01
NCGC00091641-03
HMS3259N03
EN300-61517
NCGC00260139-01
tox21_202591
A828129
AKOS005224624
pharmakon1600-01500387
nsc759614
cas-50-44-2
tox21_111158
dtxcid00810
dtxsid0020810 ,
STL257085
HMS2236L06
CCG-35344
CCG-39915
mercaptopurine [usan:usp:inn]
merkaptopuryna
6-merkaptopurin
mercaptopurin
unii-pkk6muz20g
xaluprine
pkk6muz20g ,
FT-0621175
NCGC00094717-05
mercaptopurine [inn]
mercaptopurine anhydrous [who-dd]
6-mercaptopurine [iarc]
mercaptopurine [hsdb]
azathioprine impurity b [ep impurity]
6-mercaptopurine [mi]
S1305
gtpl7226
HMS3369M05
bdbm50423778
HY-13677
CS-1499
AB00876276-13
AM81386
NC00613
SCHEMBL3893
NCGC00094717-06
tox21_111158_1
AB00641894-03
SCHEMBL2790086
7h-purin-6-yl hydrosulfide #
thiohypoxanthine
h-purine-6(1h)-thione
MLS006011869
smr004703503
W-105961
SCHEMBL12683725
157930-13-7
mercaptopurine (6-mp)
3,7-dihydro-6h-purine-6-thione
AB00641894_05
AB00171799_05
6,9-dihydro-1h-purine-6-thione
mfcd00233552
6,7-dihydro-3h-purine-6-thione
6-mercaptopurine, analytical standard
CHEBI:94796
HMS3651G07
SR-05000001925-2
SR-05000001925-1
sr-05000001925
SBI-0051437.P004
HMS3713N10
SW199090-2
NCGC00188973-02
Q418529
1h-purine-6(7h)-thione.
157930-11-5
mercaptopurine; 7h-purine-6-thiol; azathioprine bp impurity b
azathioprine ep impurity b
AS-13109
sk5357
HMS3872N13
HMS3747A17
CCG-266232
a thiopurine
mercaptopurine;6-mp
NCGC00091641-16
discontinued, see m225450
nsc817004
nsc-817004
l01bb02
6-mercaptopurine (iarc)
mercaptopurine monohydrate (ep monograph)
mercaptopurine (usp monograph)
mercaptopurine (usp-rs)
azathioprine impurity b (ep impurity)
mercaptopurine (ep impurity)
mercaptopurinum (latin)
mercaptopurine (mart.)

Research Excerpts

Overview

6-mercaptopurine is a chemotherapeutic drug that exhibits hepatotoxic effects due to its toxic metabolites. Mercaptopurine (6-MP) is an indispensable, first-line, drug in the treatment of pediatric acute lymphoblastic leukemia (ALL)

ExcerptReferenceRelevance
"6-Mercaptopurine (6-MP) is a potential anti-cancer agent which its therapeutic and limitation applicability due to its high toxicity."( Mercaptopurine-Loaded Sandwiched Tri-Layered Composed of Electrospun Polycaprolactone/Poly(Methyl Methacrylate) Nanofibrous Scaffolds as Anticancer Carrier with Antimicrobial and Antibiotic Features: Sandwich Configuration Nanofibers, Release Study and in
Abdel-Aziz, AF; Abou-Saleh, RH; El-Fakharany, EM; El-Moslamy, SH; Elmazar, MM; Evans, S; Kamoun, EA; Salaheldin, TA; Salim, SA, 2021
)
2.79
"6-mercaptopurine is a chemotherapeutic drug that exhibits hepatotoxic effects due to its toxic metabolites. "( Suspected Drug-induced Liver Injury Due to 6-Mercaptopurine With a Superimposed SARS-CoV-2 Infection in a Patient With B-ALL.
Borowicz, VM; Cablay, K; Fulton, R, 2022
)
1.7
"6-mercaptopurine is a mainstay of acute lymphoblastic leukemia treatment. "( Acral Skin Rash Caused by Altered Mercaptopurine Metabolism in Maintenance Therapy for B-Cell Acute Lymphoblastic Leukemia.
Alexander, TB; Geib, KB; Gold, S; Newcome, J; Thompson, P, 2022
)
1.72
"Mercaptopurine (6-MP) is an indispensable, first-line, drug in the treatment of pediatric acute lymphoblastic leukemia (ALL). "( Analysis of mono-, di-, and triphosphates of thioguanosine and methylthioinosine in children with acute lymphoblastic leukemia by LC-MS/MS.
Han, J; Jin, S; Mei, D; Sun, N; Wang, X; Xu, J; Zhao, L, 2022
)
2.16
"Mercaptopurine is an immunologic agent commonly used for treating Acute lymphoblastic leukemia and inflammatory bowel disease."( Anti-inflammation and anti-aging mechanisms of mercaptopurine in vivo and in vitro.
Dai, Q; Ge, Y; He, F; Jia, H; Vashisth, MK; Wang, X, 2023
)
1.89
"Mercaptopurine intolerance is an adverse effect of mercaptopurine administration in pediatric patients with acute lymphoblastic leukemia (ALL). NUDT15 variants have emerged as major determinants of mercaptopurine intolerance, especially in the Asian population. "( Allele-specific polymerase chain reaction can determine the diplotype of NUDT15 variants in patients with childhood acute lymphoblastic Leukemia.
Chang, HH; Chang, YH; Chen, HY; Cheng, CN; Chou, SW; Jou, ST; Lin, CY; Lin, DT; Lin, KH; Lin, SW; Lu, MY; Ni, YL; Su, MY; Wang, DS; Wu, KH; Xu, PY; Yang, YL; Yu, CH, 2023
)
2.35
"Mercaptopurine is a cornerstone of maintenance chemotherapy in childhood acute lymphoblastic leukemia (ALL). "( Thiopurine Methyltransferase Intermediate Metabolizer Status and Thiopurine-Associated Toxicity During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia.
Cacciotti, C; Cairney, E; Kim, RB; Mikhail, M; Patel, S; Schwarz, UI; Seelisch, J; Swanston, V; Tirona, RG; Tole, S; Wilejto, M; Woldanski-Travaglini, M; Zorzi, AP, 2023
)
2.35
"Mercaptopurine is a crucial component in the treatment of acute lymphoblastic leukemia. "( Skin Toxicity Due to Mercaptopurine in Maintenance Therapy Among Children With Acute Lymphoblastic Leukemia.
Flatt, T; Higgerson, K, 2023
)
2.67
"6-Mercaptopurine (6-MCP) is an antiproliferative purine analog used in acute lymphoblastic leukemia, non-Hodgkin lymphoma, and inflammatory bowel disease (Crohn's disease, ulcerative colitis). "( Enhanced Cytotoxic Activity of 6-Mercaptopurine-Loaded Solid Lipid Nanoparticles in Hepatic Cancer Treatment.
Ergin, AD; Koç, B; Oltulu, Ç, 2023
)
1.91
"Mercaptopurine is an effective anticancer medicine yet known with serious adverse reactions, thus requiring further attempts to enhance its biological targeting. "( Theoretical study of the binding mechanism between anticancerous drug mercaptopurine and gold nanoparticles using a cluster model.
Bui, TQ; Huyen, DT; Nhat, PV; Nhung, NTA; Quy, PT; Si, NT, 2023
)
2.59
"Mercaptopurine intolerance is an adverse effect of mercaptopurine administration in pediatric acute lymphoblastic leukemia. "( Determination of NUDT15 variants by targeted sequencing can identify compound heterozygosity in pediatric acute lymphoblastic leukemia patients.
Chang, HH; Chang, YH; Chen, HY; Chou, SW; Jou, ST; Lin, CY; Lin, DT; Lin, KH; Lin, SW; Lu, MY; Ni, YL; Raghav, L; Wang, DS; Wu, KH; Yang, YL; Yu, CH, 2020
)
2
"Mercaptopurine (MCP) is an anticancer drug that is used to treat acute lymphoblastic leukemia. "( Investigation of nanotubes as the smart carriers for targeted delivery of mercaptopurine anticancer drug.
Raissi, H; Zaboli, M, 2022
)
2.39
"Mercaptopurine (6-MP) is a cytostatic compound clinically used for the treatment of inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn's disease."( Limited Impact of 6-Mercaptopurine on Inflammation-Induced Chemokines Expression Profile in Primary Cultures of Enteric Nervous System.
Cascorbi, I; Cossais, F; Kaehler, M; Kneusels, J; Lucius, R; Neunlist, M; Wedel, T, 2021
)
1.67
"6-Mercaptopurine (6-MP) is a main component of childhood acute lymphoblastic leukemia (ALL) treatment. "( Interaction between NUDT15 and ABCC4 variants enhances intolerability of 6-mercaptopurine in Japanese patients with childhood acute lymphoblastic leukemia.
Koh, K; Kondoh, K; Manabe, A; Nakadate, H; Nakamura, K; Tanaka, Y, 2018
)
1.43
"Mercaptopurine is a common chemotherapeutic drug and immunosuppressive agent and plays an important role in the treatment of acute lymphoblastic leukemia and inflammatory bowel disease. "( [Research advances in pharmacogenomics of mercaptopurine].
Chen, XX; Shen, SH, 2017
)
2.16
"Mercaptopurine (MP) is a cytotoxic thiopurine important for the treatment of cancer and autoimmune diseases. "( Three Faces of Mercaptopurine Cytotoxicity In Vitro: Methylation, Nucleotide Homeostasis, and Deoxythioguanosine in DNA.
Berry, P; Coulthard, SA; McGarrity, S; Redfern, CPF; Sahota, K, 2018
)
2.28
"Mercaptopurine is a drug commonly used in the treatment of different types of cancer, especially acute lymphoblastic leukaemia, and autoimmune diseases such as ulcerative colitis or Crohn's disease and in patients receiving organ transplants. "( Influence of thiopurine S-methyltransferase polymorphisms in mercaptopurine pharmacokinetics in healthy volunteers.
Abad-Santos, F; Belmonte, C; Herrador, C; Martínez-Ingelmo, C; Ochoa, D; Ortega-Ruíz, L; Román, M; Saiz-Rodríguez, M; Sarmiento-Iglesias, C, 2019
)
2.2
"6-Mercaptopurine (6-MP) is a nucleobase analog used in the treatment of acute lymphoblastic leukemia and inflammatory bowel disorders. "( Characterization of 6-Mercaptopurine Transport by the SLC43A3-Encoded Nucleobase Transporter.
Hammond, JR; Nguyen, KH; Ruel, NM; Vilas, G, 2019
)
1.55
"6-mercaptopurine (6-MP) is a purine antimetabolite and prodrug that undergoes extensive intracellular metabolism to produce thionucleotides, active metabolites which have cytotoxic and immunosuppressive properties. "( Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Aarons, L; Ogungbenro, K, 2014
)
1.36
"6-Mercaptopurine (6MP) is a well-known purine antimetabolite used to treat childhood acute lymphoblastic leukemia and other diseases. "( Redox cycling of Cu(II) by 6-mercaptopurine leads to ROS generation and DNA breakage: possible mechanism of anticancer activity.
Husain, MA; Ishqi, HM; Nehar, S; Rehman, SU; Sarwar, T; Tabish, M; Zubair, H, 2015
)
1.43
"6-Mercaptopurine (6-MP) is a clinically important antitumor drug. "( Improving the dissolution and bioavailability of 6-mercaptopurine via co-crystallization with isonicotinamide.
Chen, C; Lin, Y; Mei, X; Pan, G; Wang, JR; Yu, X; Zhou, C, 2015
)
1.39
"6-Mercaptopurine (6-MP) is an immunosuppressive drug that is widely used in several inflammatory disorders."( 6-Mercaptopurine reduces cytokine and Muc5ac expression involving inhibition of NFκB activation in airway epithelial cells.
de Vries, CJ; Hamers, AA; Kurakula, K; van Loenen, P, 2015
)
1.7
"6-Mercaptopurine is a cytotoxic and immunosuppressant drug. "( Anti-cancerous efficacy and pharmacokinetics of 6-mercaptopurine loaded chitosan nanoparticles.
Amaresha, S; Janardhana, PB; Kumar, GP; Manohara, C; Phani, AR; Prasad, RG; Raghavendra, HL; Sanganal, JS; Swamy, KB; Tripathi, SM, 2015
)
1.39
"6-Mercaptopurine (6-MP) is a well-established immunosuppressive drug."( 6-Mercaptopurine attenuates tumor necrosis factor-α production in microglia through Nur77-mediated transrepression and PI3K/Akt/mTOR signaling-mediated translational regulation.
Chang, HF; Chen, JS; Huang, HY; Tsai, MJ; Wang, MJ, 2016
)
1.71
"6-Mercaptopurine (6-MP) is a clinically important antitumor drug and its commercially available form is provided as monohydrate, belonging to biopharmaceuticals classification system (BCS) class II category. "( Improvement in the Anticancer Activity of 6-Mercaptopurine via Combination with Bismuth(III).
Cao, P; Feng, K; Guo, N; Li, Y; Miao, Y; Ouyang, R; Tao, H; Xiong, F; Yang, Y; Zhang, X; Zhou, S; Zong, T, 2016
)
1.42
"6-Mercaptopurine (6-MP) is a drug with demonstrated cell-type specific effects on vascular cells both in vitro and in vivo, inhibiting proliferation of SMCs while promoting survival of endothelial cells."( Long-term effect of stents eluting 6-mercaptopurine in porcine coronary arteries.
Attevelt, NJ; de Vries, CJ; de Waard, V; de Winter, RJ; Doornbos, A; Ruiter, MS; Steendam, R, 2016
)
1.27
"Six-mercaptopurine (6-MP) is a pro-drug widely used in treatment of various diseases, including acute lymphoblastic leukaemia (ALL). "( S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts.
Karas Kuzelicki, N; Milek, M; Mlinaric-Rascan, I; Smid, A, 2009
)
1.13
"6-Mercaptopurine (6-MP) is an effective maintenance medication in patients with ulcerative colitis (UC), but toxic effects like myelosuppression limit its clinical benefit. "( Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.
Abe, J; Arai, O; Hanai, H; Hosoda, Y; Iida, T; Ikeya, K; Kageoka, M; Kubota, T; Maruyama, Y; Miwa, I; Oohata, A; Takeuchi, K; Watanabe, F; Yoshirou, S, 2010
)
1.08
"Mercaptopurine is a safe alternative in patients with digestive intolerance or hepatotoxicity due to azathioprine."( Common misconceptions about 5-aminosalicylates and thiopurines in inflammatory bowel disease.
Chaparro, M; Gisbert, JP; Gomollón, F, 2011
)
1.09
"Mercaptopurine is an essential component of continuation therapy in all ALL treatment protocols worldwide."( PACSIN2 polymorphism influences TPMT activity and mercaptopurine-related gastrointestinal toxicity.
Cheng, C; Crews, KR; Decorti, G; Diouf, B; Evans, WE; Franca, R; Jones, TS; Londero, M; McCorkle, JR; Paugh, SW; Pei, D; Pui, CH; Rabusin, M; Ramsey, LB; Relling, MV; Stocco, G; Thierfelder, WE; Valsecchi, MG; Yang, W, 2012
)
1.35
"6-Mercaptopurine is a competitive inhibitor of guanine phosphoribosyltransferase (K(i) 4.7 mum) and hypoxanthine phosphoribosyltransferase (K(i) 8.3 mum)."( INHIBITION OF PRUINE PHOSPHORIBOSYLTRANSFERASES OF EHRLICH ASCITES-TUMOUR CELLS BY 6-MERCAPTOPURINE.
ATKINSON, MR; MURRAY, AW, 1965
)
1.03
"Mercaptopurine is an important antimetabolite for treatment of childhood acute lymphoblastic leukemia (ALL). "( A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell, BA; Bostrom, B; Brockway, GN; Camitta, BM; Erdmann, G; Shuster, JJ; Sterikoff, S, 2004
)
1.98
"6-Mercaptopurine (6-MP) is an orally administered, water-insoluble purine analog that is effective against acute lymphatic leukemia. "( PEG prodrugs of 6-mercaptopurine for parenteral administration using benzyl elimination of thiols.
Choe, YH; Conover, CD; Greenwald, RB; Guan, S; Longley, CB; Xia, J; Zhao, H; Zhao, Q, 2004
)
1.38
"6-mercaptopurine (6-MP) is an antineoplastic and immunosuppressive drug. "( The effect of 6-mercaptopurine on early human placental explants.
Drucker, L; Fishman, A; Lishner, M; Matalon, ST; Ornoy, A, 2005
)
1.4
"6-Mercaptopurine (6-MP) is an antimetabolite. "( Effects of 6-mercaptopurine (6-MP) on histomorphometric parameters of the rat bones.
Cegieła, U; Kaczmarczyk-Sedlak, I; Nowińska, B; Sliwiński, L,
)
1.22
"6-mercaptopurine (6-MP) is a purine analogue used in childhood leukemia. "( 6-mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity.
Ghosh, PK; Majithya, R; Murthy, RS; Umrethia, M, 2007
)
1.78
"6-Mercaptopurine (6MP) is an essential anticancer drug used in the treatment of childhood acute lymphoblastic leukemia (ALL). "( The low frequency of defective TPMT alleles in Turkish population: a study on pediatric patients with acute lymphoblastic leukemia.
Adali, O; Arinç, E; Gozdasoglu, S; Sahin, G; Tumer, TB; Ulusoy, G, 2007
)
1.06
"Mercaptopurine is a purine analog used for acute lymphoblatic leukemia and chronic myelogenous leukemias. "( Interaction between mercaptopurine and milk.
de Lemos, ML; Hamata, L; Jennings, S; Leduc, T, 2007
)
2.11
"6-Mercaptopurine (6-MP) is an adenine antagonist which has been shown to cause skeletal muscle atrophy in neonatal rats. "( Investigating the myopathic effects of 6-mercaptopurine on developing skeletal muscle cells in vitro.
Kaji, H; Yander, G, 1984
)
1.25
"6-Mercaptopurine is an inactive prodrug that requires intestinal absorption, cellular uptake and intracellular anabolism for cytotoxic activity."( The absorption of 6-mercaptopurine from 6-mercaptopurine riboside in rat small intestine: effect of phosphate.
Bronk, JR; Pennington, AM, 1995
)
1.17
"6-Mercaptopurine (6-MP) is a cycle specific antineoplastic agent with a short serum half-life following bolus administration, providing a rationale for continuous infusional administration of the parenteral formulation. "( Phase I-II trial of 14 day infusional 6-mercaptopurine in advanced colorectal cancer.
Anderson, N; Bern, M; Coco, F; Dow, E; Lokich, J; Moore, C; Zipoli, T, 1998
)
1.29
"Mercaptopurine is a prodrug requiring intracellular activation to thiopurine nucleotides to exert antileukemic effect. "( HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy.
Chu, Y; Dervieux, T; Evans, WE; Pui, CH; Relling, MV; Su, Y, 2002
)
1.98
"6-Mercaptopurine is a possible alternative to long-term corticosteroid therapy or surgical treatment in selected patients with severe Crohn's disease."( 6-mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease.
Greseth, JL; Perrault, J; Tremaine, WJ, 1991
)
1.56
"6-mercaptopurine is an effective long-term therapy for adolescents with intractable Crohn's disease."( Long-term 6-mercaptopurine treatment in adolescents with Crohn's disease.
Aiges, H; Daum, F; Grancher, K; Markowitz, J; Rosa, J, 1990
)
1.22
"Mercaptopurine (MP) is a purine antimetabolite widely used for remission maintenance in the therapy of acute lymphoblastic leukemia. "( Biochemical parameters of mercaptopurine activity in patients with acute lymphoblastic leukemia.
Murphy, RF; Poplack, DG; Reaman, G; Zimm, S, 1986
)
2.01
"6-Mercaptopurine is an effective and useful drug in the treatment of fistulae, as it is in other manifestations of chronic unrelenting Crohn's disease."( Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease.
Korelitz, BI; Present, DH, 1985
)
1.14

Effects

Mercaptopurine-induced fever has been reported in patients with inflammatory bowel diseases, but this case report is the first, to our knowledge, in a patient with acute lymphoblastic leukemia. 6-mercaptopurine (6MP) or 6-thioguanine (TG) have been used as anticancer agents for more than 40 years.

ExcerptReferenceRelevance
"6-Mercaptopurine (6-MP) has an important role in the treatment of inflammatory bowel disease. "( Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease.
Haber, CJ; Korelitz, BI; Meltzer, SJ; Present, DH, 1986
)
1.25
"Mercaptopurine-induced fever has been reported in patients with inflammatory bowel diseases, but this case report is the first, to our knowledge, in a patient with acute lymphoblastic leukemia."( Mercaptopurine-induced fever: hypersensitivity reaction in a patient with acute lymphoblastic leukemia.
Baer, MR; Chen, LJ; Nightingale, G, 2010
)
2.52
"6-Mercaptopurine (6-MP) has been the backbone of maintenance chemotherapy for acute lymphoblastic leukemia (ALL), the response to 6-MP is highly variable, adverse events leading to discontinuation or dose-reduction (children intolerant) of 6-MP occur in many children with ALL. "( [Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia].
Duan, YL; Guo, HY; Jin, L; Ma, XL; Wang, B; Wu, MY; Xie, J; Yang, J; Zhang, DW; Zhang, L; Zhang, R; Zhang, YH; Zhu, GH, 2010
)
1.41
"Mercaptopurine has been used in continuing treatment of childhood acute lymphoblastic leukaemia since the mid 1950s. "( Meta-analysis of randomised trials comparing thiopurines in childhood acute lymphoblastic leukaemia.
Escherich, G; Richards, S; Stork, LC; Vora, AJ, 2011
)
1.81
"Mercaptopurines have been used as anticancer agents for more than 40 years, and most acute lymphoblastic leukemias are treated with 6-mercaptopurine (6MP) or 6-thioguanine (TG). "( Thiopurine metabolism and identification of the thiopurine metabolites transported by MRP4 and MRP5 overexpressed in human embryonic kidney cells.
Beijnen, JH; Borst, P; Brouwer, C; Challa, EE; De Abreu, RA; de Haas, M; Groeneveld, E; Kuil, AJ; Mol, C; Reid, G; Schuetz, JD; van Deemter, L; van der Heijden, I; Wielinga, PR; Wijnholds, J, 2002
)
1.76
"6-Mercaptopurine (6-MP) has proven efficacy in the therapy of inflammatory bowel disease. "( Complications of pregnancy and child development after cessation of treatment with 6-mercaptopurine for inflammatory bowel disease.
Baiocco, PJ; Kim, PS; Korelitz, BI; Panagopoulos, G; Rajapakse, R; Rubin, SD; Zlatanic, J, 2003
)
1.26
"6-mercaptopurine has proven to be effective in the treatment and maintenance of remission of ulcerative colitis (UC). "( A search for the optimal duration of treatment with 6-mercaptopurine for ulcerative colitis.
Korelitz, BI; Lobel, EZ; Panagopoulos, G; Xuereb, MA, 2004
)
1.29
"6-Mercaptopurine (6-MP) has shown efficacy in the treatment of Crohn's disease when used in conjunction with corticosteroids. "( 6-Mercaptopurine is effective in Crohn's disease without concomitant steroids.
Goldstein, ES; Marion, JF; Present, DH, 2004
)
1.77
"6-mercaptopurine has been a standard component of long-term continuing treatment for childhood lymphoblastic leukaemia, whereas 6-thioguanine has been mainly used for intensification courses. "( Toxicity and efficacy of 6-thioguanine versus 6-mercaptopurine in childhood lymphoblastic leukaemia: a randomised trial.
Eden, TO; Kinsey, SE; Lennard, L; Lilleyman, J; Mitchell, CD; Richards, SM; Vora, A, 2006
)
1.31
"6-Mercaptopurine has been used with increasing frequency in refractory inflammatory bowel disease; the use of cyclosporine A for this condition is still under investigation."( Cyclosporine and 6-mercaptopurine in pediatric inflammatory bowel disease.
La Tulippe Naccarini, DA; Minor, ML, 1994
)
1.18
"6-Mercaptopurine (6-MP) has confirmed short and longterm efficacy in the treatment of IBD. "( 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
Cuffari, C; Latour, S; Seidman, G; Théorêt, Y, 1996
)
1.74
"Mercaptopurine (6MP) has been the standard drug for maintenance therapy of acute lymphoblastic leukemia. "( Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb, N; Harms, DO; Janka-Schaub, G, 1998
)
1.95
"6-Mercaptopurine (6MP) has been regarded as nonleukemogenic, even though the cytotoxicity of 6MP depends on the incorporation of 6-thioguanine nucleotides (6TGN) into DNA. "( Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism.
Andersen, JB; Bo, J; Kristinsson, J; Madsen, B; Schmiegelow, K; Schrøder, H; Szumlanski, C; Weinshilboum, R, 1999
)
1.3
"6-mercaptopurine (6-MP) has been used clinically for 40 years to maintain remission in patients with acute lymphoblastic leukemia (ALL). "( Brain distribution of 6-mercaptopurine is regulated by the efflux transport system in the blood-brain barrier.
Deguchi, Y; Hayashi, H; Kimura, R; Naito, T; Sakamoto, T; Yamada, S; Yokoyama, Y, 2000
)
1.34
"6-Mercaptopurine (6-MP) has an important role in the treatment of inflammatory bowel disease. "( Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease.
Haber, CJ; Korelitz, BI; Meltzer, SJ; Present, DH, 1986
)
1.25

Actions

6-Mercaptopurine (6-MP) plays an important role in treatment of childhood acute lymphoblastic leukemia (ALL) It may inhibit gastrointestinal absorption of warfarin, or it may induce hepatic enzymes that metabolize the anticoagulant.

ExcerptReferenceRelevance
"Mercaptopurine (6-MP) plays a pivotal role in treatment of childhood acute lymphoblastic leukemia (ALL); however, interindividual variability in toxicity of this drug due to genetic polymorphism in 6-MP metabolizing enzymes has been described. "( Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.
Canales, C; Farfan, MJ; Kopp, K; Morales, J; Salas, C; Santolaya, ME; Silva, F; Torres, JP; Villarroel, M, 2014
)
2.09
"6-Mercaptopurine (6-MP) plays an important role in treatment of childhood acute lymphoblastic leukemia (ALL). "( Frequency of ITPA gene polymorphisms in Iranian patients with acute lymphoblastic leukemia and prediction of its myelosuppressive effects.
Alavi, S; Azimi, F; Khalili, M; Mortazavi, Y; Ramazani, A, 2015
)
1.14
"Mercaptopurine may inhibit gastrointestinal absorption of warfarin, or it may induce hepatic enzymes that metabolize the anticoagulant."( Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy.
Martin, LA; Mehta, SD, 2003
)
1.28
"6-Mercaptopurine was found to inhibit the growth of cultured human lymphoma P3HR-1 cells and the incorporation of [3H]-uridine into trichloroacetic acid-precipitable materials of the cells. "( Inhibition of human lymphoma DNA-dependent RNA polymerase activity by 6-mercaptopurine ribonucleoside triphosphate.
Chuang, LF; Chuang, RY; Holmberg, CA; Kawahata, RT; Osburn, BI, 1983
)
1.22
"6-Mercaptopurine produced an increase in the hypoxanthine-containing peaks, which was consistent with suppression of purine salvage."( High performance liquid chromatography analysis of hypoxanthine metabolism in mouse oocyte-cumulus cell complexes: effects of purine metabolic perturbants.
Downs, SM, 1994
)
0.85

Treatment

Mercaptopurine treatment showed marekd reduction in both atherosclerotic lesions and cholesterol concentrations. Treatment also inhibits the expression of inflammatory factors and reduces inflammatory cell infiltration of the skin.

ExcerptReferenceRelevance
"2. Mercaptopurine treatment showed marekd reduction in both atherosclerotic lesions and cholesterol concentrations of the serum and aorta."( Study of drugs affecting cholesterol-induced atherosclerosis in rabbits.
Kim, DN; Kwak, YS; Lee, KT, 1976
)
0.77
"In 6-mercaptopurine-treated fetuses, although the chronological appearance of primordia of all three structures was normal, DNA synthesis was inhibited in all three structures."( Does the tongue play a role in the initial development of vertical palatal shelf in hamster?
Feeley, E; Shah, RM; Young, A,
)
0.59
"Treatment with mercaptopurine also inhibits the expression of inflammatory factors and reduces inflammatory cell infiltration of the skin."( Anti-inflammation and anti-aging mechanisms of mercaptopurine in vivo and in vitro.
Dai, Q; Ge, Y; He, F; Jia, H; Vashisth, MK; Wang, X, 2023
)
1.51

Toxicity

Thioguanine (TG) is a thiopurine which has been used for patients with inflammatory bowel disease (IBD) The purine analogues 6-mercaptopurine (6-MP) and azathioprine have been found to be safe and efficacious in inducing remission of Crohn's disease in adults.

ExcerptReferenceRelevance
" The level of 6-thioguanine nucleotide in the patient's erythrocytes was seven times the population median value, and she had intolerable hematologic toxic effects during postremission therapy with a standard dosage of mercaptopurine (75 mg/m2 per day)."( Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
Chu, YQ; Evans, WE; Horner, M; Kalwinsky, D; Roberts, WM, 1991
)
0.9
" Although these derivatives did not display selective toxicity toward the hypoxic cells, they were significantly more toxic than 6-TC to this cell line at 500 microM after a 2-h exposure."( Modification of antitumor disulfide cytotoxicity by glutathione depletion in murine cells.
Kirkpatrick, DL, 1987
)
0.27
" In the absence of hepatocytes, this compound was neither toxic nor mutagenic to V79 cells, but in their presence it was highly mutagenic and extremely toxic."( Toxicity and mutagenicity of 6 anti-cancer drugs in Chinese hamster V79 cells co-cultured with rat hepatocytes.
Dickins, M; Phillips, M; Todd, N; Wright, K,
)
0.13
" The mean lethal dose values of heated and unheated pertussis vaccines were similar in the actinomycin D enhancement assay, but the unheated vaccine was significantly more toxic in the mouse weight gain test."( Determination of endotoxicity in bacterial vaccines.
Chan, YK; Feeley, JC; Miller, CE; Wong, KH, 1973
)
0.25
"Treatment with 6-mercaptopurine (6MP) is associated with adverse gastrointestinal (GI) and hepatic effects."( Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.
Berkovitch, M; Blanchette, VS; Evans, WE; Giesbrecht, E; Koren, G; Matsui, D; Saunders, EF; Verjee, Z; Zipursky, A, 1996
)
0.96
"To assay 6-MP metabolites and to correlate levels with drug compliance, disease activity, and adverse effects of treatment."( 6-Mercaptopurine metabolism in Crohn's disease: correlation with efficacy and toxicity.
Cuffari, C; Latour, S; Seidman, G; Théorêt, Y, 1996
)
1.02
" Medical files were reviewed for adverse side effects: fever, pancreatitis, infections, gastrointestinal intolerance, aminotransferase level increase, leukopenia, and thrombocytopenia."( Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease.
Kirschner, BS, 1998
)
0.59
"AZA or 6-MP was tolerated in 51 of 95 patients (54%) without adverse reaction; 27 of 95 (28%) experienced side effects that responded to dose reduction (23 patients) or spontaneously (4 patients), most commonly increased aminotransferase level (13."( Safety of azathioprine and 6-mercaptopurine in pediatric patients with inflammatory bowel disease.
Kirschner, BS, 1998
)
0.59
" However, adverse events leading to discontinuation may occur in 10-20% of patients."( 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
de Jong, DJ; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Jansen, JB; Mulder, CJ, 2003
)
0.57
" Primary outcome measures were the ability to tolerate 6-TG and the occurrence of adverse events."( 6-Thioguanine seems promising in azathioprine- or 6-mercaptopurine-intolerant inflammatory bowel disease patients: a short-term safety assessment.
de Jong, DJ; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Jansen, JB; Mulder, CJ, 2003
)
0.57
" Adverse events included phototoxicity, pancreatitis, headache, nausea, alopecia, arthralgia, minor infections and reversible elevation of transaminases."( 6-thioguanine--efficacy and safety in chronic active Crohn's disease.
Deibert, P; Fellermann, K; Fleig, WE; Greinwald, R; Herrlinger, KR; Kreisel, W; Reinshagen, M; Ruhl, A; Schoelmerich, J; Schwab, M; Stange, EF, 2003
)
0.32
"The purine analogues 6-mercaptopurine (6-MP) and azathioprine have been found to be safe and efficacious in both inducing remission of Crohn's disease in adults and maintaining remission in adults and children."( Therapeutic efficacy and safety of 6-mercaptopurine and azathioprine in patients with Crohn's disease.
Markowitz, JF, 2003
)
0.9
"In clinical trials, up to 15% of patients discontinued 6-mercaptopurine or its pro-drug azathioprine prematurely due to adverse events."( Safety of thiopurines in the treatment of inflammatory bowel disease.
de Jong, DJ; Derijks, LJ; Hooymans, PM; Mulder, CJ; Naber, AH, 2003
)
0.56
" Fifteen adverse effects were observed in 13 patients (38%)."( Efficacy and safety of thiopurinic immunomodulators (azathioprine and mercaptopurine) in steroid-dependent ulcerative colitis.
Bermejo, F; Carrera, E; Garcia-Plaza, A; Lopez-Sanroman, A, 2004
)
0.56
" However, 6-methyl mercaptopurine levels were significantly elevated into the toxic range."( Diagnosis of 6 mercaptopurine hepatotoxicity post liver transplantation utilizing metabolite assays.
Agarwal, K; Fiel, MI; Gondolesi, G; Kontorinis, N; O'Rourke, M; Schiano, TD, 2004
)
1
" However, their use is limited by serious adverse effects that can lead to cessation of therapy."( Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Barclay, ML; Burt, MJ; Chapman, BA; Collett, JA; Gearry, RB, 2004
)
0.32
" The case notes were then reviewed to identify those patients who had suffered an adverse effect that required cessation of the drug."( Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Barclay, ML; Burt, MJ; Chapman, BA; Collett, JA; Gearry, RB, 2004
)
0.32
"9%) had an adverse reaction requiring cessation of the drug."( Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Barclay, ML; Burt, MJ; Chapman, BA; Collett, JA; Gearry, RB, 2004
)
0.32
"In Canterbury, New Zealand, patients with IBD have a high rate of therapy-limiting adverse effects to thiopurine drugs."( Thiopurine drug adverse effects in a population of New Zealand patients with inflammatory bowel disease.
Barclay, ML; Burt, MJ; Chapman, BA; Collett, JA; Gearry, RB, 2004
)
0.32
" minnesota Re 595, a mutant containing only the lipid A and 2-keto-3-deoxyoctonate moiety of the endotoxin molecule, exhibited the same capability to enhance the toxic action of 6-MP."( Enhanced toxicity for mice of 6-mercaptopurine with bacterial endotoxin.
Bradley, SG; Marecki, NM, 1974
)
0.54
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
"The Food and Drug Administration (FDA) has approved label changes for two anticancer drugs, 6-mercaptopurine (6-MP) and irinotecan, to include pharmacogenetic testing as a potential means to reduce the rate of severe toxic events."( TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Maitland, ML; Ratain, MJ; Vasisht, K, 2006
)
0.55
" Azathioprine/6-MP-related pulmonary toxicity is a rare but serious side effect, and it is important for clinicians to have a high index of suspicion for this adverse reaction which occurs within 1 month after initiation of treatment for IBD."( Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease.
Ananthakrishnan, AN; Attila, T; Binion, DG; Komorowski, RA; Lipchik, RJ; Massey, BT; Otterson, MF, 2007
)
0.6
" Mercaptopurine intolerance was frequently for a different adverse event."( Tolerability and safety of mercaptopurine in azathioprine-intolerant patients with inflammatory bowel disease.
Arnott, ID; Hansoti, B; Lees, CW; Maan, AK; Satsangi, J, 2008
)
1.55
" Despite these advantages, their therapeutic potential is limited by occasional adverse effects (myelotoxicity and hepatotoxicity) and by a relatively frequent lack of efficacy."( Differential toxic effects of azathioprine, 6-mercaptopurine and 6-thioguanine on human hepatocytes.
Akhdar, H; Guillouzo, A; Langouet, S; Morel, F; Nicolas-Nicolaz, C; Petit, E, 2008
)
0.6
"This study was to evaluate the frequency and the course of the adverse effects of AZA/6-MP in Korean patients with inflammatory bowel disease (IBD)."( [The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease].
Cheon, JH; Kim, JH; Kim, WH, 2008
)
0.58
" Adverse effects included leukopenia occurred in 75 cases (56."( [The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease].
Cheon, JH; Kim, JH; Kim, WH, 2008
)
0.58
"Leukopenia was the most common adverse effect of AZA/6-MP treatment."( [The frequency and the course of the adverse effects of azathioprine/6-mercaptopurine treatment in patients with inflammatory bowel disease].
Cheon, JH; Kim, JH; Kim, WH, 2008
)
0.58
"Probably, the most important and potentially lethal adverse event of azathioprine (AZA) and mercaptopurine (MP) is myelosuppression."( Thiopurine-induced myelotoxicity in patients with inflammatory bowel disease: a review.
Gisbert, JP; Gomollón, F, 2008
)
0.57
"Fourteen members of the Japanese Society for Pediatric Inflammatory Bowel Disease reported 35 retrospective cases that received AZA/6-MP and were evaluated for adverse drug effects."( Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease.
Etani, Y; Kobayashi, A; Konno, M; Maisawa, S; Nakacho, M; Sasaki, M; Shimizu, T; Sumazaki, R; Tajiri, H; Tomomasa, T; Toyoda, S; Ushijima, K; Yoden, A, 2008
)
0.61
"AZA or 6-MP was safely used in 21 of 35 patients (60%) without adverse drug effects."( Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease.
Etani, Y; Kobayashi, A; Konno, M; Maisawa, S; Nakacho, M; Sasaki, M; Shimizu, T; Sumazaki, R; Tajiri, H; Tomomasa, T; Toyoda, S; Ushijima, K; Yoden, A, 2008
)
0.61
" However, 40% experienced adverse drug effects, mainly myelosuppression."( Efficacy and safety of azathioprine and 6-mercaptopurine in Japanese pediatric patients with ulcerative colitis: a survey of the Japanese Society for Pediatric Inflammatory Bowel Disease.
Etani, Y; Kobayashi, A; Konno, M; Maisawa, S; Nakacho, M; Sasaki, M; Shimizu, T; Sumazaki, R; Tajiri, H; Tomomasa, T; Toyoda, S; Ushijima, K; Yoden, A, 2008
)
0.61
"The influence of genetic polymorphism in inosine triphosphate pyrophosphatase (ITPA) on thiopurine-induced adverse events has not been investigated in the context of combination chemotherapy for acute lymphoblastic leukemia (ALL)."( Genetic polymorphism of inosine triphosphate pyrophosphatase is a determinant of mercaptopurine metabolism and toxicity during treatment for acute lymphoblastic leukemia.
Cheng, C; Cheok, MH; Crews, KR; Dervieux, T; Evans, WE; French, D; Pei, D; Pui, CH; Relling, MV; Stocco, G; Yang, W, 2009
)
0.58
" Drug adverse effects and the lack of efficacy, however, commonly require withdrawal of therapy."( Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Gearry, RB; Leong, RW; Sparrow, MP, 2008
)
0.35
"The addition of low dose allopurinol to dose-reduced thiopurine analogue seems safe but careful monitoring for adverse effects and profiling of thiopurine metabolites is essential."( Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol.
Gearry, RB; Leong, RW; Sparrow, MP, 2008
)
0.35
"These data indicate that the Israeli population displays a distinct TPMT genetic variability that is comprised of a mix of three major genetically diverse subpopulations, each with its unique TPMT allelic frequency distribution pattern and likelihood of developing an adverse reaction to thiopurine drugs."( Distribution of TPMT risk alleles for thiopurine [correction of thioupurine] toxicity in the Israeli population.
Adler, L; Efrati, E; Krivoy, N; Sprecher, E, 2009
)
0.35
" It appears safe and effective for long-term use, but requires monitoring for myelotoxicity."( Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease.
Ansari, A; Baburajan, B; Chocair, P; Duley, J; Elliott, T; Mayhead, P; O'Donohue, J; Sanderson, J, 2008
)
0.35
" Our results show that exogenous SAM (10-50microM) rescues cells from the toxic effects of 6-MP (5microM) by delaying the onset of apoptosis."( S-adenosylmethionine regulates thiopurine methyltransferase activity and decreases 6-mercaptopurine cytotoxicity in MOLT lymphoblasts.
Karas Kuzelicki, N; Milek, M; Mlinaric-Rascan, I; Smid, A, 2009
)
0.58
"We sought to determine whether treatment with steroids, immunosuppressives (ISs), and anti-tumor necrosis factor (TNF) agents is associated with an increased risk of adverse events in patients with Crohn's disease (CD)."( Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.
Arrighi, HM; Hass, S; Marehbian, J; Sandborn, WJ; Tian, H, 2009
)
0.35
" Follow-up adverse events in patients with CD and controls were compared across different treatment categories and are presented as hazard ratios (HRs) and 95% confidence intervals (CIs)."( Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease.
Arrighi, HM; Hass, S; Marehbian, J; Sandborn, WJ; Tian, H, 2009
)
0.35
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36
"To evaluate the relationship between thiopurine S-methyltransferase (TPMT) polymorphisms and thiopurine-induced adverse drug reactions (ADRs) in inflammatory bowel disease (IBD)."( Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.
Dong, XW; Ran, ZH; Tong, JL; Zheng, Q; Zhu, MM, 2010
)
0.36
" Adverse events with CSA are frequent, but most are mild."( Cyclosporine is safe and effective in patients with severe ulcerative colitis.
Cheifetz, AS; Garud, S; Goldstein, E; Malter, L; Moss, AC; Present, DH; Stern, J, 2011
)
0.37
" We conclude that valproic acid+ATRA+theophylline combined with 6-mercaptopurin or hydroxyurea can be safe and effective in palliative treatment of human AML."( Combination of the histone deacetylase inhibitor valproic acid with oral hydroxyurea or 6-mercaptopurin can be safe and effective in patients with advanced acute myeloid leukaemia--a report of five cases.
Bruserud, Ø; Fredly, H; Gjertsen, BT; Stapnes Bjørnsen, C, 2010
)
0.36
"Allopurinol has been presented as a safe and effective adjunct to thiopurine therapy in inflammatory bowel disease (IBD)."( Combination of thiopurines and allopurinol: adverse events and clinical benefit in IBD.
Govani, SM; Higgins, PD, 2010
)
0.36
"Genetic polymorphisms of thiopurine S-methyltransferase (TPMT) and inosine triphosphate pyrophosphohydrolase (ITPA 94C>A) contribute to variable responses, including fatal adverse effects, among subjects treated with 6-mercaptopurine (6-MP)."( Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
Baba, AA; Mohamad, N; Nasir, A; Salleh, MZ; Teh, LK; Wan Rosalina, WR; Yusoff, R, 2012
)
0.77
"Our results suggest that ITPA 94C>A testing, but not TPMT testing, may help in minimizing the adverse effects of 6-MP in Malaysian patients."( Polymorphism of ITPA 94C>A and risk of adverse effects among patients with acute lymphoblastic leukaemia treated with 6-mercaptopurine.
Baba, AA; Mohamad, N; Nasir, A; Salleh, MZ; Teh, LK; Wan Rosalina, WR; Yusoff, R, 2012
)
0.59
" Though lack of difference may be attributed to the small sample size, suboptimal supportive care for intensive treatment would increase risk of toxic deaths."( Outcome and haemato-toxicity of two chemotherapy regimens for childhood non-Hodgkin's lymphoma in a Kenyan hospital.
Macharia, WM, 2009
)
0.35
"To evaluate the incidence of adverse events (AE) in patients with inflammatory bowel disease treated with azathioprine (AZA) or 6-mercaptopurine (MP) in our hospital, the features of these effects, the distribution of socio-demographic factors, and the possible predisposing factors."( Adverse events of thiopurine immunomodulators in patients with inflammatory bowel disease.
Bejerano, A; Chaparro, M; Espinosa, L; Gisbert, JP; López-Martín, C; Maté, J,
)
0.34
" The primary outcome was the occurrence of 6-thioguanine induced hepatotoxicity, scaled according to the Common Terminology Criteria for Adverse Events."( Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
de Boer, NK; Mulder, CJ; Seinen, ML; van Asseldonk, DP; van Bodegraven, AA, 2012
)
0.65
" Since it is likely that response to therapy and adverse events depends on the genetic background of patients our study aimed to evaluate retrospectively response to therapy and safety in a mixed IBD population in Southern Europe."( Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up.
Alibrandi, A; Belvedere, A; Costantino, G; Fries, W; Furfaro, F, 2012
)
0.38
" Moreover the likelihood to remain in thiopurine monotherapy was evaluated in responders, whereas adverse events were investigated in all patients."( Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up.
Alibrandi, A; Belvedere, A; Costantino, G; Fries, W; Furfaro, F, 2012
)
0.38
" Flu-like syndrome represented the most frequent adverse event followed by abnormalities of liver function tests and myelotoxicity."( Thiopurine treatment in inflammatory bowel disease: response predictors, safety, and withdrawal in follow-up.
Alibrandi, A; Belvedere, A; Costantino, G; Fries, W; Furfaro, F, 2012
)
0.38
" Adverse events were monitored and therapeutic adherence was assessed."( Safety and effectiveness of long-term allopurinol-thiopurine maintenance treatment in inflammatory bowel disease.
Bouma, G; de Boer, NK; Hanauer, SB; Harrell, LE; Hoentjen, F; Rubin, DT; Seinen, ML; van Bodegraven, AA, 2013
)
0.39
"Hepatotoxicity is an important side effect of thiopurine analog treatment for inflammatory bowel disease."( A histopathologic pattern of centrilobular hepatocyte injury suggests 6-mercaptopurine-induced hepatotoxicity in patients with inflammatory bowel disease.
Masia, R; Misdraji, J; Pratt, DS, 2012
)
0.61
"The treatment with thiopurines and anti-TNF-α drugs does not seem to increase the risk of complications during pregnancy and does seem to be safe for the newborn."( Safety of thiopurines and anti-TNF-α drugs during pregnancy in patients with inflammatory bowel disease.
Barreiro-de Acosta, M; Beltrán, B; Bermejo, F; Botella, B; Calvet, X; Calvo, M; Casanova, MJ; Chaparro, M; Domènech, E; Dueñas, C; Esteve, M; García-López, S; García-Planella, E; García-Sánchez, V; Garrido, E; Ginard, D; Gisbert, JP; Gómez-García, M; Gomollón, F; Iglesias, E; López, M; Mañosa, M; Maté, J; Pérez-Calle, JL; Piqueras, M; Ponferrada, A; Rodrigo, L; Saro, C; Taxonera, C, 2013
)
0.39
" Increased disease activity during pregnancy has been associated with adverse outcomes."( Editorial: Are thiopurines and anti-TNFα agents safe to use in pregnant patients with inflammatory bowel disease?
Mahadevan, U; Sheibani, S, 2013
)
0.39
" The major drawback of these drugs are their serious adverse effects (SAE), highlighting the importance of preemptive identification of patients at risk."( Risk factors for serious adverse effects of thiopurines in patients with Crohn's disease.
Chowers, Y; Efrati, E; Elkin, H; Karban, A; Koifman, E; Krivoy, N; Mazor, Y, 2013
)
0.39
" Among those patients who ceased mercaptopurine for further adverse effects, 59% experienced the same adverse effect as they had with azathioprine."( A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis.
Arnott, ID; Kennedy, NA; Lees, CW; Noble, CL; Rhatigan, E; Satsangi, J; Shand, AG, 2013
)
1.06
"This meta-analysis shows that switching to mercaptopurine is a safe therapeutic strategy for over two-thirds of azathioprine-intolerant patients and may help optimise immunomodulatory therapy in inflammatory bowel disease."( A trial of mercaptopurine is a safe strategy in patients with inflammatory bowel disease intolerant to azathioprine: an observational study, systematic review and meta-analysis.
Arnott, ID; Kennedy, NA; Lees, CW; Noble, CL; Rhatigan, E; Satsangi, J; Shand, AG, 2013
)
1.04
" Herein, we investigate how pretreatment characteristics relate to early adverse outcomes in such patients, studying 205 consecutive individuals receiving curative-intent induction chemotherapy with cytarabine and an anthracycline ("7 + 3"; n = 175) or a "7 + 3"-like regimen (n = 30)."( Prediction of adverse events during intensive induction chemotherapy for acute myeloid leukemia or high-grade myelodysplastic syndromes.
Abkowitz, JL; Buckley, SA; Estey, EH; Othus, M; Vainstein, V; Walter, RB, 2014
)
0.4
" Unfortunately, these agents are associated with adverse events ranging from mild nuisance symptoms to potentially life-threatening complications including infections and malignancies."( Adverse events in IBD: to stop or continue immune suppressant and biologic treatment.
Cross, RK; McLean, LP, 2014
)
0.4
" Differences in metabolism of these drugs lead to individual variation in thiopurine metabolite levels that can determine its therapeutic efficacy and development of adverse reactions."( Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
Amin, J; Huang, B; Shih, DQ; Yoon, J, 2015
)
0.69
" Of the dosing strategies reviewed, we found evidence for monitoring thiopurine metabolite level, use of allopurinol with thiopurine, use of mesalamine with thiopurine, combination therapy with thiopurine and anti-tumor necrosis factor agents, and split dosing of AZA or 6-MP to optimize thiopurine therapy and minimize adverse effects in IBD."( Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
Amin, J; Huang, B; Shih, DQ; Yoon, J, 2015
)
0.69
"Based on the currently available literature, various dosing strategies to improve therapeutic response and reduce adverse reactions can be considered, including use of allopurinol with thiopurine, use of mesalamine with thiopurine, combination therapy with thiopurine and anti-tumor necrosis factor agents, and split dosing of thiopurine."( Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
Amin, J; Huang, B; Shih, DQ; Yoon, J, 2015
)
0.69
" DR-6MP was safer than Purinethol, with significantly fewer adverse events (AEs)."( Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.
Chowers, Y; Fishman, S; Goldin, E; Ilan, Y; Israeli, E; Konikoff, F; Lahat, A; Lavy, A; Mahamid, M; Melzer, E; Nussinson, E; Segol, O; Shabbat, Y; Shirin, H; Ya'acov, AB, 2015
)
0.66
" Fortunately, the absolute incidence of serious toxicity remains low, and an improved understanding of how best to minimize risk and the recognition of groups of patients at higher risk of toxicity from thiopurines means that they remain a relatively safe therapy in the majority of patients."( Toxicity and response to thiopurines in patients with inflammatory bowel disease.
Goldberg, R; Irving, PM, 2015
)
0.42
"To determine the incidence and predictors of thiopurine-related adverse events."( Clinical predictors of thiopurine-related adverse events in Crohn's disease.
Dubeau, MF; Eksteen, B; Ghosh, S; Kaplan, GG; Moran, GW; Panaccione, R; Yang, H, 2015
)
0.42
" The primary outcome of interest was the first adverse event that led to discontinuation of the first thiopurine medication used."( Clinical predictors of thiopurine-related adverse events in Crohn's disease.
Dubeau, MF; Eksteen, B; Ghosh, S; Kaplan, GG; Moran, GW; Panaccione, R; Yang, H, 2015
)
0.42
"Thiopurine withdrawal due to adverse events is commoner in women over the age of 40 at prescription."( Clinical predictors of thiopurine-related adverse events in Crohn's disease.
Dubeau, MF; Eksteen, B; Ghosh, S; Kaplan, GG; Moran, GW; Panaccione, R; Yang, H, 2015
)
0.42
" Unfortunately, the high rate of adverse events (AEs) leading to drug withdrawal represents a major limitation in the use of these drugs."( Safety Profile of Thiopurines in Crohn Disease: Analysis of 893 Patient-Years Follow-Up in a Southern China Cohort.
Chen, BL; Chen, MH; Guo, J; He, Y; Li, MY; Mao, R; Qiu, Y; Zeng, ZR; Zhang, SH, 2015
)
0.42
" Patients' derived iPSC are an innovative model to study mechanisms of adverse drug reactions in individual patients and in cell types that cannot be easily obtained from human subjects."( Patients' Induced Pluripotent Stem Cells to Model Drug Induced Adverse Events: A Role in Predicting Thiopurine Induced Pancreatitis?
Decorti, G; Giliani, S; Lanzi, G; Martelossi, S; Pelin, M; Sasaki, K; Stocco, G; Tommasini, A; Ventura, A; Yue, F, 2015
)
0.42
" The risk of serious adverse events was higher in patients aged ≥10 years compared to those aged 9 or younger (P < 0·0001) and novel age-specific patterns of treatment-related toxicity were observed."( Efficacy and toxicity of a paediatric protocol in teenagers and young adults with Philadelphia chromosome negative acute lymphoblastic leukaemia: results from UKALL 2003.
Goulden, N; Hough, R; Mitchell, C; Moorman, A; Rowntree, C; Vora, A; Wade, R, 2016
)
0.43
" However, because of their complex metabolism and potential toxicities, optimal use of biomarkers to predict adverse effects and therapeutic response is paramount."( Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
Loftus, EV; Moon, W, 2016
)
0.43
"To provide a comprehensive review focused on pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in IBD."( Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
Loftus, EV; Moon, W, 2016
)
0.43
"Pre-treatment thiopurine S-methyltransferase typing plus measurement of 6-tioguanine nucleotides and 6-methylmercaptopurine ribonucleotides levels during treatment have emerged with key roles in facilitating safe and effective thiopurine therapy."( Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
Loftus, EV; Moon, W, 2016
)
0.65
"Measurement of thiopurine-related enzymes and metabolites reduces the risk of adverse effects and improves efficacy, and should be considered part of standard management."( Review article: recent advances in pharmacogenetics and pharmacokinetics for safe and effective thiopurine therapy in inflammatory bowel disease.
Loftus, EV; Moon, W, 2016
)
0.43
" Screening of candidate genes at diagnosis is recommended in order to avoid serious adverse events."( Severe 6-mercaptopurine-induced hematotoxicity in childhood an ALL patient with homozygous NUDT15 missence variants.
Hasegawa, D; Hirabayashi, S; Hosoya, Y; Kimura, S; Kumamoto, T; Manabe, A; Tanaka, Y; Yoshihara, H; Yoshimoto, Y, 2016
)
0.85
"Many adverse drug reactions are caused by the cytochrome P450 (CYP)-dependent activation of drugs into reactive metabolites."( Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Jones, LH; Nadanaciva, S; Rana, P; Will, Y, 2016
)
0.43
" Thiopurines are used in the treatment of Crohn's disease (CD) and thiopurine S-methyltransferase (TPMT) activity can guide thiopurine dosing to avoid adverse events."( Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity-A Retrospective Study.
Afif, W; AlYafi, M; Benmassaoud, A; Bessissow, T; Bitton, A; Theoret, Y; Xie, X, 2016
)
0.43
" Exome data for 100 patients were assessed against biochemically measured TPMT enzyme activity, clinical response and adverse effects."( Genes implicated in thiopurine-induced toxicity: Comparing TPMT enzyme activity with clinical phenotype and exome data in a paediatric IBD cohort.
Afzal, NA; Andreoletti, G; Ashton, JJ; Batra, A; Beattie, RM; Coelho, T; Ennis, S; Gao, Y; Williams, AP, 2016
)
0.43
"Hepatotoxicity, gastrointestinal complaints and general malaise are common limiting adverse reactions of azathioprine and mercaptopurine in IBD patients, often related to high steady-state 6-methylmercaptopurine ribonucleotide (6-MMPR) metabolite concentrations."( Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
Coenen, MJ; de Jong, DJ; Derijks, LJ; Engels, LG; Franke, B; Guchelaar, HJ; Hooymans, PM; Klungel, OH; Scheffer, H; van Marrewijk, CJ; Verbeek, AL; Vermeulen, SH; Wong, DR, 2017
)
0.66
"To determine the predictive value of 6-MMPR concentrations 1 week after treatment initiation (T1) for the development of these adverse reactions, especially hepatotoxicity, during the first 20 weeks of treatment."( Early prediction of thiopurine-induced hepatotoxicity in inflammatory bowel disease.
Coenen, MJ; de Jong, DJ; Derijks, LJ; Engels, LG; Franke, B; Guchelaar, HJ; Hooymans, PM; Klungel, OH; Scheffer, H; van Marrewijk, CJ; Verbeek, AL; Vermeulen, SH; Wong, DR, 2017
)
0.46
" Adverse events [AEs] in pre-specified categories and serious AEs were recorded at least every 6 months of the 5-year observation period."( Five-year Safety Data From ENCORE, a European Observational Safety Registry for Adults With Crohn's Disease Treated With Infliximab [Remicade®] or Conventional Therapy.
Boice, J; Colombel, JF; Cornillie, F; D'Haens, G; Ghosh, S; Hommes, DW; Huang, Z; Huyck, S; Lindgren, S; Panes, J; Prantera, C; Reinisch, W, 2017
)
0.46
"Despite NUDT15 variants showing significant association with thiopurine-induced adverse events (AEs) in Asians, it remains unclear which variants of NUDT15 or whether additional genetic variants should be tested to predict AEs."( NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.
Andoh, A; Araki, H; Endo, K; Hanai, H; Hiraoka, S; Hisamatsu, T; Hokari, R; Ikeya, K; Ishiguro, Y; Kakuta, Y; Kawai, Y; Kinouchi, Y; Kobayashi, T; Masamune, A; Matsumoto, T; Miura, M; Mizuno, S; Moroi, R; Motoya, S; Naganuma, M; Nagasaki, M; Naito, T; Nakagawa, S; Nakagawa, T; Nakamura, S; Nakase, H; Nishida, A; Okamoto, D; Onodera, K; Sakuraba, H; Sasaki, M; Shiga, H; Shimosegawa, T; Shinozaki, M; Suzuki, Y; Takagawa, T; Takahara, M; Toyonaga, T; Yanai, S, 2018
)
0.48
" The second approach was based on the toxic mechanism of trichloroethylene-cysteine S-conjugate sulfoxide, a Michael acceptor that undergoes rapid addition-elimination reactions with biological thiols."( Toxicity mechanism-based prodrugs: glutathione-dependent bioactivation as a strategy for anticancer prodrug design.
Elfarra, AA; Zhang, XY, 2018
)
0.48
" During the follow-up, adverse events occurred in 6 patients."( Efficacy and safety of long-term thiopurine maintenance treatment for ulcerative colitis in Turkey: A single-center experience.
Ecevit, Ç; Erdemir, G; Hekimci, H; Karakoyun, M; Kıran Taşçı, E; Özgenç, F, 2018
)
0.48
" Data on the incidence of clinical and laboratory adverse events (AEs), including hepatotoxicity and myelotoxicity resulting in imposing LDTA therapy cessation and associated risk factors were collected."( Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
de Boer, NK; de Jong, DJ; de Veer, RC; de Vries, AC; Dijkstra, G; Kreijne, JE; Moorsel, SAW; van der Woude, CJ; West, R, 2019
)
0.51
"LDTA therapy is a safe and beneficial optimisation strategy in IBD patients."( Real-life study of safety of thiopurine-allopurinol combination therapy in inflammatory bowel disease: myelotoxicity and hepatotoxicity rarely affect maintenance treatment.
de Boer, NK; de Jong, DJ; de Veer, RC; de Vries, AC; Dijkstra, G; Kreijne, JE; Moorsel, SAW; van der Woude, CJ; West, R, 2019
)
0.51
"Thiopurines are the most widely used immunosuppressants in IBD although drug-related adverse events (AE) occur in 20%-30% of cases."( Increased risk of thiopurine-related adverse events in elderly patients with IBD.
Argüelles, F; Arias, L; Calafat, M; Calvet, X; Calvo, M; Cañete, F; Cimavilla, M; de Francisco, R; Domènech, E; García-López, S; Garcia-Planella, E; Gisbert, JP; Gomollón, F; Iglesias, E; Mañosa, M; Martín-Arranz, MD; Martínez-Cadilla, J; Mesonero, F; Mínguez, M; Nos, P; Ricart, E; Rivero, M; Rodríguez-Moranta, F; Taxonera, C; Zabana, Y, 2019
)
0.51
" Food and Drug Administration Adverse Event Reporting System (FAERS) and published medical literature."( Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature.
Harinstein, L; Logan, JK; Muñoz, M; Neuner, R; Sahajwalla, C; Saluja, B; Seymour, S; Wickramaratne Senarath Yapa, S, 2020
)
0.56
" This case series demonstrates that the DI can result in clinically significant adverse events and is supportive of current febuxostat labeling."( Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature.
Harinstein, L; Logan, JK; Muñoz, M; Neuner, R; Sahajwalla, C; Saluja, B; Seymour, S; Wickramaratne Senarath Yapa, S, 2020
)
0.56
"Metronomic chemotherapy could prolong survival time of unfit AML patients, especially in the first 12 months after diagnosis without increasing treatment-associated adverse events."( Efficacy and Safety of Metronomic Chemotherapy Versus Palliative Hydroxyurea in Unfit Acute Myeloid Leukemia Patients: A Multicenter, Open-Label Randomized Controlled Trial.
Charoenprasert, K; Chinthammitr, Y; Kasyanan, H; Panoi, N; Phinyo, P; Pongudom, S; Purattanamal, J; Surawong, A; Wongyai, K, 2020
)
0.56
" The routine clinical use of thiopurines has, however, been questioned due to a number of potential adverse effects."( Safety of Thiopurine Use in Paediatric Gastrointestinal Disease.
Benninga, MA; Broekaert, I; Dolinsek, J; Mas, E; Miele, E; Orel, R; Pienar, C; Ribes-Koninckx, C; Thapar, N; Thomassen, RA; Thomson, M; Tzivinikos, C, 2020
)
0.56
" Allopurinol was well tolerated, without significant adverse events."( Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity.
Annesley, C; Bhuiyan, M; Brown, P; Cohen, G; Cooper, S; Sison, EA, 2020
)
0.77
"Thioguanine (TG) is a thiopurine which has been used for patients with inflammatory bowel disease (IBD), who have failed azathioprine (AZA) or mercaptopurine (MP) due to adverse events or suboptimal response."( Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
Anderson, S; Ansari, A; Bayoumy, AB; de Boer, NK; Loganayagam, A; Mulder, CJJ; Nolan, J; Sanderson, JD; Simsek, M; van Liere, ELSA; Warner, B, 2020
)
0.76
" Clinical response, adverse events, laboratory results, imaging and liver biopsies were retrospectively collected."( Efficacy, safety and drug survival of thioguanine as maintenance treatment for inflammatory bowel disease: a retrospective multi-centre study in the United Kingdom.
Anderson, S; Ansari, A; Bayoumy, AB; de Boer, NK; Loganayagam, A; Mulder, CJJ; Nolan, J; Sanderson, JD; Simsek, M; van Liere, ELSA; Warner, B, 2020
)
0.56
"Thiopurines are important for treating inflammatory bowel disease, but are often discontinued due to adverse effects."( Influence of allopurinol on thiopurine associated toxicity: A retrospective population-based cohort study.
de Boer, A; Egberts, ACG; Houwen, JPA; Houwen, RHJ; Lalmohamed, A; van Maarseveen, EM, 2021
)
0.62
"We assessed the incidence and predictive factors of thiopurine-induced adverse events (AE) resulting in therapy cessation in pediatric inflammatory bowel disease (IBD), related to thiopurine metabolites and biochemical abnormalities, and determined overall drug survival."( Adverse Events of Thiopurine Therapy in Pediatric Inflammatory Bowel Disease and Correlations with Metabolites: A Cohort Study.
Benninga, MA; Buiter, HJC; de Boer, NKH; de Meij, TGJ; Jagt, JZ; Pothof, CD; van Limbergen, JE; van Wijk, MP, 2022
)
0.72
" Elevated levels of 6MMP have been associated with toxic effects that may interfere with therapy."( Allopurinol to Prevent Mercaptopurine Adverse Effects in Children and Young Adults With Acute Lymphoblastic Leukemia.
Bostrom, B; Kamojjala, R, 2021
)
0.93
" Therefore, TPMT genetic variants have been used to adjust dosing for poor and intermediate metabolizers, significantly preventing adverse drug reactions."( Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Gonzalez-Covarrubias, V; Guzmán-Cruz, C; Mino-León, D; Rodríguez-Dorantes, M; Sánchez-García, S; Texis, T, 2022
)
0.72
"Though not exempt from adverse events, azathioprine (AZA) is an inexpensive and effective drug in the induction and maintenance treatment of patients with inflammatory bowel disease."( Azathioprine-induced alopecia: a rare adverse event, early marker of myelotoxicity.
Baños Arévalo, AJ; Gallardo Sánchez, F; Merino Gallego, E; Miras Lucas, L; Pérez González, Á; Vázquez Rodríguez, JA, 2022
)
0.72
" Adverse reactions to these agents are one of the main causes of treatment discontinuation or interruption."( Biomarkers for gastrointestinal adverse events related to thiopurine therapy.
Decorti, G; Franca, R; Stocco, G; Zudeh, G, 2021
)
0.62
" In the present study we performed a systematic review and a meta-analysis, comprising 30 studies and 3582 individuals, to investigate the putative genetic association of two inosine triphosphatase (ITPA) polymorphisms with adverse effects in patients treated with AZA/6-MP."( Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis.
Bagos, PG; Barba, E; Braliou, GG; Kontou, PI; Michalopoulos, I, 2022
)
0.72
"Approximately 25% of patients with inflammatory bowel disease (IBD) discontinue azathioprine (AZA) or mercaptopurine (MP) therapy within 3 months of treatment initiation because of adverse drug reactions."( Predictive Algorithm for Thiopurine-Induced Hepatotoxicity in Inflammatory Bowel Disease Patients.
Bus, P; Creemers, RH; de Boer, NKH; Deben, DS; Pierik, MJ; Simsek, M; van Bodegraven, AA; van Moorsel, SAW; Winkens, B; Wong, DR, 2022
)
0.94
"Thioguanine (TG) has been shown as a safe alternative in adults with inflammatory bowel disease (IBD) who did not tolerate conventional thiopurines [azathioprine (AZA)/mercaptopurine]."( Safety of Thioguanine in Pediatric Inflammatory Bowel Disease: A Multi-Center Case Series.
Bayoumy, AB; Benninga, MA; de Boer, NKH; de Meij, TGJ; de Ridder, L; Hummel, T; Jagt, JZ; Mulder, CJJ; Stapelbroek, J; van Wering, HM; Wolters, VM, 2022
)
0.92
" TG-related adverse events (AE) were assessed and listed according to the common terminology criteria for AE."( Safety of Thioguanine in Pediatric Inflammatory Bowel Disease: A Multi-Center Case Series.
Bayoumy, AB; Benninga, MA; de Boer, NKH; de Meij, TGJ; de Ridder, L; Hummel, T; Jagt, JZ; Mulder, CJJ; Stapelbroek, J; van Wering, HM; Wolters, VM, 2022
)
0.72
"In pediatric IBD, TG seems a safe alternative in case of AZA-induced pancreatitis."( Safety of Thioguanine in Pediatric Inflammatory Bowel Disease: A Multi-Center Case Series.
Bayoumy, AB; Benninga, MA; de Boer, NKH; de Meij, TGJ; de Ridder, L; Hummel, T; Jagt, JZ; Mulder, CJJ; Stapelbroek, J; van Wering, HM; Wolters, VM, 2022
)
0.72
" The latter shows higher efficacy but a higher side effect rate, suggesting the use of split-dose regimen as the first-line approach."( Safety and Efficacy of Split-Dose Thiopurine vs Low-Dose Thiopurine-Allopurinol Cotherapy in Pediatric Inflammatory Bowel Disease.
Borrelli, O; Buckingham, R; Chadokufa, S; Cococcioni, L; El-Kouly, S; Gaynor, E; Kiparissi, F; Pensabene, L; Puoti, MG; Saliakellis, E, 2023
)
0.91

Pharmacokinetics

6-mercaptopurine (6-MP) was entrapped in poly (L-lactide) matrix to form microcomposite spheres (MPs) in order to reduce the cell toxicity. Physiologically based pharmacokinetic models were developed to simulate concentrations of mercaptopurine in plasma, kidneys, liver, muscle, spleen, bone marrow, and gut lumen.

ExcerptReferenceRelevance
" Physiologically based pharmacokinetic models were developed to simulate concentrations of mercaptopurine in plasma, kidneys, liver, muscle, spleen, bone marrow, and gut lumen."( Pharmacokinetics of mercaptopurine.
Day, JL; Ortega, E; Solomon, R; Tterlikkis, L, 1977
)
0.8
" The dose required to achieve the desired cerebrospinal fluid concentrations in humans was derived from pharmacokinetic parameters determined in rhesus monkeys."( Intrathecal 6-mercaptopurine: preclinical pharmacology, phase I/II trial, and pharmacokinetic study.
Adamson, PC; Arndt, CA; Balis, FM; Gillespie, AJ; Holcenberg, JS; Murphy, RF; Narang, PK; Poplack, DG, 1991
)
0.64
"To evaluate the reasons for the wide variability in bioavailability of orally administered 6-mercaptopurine in children with acute lymphoblastic leukemia, we studied several pharmacokinetic parameters of the drug in 18 affected children receiving remission maintenance therapy, and compared them with their anthropometric data and with the results of intestinal function tests."( Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Di Martino, L; Di Tullio, MT; Giuliano, M; Guandalini, S; Guiducci, M; Pacifici, R; Pettoello Mantovani, M; Pichini, S; Zuccaro, P, 1991
)
0.76
" A 4- to 11-fold variation between individuals was found in the pharmacokinetic parameters: peak concentration, time to reach peak, area under the plasma concentration-time curve (AUC), and fraction of dose excreted in the urine."( Pharmacokinetics of oral 6-mercaptopurine: relationship between plasma levels and urine excretion of parent drug.
Endresen, L; Lie, SO; Rugstad, HE; Stokke, O; Storm-Mathisen, I, 1990
)
0.58
" Elimination half-life of mercaptopurine was significantly longer in the evening than during the day (423 +/- 142 minutes vs 176 +/- 22 minutes, mean +/- SEM)."( Diurnal variation in the pharmacokinetics and myelotoxicity of mercaptopurine in children with acute lymphocytic leukemia.
Giesbrecht, E; Greenberg, M; Koren, G; Langevin, AM; Olivieri, N; Zipursky, A, 1990
)
0.82
" The risk for a drug interaction under these conditions is high, and the pharmacological characteristics of the anti-cancer drugs, such as steep dose-response curves, low therapeutic indices and severe toxicities, suggest that even small changes in the pharmacokinetic profile of the affected drug could significantly alter its toxicity or efficacy."( Pharmacokinetic drug interactions of commonly used anticancer drugs.
Balis, FM,
)
0.13
" 6-MP plasma concentrations in the patients were low (mean peak concentration 36."( Pharmacokinetics of 6-thiouric acid and 6-mercaptopurine in renal allograft recipients after oral administration of azathioprine.
Ascher, NL; Canafax, DM; Chan, GL; Chen, S; Erdmann, GR; Gruber, SA; Stock, P, 1989
)
0.54
" The relation between doses and the means of AUC (area under the curve) and Cmax (maximum concentration) suggested a non-linear pharmacokinetics."( [Pharmacokinetics of 6-mercaptopurine in children with acute lymphoblastic leukemia--interindividual and intraindividual variations].
Hijiya, N; Kato, Y; Matsushita, T; Yokoyama, T, 1989
)
0.59
"The chronopharmacokinetics of the orally administered antileukemic drugs, 6-mercaptopurine and methotrexate, were examined in 13 children with acute lymphoblastic leukemia (ALL) to establish if there is a pharmacokinetic basis for the lower relapse rate associated with administration of these agents in the evening."( Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy?
Arndt, CA; Balis, FM; Doherty, KM; Jeffries, SL; Lange, B; Luery, N; Murphy, RF; Poplack, DG, 1989
)
0.76
" There was a high interpatient variation in all the pharmacokinetic parameters measured."( Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations.
Keen, D; Lennard, L; Lilleyman, JS, 1986
)
0.73
" Our results indicate that pharmacokinetic variability may contribute to either severe myelotoxicity or therapeutic failures."( Pharmacokinetic determinants of 6-mercaptopurine myelotoxicity and therapeutic failure in children with acute lymphoblastic leukemia.
Greenberg, M; Koren, G; Soldin, S; Sulh, H; Whalen, C; Zipursky, A, 1986
)
0.55
"The widespread use of neurosurgical devices for intraventricular drug delivery has led to an escalation in the number of CSF pharmacokinetic studies."( Pharmacokinetics of intraventricular administration.
Collins, JM, 1983
)
0.27
" The influence of allopurinol on the pharmacokinetic parameters of 6MP was as follows: (a) a 2-fold increase in the half-life and area under the concentration-time curve; (b) a 2-fold decrease in the total body clearance; and (c) an approximate 3-fold decrease in elimination rate constant."( Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine in rabbits.
Brown, DA; Day, JL; Schroeder, EC; Tterlikkis, L, 1983
)
0.52
" Pharmacokinetic data of the symptomatic patients were compared with those of 25 ALL patients on the same protocol but without GI symptoms or hepatotoxicity."( Hepatotoxicity of 6-mercaptopurine in childhood acute lymphocytic leukemia: pharmacokinetic characteristics.
Berkovitch, M; Blanchette, VS; Evans, WE; Giesbrecht, E; Koren, G; Matsui, D; Saunders, EF; Verjee, Z; Zipursky, A, 1996
)
0.62
"Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine (6-MP) and methotrexate (MTX) was investigated in patients as well as in rats and in HL-60 human leukemic cells."( Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.
Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A; Favre, C; Innocenti, F; Loru, B; Macchia, P; Nardi, M; Nardini, D, 1996
)
0.77
" There was a marked interindividual difference in the plasma kinetics of the two drugs; after identical doses of 100 mg/m2 an about 4-fold higher peak concentration of the parent drug was reached with 6MP."( Pharmacokinetics and metabolism of thiopurines in children with acute lymphoblastic leukemia receiving 6-thioguanine versus 6-mercaptopurine.
Erb, N; Harms, DO; Janka-Schaub, G, 1998
)
0.51
"We prospectively assessed the pharmacokinetics of methotrexate, mercaptopurine, and erythrocyte thioguanine nucleotide levels in a homogenous population of children with lower risk acute lymphoblastic leukemia and correlated pharmacokinetic parameters with disease outcome."( Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study.
Ames, MM; Balis, FM; Bleyer, WA; Ge, J; Gilchrist, GS; Holcenberg, JS; Murphy, RF; Poplack, DG; Sather, HN; Tubergen, DG; Waskerwitz, MJ; Zimm, S, 1998
)
0.78
" The thiopurine derivative 6-mercaptopurine is the active metabolite of azathioprine, and it would be of interest to measure, after validation of plasma measurements, the mean values of the pharmacokinetic parameters in transplant patients with high or intermediate TPMTase phenotypes (85 and 14% of the Caucasian population, respectively)."( 6-Mercaptopurine pharmacokinetics after use of azathioprine in renal transplant recipients with intermediate or high thiopurine methyl transferase activity phenotype.
D'Athis, P; Escousse, A; Guedon, F; Mounie, J; Mousson, C; Rifle, G, 1998
)
1.31
" Pharmacokinetic monitoring could be useful for optimizing MTX/6MP maintenance therapy."( Myelotoxicity, pharmacokinetics, and relapse rate with methotrexate/6-mercaptopurine maintenance therapy of childhood acute lymphoblastic leukemia.
Ifversen, M; Schmiegelow, K,
)
0.37
"Proper prospective pharmacokinetic studies of 6-mercaptopurine (6-MP) in inflammatory bowel disease (IBD) patients are lacking."( Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.
Bos, LP; Bus, PJ; Curvers, WL; Derijks, LJ; Engels, LG; Gilissen, LP; Hommes, DW; Hooymans, PM; Lohman, JJ; Van Deventer, SJ, 2004
)
0.89
"To examine the in vivo pharmacokinetic interaction between mesalazine and mercaptopurine."( The pharmacokinetic effect of discontinuation of mesalazine on mercaptopurine metabolite levels in inflammatory bowel disease patients.
Bierau, J; Bos, LP; Derijks, LJ; Engels, LG; Gilissen, LP; Hooymans, PM; Stockbrügger, RW; van Gennip, A, 2005
)
0.8
" Pharmacokinetic and pharmacodynamic studies of mercaptopurine and thioguanine were done in Tpmt(-/-), Tpmt(+/-), and Tpmt(+/+) mice and variables were compared among genotypes."( Differential effects of targeted disruption of thiopurine methyltransferase on mercaptopurine and thioguanine pharmacodynamics.
Edick, MJ; Evans, WE; Grosveld, G; Hartford, C; Pui, CH; Rehg, JE; Relling, MV; Schwab, M; Vasquez, E, 2007
)
0.82
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
" Population pharmacokinetic analysis was performed with the nonlinear mixed effects modelling program (nonmem) to determine the population mean parameter estimate of clearance for the active metabolites."( Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
Cairns, C; Collier, PS; Dempsey, S; Hawwa, AF; McCarthy, A; McElnay, JC; Millership, JS, 2008
)
0.59
"The developed pharmacokinetic model (if successful at external validation) would offer a more rational dosing approach for 6-MP than the traditional empirical method since it combines the current practice of using body surface area in 6-MP dosing with a pharmacogenetically guided dosing based on TPMT genotype."( Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
Cairns, C; Collier, PS; Dempsey, S; Hawwa, AF; McCarthy, A; McElnay, JC; Millership, JS, 2008
)
0.59
"Intercalation of 6-mercaptopurine (6-MP), an antineoplastic drug in interlayer gallery of Na(+)-clay (MMT) was further entrapped in poly (L-lactide) matrix to form microcomposite spheres (MPs) in order to reduce the cell toxicity and enhance in vitro release and pharmacokinetic proficiency."( Evaluation of clay/poly (L-lactide) microcomposites as anticancer drug, 6-mercaptopurine reservoir through in vitro cytotoxicity, oxidative stress markers and in vivo pharmacokinetics.
Bajaj, HC; Brahmbhatt, H; Chettiar, SS; Gosai, KA; Kevadiya, BD; Rajkumar, S, 2013
)
0.95
" A physiological based pharmacokinetic model was proposed for 6-MP, this model has compartments for stomach, gut lumen, enterocyte, gut tissue, spleen, liver vascular, liver tissue, kidney vascular, kidney tissue, skin, bone marrow, thymus, muscle, rest of body and red blood cells."( Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Aarons, L; Ogungbenro, K, 2014
)
0.64
"To extend the physiologically based pharmacokinetic (PBPK) model developed for 6-mercaptopurine to account for intracellular metabolism and to explore the role of genetic polymorphism in the TPMT enzyme on the pharmacokinetics of 6-mercaptopurine."( Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity.
Aarons, L; Ogungbenro, K, 2015
)
0.64
" This study aimed to assess whether expression and activity of Rac1 or phosphorylated ezrin-radixin-moesin (pERM) in patients with IBD could provide a useful biomarker for the pharmacodynamic thiopurine effect and might be related to clinical effectiveness."( Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.
de Boer, NK; Mulder, CJ; Seinen, ML; van Bezu, J; van Bodegraven, AA; van Nieuw Amerongen, GP, 2016
)
0.43
" Therefore, Rac1-GTP and expression of Rac1, but not phosphorylation of ERM, form potentially pharmacodynamic markers of therapeutic thiopurine effectiveness in patients with IBD."( Rac1 as a Potential Pharmacodynamic Biomarker for Thiopurine Therapy in Inflammatory Bowel Disease.
de Boer, NK; Mulder, CJ; Seinen, ML; van Bezu, J; van Bodegraven, AA; van Nieuw Amerongen, GP, 2016
)
0.43
"Upon 6MP/azathioprine discontinuation, a 6-TGN elimination half-life of less than 10 days is expected in most patients."( Pharmacokinetics and Immune Reconstitution Following Discontinuation of Thiopurine Analogues: Implications for Drug Withdrawal Strategies.
Ben-Horin, S; Chen, MH; Chowers, Y; Eliakim, R; Fudim, E; Gueta, I; Kopylov, U; Loebstein, R; Mao, R; Markovits, N; Peled, Y; Picard, O; Ungar, B; Van Assche, G; Yavzori, M, 2018
)
0.48
" For that purpose, we used collected pharmacokinetic data from 48 healthy volunteers (all males) who received a single oral dose of mercaptopurine 50 mg in two bioequivalence studies."( Influence of thiopurine S-methyltransferase polymorphisms in mercaptopurine pharmacokinetics in healthy volunteers.
Abad-Santos, F; Belmonte, C; Herrador, C; Martínez-Ingelmo, C; Ochoa, D; Ortega-Ruíz, L; Román, M; Saiz-Rodríguez, M; Sarmiento-Iglesias, C, 2019
)
0.96
" This study investigated the pharmacokinetic profiles of mini-tablets and conventional tablets with an improved ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method."( Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs.
Han, J; Jin, S; Mei, S; Xu, J; Zhang, D; Zhao, L; Zhao, Z, 2020
)
0.82
"After giving 8 healthy beagle dogs 50 mg 6-MP in different dosage forms, plasma samples collected at different time points were analyzed for pharmacokinetic evaluation."( Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs.
Han, J; Jin, S; Mei, S; Xu, J; Zhang, D; Zhao, L; Zhao, Z, 2020
)
0.82
"Two dosage forms showed the same pharmacokinetic characteristics."( Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs.
Han, J; Jin, S; Mei, S; Xu, J; Zhang, D; Zhao, L; Zhao, Z, 2020
)
0.82
" Ras-related C3 botulinum toxin substrate 1 (Rac1) has been suggested as a potential pharmacodynamic marker of the thiopurine effect in lymphocytes."( Rac1/pSTAT3 expression: A pharmacodynamic marker panel as a first step toward optimization of thiopurine therapy in inflammatory bowel disease patients.
Deben, DS; Drent, R; Leers, MPG; Pelzer, KEJM; Puts, S; van Adrichem, AJ; van Bodegraven, AA; Wong, DR, 2022
)
0.72
" A functional pharmacodynamic marker in T lymphocytes may be useful to predict therapeutic outcome of thiopurine therapy."( A report on the potential of Rac1/pSTAT3 protein levels in T lymphocytes to assess the pharmacodynamic effect of thiopurine therapy in Inflammatory Bowel Disease patients.
Creemers, RH; Deben, DS; Drent, R; Leers, MPG; Merry, AHH; van Adrichem, AJ; van Bodegraven, AA; Wong, DR, 2022
)
0.72
" We use a detailed data set with measurements of thioguanine nucleotides and MTX in red blood cells and absolute neutrophil count (ANC) to develop pharmacokinetic models for 6MP and MTX, as well as a pharmacokinetic-pharmacodynamic (PKPD) model capable of predicting individual ANC levels and thus contributing to the development of personalized treatment strategies."( Pharmacokinetic-pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia.
Gebhard, A; Lilienthal, P; Metzler, M; Rauh, M; Sager, S; Schmiegelow, K; Toksvang, LN; Zierk, J, 2023
)
0.91

Compound-Compound Interactions

cytological analysis of proliferating neoplasic and intestinal epithelium tissues of rats under the effect of cyclophosphane, 6-mercaptopurine, furosemide, diacarbum and of their combination with course-wise introduction.

ExcerptReferenceRelevance
"A cytological analysis of proliferating neoplasic and intestinal epithelium tissues of rats under the effect of cyclophosphane, 6-mercaptopurine, furosemide, diacarbum and of their combination with course-wise introduction was effected."( [Effect of diacarb and furosemide in combination with cytostatics on the mitotic activity of tumor and intestines of rats with sarcoma 45].
Aref'eva, AK; Pashinskiĭ, VG,
)
0.34
"Three hundred twenty-six patients with acute myelocytic leukemia were randomly and prospectively assigned to four therapeutic regimens: cytosine arabinoside either alone or in combination with daunorubicin, 6-mercaptopurine, or 6-thioguanine."( Comparative study of cytosine arabinoside therapy alone and combined with thioguanine, mercaptopurine, or daunorubicin in acute myelocytic leukemia.
Blom, J; Carey, RW; Cuttner, J; Eagan, RT; Ellison, RR; Glidewell, O; Harley, JB; Haurani, F; Holland, JH; Kyle, R; Lee, ST; Levy, RN; Moon, JH; Ribas-Mundo, M; Silver, R; Spurr, CL, 1975
)
0.66
" Forty patients with ALL, aged 55 years or older, and with good performance status (ECOG <3) were prospectively treated according to an age-adapted regimen: induction therapy was derived from the LALA87 protocol while the feasibility of treatment with interferon combined with chemotherapy was assessed during maintenance."( Age-adapted induction treatment of acute lymphoblastic leukemia in the elderly and assessment of maintenance with interferon combined with chemotherapy. A multicentric prospective study in forty patients. French Group for Treatment of Adult Acute Lymphobl
Bouabdallah, R; Broustet, A; Cahn, JY; Cazin, B; Cony-Makhoul, P; Cordonnier, C; Delannoy, A; Dreyfus, F; Fière, D; Gay, C; Michaux, JL; Sadoun, A; Sebban, C; Vernant, JP, 1997
)
0.3
" Because of its wide spectrum of actions, it is reasonable to consider the combination with other anticancer drugs in clinical application."( Cytotoxic effects of histone deacetylase inhibitor FK228 (depsipeptide, formally named FR901228) in combination with conventional anti-leukemia/lymphoma agents against human leukemia/lymphoma cell lines.
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Kobayashi, H; Mano, H; Tsunoda, S, 2007
)
0.34
"5 U combined with a post-treatment 6-thioguanine nucleotide level > 230 pmol/8 x 10(8) erythrocytes was the best predictor of response."( Thiopurine methyltransferase activity combined with 6-thioguanine metabolite levels predicts clinical response to thiopurines in patients with inflammatory bowel disease.
Devlin, SM; Kwan, LY; Mirocha, JM; Papadakis, KA, 2008
)
0.35
" The aim of this study was to investigate the cytotoxic effects of this agent in combination with conventional antileukemic agents."( The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009
)
0.35
"The cytotoxic effects of GO in combination with antileukemic agents were studied against human CD33 antigen-positive leukemia HL-60, U937, TCC-S and NALM20 cells."( The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro.
Akutsu, M; Furukawa, Y; Izumi, T; Kano, Y; Mano, H; Miyawaki, S; Tanaka, M; Tsunoda, S; Yazawa, Y, 2009
)
0.35
" The aim of the study was quantification of 6-TG and 6-MMP, with the use of liquid chromatography combined with tandem mass spectrometry (LC/MS/MS) in solid-organ transplant recipients."( Determination of Concentrations of Azathioprine Metabolites 6-Thioguanine and 6-Methylmercaptopurine in Whole Blood With the Use of Liquid Chromatography Combined With Mass Spectrometry.
Borowiec, A; Dadlez, M; Hryniewiecka, E; Jazwiec, R; Paczek, L; Samborowska, E; Tszyrsznic, W; Zegarska, J; Zochowska, D, 2016
)
0.66
" We aimed to describe our center's experience with thiopurine optimization through the use of reduced thiopurine dosing in combination with allopurinol upon hepatotoxicity, drug metabolite levels, and clinical outcomes in children with IBD."( Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.
Boyle, B; Bricker, J; Crandall, W; Dotson, JL; Kim, SC; Maltz, R; Serpico, MR, 2018
)
0.48
"Low-dose thiopurines in combination with allopurinol improved hepatotoxicity and increased 6-TG levels in children with IBD."( Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.
Boyle, B; Bricker, J; Crandall, W; Dotson, JL; Kim, SC; Maltz, R; Serpico, MR, 2018
)
0.48
"6 months elapsed from initiation of the drug combination until discovery of the event."( Drug Interaction Between Febuxostat and Thiopurine Antimetabolites: A Review of the FDA Adverse Event Reporting System and Medical Literature.
Harinstein, L; Logan, JK; Muñoz, M; Neuner, R; Sahajwalla, C; Saluja, B; Seymour, S; Wickramaratne Senarath Yapa, S, 2020
)
0.56
" In this review we will explore the history, pharmacology, recent studies and give recommendations for the utilisation of the usual duo of azathioprine combined with allopurinol."( Low-Dose Azathioprine in Combination with Allopurinol: The Past, Present and Future of This Useful Duo.
Sparrow, MP; Turbayne, AK, 2022
)
0.72

Bioavailability

The bioavailability of oral mercaptopurine (MP) is poor. Since it is inactivated by xanthine oxidase (XO), concurrent intake of substances containing XO may potentially reduce bioavailability.

ExcerptReferenceRelevance
" The therapeutic advantage of combination chemotherapy may reside in the whole organism, reflecting increased bioavailability of drug, reduced dose-limiting toxicity or reduced impairment of host defenses; it may reside in the tumor cells, reflecting the multiple molecular mechanisms of interaction mentioned above."( Multiple basis of combination chemotherapy.
Grindey, GB; Mihich, E, 1977
)
0.26
"Several reports document an inverse correlation between bioavailability of maintenance chemotherapeutic agents and the likelihood of relapse in childhood."( Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy.
Blatt, J; Gula, MJ; Lucas, K,
)
0.13
" 6MP given on the present continuous intravenous infusion schedule overcomes the limited and variable bioavailability of oral 6MP but shows limited activity as induction agent in children with recurrent ALL."( A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia.
Adamson, PC; Balis, F; Gillespie, A; Kamen, BA; Poplack, DG; Ragab, AH; Steinberg, SM; Vietti, TJ; Zimm, S, 1992
)
0.55
"To evaluate the reasons for the wide variability in bioavailability of orally administered 6-mercaptopurine in children with acute lymphoblastic leukemia, we studied several pharmacokinetic parameters of the drug in 18 affected children receiving remission maintenance therapy, and compared them with their anthropometric data and with the results of intestinal function tests."( Fat body mass and pharmacokinetics of oral 6-mercaptopurine in children with acute lymphoblastic leukemia.
Di Martino, L; Di Tullio, MT; Giuliano, M; Guandalini, S; Guiducci, M; Pacifici, R; Pettoello Mantovani, M; Pichini, S; Zuccaro, P, 1991
)
0.76
" Recently, wide variability in the bioavailability of oral mercaptopurine has been demonstrated, and there is concern that this may affect the risk of relapse."( Systemic exposure to mercaptopurine as a prognostic factor in acute lymphocytic leukemia in children.
Ferrazini, G; Giesbrecht, E; Greenberg, M; Kapelushnik, J; Klein, J; Koren, G; Langevin, AM; Soldin, S; Sulh, H, 1990
)
0.84
"The bioavailability of 6-mercaptopurine (6-MP) administered orally for maintenance therapy of children with acute lymphoblastic leukemia is highly variable."( Milk could decrease the bioavailability of 6-mercaptopurine.
David, M; Leclerc, JM; Lin, KT; Rivard, GE, 1989
)
0.84
" In summary, marked interindividual differences in pharmacokinetics were found, probably due to highly variable bioavailability of oral 6-MP."( Plasma and erythrocyte concentrations of mercaptopurine after oral administration in children.
Kreuger, A; Lindström, B; Lönnerholm, G; Ludvigsson, J; Myrdal, U, 1986
)
0.54
"The bioavailability of oral 6-mercaptopurine (6MP) at standard doses is very low, largely as a result of extensive first-pass metabolism by xanthine oxidase."( Bioavailability of low-dose vs high-dose 6-mercaptopurine.
Arndt, CA; Balis, FM; Doherty, K; Jeffries, SL; McCully, CL; Murphy, R; Poplack, DG, 1988
)
0.83
" Studies of oral 6-MP indicate that, contrary to previous information, the bioavailability of this drug is relatively poor after oral administration, and that plasma 6-MP concentrations achieved after uniform oral dosing are highly variable."( The pharmacology of orally administered chemotherapy. A reappraisal.
Balis, FM; Poplack, DG; Zimm, S, 1986
)
0.27
" It is suggested that the bioavailability and thereby, the antileukaemic effect) during maintenance therapy of ALL of 6-MP may be decreased by the co-administration of CTX."( The effect of cotrimoxazole on the absorption of orally administered 6-mercaptopurine in the rat.
Aherne, GW; Burton, NK, 1986
)
0.5
"The effect of food on the bioavailability of 6-mercaptopurine (6-MP) has been investigated."( The effect of food on the oral administration of 6-mercaptopurine.
Aherne, GW; Barnett, MJ; Burton, NK; Douglas, I; Evans, J; Lister, TA, 1986
)
0.78
" The bioavailability of the drug over 12 hours was 21."( Ocular pharmacokinetics of subconjunctivally versus intravenously administered 6-mercaptopurine.
Bussanich, N; Dedhar, C; Gudauskas, G; Kumi, C; Rootman, J, 1985
)
0.5
" Administration of 6-MP with 20% (w/v) sodium benzoate to rat rectum resulted in enhanced absorption and the area under the plasma concentration-time curve was comparable to that obtained by intravenous administration (bioavailability = 100%), while the bioavailability after intrarectal administration of 6-MP with 20% (w/v) sodium hippurate was only 9%."( Improvement of aqueous solubility and rectal absorption of 6-mercaptopurine by addition of sodium benzoate.
Kimura, T; Takeichi, Y, 1994
)
0.53
" The reasons are the better and more consistent bioavailability of intravenous versus oral MP, higher blood and CSF levels, compliance, and preliminary evidence suggesting superior remission experience for intravenous Mtx and 6MP than for Mtx alone."( Intravenous mercaptopurine: life begins at 40.
Pinkel, D, 1993
)
0.66
"In an attempt to improve the effectiveness and bioavailability of 6-mercaptopurine, various kinds of water-soluble analogues, such as 6-S-aminoacyloxymethyl mercaptopurine derivatives (3a--m) and 6-S,9-disubstituted derivates (7a,b and 9a,b), were synthesized."( Water-soluble antitumor agents. I. Synthesis and biological activity of 6-S-aminoacyloxymethyl mercaptopurine derivatives.
Harada, N; Hashiyama, T; Hongu, M; Kashida, T; Narasaki, N; Oda, K; Ohohashi, M; Tanaka, T; Tsujihara, K, 1995
)
0.75
" The present findings indicate that high-dose MTX enhances the bioavailability of 6-MP as evidenced by the observed increases in the plasma Cmax and AUC of 6-MP in humans and animals."( Clinical and experimental pharmacokinetic interaction between 6-mercaptopurine and methotrexate.
Bocci, G; Danesi, R; Del Tacca, M; Di Paolo, A; Favre, C; Innocenti, F; Loru, B; Macchia, P; Nardi, M; Nardini, D, 1996
)
0.53
" Colonic delivery of azathioprine may reduce its systemic bioavailability and limit toxicity."( Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
Lipsky, JJ; Mahoney, DW; Mays, DC; Sandborn, WJ; Tremaine, WJ; Van Os, EC; Zins, BJ; Zinsmeister, AR, 1996
)
0.29
"To determine the bioavailability of 6-mercaptopurine after administration of azathioprine via three colonic delivery formulations."( Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
Lipsky, JJ; Mahoney, DW; Mays, DC; Sandborn, WJ; Tremaine, WJ; Van Os, EC; Zins, BJ; Zinsmeister, AR, 1996
)
0.57
"The bioavailabilities of 6-mercaptopurine after colonic azathioprine administration via delayed release oral, hydrophobic rectal foam, and hydrophilic rectal foam (7%, 5%, 1%; respectively) were significantly lower than the bioavailability of 6-mercaptopurine after oral azathioprine administration (47%) by Wilcoxon rank sum pairwise comparison."( Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
Lipsky, JJ; Mahoney, DW; Mays, DC; Sandborn, WJ; Tremaine, WJ; Van Os, EC; Zins, BJ; Zinsmeister, AR, 1996
)
0.59
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Pharmacokinetic studies showed an increase in half-life and bioavailability from multiple emulsion formulations administered intravenously."( Concanavalin-A conjugated fine-multiple emulsion loaded with 6-mercaptopurine.
Jain, NK; Khopade, AJ,
)
0.37
" Patients treated with either branded azathioprine or 6-mercaptopurine achieved significantly higher erythrocyte 6-thioguanine levels than patients treated with generic azathioprine, thereby suggesting that branded azathioprine has improved oral bioavailability compared to generic azathioprine."( Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy.
Bayless, TM; Cuffari, C; Hunt, S, 2000
)
0.8
"Our results suggest that differences in bioavailability may have clinical relevance when considering the need to optimize erythrocyte 6-thioguanine metabolite levels in patients deemed unresponsive to treatment on conventional drug dosages."( Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy.
Bayless, TM; Cuffari, C; Hunt, S, 2000
)
0.55
" The introduction of the microemulsion formulation of cyclosporine with its more consistent bioavailability has renewed interest in the use of alternative sampling strategies to the trough cyclosporine concentration."( New developments in the immunosuppressive drug monitoring of cyclosporine, tacrolimus, and azathioprine.
Armstrong, VW; Oellerich, M, 2001
)
0.31
"Through inhibition of purine de novo synthesis and enhancement of 6-mercaptopurine (6MP) bioavailability high-dose methotrexate (HDM) may increase the incorporation into DNA of 6-thioguanine nucleotides (6TGN), the cytoxic metabolites of 6MP."( 6-mercaptopurine dosage and pharmacokinetics influence the degree of bone marrow toxicity following high-dose methotrexate in children with acute lymphoblastic leukemia.
Bretton-Meyer, U; Schmiegelow, K, 2001
)
1.27
" Because of the oral bioavailability of 6-MP is low and highly variable, the aim of this study was to develop a new parenteral formulation that can prolong the biological half-life of the drug, improve its therapeutic efficacy, and its associated reduce side effects."( 6-mercaptopurine (6-MP) entrapped stealth liposomes for improvement of leukemic treatment without hepatotoxicity and nephrotoxicity.
Ghosh, PK; Majithya, R; Murthy, RS; Umrethia, M, 2007
)
1.06
" Since it is inactivated by xanthine oxidase (XO), concurrent intake of substances containing XO may potentially reduce bioavailability of mercaptopurine."( Interaction between mercaptopurine and milk.
de Lemos, ML; Hamata, L; Jennings, S; Leduc, T, 2007
)
0.87
" Bioavailability of thiopurines may be competitively inhibited by dietary purines."( Influence of xanthine oxidase on thiopurine metabolism in Crohn's disease.
Ansari, A; Aslam, Z; De Sica, A; Duley, J; Fairbanks, L; Gilshenan, K; Marinaki, A; Sanderson, J; Smith, M, 2008
)
0.35
"Increased endothelin-1 (ET-1) production and diminished nitric oxide synthase (NOS) bioavailability has been observed in aneurysmal subarachnoid hemorrhage (SAH)."( 6-Mercaptopurine reverses experimental vasospasm and alleviates the production of endothelins in NO-independent mechanism-a laboratory study.
Chang, CZ; Hwang, SL; Kwan, AL; Lin, CL; Wu, SC, 2011
)
1.09
" 6-MP undergoes very extensive intestinal and hepatic metabolism following oral dosing due to the activity of xanthine oxidase leading to very low and highly variable bioavailability and methotrexate has been demonstrated as an inhibitor of xanthine oxidase."( Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Aarons, L; Ogungbenro, K, 2014
)
0.64
"Based upon trough levels of the principal active metabolite,6-thioguanine nucleotides (6-TGN),a relative bioavailability of the liquid vs."( A novel 6-mercaptopurine oral liquid formulation for pediatric acute lymphoblastic leukemia patients - results of a randomized clinical trial.
Hanff, LM; Mathot, RA; Pieters, R; Postma, DJ; Ramnarain, S; Smeets, O; Vermes, A; Zwaan, CM, 2014
)
0.8
"Through enhancement of 6-mercaptopurine (6MP) bioavailability and inhibition of purine de novo synthesis, high-dose methotrexate (HD-MTX) may increase incorporation into DNA of 6-thioguanine nucleotides, the cytotoxic metabolites of 6MP."( Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Abrahamsson, J; Bechensteen, AG; Frandsen, TL; Harila-Saari, A; Heldrup, J; Jonsson, OG; Lausen, B; Levinsen, M; Nygaard, U; Rosthøj, S; Schmiegelow, K; Weinshilboum, RM, 2015
)
0.94
" Noticeably, the in vitro and in vivo studies revealed that co-crystal 1 possesses improved dissolution rate and superior bioavailability on animal model."( Improving the dissolution and bioavailability of 6-mercaptopurine via co-crystallization with isonicotinamide.
Chen, C; Lin, Y; Mei, X; Pan, G; Wang, JR; Yu, X; Zhou, C, 2015
)
0.67
"6-MP has short elimination time (<2 h) and low bioavailability (~ 50%)."( Optimization of Time Controlled 6-mercaptopurine Delivery for Site- Specific Targeting to Colon Diseases.
Hude, RU; Jagdale, SC, 2016
)
0.71
" It is clinically effective, exerting a systemic immune response with low systemic bioavailability and a low incidence of side effects."( Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trial.
Chowers, Y; Fishman, S; Goldin, E; Ilan, Y; Israeli, E; Konikoff, F; Lahat, A; Lavy, A; Mahamid, M; Melzer, E; Nussinson, E; Segol, O; Shabbat, Y; Shirin, H; Ya'acov, AB, 2015
)
0.66
" The use of this drug is limited due to its poor bioavailability and short plasma half-life."( Anti-cancerous efficacy and pharmacokinetics of 6-mercaptopurine loaded chitosan nanoparticles.
Amaresha, S; Janardhana, PB; Kumar, GP; Manohara, C; Phani, AR; Prasad, RG; Raghavendra, HL; Sanganal, JS; Swamy, KB; Tripathi, SM, 2015
)
0.67
" The bioavailability and palatability of a single 50mg fixed dose of Loulla compared to 50mg registered tablets were evaluated in a random order on two consecutive days."( Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children.
Baruchel, A; Bertrand, Y; Breitkreutz, J; Hjalgrim, LL; Jacqz-Aigrain, E; Leverger, G; Nelken, B; Nersting, J; Schmiegelow, K; Schrappe, M; Stanulla, M; Thomas, C; Tiphaine, Ade B, 2016
)
0.68
" The relative bioavailability of liquid Loulla formulation compared to the reference presentation is 76% for AUC0-9 and AUC0-∞ and 80% for Cmax."( Evaluation of a pediatric liquid formulation to improve 6-mercaptopurine therapy in children.
Baruchel, A; Bertrand, Y; Breitkreutz, J; Hjalgrim, LL; Jacqz-Aigrain, E; Leverger, G; Nelken, B; Nersting, J; Schmiegelow, K; Schrappe, M; Stanulla, M; Thomas, C; Tiphaine, Ade B, 2016
)
0.68
" The hemihydrate shows increased solubility and bioavailability when compared to the monohydrate form, better stability against conversion in aqueous media than the anhydrate form, and a dehydration temperature of 240 °C, the highest of any known hydrate crystal."( Improved pharmacokinetics of mercaptopurine afforded by a thermally robust hemihydrate.
Kersten, KM; Matzger, AJ, 2016
)
0.73
" These guidelines discuss the use of aminosalicylates, systemic and low bioavailability corticosteroids, antibiotics (metronidazole, ciprofloxacin, rifaximin), thiopurines, methotrexate, cyclosporine A, TNFα antagonists, vedolizumab, and combination therapies."( Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
Annese, V; Ardizzone, S; Armuzzi, A; Biancone, L; Calabrese, E; Caprioli, F; Castiglione, F; Comberlato, M; Cottone, M; D'Incà, R; Danese, S; Daperno, M; Frieri, G; Fries, W; Gionchetti, P; Kohn, A; Latella, G; Meucci, G; Milla, M; Orlando, A; Papi, C; Petruzziello, C; Riegler, G; Rizzello, F; Saibeni, S; Scribano, ML; Vecchi, M; Vernia, P, 2017
)
0.46
"A liquid formulation of 6-mercaptopurine (6-MP) was recently approved by the Food and Drug Administration (Purixan®) based on bioavailability (BA) data from healthy adults."( Pharmacokinetics of two 6-mercaptopurine liquid formulations in children with acute lymphoblastic leukemia.
Abdel-Rahman, SM; August, KJ; Bai, S; Kearns, GL; Neville, KA; Tolbert, JA; Weir, SJ, 2017
)
1.06
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" Dose-restricted tioguanine (thioguanine) could expand treatment options by reducing methylated metabolites, increasing the bioavailability of 6-tioguanine nucleotides and ameliorating thiopurine intolerance or resistance."( Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Czaja, AJ, 2020
)
0.56
"The efficacy and safety of thiopurines in autoimmune hepatitis can be improved by investigational efforts that establish monitoring strategies that allow individualisation of dosage and prediction of outcome, increase bioavailability of the active metabolites and demonstrate superiority to alternative agents."( Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Czaja, AJ, 2020
)
0.56
" For this reason, various 6-MP nano drug-loading systems have been designed to increase the water solubility of 6-MP, extend the circulation time, and increase the bioavailability of 6-MP to a certain extent, reducing its toxic and side effects."( Application and Analysis of 6-Mercaptopurine Nanomedicine in the Treatment of Leukemia.
Lu, X; Wang, F; Xie, Y, 2021
)
0.91
" Unfortunately, its efficacy has been limited due to its insolubility, poor bioavailability and serious adverse effects."( Preparation, Characterization, Pharmacokinetic, and Therapeutic Potential of Novel 6-Mercaptopurine-Loaded Oral Nanomedicines for Acute Lymphoblastic Leukemia.
Han, J; He, H; Mei, D; Sun, N; Xu, J; Yang, C; Yuan, J; Zhao, L; Zou, Y, 2021
)
0.85
"Nanomedicines have significant advantages in enhancing the oral bioavailability of drugs, but a deeper understanding of the underlying mechanisms remains to be interpreted."( Cellular Uptake and Transport Mechanism of 6-Mercaptopurine Nanomedicines for Enhanced Oral Bioavailability.
Gao, W; Jin, H; Mao, C; Mei, D; Wang, X; Zhang, Y; Zhao, L; Zou, Y, 2023
)
1.17
"6-MPNs improve the oral bioavailability through multiple pathways, including active transport, paracellular transport, lymphatic delivery and MRP4 transporter."( Cellular Uptake and Transport Mechanism of 6-Mercaptopurine Nanomedicines for Enhanced Oral Bioavailability.
Gao, W; Jin, H; Mao, C; Mei, D; Wang, X; Zhang, Y; Zhao, L; Zou, Y, 2023
)
1.17
"5 h), and implies a low bioavailability (16%)."( Enhanced Cytotoxic Activity of 6-Mercaptopurine-Loaded Solid Lipid Nanoparticles in Hepatic Cancer Treatment.
Ergin, AD; Koç, B; Oltulu, Ç, 2023
)
1.19
" wexlerae colonization reduced 6-mercaptopurine (6-MP) bioavailability by enhancing selenium-dependent xanthine dehydrogenase (sd-XDH) activity."( Commensal bacteria promote azathioprine therapy failure in inflammatory bowel disease via decreasing 6-mercaptopurine bioavailability.
Chen, H; Cui, Z; Fang, JY; Gao, Z; Hong, J; Hu, M; Huang, X; Ma, Y; Ning, L; Tong, T; Wang, Z; Xuan, B; Yan, Y; Zhao, Y; Zhou, YL, 2023
)
1.41

Dosage Studied

The mechanism of action of 6-mercaptopurine (6-MP) on an egg albumin-induced inflammatory lesion in the skin has been studied in rabbits treated with 6-MP. Dose-response relationships of skeleton variations and malformations induced by three antineoplastic drugs were evaluate.

ExcerptRelevanceReference
" The analysis of the maintaining therapy in 22 patients affected with an acute myelocytic leukemia and living for more than 6 months revealed that the interval therapy with a high dosage of cytostatic combinations in the sense of the COAP scheme is preferable compared with the daily administration of 6-mercaptopurin, in addition methotrexate twice a week."( [Problems in maintenance therapy in acute myeloid leukemias in adults].
Gürtler, R; Raderecht, C, 1975
)
0.25
" 46% complete and 12% partial remissions were obtained in 37 patients treated with cytosine arabinoside and 6-thioguanine doubling the dosage of the above mentioned regimen followed by 3 cycles of TRAP (and COAP)."( [Induction and maintenance treatment of acute myelogenous leukemia in adults by sequential use of combination chemotherapy (author's transl)].
Fülle, HH, 1977
)
0.26
" The modified chemotherapy consisted of MP at reduced dosage before and during cranial irradiation and omission of MP and MTX for 3 weeks after irradiation, during which time daily prednisolone with 2 doses of vincristine were substituted."( Analysis of treatment of childhood leukaemia. V. Advantage of reduced chemotherapy during and immediately after cranial irradiation.
Kay, HE; MacLennan, IC; Peto, J, 1977
)
0.26
"Six-mercaptopurine and its Pt, Pd and Bi complexes were used at various dosage levels to treat Dunning ascitic leukemia in rats."( Anti leukemia activity (Dunning ascitic) of 6-mercaptopurine and its metallo complexes in rats.
Lewis, RW; Skinner, SM; Swatzell, JM, 1978
)
1.07
"Six-mercaptopurine in the free form and complexed with Pt, Pd, or Bi metals was used at various dosage levels to treat L1210 leukemia in mice."( Anti leukemia activity (L1210) of 6-mercaptopurine and its metallo complexes in mice.
Lewis, RW; Skinner, SM, 1977
)
1.09
" A short course of therapy during the sensitization period (day - 1 to day 5 when the day of adjuvant injection is designated as day 0) appeared to be almost as effective as continued daily dosing (day - 1 to day 15)."( Mechanisms underlying the suppression of adjuvant-induced arthritis by 6-mercaptopurine.
Chang, YH, 1977
)
0.49
" High dosage immunosuppressive chemotherapy caused a marked reduction in serum IgM."( Patterned relationships between IgM and blast cells in peripheral blood in a child with acute leukemia.
Parker, JE; Rockerbie, RA, 1976
)
0.26
" Maintenance chemotherapy in both trials used a similar total dosage of these drugs but the timing of their administration was different in the two schedules."( Analysis of treatment in childhood leukaemia. II. Timing and the toxicity of combined 6-mercaptopurine and methotrexate maintenance therapy.
Festenstein, M; Kay, HE; MacLennan, IC; Smith, PG, 1976
)
0.48
" The kinetics of the monocyte also changes under the low dosage of azathioprine."( The effect of azathioprine (Imuran) on the cell cycle of promonocytes and the production of monocytes in the bone marrow.
Diesselhoff-Den Dulk, MM; Gassmann, AE; van Furth, R, 1975
)
0.25
" Two dosage levels were used: a high dose of 200mg/kg which is the maximum tolerated daily dose in mice, and low dose of 3 mg/kg which is about equivalent to a nontoxic, immunosuppressive, anti-inflammatory dose in man."( The effect of azathioprine (Imuran) on the kinetics of monocytes and macrophages during the normal steady state and an acute inflammatory reaction.
Gassmann, AE; van Furth, R, 1975
)
0.25
" A nearly linear dose-response relationship with a low quadratic component was observed."( In vivo cytogenetic investigations in bone marrow cells of rats, Chinese hamsters and mice treated with 6-mercaptopurine.
Frohberg, H; Schencking, MS, 1975
)
0.47
" The proportion of unchanged drug excreted after oral dosage in the morning was greater than after an evening dose (5."( Pattern of 6-mercaptopurine urinary excretion in children with acute lymphoblastic leukemia: urinary assays as a measure of drug compliance.
Greeff, MC; Macdougall, LG; McElligott, SE; Poole, JE; Ross, E, 1992
)
0.65
" Larger numbers of patients will be needed to ascertain whether specific guidelines for dosage modifications can be made on the basis of serial WBC."( Relapse in acute lymphoblastic leukemia as a function of white blood cell and absolute neutrophil counts during maintenance chemotherapy.
Blatt, J; Gula, MJ; Lucas, K,
)
0.13
" The dosing schedule, 50 mg m-2 h-1 for 48 h, was based on the results of a previous phase I trial of this approach."( A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia.
Adamson, PC; Balis, F; Gillespie, A; Kamen, BA; Poplack, DG; Ragab, AH; Steinberg, SM; Vietti, TJ; Zimm, S, 1992
)
0.55
" Rectal administration of 6-MP may be more effective than empirical oral dosing for the treatment of children with ALL, especially for patients with nausea and/or vomiting."( Rectal bioavailability of 6-mercaptopurine in children with acute lymphoblastic leukaemia: partial avoidance of "first-pass" metabolism.
Egi, S; Kato, Y; Matsushita, T; Mohri, K; Uchida, H; Yokoyama, T, 1992
)
0.58
" All patients received a daily dose of 6-mercaptopurine of 50 mg; in two pediatric patients with a poor response after 2 months, the dosage was increased to 75 mg/day."( 6-mercaptopurine therapy in selected cases of corticosteroid-dependent Crohn's disease.
Greseth, JL; Perrault, J; Tremaine, WJ, 1991
)
1.27
" Emphasis is given to the mechanism of the primary pharmacological response of the drugs to the immunocompetent cells, the grounding of their clinical use, dosage and mechanisms of possible side effects."( [Immunodepressants used in immune system pathology. I. Cyclosporin, cyclophosphane, azathioprine and mercaptopurine].
Borisov, KB; Napolov, IuK,
)
0.35
" Late intensification consisted of a 5-day course of ARA-C and one dose of ADR which was repeated until the cumulative dosage of ADR reached 465 mg/m2."( Improved prognosis of acute nonlymphocytic leukemia in children: results of the 12th-ANLL protocol of Tokyo Children's Cancer Study Group.
Bessho, F; Kigasawa, H; Nakazawa, S; Ohkawa, Y; Sugita, K; Tsuchida, M; Tsukimoto, I; Tsunematsu, Y; Yamada, K; Yamamoto, M, 1991
)
0.28
" The level of 6-thioguanine nucleotide in the patient's erythrocytes was seven times the population median value, and she had intolerable hematologic toxic effects during postremission therapy with a standard dosage of mercaptopurine (75 mg/m2 per day)."( Altered mercaptopurine metabolism, toxic effects, and dosage requirement in a thiopurine methyltransferase-deficient child with acute lymphocytic leukemia.
Chu, YQ; Evans, WE; Horner, M; Kalwinsky, D; Roberts, WM, 1991
)
0.9
"To explore the possibility that higher total dosage of 'maintenance' treatment may have contributed to the recent improvement in outlook of children in the United Kingdom with lymphoblastic leukaemia, details of the amount of 6-mercaptopurine prescribed during the first two years of treatment were studied in an unselected cohort of children diagnosed between 1973 and 1987."( Importance of 6-mercaptopurine dose in lymphoblastic leukaemia.
Hale, JP; Lilleyman, JS, 1991
)
0.81
" The dosing schedule of 50 mg/m2 per hour for 48 h was chosen to produce optimal cytotoxic concentrations of 6-MP."( A phase II trial of continuous-infusion 6-mercaptopurine for childhood solid tumors.
Adamson, PC; Balis, F; Gillespie, A; Kamen, BA; Poplack, DG; Ragab, AH; Steinberg, SM; Vietti, TJ; Zimm, S, 1990
)
0.54
" The risk for a drug interaction under these conditions is high, and the pharmacological characteristics of the anti-cancer drugs, such as steep dose-response curves, low therapeutic indices and severe toxicities, suggest that even small changes in the pharmacokinetic profile of the affected drug could significantly alter its toxicity or efficacy."( Pharmacokinetic drug interactions of commonly used anticancer drugs.
Balis, FM,
)
0.13
" The dosage of 6-MP ranged from 50 to 100 mg daily, and the pancreatitis, which was uncomplicated in all cases, occurred within 8-32 days with one exception (6."( Nature and course of pancreatitis caused by 6-mercaptopurine in the treatment of inflammatory bowel disease.
Haber, CJ; Korelitz, BI; Meltzer, SJ; Present, DH, 1986
)
0.53
" Treatment with 24-hr infusions of MTX in a dosage of 5 g/m2, as recommended in the new BFM-86/SNWLK ALL VII protocol, seems to be optimal."( [Biochemical and clinico-pharmacological aspects of antimetabolites in the treatment of leukemia].
Bökkerink, JP; de Abreu, RA; de Vaan, GA; Lippens, RJ; Schouten, TJ, 1988
)
0.27
" Side effects can be serious but are usually manageable and, to some extent, preventable by appropriate dosage schedules."( Immunosuppressant therapy of inflammatory bowel disease. Pharmacologic and clinical aspects.
Goldstein, F, 1987
)
0.27
" Studies of oral 6-MP indicate that, contrary to previous information, the bioavailability of this drug is relatively poor after oral administration, and that plasma 6-MP concentrations achieved after uniform oral dosing are highly variable."( The pharmacology of orally administered chemotherapy. A reappraisal.
Balis, FM; Poplack, DG; Zimm, S, 1986
)
0.27
"001) and had spent a longer time receiving reduced 6MP dosage in the 12 weeks before the study (U = 19."( Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabolite concentrations.
Keen, D; Lennard, L; Lilleyman, JS, 1986
)
0.73
" Children with relatively low neutrophil MTX exhibited the widest intraindividual variation of neutrophil MTX upon reexamination during continued MTX administration with the same dosage schedule."( Methotrexate in neutrophils in children with acute lymphoblastic leukemia.
Schrøder, H, 1987
)
0.27
" In vitro, the dose-response curves to MP were examined in pretransplant PHA cultures."( The impact of high lymphocyte sensitivity to glucocorticoids on kidney graft survival in patients treated with azathioprine and cyclosporine.
Ladefoged, J; Langhoff, E, 1987
)
0.27
" dosing are highly variable."( Phase I and clinical pharmacological study of mercaptopurine administered as a prolonged intravenous infusion.
Balis, F; Belasco, J; Cogliano-Shutta, N; Collins, JM; Ettinger, LJ; Holcenberg, JS; Kamen, BA; Lavi, LE; Vietti, TJ; Zimm, S, 1985
)
0.53
"One hundred and ninety-one cases of acute lymphoblastic leukaemia were entered in a trial in which, for five months, all received cytotoxic therapy with prednisolone, vincristine, mercaptopurine, L-asparaginase, and methotrexate (the latter in high dosage followed by folinic acid)."( Treatment of acute lymphoblastic leukaemia. Comparison of immunotherapy (B.C.G.), intermittent methotrexate, and no therapy after a five-month intensive cytotoxic regimen ((Concord trial). Preliminary report to the Medical Research Council by the Leukaemi
, 1971
)
0.44
"The mechanism of action of 6-mercaptopurine (6-MP) on an egg albumin-induced inflammatory lesion in the skin has been studied in rabbits treated with 6-MP in a daily dosage of 18 mg/kg."( Studies on the anti-inflammatory action of 6-mercaptopurine.
Hurd, ER; Ziff, M, 1968
)
0.8
" The importance of dosage schedule for remission maintenance chemotherapy is stressed."( The management of acute leukemia.
Freireich, EJ, 1967
)
0.25
"Large dosage of 5-fluorouracil given by slow intravenous infusion has proved to be very effective in the treatment of gestational trophoblastic neoplasms."( Reevaluation of 5-fluorouracil as a single therapeutic agent for gestational trophoblastic neoplasms.
Sung, HC; Wu, PC; Yang, HY, 1984
)
0.27
" The drug was more effective than placebo in closing fistulas (31 vs 6%) and in permitting discontinuation or reduction of steroid dosage (75 vs."( Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study.
Glass, JL; Korelitz, BI; Pasternack, BS; Present, DH; Sachar, DB; Wisch, N, 1980
)
0.54
" In the absence of evidence of a dose-response curve for platinum, the lower dosage schedules that can be used with acceptable toxicity on an outpatient basis should be selected."( Chemotherapy for squamous cell carcinoma of the head and neck: a progress report.
Glick, JH; Taylor, SG; Zehngebot, LM, 1980
)
0.26
" Both indices of inflammation were also examined in groups of rats dosed with 6-mercaptopurine, the best inhibitor found so far of elevated levels of alpha 2-macroglobulin in rat serum."( Inflammation, counter irritation and rat serum acute phase alpha 2-macroglobulin levels.
Baldo, BA, 1982
)
0.49
" cytostatic antibiotic), the dosage (20% LD50 vs."( Immunosuppression by cytostatic drugs?
Duncker, D; Müller-Ruchholtz, W; Ulrichs, K; Yu, MY, 1984
)
0.27
" There was no correlation between drug dosage and length of survival, whereas the disappearance of blast cells from the peripheral blood appeared to be directly correlated with a longer survival."( Characterization and treatment of the non-lymphoblastic crisis of chronic myelogenous leukemia.
Annino, L; Mandelli, F; Mariani, G; Solinas, S, 1983
)
0.27
" at two dosage levels (2."( Effect of allopurinol on the pharmacokinetics of 6-mercaptopurine in rabbits.
Brown, DA; Day, JL; Schroeder, EC; Tterlikkis, L, 1983
)
0.52
" injection at dosage levels of 12."( Detection of dominant lethal mutation in mice after repeated low-dose administration of 6-mercaptopurine.
Moreland, FM; Sheu, CJ, 1983
)
0.49
"A dominant-lethal test of 6-mercaptopurine (Spofa, CSSR) was carried out in male mice with four intraperitoneal, two oral, and one subcutaneous dosage levels."( Dominant-lethal test of 6-mercaptopurine: dependence on dosage, duration and route of administration.
Sýkora, I, 1981
)
0.86
" This was associated with delivery of 100% of the planned dosage of vincristine, prednisone, and daunorubicin at induction."( Poor outcome of intensive chemotherapy for adult acute lymphoblastic leukemia: a possible dose effect.
Chan, LC; Chan, TK; Chiu, EK; Kwong, YL; Liang, R; Lie, A; Todd, D, 1994
)
0.29
"A direct semimicro conductometric method is described for the determination of five pharmaceutically-important thiol compounds, namely: N-acetylcysteine, captopril, D-penicillamine, 6-mercaptopurine and thioguanine, in bulk and in dosage forms."( Conductometric determination of some pharmaceutically important thiol compounds in dosage forms.
Belal, F; Eid, MM; Rizk, MS, 1993
)
0.48
" In individual patients, 6-TGN levels were relatively stable throughout the dosing interval ("within-dose-interval-CV" < 19%), even when sharp and high 6-MP peaks in plasma were observed."( Kinetics of mercaptopurine and thioguanine nucleotides in renal transplant recipients during azathioprine treatment.
Bentdal, O; Bergan, S; Endresen, L; Rugstad, HE; Stokke, O, 1994
)
0.67
" dosage and was switched to oral CSA when a clinical response was observed."( Cyclosporine and 6-mercaptopurine for active, refractory Crohn's colitis in children.
Hassall, E; Israel, DM; Mahdi, G, 1996
)
0.62
" After initial chemotherapy, he received intravenous methotrexate (total dosage 1,035 mg), intrathecal methotrexate (total dosage 221 mg), and whole brain irradiation (2,400 cGy)."( Lenńox-Gastaut syndrome associated with leukoencephalopathy.
Ikuta, H; Mitsufuji, N; Sawada, T; Yoshioka, H, 1996
)
0.29
"(1) multiagent chemotherapy is of major impact for growth and puberty; (2) 18 Gy cranial irradiation is below the critical dosage responsible for blunted growth; (3) loss in potential growth might be prevented by current CT strategies; (4) onset of puberty depends on age when antileukaemic therapy is applied."( Final height and puberty in 40 patients after antileukaemic treatment during childhood.
Aumann, V; Dörffel, W; Kluba, U; Mittler, U; Mohnike, K; Timme, J; Vorwerk, P, 1997
)
0.3
" Grossly elevated TGN concentrations were also produced at 10% standard 6MP dosage (7."( Thiopurine methyltransferase deficiency in childhood lymphoblastic leukaemia: 6-mercaptopurine dosage strategies.
Lennard, L; Lewis, IJ; Lilleyman, JS; Michelagnoli, M, 1997
)
0.52
" These studies illustrate the potential clinical benefits of elucidating the molecular basis of inherited differences in drug metabolism and disposition, and future automation of molecular diagnostics will make it feasible to more precisely select the optimal drug and dosage for individual patients."( Pharmacogenetics as a molecular basis for individualized drug therapy: the thiopurine S-methyltransferase paradigm.
Evans, WE; Krynetski, EY, 1999
)
0.3
" Corticosteroid dosing at a level >7."( Risk factors for low bone mineral density in children and young adults with Crohn's disease.
Jawad, AF; Piccoli, DA; Semeao, EJ; Stallings, VA; Stouffer, NO; Zemel, BS, 1999
)
0.3
" Rats were treated with saline or one of three genotoxic agents (6-mercaptopurine, ethyl methanesulfonate or propane sultone) in an acute dosing protocol."( Enumeration of micronucleated reticulocytes in rat peripheral blood: a flow cytometric study.
Dertinger, SD; Hall, NE; Tometsko, CR; Torous, DK, 2000
)
0.54
" However, TPMT-deficient patients can be successfully treated with a 10- to 15-fold lower dosage of these medications."( Genetic polymorphism of thiopurine methyltransferase and its clinical relevance for childhood acute lymphoblastic leukemia.
Evans, WE; Krynetski, EY; McLeod, HL; Relling, MV, 2000
)
0.31
"To perform a dosing equivalency analysis and comparison of clinical efficacy in 82 patients with inflammatory bowel disease on long-term (> 2 months) therapy with either branded azathioprine (Imuran) (n=26), generic azathioprine (n=38), or 6-mercaptopurine (n=18), based on the measurement of erythrocyte 6-thioguanine metabolite levels."( Enhanced bioavailability of azathioprine compared to 6-mercaptopurine therapy in inflammatory bowel disease: correlation with treatment efficacy.
Bayless, TM; Cuffari, C; Hunt, S, 2000
)
0.74
" Prednisone dosage adjustments were based on a defined schedule determined by the change in a subject's disease activity score, and steroid administration was discontinued as remission was achieved."( A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease.
Daum, F; Grancher, K; Kohn, N; Lesser, M; Markowitz, J, 2000
)
0.61
"1 mg/kg/dose given twice a day, and the dosage was adjusted to achieve blood levels between 10 and 15 ng/mL."( Oral tacrolimus treatment of severe colitis in children.
Balint, JP; Bousvaros, A; Daum, F; Day, AS; Ferry, GD; Freeman, KB; Griffiths, AM; Kirschner, BS; Leichtner, AM; Parker-Hartigan, L; Werlin, SL; Zurakowski, D, 2000
)
0.31
" Nevertheless, beside the use of RBC 6TGN determination to confirm compliance to therapy, this dosage could be useful in non-responding patients, allowing, in absence of leukopenia, to increase the dose of AZA/6-MP safely."( Therapeutic drug monitoring of azathioprine and 6-mercaptopurine metabolites in Crohn disease.
Belaiche, J; Desager, JP; Horsmans, Y; Louis, E, 2001
)
0.56
" Before thiopurine dosage adjustments, TPMT-deficient patients experienced more frequent hospitalization, more platelet transfusions, and more missed doses of chemotherapy."( Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
Bomgaars, L; Coutre, S; Evans, WE; Holdsworth, M; Hon, YY; Janco, R; Kalwinsky, D; Keller, F; Khatib, Z; Kornegay, N; Krynetski, EY; Margolin, J; Murray, J; Quinn, J; Ravindranath, Y; Relling, MV; Ritchey, K; Roberts, W; Rogers, ZR; Schiff, D; Steuber, C; Tucci, F, 2001
)
0.52
" However, with appropriate dosage adjustments, TPMT-deficient and heterozygous patients can be treated with thiopurines, without acute dose-limiting toxicity."( Preponderance of thiopurine S-methyltransferase deficiency and heterozygosity among patients intolerant to mercaptopurine or azathioprine.
Bomgaars, L; Coutre, S; Evans, WE; Holdsworth, M; Hon, YY; Janco, R; Kalwinsky, D; Keller, F; Khatib, Z; Kornegay, N; Krynetski, EY; Margolin, J; Murray, J; Quinn, J; Ravindranath, Y; Relling, MV; Ritchey, K; Roberts, W; Rogers, ZR; Schiff, D; Steuber, C; Tucci, F, 2001
)
0.52
" CNS relapse and neurotoxicity in patients with acute lymphoblastic leukaemia, especially younger children, may be reduced by using age-related dosing of intrathecal MTX and Ara-C."( Intrathecal chemotherapy with antineoplastic agents in children.
Biagi, E; Conter, V; Lazzareschi, I; Milani, M; Riccardi, R; Ruggiero, A; Sparano, P, 2001
)
0.31
" dosage form would eliminate this problem."( Comparative pharmacokinetics of oral 6-mercaptopurine and intravenous 6-mercaptopurine riboside in children.
Mawatari, H; Nishimura, S; Sakura, N; Ueda, K; Unei, K, 2001
)
0.58
"This sensitive and reproducible HPLC assay for determination of TPMT activity in RBC clinical studies has been designed to optimize dosage regimens of thiopurine drugs."( Thiopurine S-methyltransferase activity in Japanese subjects: metabolic activity of 6-mercaptopurine 6-methylation in different TPMT genotypes.
Higashi, K; Iga, T; Kitamura, K; Kubota, T; Nakahara, K; Nishida, A; Yamada, Y, 2002
)
0.54
" During delayed intensification, all patients received a dexamethasone dosage of 10 mg/m(2)/d for 21 days, with taper."( Dexamethasone versus prednisone and daily oral versus weekly intravenous mercaptopurine for patients with standard-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group.
Bostrom, BC; Erdmann, GR; Gaynon, PS; Gold, S; Heerema, NA; Hutchinson, RJ; Johnston, K; La, MK; Provisor, AJ; Sather, HN; Sensel, MR; Trigg, ME, 2003
)
0.55
" An increased warfarin dosage was required for a patient receiving 12-week cycles of mercaptopurine for acute promyelocytic leukemia."( Diminished anticoagulant effects of warfarin with concomitant mercaptopurine therapy.
Martin, LA; Mehta, SD, 2003
)
0.78
" Pharmacogenomics is the study of inherited differences in interindividual drug disposition and effects, with the goal of selecting the optimal drug therapy and dosage for each patient."( Cancer pharmacogenomics: current and future applications.
McLeod, HL; Watters, JW, 2003
)
0.32
" Prednisone dosage was reduced from a mean of 19."( Immunomodulators and "on demand" therapy with infliximab in Crohn's disease: clinical experience with 400 infusions.
France, R; Kinney, T; Kozarek, R; Patterson, D; Rawlins, M, 2003
)
0.32
" The reduction of 6MP dosage during HDM can significantly reduce the risk of severe myelotoxicity and prevent treatment interruptions."( Dose reduction of coadministered 6-mercaptopurine decreases myelotoxicity following high-dose methotrexate in childhood leukemia.
Nygaard, U; Schmiegelow, K, 2003
)
0.6
" Pharmacogenomics aims to elucidate further the inherited nature of interindividual differences in drug disposition and effects, with the ultimate goal of providing a stronger scientific basis for selecting the optimal drug therapy and dosage for each patient."( Cancer pharmacogenomics: SNPs, chips, and the individual patient.
McLeod, HL; Yu, J, 2003
)
0.32
" Traditional dosing strategies for initiation of thiopurines are often based on weight or empirically chosen."( Optimizing immunomodulator therapy for inflammatory bowel disease.
Dubinsky, MC, 2003
)
0.32
" Before dosage adjustments for thiopurine, the hematologic toxicity and hepatotoxicity in TPMT heterozygous individuals occurred more frequently than in homozygous."( [Relationship between single nucleotide polymorphisms in thiopurine methyltransferase gene and tolerance to thiopurines in acute leukemia].
Hu, YM; Li, ZG; Ma, XL; Wu, MY; Zhu, P, 2003
)
0.32
" Oral steroid dosage had slowly been tapered over 1 month."( Pulmonary involvement in Crohn's disease report of a case and review of the literature.
Asahi, H; Inoue, Y; Irinoda, T; Omori, H; Saito, K, 2004
)
0.32
" A rational therapeutic strategy for thiopurine drug use is to first determine TPMT phenotype/genotype and then to adjust the dosage on an individual basis."( Analytic aspects of monitoring therapy with thiopurine medications.
Armstrong, VW; Oellerich, M; Shipkova, M; von Ahsen, N, 2004
)
0.32
"Daily dosing of mercaptopurine resulted in higher mean red cell methylated mercaptopurine metabolites when compared to split (twice a day dosing)."( A comparison of red blood cell thiopurine metabolites in children with acute lymphoblastic leukemia who received oral mercaptopurine twice daily or once daily: a Pediatric Oncology Group study (now The Children's Oncology Group).
Bell, BA; Bostrom, B; Brockway, GN; Camitta, BM; Erdmann, G; Shuster, JJ; Sterikoff, S, 2004
)
0.88
"In our experience 6-MP is relatively safe and appears to be as effective at a lower dosage (0."( The ten-year single-center experience with 6-mercaptopurine in the treatment of inflammatory bowel disease.
Das, KM; Glazier, KD; Griffel, LH; Palance, AL, 2005
)
0.59
" This review provides the latest information for clinicians on efficacy, side-effects, dosing and monitoring of these medications for treatment of inflammatory bowel disease."( Review article: monitoring of immunomodulators in inflammatory bowel disease.
Aberra, FN; Lichtenstein, GR, 2005
)
0.33
" Dosage was split with 18 mg given at breakfast and 18 mg zinc with supper."( Treatment of acute lymphocytic leukemia using zinc adjuvant with chemotherapy and radiation--a case history and hypothesis.
Eby, GA, 2005
)
0.33
" In ten cases the reported dosage of drugs was not that which was prescribed."( [Evaluation of compliance through specific interviews: a prospective study of 73 children with acute lymphoblastic leukemia].
de Mattos Arruda, L; de Oliveira, BM; Romanha, AJ; Viana, MB; Ybarra, MI,
)
0.13
" AZA dose selection based on pharmacogenetic testing of TPMT and metabolite monitoring (MM) may offer a safety and efficacy advantage over traditional dosing strategies."( A cost-effectiveness analysis of alternative disease management strategies in patients with Crohn's disease treated with azathioprine or 6-mercaptopurine.
Chiou, CF; Dubinsky, MC; Ofman, J; Reyes, E; Sandborn, WJ; Wade, S, 2005
)
0.53
"61); among the 34 responders, the median dosage of the drug required to obtain remission was lower for mutated than for wild type patients (1."( TPMT genotype and the use of thiopurines in paediatric inflammatory bowel disease.
Barabino, A; Bartoli, F; Decorti, G; Fezzi, M; Fontana, M; Giraldi, T; Lionetti, P; Malusà, N; Martelossi, S; Stocco, G; Ventura, A, 2005
)
0.33
"To evaluate pharmacokinetics and tolerance after initiation of thiopurine treatment with a fixed dosing schedule in patients with IBD."( Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.
Almer, S; Hindorf, U; Hjortswang, H; Lindqvist, M; Peterson, C; Pousette, A; Söderkvist, P; Ström, M, 2006
)
0.33
"After initiation of thiopurine treatment using a fixed dosing schedule, no general induction of TPMT enzyme activity occurred, though TPMT gene expression decreased."( Pharmacogenetics during standardised initiation of thiopurine treatment in inflammatory bowel disease.
Almer, S; Hindorf, U; Hjortswang, H; Lindqvist, M; Peterson, C; Pousette, A; Söderkvist, P; Ström, M, 2006
)
0.33
" However, the FDA decided that evidence indicates sufficient benefit to warrant informing prescribers, pharmacists and patients of the availability of pharmacogenetic tests and their possible role in the selection and dosing of these anticancer agents."( TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Maitland, ML; Ratain, MJ; Vasisht, K, 2006
)
0.33
" All errors were due to incorrect dosing or failure to administer an indicated medication."( Oral outpatient chemotherapy medication errors in children with acute lymphoblastic leukemia.
Geyer, LJ; Hawkins, DS; Taylor, JA; Winter, L, 2006
)
0.33
" Randomized trials comparing the routine strategy of AZA/6-MP dosing (based exclusively on the patient's weight) versus individualized monitoring (based on quantification of TPMP activity and/or thiopurine metabolites) are required before definitive conclusions on the most effective alternative can be drawn."( [Monitoring of thiopurine methyltransferase and thiopurine metabolites to optimize azathioprine therapy in inflammatory bowel disease].
Gisbert, JP; González-Lama, Y; Maté, J, 2006
)
0.33
" However, many physicians prescribe AZA/6MP using milligrams per kilogram (mg/kg) dosing regimens without measuring 6-TGN levels."( Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease.
Lewis, JD; Miao, CL; Morales, A; Salguti, S, 2007
)
0.65
" The use of standard mg/kg dosing regimens will result in low 6-TGN levels in most patients."( Relationship between 6-mercaptopurine dose and 6-thioguanine nucleotide levels in patients with inflammatory bowel disease.
Lewis, JD; Miao, CL; Morales, A; Salguti, S, 2007
)
0.65
" 6-TGN accumulation may result in azathioprine (AZA)-induced bone marrow myelosuppression in the course of treatment with the drug in a standard dosage regimen in patients following renal transplantation."( Thiopurine S-methyltransferase phenotype-genotype correlation in hemodialyzed patients.
Chrzanowska, M; Czekalski, S; Droździk, M; Kurzawski, M; Mazik, M; Oko, A,
)
0.13
" The addition of allopurinol enabled a reduction in mean daily prednisone dosage from 17."( Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine.
Cao, D; Friedman, S; Hanauer, SB; Hande, SA; Sparrow, MP, 2007
)
0.55
" Current knowledge of pharmacogenetically guided dosing is discussed for individualisation of thiopurine therapy, particularly to avoid severe adverse effects."( Thiopurine treatment in inflammatory bowel disease: clinical pharmacology and implication of pharmacogenetically guided dosing.
Herrlinger, KR; Klotz, U; Schaeffeler, E; Schwab, M; Teml, A, 2007
)
0.34
" IVIG was given monthly or twice monthly at the dosage of 250-400 mg/kg/dose."( Treatment of neurodegenerative CNS disease in Langerhans cell histiocytosis with a combination of intravenous immunoglobulin and chemotherapy.
Fujita, N; Fukuyama, T; Imashuku, S; Kobayashi, R; Koike, K; Minato, T; Morimoto, A; Nakayama, M; Okazaki, N', 2008
)
0.35
"Standard and adapted dosing with the provided dosing scheme led to identical 6-TGN concentrations and remission rates."( 6-thioguanine nucleotide-adapted azathioprine therapy does not lead to higher remission rates than standard therapy in chronic active crohn disease: results from a randomized, controlled, open trial.
Adler, G; Armstrong, VW; Behrens, C; Bias, P; Herfarth, H; Kruis, W; Oellerich, M; Reinshagen, M; Schütz, E; Shipkova, M; Stallmach, A; Stein, J; von Ahsen, N; von Tirpitz, C, 2007
)
0.34
" However, there are inconsistencies in dosing regimes, blood monitoring and duration of therapy."( A triangulation study of the clinician and patient experiences of the use of the immunosuppressant drugs azathioprine and 6-mercaptopurine for the management of inflammatory bowel disease.
Holbrook, K, 2007
)
0.55
" Previous studies have suggested adjusting purine analogues dosing according to TPMT activity but measurements are costly and time-consuming."( Should TPMT genotype and activity be used to monitor 6-mercaptopurine treatment in children with acute lymphoblastic leukaemia?
Andreu-Gallien, J; Azougagh, S; Fakhoury, M; Jacqz-Aigrain, E; Mahr, A; Medard, Y; Vilmer, E, 2007
)
0.59
" Although general guidelines have been suggested for weight-based dosing of thiopurines, no standard of care has been established."( How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice.
Abreu, MT; Sparrow, MP; Woodward, M; Yip, JS, 2008
)
0.64
" The majority used weight-based dosing as their target of therapy."( How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice.
Abreu, MT; Sparrow, MP; Woodward, M; Yip, JS, 2008
)
0.64
" Optimizing dosing of AZA/6-MP may improve efficacy and reduce the need to use additional therapy."( How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice.
Abreu, MT; Sparrow, MP; Woodward, M; Yip, JS, 2008
)
0.64
" Closely monitored dose escalation beyond the standard dosing range is effective and well-tolerated."( Increased dosing requirements for 6-mercaptopurine and azathioprine in inflammatory bowel disease patients six years and younger.
Baldassano, RN; Grossman, AB; Mamula, P; Noble, AJ, 2008
)
0.62
" For patients with severe ulcerative colitis (UC), steroid dosing has been clarified, and a mega-analysis of steroid outcomes and toxicities has been reported."( Optimizing drug therapy in inflammatory bowel disease.
Kornbluth, A; Swaminath, A, 2007
)
0.34
" Primary end point was the proportion of patients who required a decrease in IFX dosing interval or stopped IFX therapy."( Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
Baert, F; D'Haens, G; Magdelaine-Beuzelin, C; Noman, M; Paintaud, G; Rutgeerts, P; Ternant, D; Van Assche, G; Vermeire, S; Watier, H, 2008
)
0.35
"A similar proportion (24/40, 60% Con) and (22/40, 55% Dis) of patients needed a change in IFX dosing interval or stopped IFX therapy (11/40 Con, 9/40 Dis)."( Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial.
Baert, F; D'Haens, G; Magdelaine-Beuzelin, C; Noman, M; Paintaud, G; Rutgeerts, P; Ternant, D; Van Assche, G; Vermeire, S; Watier, H, 2008
)
0.35
" Maintenance chemotherapy with 6MP and MTX was repeated on a weekly basis, and any week during which 6MP and/or MTX dosing was withheld was counted as an interrupted episode."( Influence of MTHFR and RFC1 polymorphisms on toxicities during maintenance chemotherapy for childhood acute lymphoblastic leukemia or lymphoma.
Kosaki, K; Mori, T; Sato, R; Shimada, H; Shimasaki, N; Takahashi, T; Tanigawara, Y; Torii, C, 2008
)
0.35
" Pharmacogenetically guided dosing is recommended for safe use of thiopurines but ongoing routine laboratory monitoring remains important."( Laboratory evaluation of inflammatory bowel disease.
Bass, D; Wong, A, 2008
)
0.35
"The developed pharmacokinetic model (if successful at external validation) would offer a more rational dosing approach for 6-MP than the traditional empirical method since it combines the current practice of using body surface area in 6-MP dosing with a pharmacogenetically guided dosing based on TPMT genotype."( Population pharmacokinetic and pharmacogenetic analysis of 6-mercaptopurine in paediatric patients with acute lymphoblastic leukaemia.
Cairns, C; Collier, PS; Dempsey, S; Hawwa, AF; McCarthy, A; McElnay, JC; Millership, JS, 2008
)
0.59
" A total of 10% of patients were found to be intermediate metabolizers and the mean dosage (in mg/kg equivalent) was lower in intermediate metabolizers than extensive metabolizers."( Thiopurine methyltransferase and thiopurine metabolite testing in patients with inflammatory bowel disease who are taking thiopurine drugs.
Byron, K; Dixon, B; Dooley, M; Dronavalli, M; George, P; Gupta, A; Irving, P; Macrae, FA; Phillimore, H; Poole, S; Rose, R; Sheffield, LJ; Sparrow, M; Walmsley, T, 2009
)
0.35
" Dose-response relationships of skeleton variations and malformations induced by three antineoplastic drugs (FUDR: 5-fluoro-2'-deoxyuridine, HU: hydroxyurea and 6-MPr: 6-mercaptopurine-riboside) were evaluated."( Dose-response relationships of rat fetal skeleton variations: Relevance for risk assessment.
Chahoud, I; Paumgartten, FJ, 2009
)
0.55
" Dosing was guided by measuring thiopurine methyltransferase (for UK patients) or thioguanine nucleotides and methyl-6MP (Australian patients)."( Low-dose azathioprine or mercaptopurine in combination with allopurinol can bypass many adverse drug reactions in patients with inflammatory bowel disease.
Ansari, A; Duley, JA; Florin, TH; O'Donohue, J; Patel, N; Sanderson, J, 2010
)
0.66
" In the main dosing study, the mean RBC 6-TGN level in patients who remained in remission during the 1-year observation time (n = 151) was 322."( Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.
Abe, J; Arai, O; Hanai, H; Hosoda, Y; Iida, T; Ikeya, K; Kageoka, M; Kubota, T; Maruyama, Y; Miwa, I; Oohata, A; Takeuchi, K; Watanabe, F; Yoshirou, S, 2010
)
0.36
" However, 46% developed severe granulopenia or hepatotoxicity, the dosage had to be reduced in order to decrease the probability of severe toxicity."( [Tolerability of 6-mercaptopurine in children with acute lymphoblastic leukemia].
Duan, YL; Guo, HY; Jin, L; Ma, XL; Wang, B; Wu, MY; Xie, J; Yang, J; Zhang, DW; Zhang, L; Zhang, R; Zhang, YH; Zhu, GH, 2010
)
0.69
" Presently, the most debated issues surrounding the thiopurines include: the role of thiopurine methyltransferase and metabolite-adjusted dosing in enhancing efficacy and minimizing toxicity; the timing of thiopurine use, that is, earlier versus later use during the course of the disease; the selection of thiopurine monotherapy versus combination therapy with an anti-TNF-α; agent; and the safety profile of thiopurines."( Thiopurine therapy in inflammatory bowel disease.
Dassopoulos, T; Ha, C, 2010
)
0.36
" Pharmacogenomic advances and increased knowledge of their metabolism are allowing dosage optimization."( Optimizing thiopurine therapy in inflammatory bowel disease.
Chevaux, JB; Peyrin-Biroulet, L; Sparrow, MP, 2011
)
0.37
" In addition, topical rectal steroids were considered as effective as topical mesalazine by 48% of the GGs vs 31% of the GSIBDs, indefinite treatment with 5-ASA was prescribed by only 26% of the GGs vs 41% of the GSIBDs, and the once daily dosing of 5-ASA was generally used by 46% of the GGs vs 51% of the GSIBDs."( Adherence of gastroenterologists to European Crohn's and Colitis Organisation consensus on ulcerative colitis: a real-life survey in Spain.
Gisbert, JP; Gomollón, F; Hinojosa, J; López San Román, A, 2010
)
0.36
" We provide dosing recommendations (updates at http://www."( Clinical Pharmacogenetics Implementation Consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing.
Carrillo, M; Evans, WE; Gardner, EE; Klein, TE; Pui, CH; Relling, MV; Sandborn, WJ; Schmiegelow, K; Stein, CM; Yee, SW, 2011
)
0.37
" Being able to determine the TPMT activity before starting a treatment using 6-mercaptopurine, an optimized dosage can be applied to each patient and serious toxicity appearing within thiopurine treatment will be prevented."( Detection of thiopurine methyltransferase activity in lysed red blood cells by means of lab-on-a-chip surface enhanced Raman spectroscopy (LOC-SERS).
Henkel, T; Kiehntopf, M; März, A; Mönch, B; Popp, J; Rösch, P, 2011
)
0.6
" We also explore some of the recent evidence emerging in regards to the risks of lymphoproliferative disease, dosage optimization strategies and the role of thiopurines in achieving mucosal healing in UC and ultimately changing natural history outcomes for our patients."( Thiopurine immunomodulators in ulcerative colitis: moving forward with current evidence.
La Nauze, RJ; Sparrow, MP, 2011
)
0.37
" We proposed a systematic classification scheme using FDA-approved drug labeling to assess the DILI potential of drugs, which yielded a benchmark dataset with 287 drugs representing a wide range of therapeutic categories and daily dosage amounts."( FDA-approved drug labeling for the study of drug-induced liver injury.
Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V, 2011
)
0.37
" This study shows individualized toxicity-titrated 6MP dosing during consolidation is feasible without increased risk of toxicity."( Individualized toxicity-titrated 6-mercaptopurine increments during high-dose methotrexate consolidation treatment of lower risk childhood acute lymphoblastic leukaemia. A Nordic Society of Paediatric Haematology and Oncology (NOPHO) pilot study.
Abrahamsson, J; Andersen, EW; Behrentz, M; Castor, A; Frandsen, TL; Frost, BM; Heyman, M; Lausen, B; Schmiegelow, K; Vettenranta, K; Wehner, PS, 2011
)
0.65
" Measuring thiopurine metabolites is useful for dosage adjustment in children, and for the detection of potential toxicity."( Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
Armstrong, L; Bishop, J; Galloway, P; McGrogan, P; Russell, RK; Sharif, JA, 2011
)
0.37
" In this report, we will review different approaches to administer the thiopurine medications, including the administration of 6-mercaptopurine in those unsuccessfully treated with azathioprine; co-administration of thiopurine with allopurinol; co-administration of thiopurine with anti-tumor necrosis factor α; 6-TGN administration; desensitization trials; and split dosing of 6-MP."( Optimizing 6-mercaptopurine and azathioprine therapy in the management of inflammatory bowel disease.
Bradford, K; Shih, DQ, 2011
)
0.94
" Median duration of 6-thioguanine therapy (median daily dosage 21 mg (9-24)) was 23 weeks (6-96)."( Hepatotoxicity associated with 6-methyl mercaptopurine formation during azathioprine and 6-mercaptopurine therapy does not occur on the short-term during 6-thioguanine therapy in IBD treatment.
de Boer, NK; Mulder, CJ; Seinen, ML; van Asseldonk, DP; van Bodegraven, AA, 2012
)
0.65
" 13 adverse events occurred, including 6 specific to co-therapy (3 rash, 2 abnormal liver function tests, 1 dosing error)."( Optimising outcome on thiopurines in inflammatory bowel disease by co-prescription of allopurinol.
Anderson, SH; Blaker, P; Irving, PM; Marinaki, AM; Sanderson, JD; Smith, MA, 2012
)
0.38
" The role of metabolite-adjusted dosing when initiating thiopurines is not settled."( Optimizing immunomodulators and anti-TNF agents in the therapy of Crohn disease.
Dassopoulos, T; Sninsky, CA, 2012
)
0.38
" Comparing the two treatment phases revealed that low blood counts during Consolidation with ASP resulted in more dosage reductions of 6-mercaptopurine and methotrexate."( Asparaginase-associated myelosuppression and effects on dosing of other chemotherapeutic agents in childhood acute lymphoblastic leukemia.
Gostic, WJ; Merryman, R; Neuberg, D; O'Brien, J; Sallan, SE; Silverman, LB; Stevenson, KE, 2012
)
0.58
" Prospective studies are needed to determine whether routine testing to guide dosing is of benefit."( Thiopurine metabolite measurement leads to changes in management of inflammatory bowel disease.
Andrews, JM; Asser, TL; Bampton, PA; Doogue, MP; Kennedy, NA; Mountifield, RE, 2013
)
0.39
" The patient was placed on cornstarch therapy 5 h prior to dosing with 6-MP."( Continuous glucose monitoring: a valuable monitoring tool for management of hypoglycemia during chemotherapy for acute lymphoblastic leukemia.
Aledo, A; Brar, PC; Franklin, BH; Visavachaipan, N, 2013
)
0.39
" In responders, adherence and dosing issues were identified and TGN-guided dose-reduction was possible without precipitating relapse."( The impact of introducing thioguanine nucleotide monitoring into an inflammatory bowel disease clinic.
Anderson, S; Arenas, M; Blaker, P; Escuredo, E; Irving, P; Marinaki, A; Patel, C; Sanderson, J; Smith, M, 2013
)
0.39
"To assess the levels of red blood cell thiopurine methyltransferase (TPMT) in subjects with inflammatory bowel disease (IBD) and to determine how these levels impacted thiopurine dosing and leukopenia over the first six months of therapy."( The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease.
Bernstein, CN; Chisick, L; Oleschuk, C, 2013
)
0.39
"8% were dosed with ≥2."( The utility of thiopurine methyltransferase enzyme testing in inflammatory bowel disease.
Bernstein, CN; Chisick, L; Oleschuk, C, 2013
)
0.39
"This study explored the relationship between the weight-based dosage of AZA and metabolites levels in 86 pediatric IBD patients using multilevel analysis."( Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis.
Boulieu, R; Lachaux, A; Nguyen, TM; Nguyen, TV; Vu, DH, 2013
)
0.39
"The reliable AZA dose-metabolites relationship is useful for clinicians to guide the dosing regimen to maximize clinical response and minimize side effects or to consider alternative therapies when patients have preferential production of the toxic 6-MeMPN."( Relationship between azathioprine dosage and thiopurine metabolites in pediatric IBD patients: identification of covariables using multilevel analysis.
Boulieu, R; Lachaux, A; Nguyen, TM; Nguyen, TV; Vu, DH, 2013
)
0.39
" To date, however, optimal dosing has not been established."( Low allopurinol doses are sufficient to optimize azathioprine therapy in inflammatory bowel disease patients with inadequate thiopurine metabolite concentrations.
Curkovic, I; Frei, P; Fried, M; Jetter, A; Kullak-Ublick, GA; Rentsch, KM; Rogler, G, 2013
)
0.39
" These clay based composites therefore have great potential of becoming a new dosage form of 6-MP."( Evaluation of clay/poly (L-lactide) microcomposites as anticancer drug, 6-mercaptopurine reservoir through in vitro cytotoxicity, oxidative stress markers and in vivo pharmacokinetics.
Bajaj, HC; Brahmbhatt, H; Chettiar, SS; Gosai, KA; Kevadiya, BD; Rajkumar, S, 2013
)
0.62
" Determination of TPMT activity before administration of thiopurines is thus crucial for individualized dosing in order to prevent toxicity in TPMT deficient individuals."( Comparison of three methods for measuring thiopurine methyltransferase activity in red blood cells and human leukemia cells.
Appell, ML; Fotoohi, A; Karim, H, 2013
)
0.39
" Each patient had a dosage of azathioprine metabolites."( [Is there any interest to dose the azathioprine's metabolites during inflammatory bowel diseases?].
Ben Mustapha, N; Boubaker, J; Bouissorra, H; Fékih, M; Ferchichi, H; Filali, A; Klouz, A; Lakhal, M; Melaouhia, S,
)
0.13
" It is recommended that virtually all children with UC must be treated with some maintenance therapy and 5-ASA requirement and dosing are often higher in children."( Differences in the management of pediatric and adult onset ulcerative colitis--lessons from the joint ECCO and ESPGHAN consensus guidelines for the management of pediatric ulcerative colitis.
Ruemmele, FM; Turner, D, 2014
)
0.4
" Both were then switched to twice daily 6-MP dosing with one having a decrease in 6MMP and hypoglycemic symptoms."( The association between fasting hypoglycemia and methylated mercaptopurine metabolites in children with acute lymphoblastic leukemia.
Bostrom, B; Gandrud, L; Melachuri, S, 2014
)
0.64
" 6-MP undergoes very extensive intestinal and hepatic metabolism following oral dosing due to the activity of xanthine oxidase leading to very low and highly variable bioavailability and methotrexate has been demonstrated as an inhibitor of xanthine oxidase."( Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 2: 6-mercaptopurine and its interaction with methotrexate.
Aarons, L; Ogungbenro, K, 2014
)
0.64
" Conventional weight based dosing of thiopurines in IBD leads to intolerance or inefficacy in many patients."( The role of thiopurine metabolite monitoring in inflammatory bowel disease.
Beswick, L; Friedman, AB; Sparrow, MP, 2014
)
0.4
" We also analyzed a subgroup of 40 patients who completed the maintenance phase of ALL treatment, and we found that patients carrying a TPMT gene variant allele required a significantly lower median cumulative dosage and median daily dosage of 6-MP than patients carrying wild type alleles."( Prevalence of TPMT and ITPA gene polymorphisms and effect on mercaptopurine dosage in Chilean children with acute lymphoblastic leukemia.
Canales, C; Farfan, MJ; Kopp, K; Morales, J; Salas, C; Santolaya, ME; Silva, F; Torres, JP; Villarroel, M, 2014
)
0.64
" Ongoing research address the applicability of drug metabolite measurements for dose adjustments, extensive host genome profiling to understand diversity in treatment efficacy and toxicity, and alternative thiopurine dosing regimens to improve therapy for the individual patient."( Mercaptopurine/Methotrexate maintenance therapy of childhood acute lymphoblastic leukemia: clinical facts and fiction.
Frandsen, TL; Nersting, J; Nielsen, SN; Schmiegelow, K, 2014
)
1.85
" Variation in thiopurine dosing and metabolite measurement was found among practitioners."( Routine use of thiopurines in maintaining remission in pediatric Crohn's disease.
Baldassano, RN; Boyle, BM; Colletti, RB; Crandall, WV; Kappelman, MD; Milov, DE, 2014
)
0.4
" Thirteen documents provided dosing recommendations based on TPMT status."( Testing for thiopurine methyltransferase status for safe and effective thiopurine administration: a systematic review of clinical guidance documents.
Burnett, HF; Chandranipapongse, W; Ito, S; Madadi, P; Tanoshima, R; Ungar, WJ, 2014
)
0.4
" Of the dosing strategies reviewed, we found evidence for monitoring thiopurine metabolite level, use of allopurinol with thiopurine, use of mesalamine with thiopurine, combination therapy with thiopurine and anti-tumor necrosis factor agents, and split dosing of AZA or 6-MP to optimize thiopurine therapy and minimize adverse effects in IBD."( Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
Amin, J; Huang, B; Shih, DQ; Yoon, J, 2015
)
0.69
"Based on the currently available literature, various dosing strategies to improve therapeutic response and reduce adverse reactions can be considered, including use of allopurinol with thiopurine, use of mesalamine with thiopurine, combination therapy with thiopurine and anti-tumor necrosis factor agents, and split dosing of thiopurine."( Update 2014: advances to optimize 6-mercaptopurine and azathioprine to reduce toxicity and improve efficacy in the management of IBD.
Amin, J; Huang, B; Shih, DQ; Yoon, J, 2015
)
0.69
"Using linear mixed models, we explored myelo- and hepatotoxicity in relation to 6MP dosage and TPMT phenotype following 1,749 HD-MTX courses to 411 children with acute lymphoblastic leukemia on maintenance therapy."( Myelotoxicity after high-dose methotrexate in childhood acute leukemia is influenced by 6-mercaptopurine dosing but not by intermediate thiopurine methyltransferase activity.
Abrahamsson, J; Bechensteen, AG; Frandsen, TL; Harila-Saari, A; Heldrup, J; Jonsson, OG; Lausen, B; Levinsen, M; Nygaard, U; Rosthøj, S; Schmiegelow, K; Weinshilboum, RM, 2015
)
0.64
" These compounds, 4-MP-PTOX and 4-TG-PTOX, reduce the dosage and greatly improve the therapeutic effect for microtubule damage in cancer cells."( Tubulin structure-based drug design for the development of novel 4β-sulfur-substituted podophyllum tubulin inhibitors with anti-tumor activity.
Bai, JK; Chen, T; Li, HM; Tang, YJ; Zhao, W, 2015
)
0.42
" The model and the control approach can be utilized in the clinical setting to individualize 6-MP dosing based on the patient's ability to metabolize the drug instead of the traditional standard-dose-for-all approach."( Model-Based Individualized Treatment of Chemotherapeutics: Bayesian Population Modeling and Dose Optimization.
Hannemann, R; Jayachandran, D; Laínez-Aguirre, J; Ramkrishna, D; Reklaitis, G; Rundell, A; Vik, T, 2015
)
0.42
" Tacrolimus dosage was 2 mg/day (median)."( Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy.
Adams, DH; Füssel, K; Hirschfield, GM; Hodson, J; Lohse, AW; Mann, J; Oo, YH; Schramm, C; Than, NN; Weiler-Normann, C; Wiegard, C, 2016
)
0.43
" Weight-based dosing did not improve rates of therapeutic TGN levels (under-dosed 31."( Thiopurine metabolite testing in inflammatory bowel disease.
Bell, S; Brown, S; Connell, W; Cunningham, G; Goldberg, R; Kamm, MA; Lust, M; Marsh, P; Moore, G; Schulberg, J, 2016
)
0.43
" Weight-based dosing did not increase rates of therapeutic levels but was associated with increased 6MMP shunting."( Thiopurine metabolite testing in inflammatory bowel disease.
Bell, S; Brown, S; Connell, W; Cunningham, G; Goldberg, R; Kamm, MA; Lust, M; Marsh, P; Moore, G; Schulberg, J, 2016
)
0.43
" The activity in these enzymes correlates with the genetic polymorphism of the TPMT and ITPA genes, respectively, which determines an individual reaction and dosing of thiopurines."( A Simple Method for TPMT and ITPA Genotyping Using Multiplex HRMA for Patients Treated with Thiopurine Drugs.
Bartkowiak-Kaczmarek, A; Borun, P; Dobrowolska, A; Kurzawski, M; Lipinski, D; Plawski, A; Skrzypczak-Zielinska, M; Slomski, R; Walczak, M; Waszak, M; Zakerska-Banaszak, O, 2016
)
0.43
" Thiopurines are used in the treatment of Crohn's disease (CD) and thiopurine S-methyltransferase (TPMT) activity can guide thiopurine dosing to avoid adverse events."( Thiopurines in the Management of Crohn's Disease: Safety and Efficacy Profile in Patients with Normal TPMT Activity-A Retrospective Study.
Afif, W; AlYafi, M; Benmassaoud, A; Bessissow, T; Bitton, A; Theoret, Y; Xie, X, 2016
)
0.43
"Individualized therapy is a recent approach aiming to specify dosage regimen for each patient according to its genetic state."( Development and validation of LC-MS/MS assay for the simultaneous determination of methotrexate, 6-mercaptopurine and its active metabolite 6-thioguanine in plasma of children with acute lymphoblastic leukemia: Correlation with genetic polymorphism.
Abdelaziz, DH; Al-Ghobashy, MA; Attia, AS; El-Sayed, MH; Elhosseiny, NM; Hassan, SA; Sabry, NA, 2016
)
0.65
"6%), yet patients with MP were relatively higher dosed compared with those on AZA."( More Dose-dependent Side Effects with Mercaptopurine over Azathioprine in IBD Treatment Due to Relatively Higher Dosing.
Broekman, MMTJ; Coenen, MJH; de Jong, DJ; Derijks, LJJ; Guchelaar, HJ; Hooymans, PM; Klungel, OH; Scheffer, H; van Marrewijk, CJ; Verbeek, ALM; Wanten, GJA; Wong, DR, 2017
)
0.73
" Drug metabolism and pharmacogenetics have increasingly played a role in determining dosing and dose optimisation and we review the rationale for this in both thiopurine monotherapy and in combination with biologic agents."( Optimising use of thiopurines in inflammatory bowel disease.
Dart, RJ; Irving, PM, 2017
)
0.46
" As such, 6-MP must be dosed so that patients with 1 or 2 inactive thiopurine S-methyltransferase alleles will not incur an increased risk for myelosuppression or other toxicities."( The Relationship of Genetics, Nursing Practice, and Informatics Tools in 6-Mercaptopurine Dosing in Pediatric Oncology [Formula: see text].
Haylett, WJ,
)
0.36
" Early use of adequately dosed thiopurines (≥3 months before starting ADA) was associated with improved clinical outcomes."( Thiopurines Dosed to a Therapeutic 6-Thioguanine Level in Combination with Adalimumab Are More Effective Than Subtherapeutic Thiopurine-based Combination Therapy or Adalimumab Monotherapy During Induction and Maintenance in Patients with Long-standing Cro
Blaker, PA; Goel, R; Irving, PM; Kariyawasam, VC; Patel, KV; Sanderson, JD; Ward, MG, 2017
)
0.46
" To assess if IFX influenced thiopurine metabolites, eight patients who had responded to 12 weeks of intensified IFX at a constant thiopurine dosing were included."( A Role for Thiopurine Metabolites in the Synergism Between Thiopurines and Infliximab in Inflammatory Bowel Disease.
Ainsworth, MA; Brynskov, J; Mogensen, DV; Nersting, J; Schmiegelow, K; Steenholdt, C, 2018
)
0.48
" Dosing history, concomitant therapy, and comorbidity data were assessed."( Late-onset Rise of 6-MMP Metabolites in IBD Patients on Azathioprine or Mercaptopurine.
Barclay, ML; Mulder, CJ; Munnig-Schmidt, E; Zhang, M, 2018
)
0.71
" We aimed to describe our center's experience with thiopurine optimization through the use of reduced thiopurine dosing in combination with allopurinol upon hepatotoxicity, drug metabolite levels, and clinical outcomes in children with IBD."( Thiopurine Optimization Through Combination With Allopurinol in Children With Inflammatory Bowel Diseases.
Boyle, B; Bricker, J; Crandall, W; Dotson, JL; Kim, SC; Maltz, R; Serpico, MR, 2018
)
0.48
" We aimed to compare 6-month outcomes between standard and optimized dosing strategies and define long-term predictors of thiopurine durability."( The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Dubinsky, MC; Norris, E; Spencer, E; Williams, C, 2019
)
0.51
"5 mg/kg/day (group 2) and further subgrouped depending on whether dosing was optimized to achieve 6-TGN >235 pmol/8 × 108 RBC."( The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Dubinsky, MC; Norris, E; Spencer, E; Williams, C, 2019
)
0.51
" Both dosing strategies led to similar initial 6-TGN levels (group 1 = median 209 [IQR: 155-272] with 25% of patients >235; group 2 = 196 [139-274] with 29% >235)."( The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Dubinsky, MC; Norris, E; Spencer, E; Williams, C, 2019
)
0.51
"Steroid-free clinical remission and 6-TGN levels at 6 months were no different between a standardized, fixed dosing strategy and a metabolite-driven, optimized dosing strategy."( The Impact of Thiopurine Metabolite Monitoring on the Durability of Thiopurine Monotherapy in Pediatric IBD.
Dubinsky, MC; Norris, E; Spencer, E; Williams, C, 2019
)
0.51
" Nevertheless, prospective studies of genotype-guided dosing of thiopurines are warranted to prove clinical benefit and cost-effectiveness of pretreatment NUDT15 gene testing across different populations."( Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis.
Canonico, PL; Cargnin, S; Genazzani, AA; Terrazzino, S, 2018
)
0.48
" The median duration of maternal thiopurine exposure prior to pregnancy was 24 months (range 12-72 months), and median dosage was 100 mg (range 50-175 mg)."( Thiopurine Therapy for Inflammatory Bowel Disease During Pregnancy Is Not Associated with Anemia in the Infant.
Bar-Gil Shitrit, A; Goldin, E; Grisaru-Granovsky, S; Koslowsky, B; Miskin, H; Sadeh, C, 2019
)
0.51
" Continuing standard dosing regimens after primary non-response was rarely helpful; only 14 (12·4% [95% CI 6·9-19·9]) of 113 patients entered remission by week 54."( Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study.
Ahmad, T; Bewshea, C; Bouri, S; Chanchlani, N; Cummings, JRF; Gaya, DR; Goodhand, JR; Green, HD; Hamilton, B; Hart, AL; Heap, GA; Heerasing, NM; Hendy, P; Irving, PM; Kennedy, NA; Lees, CW; Lin, S; Lindsay, J; Mansfield, JC; McDonald, TJ; McGovern, D; Nice, R; Parkes, M; Perry, MH; Russell, RK; Sebastian, S; Selinger, CP; Thomas, A; Walker, GJ, 2019
)
0.51
" We have previously shown that switching 6MP dosing from evening to morning resolved hypoglycemia by reducing 6MMP; however, the reduction of 6MMP was only transient, potentially resulting in return of hypoglycemia."( Allopurinol reverses mercaptopurine-induced hypoglycemia in patients with acute lymphoblastic leukemia.
Bostrom, B; Zhang, M, 2019
)
0.83
" We have previously shown that switching 6MP dosing from evening to morning resolved hypoglycemia by reducing 6MMP; however, the reduction of 6MMP was only transient, potentially resulting in return of hypoglycemia."( Allopurinol reverses mercaptopurine-induced hypoglycemia in patients with acute lymphoblastic leukemia.
Bostrom, B; Zhang, M, 2019
)
0.83
" Low AZA dosing was defined as 6-thioguanine levels <125 pmol/8 × 10 erythrocytes and 6-methylmercaptopurine levels <5700 pmol/8 × 10 erythrocytes."( Prediction of Thiopurine Metabolite Levels Based on Haematological and Biochemical Parameters.
Bronsky, J; Hradsky, O; Karaskova, E; Lerchova, T; Mihal, V; Potuznikova, K; Siroka, J; Spenerova, M; Urbanek, L; Velganova-Veghova, M, 2019
)
0.73
" The dosage and intensity of therapy are based on surrogate markers such as peripheral blood leukocyte and neutrophil counts."( Prediction of leukocyte counts during paediatric acute lymphoblastic leukaemia maintenance therapy.
Karppinen, S; Lohi, O; Vihola, M, 2019
)
0.51
"To describe the metabolic pathways and key factors implicated in the efficacy and toxicity of the thiopurine drugs and to indicate the opportunities to improve outcomes by monitoring and manipulating metabolic pathways, individualising dosage and strengthening the response."( Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Czaja, AJ, 2020
)
0.56
" Universal pre-treatment assessment of thiopurine methyltransferase activity and individualisation of dosage to manipulate metabolite thresholds could improve outcomes."( Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Czaja, AJ, 2020
)
0.56
"The efficacy and safety of thiopurines in autoimmune hepatitis can be improved by investigational efforts that establish monitoring strategies that allow individualisation of dosage and prediction of outcome, increase bioavailability of the active metabolites and demonstrate superiority to alternative agents."( Review article: opportunities to improve and expand thiopurine therapy for autoimmune hepatitis.
Czaja, AJ, 2020
)
0.56
" Dosing was guided by thiopurine S-methyltransferase-activity at baseline and by clinical response and toxicity at 4 months; 1 year into the study, therapeutic drug monitoring at 4 months was also considered in the decision making."( Role of Thiopurines in Pediatric Inflammatory Bowel Diseases: A Real-Life Prospective Cohort Study.
Atia, O; Beeri, R; Ben-Moshe, T; Ledder, O; Lev-Tzion, R; Meyer, EO; Rachmen, Y; Renbaum, P; Shamasneh, I; Shteyer, E; Turner, D, 2020
)
0.56
"After giving 8 healthy beagle dogs 50 mg 6-MP in different dosage forms, plasma samples collected at different time points were analyzed for pharmacokinetic evaluation."( Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs.
Han, J; Jin, S; Mei, S; Xu, J; Zhang, D; Zhao, L; Zhao, Z, 2020
)
0.82
"Two dosage forms showed the same pharmacokinetic characteristics."( Simultaneous UPLC-MS/MS Determination of 6-mercaptopurine, 6-methylmercaptopurine and 6-thioguanine in Plasma: Application to the Pharmacokinetic Evaluation of Novel Dosage forms in Beagle Dogs.
Han, J; Jin, S; Mei, S; Xu, J; Zhang, D; Zhao, L; Zhao, Z, 2020
)
0.82
"Combination therapy dosed with an optimized thiopurine was superior to infliximab monotherapy for induction of response, durability of response, and clinical outcomes in the first 6 months following induction."( Thiopurines and their optimization during infliximab induction and maintenance: A retrospective study in Crohn's disease.
Dawson, L; Gibson, PR; Kariyawasam, VC; Luber, RP; Martin, C; Munari, S; Sparrow, MP; Ward, MG, 2021
)
0.62
"Patients in maintenance were considered for allopurinol treatment who had the following features: (a) Grade ≥3 hepatotoxicity; (b) Grade ≥2 nonhepatic gastrointestinal (GI) toxicity; or (c) persistently elevated absolute neutrophil count (ANC) despite >150% protocol dosing of oral chemotherapy."( Allopurinol use during pediatric acute lymphoblastic leukemia maintenance therapy safely corrects skewed 6-mercaptopurine metabolism, improving inadequate myelosuppression and reducing gastrointestinal toxicity.
Annesley, C; Bhuiyan, M; Brown, P; Cohen, G; Cooper, S; Sison, EA, 2020
)
0.77
" Therefore, TPMT genetic variants have been used to adjust dosing for poor and intermediate metabolizers, significantly preventing adverse drug reactions."( Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Gonzalez-Covarrubias, V; Guzmán-Cruz, C; Mino-León, D; Rodríguez-Dorantes, M; Sánchez-García, S; Texis, T, 2022
)
0.72
" Dosing inferences were described according to the Clinical Pharmacogenomics Implementation Consortium."( Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Gonzalez-Covarrubias, V; Guzmán-Cruz, C; Mino-León, D; Rodríguez-Dorantes, M; Sánchez-García, S; Texis, T, 2022
)
0.72
"TPMT*3B and NUDT15 rs116855232 actionable markers showed population differences that ought to be considered as dosing inferences highlight the relevance of routine genotyping of these variants for the prescription of thiopurines in Mexican populations."( Genotyping NUDT15*3 rs1166855232 reveals higher frequency of potential adverse effects of thiopurines in Natives and Mestizos from Mexico.
Gonzalez-Covarrubias, V; Guzmán-Cruz, C; Mino-León, D; Rodríguez-Dorantes, M; Sánchez-García, S; Texis, T, 2022
)
0.72
" Jude Total 15 (T15, n=365) and pegaspargase in Total 16 (T16, n=524), we tallied the dose intensities for all drugs on the low-risk or standard-risk arms, analyzing 504,039 dosing records."( Comprehensive analysis of dose intensity of acute lymphoblastic leukemia chemotherapy.
Cheng, C; Crews, KR; Evans, WE; Finch, ER; Gruber, TA; Inaba, H; Jeha, S; Karol, SE; Kornegay, NM; Liu, Y; Metzger, ML; Panetta, JC; Pei, D; Pui, CH; Relling, MV; Ribeiro, RC; Rubnitz, JE; Smith, CA; Yang, JJ; Yang, W, 2022
)
0.72
" The median daily dosage of TG was 20 mg/d (range 10-40 mg/d), and the median duration of TG use was 21."( Relationship Between Thiopurine S-Methyltransferase Genotype/Phenotype and 6-Thioguanine Nucleotide Levels in 316 Patients With Inflammatory Bowel Disease on 6-Thioguanine.
Anderson, S; Ansari, AR; Bayoumy, AB; Boekema, PJ; Derijks, LJJ; Loganayagam, A; Mulder, CJJ; Sanderson, JD, 2021
)
0.62
"Pharmacogenomic insights provide an opportunity to optimize medication dosing regimens and patient outcomes."( Pharmacogenomics insights into precision pediatric oncology.
Gregornik, D; Ramos, KN; Ramos, KS, 2021
)
0.62
"The cost-effectiveness of NUDT15 genetic testing-guided initial 6-mercaptopurine (6-MP) dosing in children with acute lymphoblastic leukemia (ALL) was evaluated."( NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China.
Cai, J; Huang, X; Li, N; Sun, H; Wei, X; Zhang, G; Zheng, B; Zhuang, J, 2022
)
1.24
"Genetic testing-guided initial 6-MP dosing reduced overall costs by $518."( NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China.
Cai, J; Huang, X; Li, N; Sun, H; Wei, X; Zhang, G; Zheng, B; Zhuang, J, 2022
)
1
"NUDT15 genetic testing prior to the initial administration of 6-MP in pediatric ALL patients in China is less expensive than standard dosing without genetic testing."( NUDT15 genetic testing-guided 6-mercaptopurine dosing in children with ALL likely to be cost-saving in China.
Cai, J; Huang, X; Li, N; Sun, H; Wei, X; Zhang, G; Zheng, B; Zhuang, J, 2022
)
1
" The incidence of hematotoxicity caused by this drug is quite high in Asians even using a standard low dosage regimen."( NUDT15 is a key genetic factor for prediction of hematotoxicity in pediatric patients who received a standard low dosage regimen of 6-mercaptopurine.
Chainansamit, SO; Dornsena, A; Hikino, K; Kanjanawart, S; Khaeso, K; Komvilaisak, P; Kuwatjanakul, P; Laoaroon, N; Nakkam, N; Suwannaying, K; Taketani, T; Tassaneeyakul, W; Vannaprasaht, S, 2022
)
0.92
" These findings suggest that ITPA polymorphisms could be used as predictive biomarkers for adverse effects of thiopurine drugs to eliminate intolerance in ALL patients and clarify dosing in patients with different ITPA variants."( Association of ITPA gene polymorphisms with adverse effects of AZA/6-MP administration: a systematic review and meta-analysis.
Bagos, PG; Barba, E; Braliou, GG; Kontou, PI; Michalopoulos, I, 2022
)
0.72
" A 16-year-old male with very high risk B-cell acute lymphoblastic leukemia was admitted for hyperbilirubinemia 2 months after a 6-mercaptopurine dosage increase and found to have an active SARS-CoV-2 infection."( Suspected Drug-induced Liver Injury Due to 6-Mercaptopurine With a Superimposed SARS-CoV-2 Infection in a Patient With B-ALL.
Borowicz, VM; Cablay, K; Fulton, R, 2022
)
1.19
" Only 39% of patients had appropriate dosing of thiopurines."( Proactive Metabolite Testing in Patients on Thiopurine May Yield Long-Term Clinical Benefits in Inflammatory Bowel Disease.
Andrews, JM; Bampton, P; Barnes, A; Bishara, M; Connor, S; Gounder, M; Grafton, R; Leach, P; Lynch, KD; Mountifield, R; Ng, W; Ooi, SJ; Parthasarathy, N; Sechi, A; van Langenberg, D, 2023
)
0.91
" New approaches are being developed to identify susceptibility to 6MP toxicity in order to appropriately tailor dosing schedules for at-risk patients."( Screening for mercaptopurine intolerance in ALL - target the genes or their product?
Barrett, J, 2022
)
1.08
" Participants with optimal dosing in the morning had an earlier chronotype by corrected midpoint of sleep."( Impact of Chronotherapy on 6-Mercaptopurine Metabolites in Inflammatory Bowel Disease: A Pilot Crossover Trial.
Biglin, M; Bishehsari, F; Chouhan, V; Francey, L; Hogenesch, J; Jochum, S; Keshavarzian, A; Raff, H; Shaikh, M; Swanson, GR, 2023
)
1.2
"In the first study on a potential role of chronotherapy in IBD, we found (i) morning dosing of AZA or 6-MP resulted in more optimal metabolite profiles and (ii) host chronotype could help identify one-third of patients who would benefit from evening dosing."( Impact of Chronotherapy on 6-Mercaptopurine Metabolites in Inflammatory Bowel Disease: A Pilot Crossover Trial.
Biglin, M; Bishehsari, F; Chouhan, V; Francey, L; Hogenesch, J; Jochum, S; Keshavarzian, A; Raff, H; Shaikh, M; Swanson, GR, 2023
)
1.2
" Although mercaptopurine-dose reduction reduces toxicity risk without compromising relapse rate in patients with TPMT deficiency, dosing recommendations for those with moderately reduced activity (intermediate metabolizer (IM)) are less clear and their clinical impacts have yet to be established."( Thiopurine Methyltransferase Intermediate Metabolizer Status and Thiopurine-Associated Toxicity During Maintenance Therapy in Childhood Acute Lymphoblastic Leukemia.
Cacciotti, C; Cairney, E; Kim, RB; Mikhail, M; Patel, S; Schwarz, UI; Seelisch, J; Swanston, V; Tirona, RG; Tole, S; Wilejto, M; Woldanski-Travaglini, M; Zorzi, AP, 2023
)
1.31
" The geometric mean ratios for AUC over the dosing interval and AUC from time zero to infinity were 104% and 104%, respectively, of the reference values, while the point estimate of the geometric mean ratio for peak plasma concentration was 104% of the reference value."( Bioequivalence of Two 6-Mercaptopurine Tablet Formulations in Healthy Fasting Chinese Volunteers.
Chen, J; Deng, Y; Jiang, G; Song, D; Tan, G; Tan, Z; Wang, G; Xu, X; Zhao, D, 2023
)
1.22
" However, dose-response relationships vary widely between patients and insight into the influencing factors, that would allow for improved personalized treatment management, is insufficient."( Pharmacokinetic-pharmacodynamic modeling of maintenance therapy for childhood acute lymphoblastic leukemia.
Gebhard, A; Lilienthal, P; Metzler, M; Rauh, M; Sager, S; Schmiegelow, K; Toksvang, LN; Zierk, J, 2023
)
0.91
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
antimetaboliteA substance which is structurally similar to a metabolite but which competes with it or replaces it, and so prevents or reduces its normal utilization.
anticoronaviral agentAny antiviral agent which inhibits the activity of coronaviruses.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (4)

ClassDescription
hydrateAn addition compound that contains water in weak chemical combination with another compound.
aryl thiolAn aryl thiol is a thiol in which a sulfanyl group, SH, is attached to an aryl group.
purinesA class of imidazopyrimidines that consists of purine and its substituted derivatives.
thiocarbonyl compoundAny compound containing the thiocarbonyl group, C=S.
purinesA class of imidazopyrimidines that consists of purine and its substituted derivatives.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (17)

PathwayProteinsCompounds
Metabolism14961108
Biological oxidations150276
Phase II - Conjugation of compounds73122
Methylation1338
Azathioprine Action Pathway4782
Mercaptopurine Action Pathway4780
Thioguanine Action Pathway4781
Mercaptopurine Metabolism Pathway1524
Azathioprine Metabolism Pathway03
Disease1278231
Diseases of metabolism69121
Metabolic disorders of biological oxidation enzymes647
Defective TPMT causes TPMT deficiency02
Nsp9 interactions (COVID-19 Disease Map)8330
Drug ADME6387
Azathioprine ADME1626
Purine metabolism and related disorders2353

Protein Targets (70)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASEHomo sapiens (human)Potency26.67950.003245.467312,589.2998AID2517
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency3.98110.631035.7641100.0000AID504339
thioredoxin reductaseRattus norvegicus (Norway rat)Potency79.43280.100020.879379.4328AID588453
TDP1 proteinHomo sapiens (human)Potency23.72460.000811.382244.6684AID686978; AID686979
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency8.91250.707912.194339.8107AID720542
regulator of G-protein signaling 4Homo sapiens (human)Potency79.43280.531815.435837.6858AID504845
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency35.48130.707936.904389.1251AID504333
IDH1Homo sapiens (human)Potency2.31090.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency3.98110.035520.977089.1251AID504332
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency3.98110.794321.275750.1187AID624246
importin subunit beta-1 isoform 1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
snurportin-1Homo sapiens (human)Potency125.89205.804836.130665.1308AID540263
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency1.12200.15855.287912.5893AID540303
gemininHomo sapiens (human)Potency1.15820.004611.374133.4983AID624296
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency35.71680.004023.8416100.0000AID485290; AID489007
Chain A, Beta-lactamaseEscherichia coli K-12Potency35.48130.044717.8581100.0000AID485294
Chain A, Putative fructose-1,6-bisphosphate aldolaseGiardia intestinalisPotency17.78800.140911.194039.8107AID2451; AID2787
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency6.30960.631035.7641100.0000AID504339
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency19.95260.177814.390939.8107AID2147
phosphopantetheinyl transferaseBacillus subtilisPotency39.81070.141337.9142100.0000AID1490
RAR-related orphan receptor gammaMus musculus (house mouse)Potency26.63340.006038.004119,952.5996AID1159521; AID1159523
Fumarate hydrataseHomo sapiens (human)Potency25.14970.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency17.05030.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency23.05630.000714.592883.7951AID1259369; AID1259392
AR proteinHomo sapiens (human)Potency9.08180.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743042; AID743054; AID743063
thioredoxin glutathione reductaseSchistosoma mansoniPotency15.84890.100022.9075100.0000AID485364
apical membrane antigen 1, AMA1Plasmodium falciparum 3D7Potency14.12540.707912.194339.8107AID720542
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency7.94330.011212.4002100.0000AID1030
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency7.07640.001022.650876.6163AID1224838; AID1224839; AID1224893
progesterone receptorHomo sapiens (human)Potency16.78550.000417.946075.1148AID1346795
EWS/FLI fusion proteinHomo sapiens (human)Potency2.47780.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency18.24860.000214.376460.0339AID720691; AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency4.89170.003041.611522,387.1992AID1159552; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency5.58410.000817.505159.3239AID1159527; AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency14.04030.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency53.59170.375827.485161.6524AID743217
pregnane X nuclear receptorHomo sapiens (human)Potency7.94330.005428.02631,258.9301AID1346985
estrogen nuclear receptor alphaHomo sapiens (human)Potency14.78990.000229.305416,493.5996AID1259244; AID1259248; AID743069; AID743078; AID743080; AID743091
GVesicular stomatitis virusPotency19.49710.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency30.90080.00108.379861.1304AID1645840
polyproteinZika virusPotency25.14970.00308.794948.0869AID1347053
bromodomain adjacent to zinc finger domain 2BHomo sapiens (human)Potency50.11870.707936.904389.1251AID504333
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency16.86570.023723.228263.5986AID743222
IDH1Homo sapiens (human)Potency2.59290.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency7.07950.035520.977089.1251AID504332
aryl hydrocarbon receptorHomo sapiens (human)Potency22.00820.000723.06741,258.9301AID743085; AID743122
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency6.73010.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency38.43890.001628.015177.1139AID1224843; AID1259385
Histone H2A.xCricetulus griseus (Chinese hamster)Potency110.21500.039147.5451146.8240AID1224845
hemoglobin subunit betaHomo sapiens (human)Potency4.73590.31629.086131.6228AID910; AID930
cellular tumor antigen p53 isoform aHomo sapiens (human)Potency8.97160.316212.443531.6228AID902; AID924
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency28.18380.001815.663839.8107AID894
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency11.22020.794321.275750.1187AID624246
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency6.35850.000627.21521,122.0200AID743202; AID743219
urokinase-type plasminogen activator precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
plasminogen precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
urokinase plasminogen activator surface receptor precursorMus musculus (house mouse)Potency2.81840.15855.287912.5893AID540303
survival motor neuron protein isoform dHomo sapiens (human)Potency4.46680.125912.234435.4813AID1458
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency39.81070.251215.843239.8107AID504327
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency7.70090.001557.789015,848.9004AID1259244
Interferon betaHomo sapiens (human)Potency19.49710.00339.158239.8107AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
Cellular tumor antigen p53Homo sapiens (human)Potency7.70180.002319.595674.0614AID651631; AID720552
Integrin beta-3Homo sapiens (human)Potency10.00000.316211.415731.6228AID924
Integrin alpha-IIbHomo sapiens (human)Potency10.00000.316211.415731.6228AID924
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency7.70090.001551.739315,848.9004AID1259244
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency2.37100.011917.942071.5630AID651632
Ataxin-2Homo sapiens (human)Potency2.37100.011912.222168.7989AID651632
cytochrome P450 2C9, partialHomo sapiens (human)Potency19.49710.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
UDP-glucose 6-dehydrogenaseRattus norvegicus (Norway rat)Ki288.00007.00007.00007.0000AID1520171
Bile salt export pumpHomo sapiens (human)IC50 (µMol)133.00000.11007.190310.0000AID1473738
UDP-glucose 6-dehydrogenaseStreptococcus pyogenesKi199.50005.00006.00007.0000AID1575592; AID1575633
Prostaglandin G/H synthase 1Homo sapiens (human)IC50 (µMol)16.24200.00021.557410.0000AID625243
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 22 member 8Mus musculus (house mouse)Km4.01000.05392.40655.5000AID681386
Hypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)Km2.07501.15002.75635.9000AID274549; AID274562
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (303)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
T cell mediated cytotoxicityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
response to amphetamineHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine nucleotide biosynthetic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
purine ribonucleoside salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
grooming behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
locomotory behaviorHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
striatum developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cerebral cortex neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
central nervous system neuron developmentHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
AMP salvageHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
positive regulation of dopamine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
GMP catabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
IMP metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
adenine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine metabolic processHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
lymphocyte proliferationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dendrite morphogenesisHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein homotetramerizationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
dopaminergic neuron differentiationHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
negative regulation of low-density lipoprotein receptor activityIntegrin beta-3Homo sapiens (human)
positive regulation of protein phosphorylationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
cell-substrate junction assemblyIntegrin beta-3Homo sapiens (human)
cell adhesionIntegrin beta-3Homo sapiens (human)
cell-matrix adhesionIntegrin beta-3Homo sapiens (human)
integrin-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
embryo implantationIntegrin beta-3Homo sapiens (human)
blood coagulationIntegrin beta-3Homo sapiens (human)
positive regulation of endothelial cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of gene expressionIntegrin beta-3Homo sapiens (human)
negative regulation of macrophage derived foam cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast migrationIntegrin beta-3Homo sapiens (human)
negative regulation of lipid storageIntegrin beta-3Homo sapiens (human)
response to activityIntegrin beta-3Homo sapiens (human)
smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell migrationIntegrin beta-3Homo sapiens (human)
platelet activationIntegrin beta-3Homo sapiens (human)
positive regulation of vascular endothelial growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
cell-substrate adhesionIntegrin beta-3Homo sapiens (human)
activation of protein kinase activityIntegrin beta-3Homo sapiens (human)
negative regulation of lipid transportIntegrin beta-3Homo sapiens (human)
regulation of protein localizationIntegrin beta-3Homo sapiens (human)
regulation of actin cytoskeleton organizationIntegrin beta-3Homo sapiens (human)
cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of cell adhesion mediated by integrinIntegrin beta-3Homo sapiens (human)
positive regulation of osteoblast proliferationIntegrin beta-3Homo sapiens (human)
heterotypic cell-cell adhesionIntegrin beta-3Homo sapiens (human)
substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
tube developmentIntegrin beta-3Homo sapiens (human)
wound healing, spreading of epidermal cellsIntegrin beta-3Homo sapiens (human)
cellular response to platelet-derived growth factor stimulusIntegrin beta-3Homo sapiens (human)
apolipoprotein A-I-mediated signaling pathwayIntegrin beta-3Homo sapiens (human)
wound healingIntegrin beta-3Homo sapiens (human)
apoptotic cell clearanceIntegrin beta-3Homo sapiens (human)
regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
positive regulation of angiogenesisIntegrin beta-3Homo sapiens (human)
positive regulation of bone resorptionIntegrin beta-3Homo sapiens (human)
symbiont entry into host cellIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
positive regulation of fibroblast proliferationIntegrin beta-3Homo sapiens (human)
mesodermal cell differentiationIntegrin beta-3Homo sapiens (human)
positive regulation of smooth muscle cell proliferationIntegrin beta-3Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationIntegrin beta-3Homo sapiens (human)
negative regulation of lipoprotein metabolic processIntegrin beta-3Homo sapiens (human)
negative chemotaxisIntegrin beta-3Homo sapiens (human)
regulation of release of sequestered calcium ion into cytosolIntegrin beta-3Homo sapiens (human)
regulation of serotonin uptakeIntegrin beta-3Homo sapiens (human)
angiogenesis involved in wound healingIntegrin beta-3Homo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeIntegrin beta-3Homo sapiens (human)
platelet aggregationIntegrin beta-3Homo sapiens (human)
cellular response to mechanical stimulusIntegrin beta-3Homo sapiens (human)
cellular response to xenobiotic stimulusIntegrin beta-3Homo sapiens (human)
positive regulation of glomerular mesangial cell proliferationIntegrin beta-3Homo sapiens (human)
blood coagulation, fibrin clot formationIntegrin beta-3Homo sapiens (human)
maintenance of postsynaptic specialization structureIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationIntegrin beta-3Homo sapiens (human)
regulation of postsynaptic neurotransmitter receptor diffusion trappingIntegrin beta-3Homo sapiens (human)
positive regulation of substrate adhesion-dependent cell spreadingIntegrin beta-3Homo sapiens (human)
positive regulation of adenylate cyclase-inhibiting opioid receptor signaling pathwayIntegrin beta-3Homo sapiens (human)
regulation of trophoblast cell migrationIntegrin beta-3Homo sapiens (human)
regulation of extracellular matrix organizationIntegrin beta-3Homo sapiens (human)
cellular response to insulin-like growth factor stimulusIntegrin beta-3Homo sapiens (human)
negative regulation of endothelial cell apoptotic processIntegrin beta-3Homo sapiens (human)
positive regulation of T cell migrationIntegrin beta-3Homo sapiens (human)
cell migrationIntegrin beta-3Homo sapiens (human)
positive regulation of leukocyte migrationIntegrin alpha-IIbHomo sapiens (human)
cell-matrix adhesionIntegrin alpha-IIbHomo sapiens (human)
integrin-mediated signaling pathwayIntegrin alpha-IIbHomo sapiens (human)
angiogenesisIntegrin alpha-IIbHomo sapiens (human)
cell-cell adhesionIntegrin alpha-IIbHomo sapiens (human)
cell adhesion mediated by integrinIntegrin alpha-IIbHomo sapiens (human)
prostaglandin biosynthetic processProstaglandin G/H synthase 1Homo sapiens (human)
response to oxidative stressProstaglandin G/H synthase 1Homo sapiens (human)
regulation of blood pressureProstaglandin G/H synthase 1Homo sapiens (human)
cyclooxygenase pathwayProstaglandin G/H synthase 1Homo sapiens (human)
regulation of cell population proliferationProstaglandin G/H synthase 1Homo sapiens (human)
cellular oxidant detoxificationProstaglandin G/H synthase 1Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (86)

Processvia Protein(s)Taxonomy
organic anion transmembrane transporter activitySolute carrier family 22 member 8Mus musculus (house mouse)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
nucleotide bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
magnesium ion bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
hypoxanthine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
identical protein bindingHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
guanine phosphoribosyltransferase activityHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
fibroblast growth factor bindingIntegrin beta-3Homo sapiens (human)
C-X3-C chemokine bindingIntegrin beta-3Homo sapiens (human)
insulin-like growth factor I bindingIntegrin beta-3Homo sapiens (human)
neuregulin bindingIntegrin beta-3Homo sapiens (human)
virus receptor activityIntegrin beta-3Homo sapiens (human)
fibronectin bindingIntegrin beta-3Homo sapiens (human)
protease bindingIntegrin beta-3Homo sapiens (human)
protein disulfide isomerase activityIntegrin beta-3Homo sapiens (human)
protein kinase C bindingIntegrin beta-3Homo sapiens (human)
platelet-derived growth factor receptor bindingIntegrin beta-3Homo sapiens (human)
integrin bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin beta-3Homo sapiens (human)
coreceptor activityIntegrin beta-3Homo sapiens (human)
enzyme bindingIntegrin beta-3Homo sapiens (human)
identical protein bindingIntegrin beta-3Homo sapiens (human)
vascular endothelial growth factor receptor 2 bindingIntegrin beta-3Homo sapiens (human)
metal ion bindingIntegrin beta-3Homo sapiens (human)
cell adhesion molecule bindingIntegrin beta-3Homo sapiens (human)
extracellular matrix bindingIntegrin beta-3Homo sapiens (human)
fibrinogen bindingIntegrin beta-3Homo sapiens (human)
protein bindingIntegrin alpha-IIbHomo sapiens (human)
identical protein bindingIntegrin alpha-IIbHomo sapiens (human)
metal ion bindingIntegrin alpha-IIbHomo sapiens (human)
extracellular matrix bindingIntegrin alpha-IIbHomo sapiens (human)
molecular adaptor activityIntegrin alpha-IIbHomo sapiens (human)
fibrinogen bindingIntegrin alpha-IIbHomo sapiens (human)
integrin bindingIntegrin alpha-IIbHomo sapiens (human)
peroxidase activityProstaglandin G/H synthase 1Homo sapiens (human)
prostaglandin-endoperoxide synthase activityProstaglandin G/H synthase 1Homo sapiens (human)
protein bindingProstaglandin G/H synthase 1Homo sapiens (human)
heme bindingProstaglandin G/H synthase 1Homo sapiens (human)
metal ion bindingProstaglandin G/H synthase 1Homo sapiens (human)
oxidoreductase activity, acting on single donors with incorporation of molecular oxygen, incorporation of two atoms of oxygenProstaglandin G/H synthase 1Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (73)

Processvia Protein(s)Taxonomy
basolateral plasma membraneSolute carrier family 22 member 8Mus musculus (house mouse)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
cytoplasmHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
extracellular exosomeHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
cytosolHypoxanthine-guanine phosphoribosyltransferaseHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
glutamatergic synapseIntegrin beta-3Homo sapiens (human)
nucleusIntegrin beta-3Homo sapiens (human)
nucleoplasmIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin beta-3Homo sapiens (human)
cell-cell junctionIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
external side of plasma membraneIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
apical plasma membraneIntegrin beta-3Homo sapiens (human)
platelet alpha granule membraneIntegrin beta-3Homo sapiens (human)
lamellipodium membraneIntegrin beta-3Homo sapiens (human)
filopodium membraneIntegrin beta-3Homo sapiens (human)
microvillus membraneIntegrin beta-3Homo sapiens (human)
ruffle membraneIntegrin beta-3Homo sapiens (human)
integrin alphav-beta3 complexIntegrin beta-3Homo sapiens (human)
melanosomeIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
postsynaptic membraneIntegrin beta-3Homo sapiens (human)
extracellular exosomeIntegrin beta-3Homo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin beta-3Homo sapiens (human)
glycinergic synapseIntegrin beta-3Homo sapiens (human)
integrin complexIntegrin beta-3Homo sapiens (human)
protein-containing complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-PKCalpha complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-IGF-1-IGF1R complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-HMGB1 complexIntegrin beta-3Homo sapiens (human)
receptor complexIntegrin beta-3Homo sapiens (human)
alphav-beta3 integrin-vitronectin complexIntegrin beta-3Homo sapiens (human)
alpha9-beta1 integrin-ADAM8 complexIntegrin beta-3Homo sapiens (human)
focal adhesionIntegrin beta-3Homo sapiens (human)
cell surfaceIntegrin beta-3Homo sapiens (human)
synapseIntegrin beta-3Homo sapiens (human)
plasma membraneIntegrin alpha-IIbHomo sapiens (human)
focal adhesionIntegrin alpha-IIbHomo sapiens (human)
cell surfaceIntegrin alpha-IIbHomo sapiens (human)
platelet alpha granule membraneIntegrin alpha-IIbHomo sapiens (human)
extracellular exosomeIntegrin alpha-IIbHomo sapiens (human)
integrin alphaIIb-beta3 complexIntegrin alpha-IIbHomo sapiens (human)
blood microparticleIntegrin alpha-IIbHomo sapiens (human)
integrin complexIntegrin alpha-IIbHomo sapiens (human)
external side of plasma membraneIntegrin alpha-IIbHomo sapiens (human)
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
photoreceptor outer segmentProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
endoplasmic reticulum membraneProstaglandin G/H synthase 1Homo sapiens (human)
Golgi apparatusProstaglandin G/H synthase 1Homo sapiens (human)
intracellular membrane-bounded organelleProstaglandin G/H synthase 1Homo sapiens (human)
extracellular exosomeProstaglandin G/H synthase 1Homo sapiens (human)
cytoplasmProstaglandin G/H synthase 1Homo sapiens (human)
neuron projectionProstaglandin G/H synthase 1Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (434)

Assay IDTitleYearJournalArticle
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID100309Cross resistance to the compound expressed as log of ratio of molar concentration of drug inducing 50% inhibition of growth in murine leukemia L1210/R71 and L1210/0 cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID337616Cytotoxicity against human NSCLC-N6 cells after 72 hrs by MTT assay1994Journal of natural products, Oct, Volume: 57, Issue:10
Bistramides A, B, C, D, and K: a new class of bioactive cyclic polyethers from Lissoclinum bistratum.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID336033Cytotoxicity against human NSCLC-N6 cells1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic diterpenoids from the brown alga Dilophus ligulatus.
AID355228Antiproliferative activity against human IGR-1 cells after 48 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID417478Antiproliferative activity against human NCI-N87 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID66321Inhibition Eimeria tenella growth1982Journal of medicinal chemistry, Jan, Volume: 25, Issue:1
Pyrazolo[3,4-d]pyrimidine ribonucleosides as anticoccidials. 1. Synthesis and activity of some nucleosides of purines and 4-(alkylthio)pyrazolo[3,4-d]pyrimidines.
AID1520188Inhibition of UGT1A in rat hepatocytes assessed as increase in unconjugated bilirubin level at 75 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID274548Antiplasmodial activity against Plasmodium falciparum 3D72006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID405486Antiproliferative activity against human HEK293 cells after 72 hrs by MTT conversion assay2008Journal of natural products, Jun, Volume: 71, Issue:6
Antiproliferative oleanane saponins from Meryta denhamii.
AID290197Antiproliferative activity against human MT4 cells by MTT assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
AID471603Cytotoxicity against human Hep2 cells at exponential phase of growth after 48 hrs by MTT assay2009Journal of natural products, Aug, Volume: 72, Issue:8
Semisynthesis and biological evaluation of abietane-type diterpenes. Revision of the structure of rosmaquinone.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID337615Cytotoxicity against human HT-29 cells after 72 hrs by MTT assay1994Journal of natural products, Oct, Volume: 57, Issue:10
Bistramides A, B, C, D, and K: a new class of bioactive cyclic polyethers from Lissoclinum bistratum.
AID268023Ratio for partition coefficient, log K in IPM to buffer at pH 42006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis, hydrolyses and dermal delivery of N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide and thiol containing drugs.
AID1520191Inhibition of UDPGDH in rat hepatocytes assessed as increase in unconjugated bilirubin level at 25 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID138602Percentage inhibition as antitumor activity in carcinoma CF1 male mice.1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antitumor agents: diazomethyl ketone and chloromethyl ketone analogues prepared from N-tosyl amino acids.
AID417676Antiproliferative activity against human MOLT4 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID425838Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as lowest drug level required for killing by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID379296Antiproliferative activity against mouse J774 cells assessed as reduction of cell growth after 72 hrs by MTT method2000Journal of natural products, Mar, Volume: 63, Issue:3
Antiproliferative triterpene saponins from Trevesia palmata.
AID425856Antituberculosis activity against Mycobacterium smegmatis mc2 155 assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID425854Antituberculosis activity against Mycobacterium smegmatis ATCC 14468 assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID425862Antituberculosis activity against Mycobacterium paratuberculosis UCF-7 isolated from Crohn's disease patient assessed as colony counts at 4 ug after 12 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID290201Antiproliferative activity against human CRL7065 cells by MTT assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
AID139117Volume of fluid collected 8 days after tumor transplantation in mice.1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antitumor agents: diazomethyl ketone and chloromethyl ketone analogues prepared from N-tosyl amino acids.
AID290205Antiproliferative activity against human HepG2 cells by MTT assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
AID417477Antiproliferative activity against human HeLa cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID417480Antiproliferative activity against human NCI-N87 at 100 uM assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay relative to control2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID1148054Antineoplastic activity against mouse EAC allografted in CF1 mouse assessed as tumor growth inhibition on day 7 measured at 33 mg/kg1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID118244Compound was tested for the ability to suppress humoral immune response in mice treated for days -2,-1,and 0 at dose of 25 mg/kg (control = 8.9)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis and biological evaluation of certain 2'-deoxy-beta-D-ribo- and -beta-D-arabinofuranosyl nucleosides of purine-6-carboxamide and 4,8-diaminopyrimido[5,4-d]pyrimidine.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID425832Antituberculosis activity against Mycobacterium avium ATCC 35712 isolated from chicken assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID96168Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 5h, using [3H]thymidine incorporation assay2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Cytotoxic activity of 6-alkynyl- and 6-alkenylpurines.
AID425835Antituberculosis activity against Mycobacterium paratuberculosis UCF-8 isolated from Crohn's disease patient assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID376743Cytotoxicity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay2000Journal of natural products, Nov, Volume: 63, Issue:11
Novel bioactive sulfated alkene and alkanes from the mediterranean ascidian Halocynthia papillosa.
AID425827Antituberculosis activity against Mycobacterium paratuberculosis B213 isolated from bovine assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID425818Antituberculosis activity against Mycobacterium paratuberculosis JTC303 isolated from bovine assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID425632Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as minimum drug level resulting in no detectable growth at 10'6 CFU of inoculum after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID681408TP_TRANSPORTER: inhibition of Indoxyl sulfate uptake (Indoxyl sulfate: 2 uM, 6-mercaptopurine: 1000 uM) in Xenopus laevis oocytes2002Journal of neurochemistry, Oct, Volume: 83, Issue:1
Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain.
AID399079Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay2006Journal of natural products, Sep, Volume: 69, Issue:9
Antiproliferative triterpene saponins from Entada africana.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID417481Antiproliferative activity against human HeLa cells at 110 uM assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay relative to control2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID268022Solubility in IPM2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis, hydrolyses and dermal delivery of N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide and thiol containing drugs.
AID376271Antiproliferative activity against mouse J774.A1 cells after 3 days by MTT conversion assay2006Journal of natural products, Apr, Volume: 69, Issue:4
Pregnane glycosides from Leptadenia pyrotechnica.
AID471317Antioxidant activity against APPH-induced hemolysis of erythrocytes assessed as lag time of inhibition2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Captopril and 6-mercaptopurine: whose SH possesses higher antioxidant ability?
AID425839Antituberculosis activity against Mycobacterium avium ATCC 25291 isolated from chicken assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID337611Cytotoxicity against human KB cells after 72 hrs by MTT assay1994Journal of natural products, Oct, Volume: 57, Issue:10
Bistramides A, B, C, D, and K: a new class of bioactive cyclic polyethers from Lissoclinum bistratum.
AID399078Antiproliferative activity against HEK293 cells after 72 hrs by MTT conversion assay2006Journal of natural products, Sep, Volume: 69, Issue:9
Antiproliferative triterpene saponins from Entada africana.
AID417675Antiproliferative activity against human U937 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID584550Cytotoxicity against mouse J774A1 cells2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID124029Percent packed cell volume at 200 mg/kg per day per mouse1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis and antitumor activity of a series of sulfone analogues of 1,4-naphthoquinone.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID290198Antiproliferative activity against human CCRF-CEM cells by MTT assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
AID712403Cytotoxicity against CHO cells2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Small Molecule Ligands For Active Targeting Of TrkC-expressing Tumor Cells.
AID376744Cytotoxicity against rat C6 cells assessed as cell viability after 96 hrs by MTT assay2000Journal of natural products, Nov, Volume: 63, Issue:11
Novel bioactive sulfated alkene and alkanes from the mediterranean ascidian Halocynthia papillosa.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID425653Renal clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID29811Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1149567Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as tumor growth inhibition at 33.3 mg/kg/day, ip after 7 days1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID101083Inhibitory concentration on parentral (sensitive) L1210 leukemia cells.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia.
AID1767037Substrate activity at hexa-his tagged Helicobacter pylori XGHPRT assessed as apparent Km using purine base and PRib-PP as substrate measured for 60 sec by spectrophotometric method2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
AID274547Inhibition of [3H]hypoxanthine uptake in Plasmodium falciparum 3D72006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID681421TP_TRANSPORTER: inhibition of Homovanillic acid uptake (HVA: 0.2 uM, 6-mercaptopurine: 1000 uM) in Xenopus laevis oocytes2003Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, Apr, Volume: 23, Issue:4
Rat organic anion transporter 3 (rOAT3) is responsible for brain-to-blood efflux of homovanillic acid at the abluminal membrane of brain capillary endothelial cells.
AID468588Antiproliferative activity against mouse J774A1 cells assessed as cell viability at 10 ug/ml after 72 hrs by MTT assay relative to LPS2009Journal of natural products, Aug, Volume: 72, Issue:8
Phenylethanoid glycosides from Lantana fucata with in vitro anti-inflammatory activity.
AID23271Partition coefficient (logD7.4)1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID425837Antituberculosis activity against Mycobacterium paratuberculosis B244 isolated from bovine assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1148041Antitumor activity against mouse EAC allografted in CF1 mouse assessed as tumor volume at 33 mg/kg/day measured on day 71977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID1293088Stability of the compound in extracted form in plasma (unknown origin) at room temperature1996Gut, Jul, Volume: 39, Issue:1
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
AID678716Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using diethoxyfluorescein as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1148048Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as host survival at 20 mg/kg, ip qd1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID1379651Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID425630Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as lowest drug level producing inhibition at 10'6 CFU of inoculum by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1148040Antitumor activity against mouse EAC allografted in CF1 mouse assessed as host survival at 33 mg/kg/day measured on day 71977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425851Antituberculosis activity against Mycobacterium phlei ATCC 11758 assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1148057Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as animal survival days at 20 mg/kg/day, ip1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID1148058Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as tumor growth inhibition at 20 mg/kg/day, ip1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID224849Antitumor activity in CF1 mice bearing Ehrlich ascites carcinoma measured as percent ascrit packed cell volume at 50 mg/kg1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Synthesis and antitumor evaluation of selected 5,6-disubstituted 1(2)H-indazole-4,7-diones.
AID337613Cytotoxicity against mouse doxorubicin resistant P388 cells after 72 hrs by MTT assay1994Journal of natural products, Oct, Volume: 57, Issue:10
Bistramides A, B, C, D, and K: a new class of bioactive cyclic polyethers from Lissoclinum bistratum.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID417487Cytotoxicity against multidrug-resistant human HT-29 cells assessed as inhibition of epithelial-like growth at 150 uM after 16 hrs using propidium iodide staining by phase-contrast microscopy2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1520182Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 5 to 10 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1148042Antitumor activity against mouse EAC allografted in CF1 mouse assessed as inhibition of tumor growth at 33 mg/kg/day measured on day 71977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID50750In vitro cytotoxic activity against human colon tumor-8r cells in culture and LD50 was reported at the end of incubation period of 72 hours.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and antitumor activity of some aromatic seleno lactones.
AID620831Cytotoxicity against human MT4 cells infected with HTLV-1 after 96 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.
AID471319Antioxidant activity assessed as protection against hemin-induced erythrocytes hemolysis up to 1 uM2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Captopril and 6-mercaptopurine: whose SH possesses higher antioxidant ability?
AID1520172Cytotoxicity against human REH cells assessed as reduction in cell viability after 48 hrs by Alamar Blue assay2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID425629Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as effect on average time to detection of growth at 10'5 CFU of inoculum by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID678712Inhibition of human CYP1A2 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using ethoxyresorufin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID425831Antituberculosis activity against Mycobacterium paratuberculosis B238 isolated from bovine assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID471600Cytotoxicity against human HeLa cells at lag phase of growth after 48 hrs by MTT assay2009Journal of natural products, Aug, Volume: 72, Issue:8
Semisynthesis and biological evaluation of abietane-type diterpenes. Revision of the structure of rosmaquinone.
AID1148052Antineoplastic activity against mouse EAC allografted in CF1 mouse assessed as packed cell volume on day 7 measured at 33 mg/kg (Rvb = 32.75 +/- 7.87%)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID425850Antituberculosis activity against Mycobacterium avium WSLH1544 isolated from water assessed as minimum drug level required for killing within 15 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID425822Antituberculosis activity against Mycobacterium paratuberculosis UCF-5 isolated from Crohn's disease patient assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID355229Antiproliferative activity against human IGR-1 cells after 72 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID379297Antiproliferative activity against HEK293 cells assessed as reduction of cell growth after 72 hrs by MTT method2000Journal of natural products, Mar, Volume: 63, Issue:3
Antiproliferative triterpene saponins from Trevesia palmata.
AID1293039Toxicity in inflammatory bowel disease patient assessed as induction of leucopenia1996Gut, Jul, Volume: 39, Issue:1
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
AID1293082Stability in whole blood (unknown origin) using compound stored in ice water slurry1996Gut, Jul, Volume: 39, Issue:1
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
AID425819Antituberculosis activity against Mycobacterium paratuberculosis JTC303 isolated from bovine assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID417666Antiproliferative activity against human NCI-N87 cells at 150 uM after 16 hrs by XTT assay2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID584547Antibacterial activity against Bacillus anthracis Sterne 34F2 infected in mouse J774A.1 cells assessed as protection against bacteria-induced cytotoxicity using propidium iodide staining after 3 hrs measured every hours for up to 7 hrs2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID471314Antioxidant activity assessed as galvinoxyl radical scavenging activity2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Captopril and 6-mercaptopurine: whose SH possesses higher antioxidant ability?
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1575592Inhibition of Streptococcus pyogenes UDPGDH expressed in Escherichia coli assessed as inhibitior constant by mesuring UDPGA production after 20 to 120 secs by HPLC analysis2019MedChemComm, May-01, Volume: 10, Issue:5
New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
AID289869Antileishmanial activity against Leishmania amazonensis MHOM/Br/75/Josefa promastigotes by MTT colorimetric method2007European journal of medicinal chemistry, Apr, Volume: 42, Issue:4
Synthesis and biological evaluation of some 6-substituted purines.
AID468587Antiproliferative activity against mouse J774A1 cells assessed as cell viability at 100 ug/ml after 72 hrs by MTT assay relative to LPS2009Journal of natural products, Aug, Volume: 72, Issue:8
Phenylethanoid glycosides from Lantana fucata with in vitro anti-inflammatory activity.
AID417665Induction of apoptosis in human B-CLL cells assessed as increase in apoptotic cells at 150 uM after 16 hrs by FACS analysis2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID96327Percent inhibition of [3H]-thymidine incorporation was determined in human chronic myelogenous leukemic K-562 cell line at 10 ug/mL after 48 hr2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Cytotoxic activity of 6-alkynyl- and 6-alkenylpurines.
AID1520174Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 50 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID409954Inhibition of mouse brain MAOA2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID118250Compound was tested for the ability to suppress humoral immune response in mice treated for days 0,+1,and +2 at dose of 100 mg/kg (control = 8.9)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis and biological evaluation of certain 2'-deoxy-beta-D-ribo- and -beta-D-arabinofuranosyl nucleosides of purine-6-carboxamide and 4,8-diaminopyrimido[5,4-d]pyrimidine.
AID670608Cytotoxicity against african green monkey Vero cells assessed as cell viability after 48 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID1293083Stability in plasma (unknown origin) using compound stored in frozen condition1996Gut, Jul, Volume: 39, Issue:1
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1520171Inhibition of UDPGDH in rat hepatocytes after 20 to 120 secs by UV/Vis spectrophotometric analysis2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID425845Antituberculosis activity against Mycobacterium avium JTC981 isolated from bongo fecal sample assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1136454Antitumor activity against mouse EAC allografted in CF1 mouse assessed as ascrit fluid volume at 20 mg/kg, ip qd for 7 days (Rvb = 6.63 +/- 1.24 mL)1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Antitumor and antiinflammatory agents: N-benzoyl-protected cyanomethyl esters of amino acids.
AID625276FDA Liver Toxicity Knowledge Base Benchmark Dataset (LTKB-BD) drugs of most concern for DILI2011Drug discovery today, Aug, Volume: 16, Issue:15-16
FDA-approved drug labeling for the study of drug-induced liver injury.
AID1184074Solubility of the compound in pH 6.5 phosphate buffer containing 5% DMSO2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID336031Cytotoxicity against mouse P388 cells1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic diterpenoids from the brown alga Dilophus ligulatus.
AID355236Cytotoxicity against mouse P388 cells after 24 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID1148053Antineoplastic activity against mouse EAC allografted in CF1 mouse assessed as ascites volume on day 7 measured at 33 mg/kg (Rvb = 4.1 +/- 1.24 mL)1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID1811641Cytotoxicity against mouse J774.A1 cells assessed as antiproliferative activity at 200 uM incubated for 24 hrs by MTT assay relative to control2021Journal of natural products, 04-23, Volume: 84, Issue:4
Nor-abietane Diterpenoids from
AID425852Antituberculosis activity against Mycobacterium phlei ATCC 11758 assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID417476Antiproliferative activity against human Daudi cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID1520193Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 25 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID274563Inhibition of Plasmodium falciparum HGXPRT at pH 8.52006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID425847Antituberculosis activity against Mycobacterium avium EPA3 isolated from water assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID471602Cytotoxicity against human Hep2 cells at lag phase of growth after 48 hrs by MTT assay2009Journal of natural products, Aug, Volume: 72, Issue:8
Semisynthesis and biological evaluation of abietane-type diterpenes. Revision of the structure of rosmaquinone.
AID681932TP_TRANSPORTER: efflux in MRP4-expressing NIH3T3 cells2001The Journal of biological chemistry, Sep-07, Volume: 276, Issue:36
Transport of cyclic nucleotides and estradiol 17-beta-D-glucuronide by multidrug resistance protein 4. Resistance to 6-mercaptopurine and 6-thioguanine.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425820Antituberculosis activity against Mycobacterium paratuberculosis UCF-4 isolated from Crohn's disease patient assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID274549Inhibition of human HGPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID139722Screening of Ehrlich ascites carcinoma cells in mice at 20 mg/kg/day, intraperitoneally1980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antitumor agents: diazomethyl ketone and chloromethyl ketone analogues prepared from N-tosyl amino acids.
AID229265Ratio of IC50 for Parental L1210 to that of multidrug resistant L1210.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia.
AID425830Antituberculosis activity against Mycobacterium paratuberculosis B238 isolated from bovine assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID379298Antiproliferative activity against mouse WEHI164 cells assessed as reduction of cell growth after 72 hrs by MTT method2000Journal of natural products, Mar, Volume: 63, Issue:3
Antiproliferative triterpene saponins from Trevesia palmata.
AID137950Compound was evaluated for immunological activity in mice as the percentage of suppression of the humoral response to EI4 tumor cells at 10 mg/kg, po1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Novel immunosuppressive agents. Potent immunological activity of some bensothiopyrano [4,3-c]pyrazol-3-ones.
AID274557Inhibition of Plasmodium chabaudi 6 oxopurine phosphoribosyl transferase2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID1216058Cytotoxicity against human PANC1 cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID1070215Inhibition of Trichomonas vaginalis uridine nucleoside ribohydrolase using 5-fluorouridine as substrate at 0.04 to 200 uM after 40 mins by NMR spectrometric analysis2014Bioorganic & medicinal chemistry letters, Feb-15, Volume: 24, Issue:4
Identification of proton-pump inhibitor drugs that inhibit Trichomonas vaginalis uridine nucleoside ribohydrolase.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1123312Cytotoxicity against wild type mouse S49 cells assessed as growth inhibition after 24 hrs by time-course study1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
2'-O-Acyl-6-thioinosine cyclic 3',5'-phosphates as prodrugs of thioinosinic acid.
AID425836Antituberculosis activity against Mycobacterium paratuberculosis B244 isolated from bovine assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID118146Percent packed cell volume at 200 mg/kg per day1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis and antitumor activity of a series of sulfone analogues of 1,4-naphthoquinone.
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID471608Cytotoxicity against african green monkey Vero cells at lag phase of growth after 48 hrs by MTT assay2009Journal of natural products, Aug, Volume: 72, Issue:8
Semisynthesis and biological evaluation of abietane-type diterpenes. Revision of the structure of rosmaquinone.
AID1136455Antitumor activity against mouse EAC allografted in CF1 mouse assessed as tumor growth inhibition at 20 mg/kg, ip qd for 7 days (Rvb = 0%)1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Antitumor and antiinflammatory agents: N-benzoyl-protected cyanomethyl esters of amino acids.
AID425821Antituberculosis activity against Mycobacterium paratuberculosis UCF-4 isolated from Crohn's disease patient assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID425855Antituberculosis activity against Mycobacterium smegmatis mc2 155 assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID584546Inhibition of inosine/L-alanine-induced Bacillus anthracis Sterne 34F2 spore germination pretreated for 15 mins before inosine/L-alanine challenge2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
Testing nucleoside analogues as inhibitors of Bacillus anthracis spore germination in vitro and in macrophage cell culture.
AID355233Cytotoxicity against mouse WEHI164 cells after 24 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID417677Antiproliferative activity against human Jurkat cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID1123301Cytotoxicity against wild type mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
2'-O-Acyl-6-thioinosine cyclic 3',5'-phosphates as prodrugs of thioinosinic acid.
AID678714Inhibition of human CYP2C19 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 3-butyryl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID678713Inhibition of human CYP2C9 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-methoxy-4-trifluoromethylcoumarin-3-acetic acid as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID670603Cytotoxicity against human A549 cells assessed as cell viability after 48 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID1123302Cytotoxicity against HGPRTase-deficient mouse S49 cells assessed as growth inhibition after 72 hrs by trypan blue exclusion assay1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
2'-O-Acyl-6-thioinosine cyclic 3',5'-phosphates as prodrugs of thioinosinic acid.
AID425841Antituberculosis activity against Mycobacterium avium 104 isolated from AIDS patient assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID471607Cytotoxicity against human sMCF7 cells at exponential phase of growth after 48 hrs by MTT assay2009Journal of natural products, Aug, Volume: 72, Issue:8
Semisynthesis and biological evaluation of abietane-type diterpenes. Revision of the structure of rosmaquinone.
AID96165Inhibitory concentration required against human chronic myelogenous leukemic K-562 cell line after 48h, using [3H]thymidine incorporation assay2003Bioorganic & medicinal chemistry letters, Mar-10, Volume: 13, Issue:5
Cytotoxic activity of 6-alkynyl- and 6-alkenylpurines.
AID670602Cytotoxicity against human HeLa cells assessed as cell viability after 48 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID1767036Substrate activity at Helicobacter pylori XGHPRT assessed as Kcat using purine base and PRib-PP as substrate measured for 60 sec by spectrophotometric method2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1520173Inhibition of UGT1A in rat hepatocytes preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID471315Antioxidant activity assessed as ABTS radical scavenging activity2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Captopril and 6-mercaptopurine: whose SH possesses higher antioxidant ability?
AID178124Antiarthritic activity in rat determined by adjuvant arthritis assay in rat1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nucleosides of azathioprine and thiamiprine as antiarthritics.
AID620833Antiproliferative activity against human WIL2-NS cells after 96 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.
AID50748In vitro cytotoxic activity against human colon tumor-8r cells in culture and LD50 was reported at the end of incubation period of 24 hours.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and antitumor activity of some aromatic seleno lactones.
AID184629Compound was tested for lethal dose at day 16 against rat1989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nucleosides of azathioprine and thiamiprine as antiarthritics.
AID355230Cytotoxicity against mouse J774 cells after 24 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1216056Cytotoxicity against human Patu-S cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID96147Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 48 h2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Cytotoxic and antibacterial activity of 2-oxopurine derivatives.
AID1293087Stability in plasma (unknown origin) at room temperature1996Gut, Jul, Volume: 39, Issue:1
Azathioprine pharmacokinetics after intravenous, oral, delayed release oral and rectal foam administration.
AID1520192Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 25 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID425823Antituberculosis activity against Mycobacterium paratuberculosis UCF-5 isolated from Crohn's disease patient assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID417479Antiproliferative activity against human Daudi cells at <=20 uM assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay relative to control2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID399077Antiproliferative activity against mouse J774A1 cells after 72 hrs by MTT conversion assay2006Journal of natural products, Sep, Volume: 69, Issue:9
Antiproliferative triterpene saponins from Entada africana.
AID225007Antitumor activity in 18 CF1 mice bearing Ehrlich ascites carcinoma measured as survivors on day 9 at 50 mg/kg; 16/181983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Synthesis and antitumor evaluation of selected 5,6-disubstituted 1(2)H-indazole-4,7-diones.
AID712404Cytotoxicity against human MCF7 cells2012ACS medicinal chemistry letters, Dec-13, Volume: 3, Issue:12
Small Molecule Ligands For Active Targeting Of TrkC-expressing Tumor Cells.
AID338730In vivo antineoplastic activity against mouse Ehrlich ascite carcinoma cells xenografted in CF1 mouse assessed as inhibition of tumor growth at 0.5 mg/kg/day after 9 days relative to control
AID1520175Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 50 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis relative to control2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1520183Inhibition of UDPGDH in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 5 to 10 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID1575633Inhibition of Streptococcus pyogenes UDPGDH expressed in Escherichia coli assessed as inhibitior constant after 20 to 120 secs by UV-VIS spectroscopic analysis2019MedChemComm, May-01, Volume: 10, Issue:5
New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
AID491531Binding affinity to Mycobacterium tuberculosis purine nucleoside phosphorylase by spectrophotometric analysis2010Bioorganic & medicinal chemistry, Jul-01, Volume: 18, Issue:13
Crystallographic and docking studies of purine nucleoside phosphorylase from Mycobacterium tuberculosis.
AID1184075Inhibition of IDO1 (unknown origin) at highest soluble concentration using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID425628Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as effect on average time to detection of growth at >10'2 CFU of inoculum by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID425853Antituberculosis activity against Mycobacterium smegmatis ATCC 14468 assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID471609Cytotoxicity against african green monkey Vero cells at exponential phase of growth after 48 hrs by MTT assay2009Journal of natural products, Aug, Volume: 72, Issue:8
Semisynthesis and biological evaluation of abietane-type diterpenes. Revision of the structure of rosmaquinone.
AID355238Antiproliferative activity against mouse P388 cells after 72 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID1473740Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1216059Cytotoxicity against human Patu-02 cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID290199Antiproliferative activity against human WIL-2NS cells by MTT assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
AID425828Antituberculosis activity against Mycobacterium paratuberculosis B236 isolated from bovine assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID421868Cytotoxicity against mouse J774A1 cells by rapid colorimetric assay2009Journal of natural products, Feb-27, Volume: 72, Issue:2
3-Alkylpyridinium alkaloids from the Pacific sponge Haliclona sp.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID290200Antiproliferative activity against human CCRF-SB cells by MTT assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID336032Cytotoxicity against mouse doxorubicin-resistant P388 cells1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic diterpenoids from the brown alga Dilophus ligulatus.
AID1132830Cytostatic activity against human KB cells assessed as growth inhibition after 72 hrs by colorimetric method1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Cytostatic quinones. 3. Synthesis of benzotriazolequinones by a new oxidation with m-chloroperbenzoic acid. Biochemical studies.
AID1379657Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID1473741Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID425840Antituberculosis activity against Mycobacterium avium ATCC 25291 isolated from chicken assessed as minimum drug level required for killing within 15 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID290202Antiproliferative activity against human SK-MEL-28 cells by MTT assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID678718Metabolic stability in human liver microsomes assessed as high signal/noise ratio (S/N of >100) by measuring GSH adduct formation at 100 uM after 90 mins by HPLC-MS analysis2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID274562Inhibition of human HGPRT at pH 8.52006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID376272Antiproliferative activity against HEK293 cells after 3 days by MTT conversion assay2006Journal of natural products, Apr, Volume: 69, Issue:4
Pregnane glycosides from Leptadenia pyrotechnica.
AID355227Cytotoxicity against human IGR-1 cells after 24 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID1216054Cytotoxicity against human Colo-357 cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID1379654Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID471601Cytotoxicity against human HeLa cells at exponential phase of growth after 48 hrs by MTT assay2009Journal of natural products, Aug, Volume: 72, Issue:8
Semisynthesis and biological evaluation of abietane-type diterpenes. Revision of the structure of rosmaquinone.
AID421867Cytotoxicity against HEK293 cells by rapid colorimetric assay2009Journal of natural products, Feb-27, Volume: 72, Issue:2
3-Alkylpyridinium alkaloids from the Pacific sponge Haliclona sp.
AID355234Antiproliferative activity against mouse WEHI164 cells after 48 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID409956Inhibition of mouse brain MAOB2008Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
AID1136453Antitumor activity against mouse EAC allografted in CF1 mouse assessed as host survival on day 7 at 20 mg/kg, ip qd for 7 days1979Journal of medicinal chemistry, Nov, Volume: 22, Issue:11
Antitumor and antiinflammatory agents: N-benzoyl-protected cyanomethyl esters of amino acids.
AID678715Inhibition of human CYP2D6 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 4-methylaminoethyl-7-methoxycoumarin as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID1216055Cytotoxicity against human Patu-T cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID1124393Cytostatic activity against human HeLa cells after 72 hrs by FCR-based colorimetric method1979Journal of medicinal chemistry, Jul, Volume: 22, Issue:7
Alkylating nucleosides. 2. Synthesis and cytostatic activity of bromomethylpyrazole and pyrazole nitrogen mustard nucleosides.
AID425859Antituberculosis activity against Enterococcus faecalis ATCC 29212 isolated from human urine assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID620844Antiproliferative activity against human SK-MEL-28 cells after 96 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.
AID137949Immunological activity in mice as the percentage of suppression of the cellular response to EI4 tumor cells at 10 mg/kg1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Novel immunosuppressive agents. Potent immunological activity of some bensothiopyrano [4,3-c]pyrazol-3-ones.
AID268024Permeability across hairless mouse skin2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis, hydrolyses and dermal delivery of N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide and thiol containing drugs.
AID468589Antiproliferative activity against mouse J774A1 cells assessed as cell viability at 1 ug/ml after 72 hrs by MTT assay relative to LPS2009Journal of natural products, Aug, Volume: 72, Issue:8
Phenylethanoid glycosides from Lantana fucata with in vitro anti-inflammatory activity.
AID417680Inhibition of T cell mitogen-induced blastogenesis in human PBMC after 4 days2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID425858Antituberculosis activity against Escherichia coli ATCC 25922 clinical isolate assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1473738Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID425829Antituberculosis activity against Mycobacterium paratuberculosis B236 isolated from bovine assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID620834Antiproliferative activity against human CCRF-SB cells after 96 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.
AID118242Compound was tested for the ability to suppress humoral immune response in mice treated for days -2,-1,and 0 at dose of 100 mg/kg (control = 8.1)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis and biological evaluation of certain 2'-deoxy-beta-D-ribo- and -beta-D-arabinofuranosyl nucleosides of purine-6-carboxamide and 4,8-diaminopyrimido[5,4-d]pyrimidine.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID620842Antiproliferative activity against human MCF7 cells after 96 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.
AID620832Antiproliferative activity against human CCRF-CEM cells after 96 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.
AID1520187Inhibition of UGT1A in rat hepatocytes assessed as decrease in bilirubin diglucuronide level at 75 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID115407Percent inhibition of Ehrlich ascites carcinoma growth at 200 mg/kg per day1981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis and antitumor activity of a series of sulfone analogues of 1,4-naphthoquinone.
AID274565Inhibition of Escherichia coli Sphi609 cells expressing human HGPRT2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID678717Inhibition of human CYP3A4 assessed as ratio of IC50 in absence of NADPH to IC50 for presence of NADPH using 7-benzyloxyquinoline as substrate after 30 mins2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID670606Cytotoxicity against human MCF7 cells assessed as cell viability after 48 hrs by MTT assay2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID289870Antileishmanial activity against Leishmania chagasi MHOM/Br/74/PP75 promastigotes by MTT colorimetric method2007European journal of medicinal chemistry, Apr, Volume: 42, Issue:4
Synthesis and biological evaluation of some 6-substituted purines.
AID45399Cross resistance of chinese hamster cells resistant to actinomycin D as log of ratio of molar concentration of compound inducing 50% inhibition of growth in resistant and sensitive cells1990Journal of medicinal chemistry, Jul, Volume: 33, Issue:7
Structure-activity relationships of antineoplastic agents in multidrug resistance.
AID1636440Drug activation in human Hep3B cells assessed as human CYP2D6-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1149566Antitumor activity against mouse EAC cells allografted in CF1 mouse assessed as survival at 33.3 mg/kg/day, ip after 7 days1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Antitumor agents. 21. A proposed mechanism for inhibition of cancer growth by tenulin and helenalin and related cyclopentenones.
AID425834Antituberculosis activity against Mycobacterium paratuberculosis UCF-8 isolated from Crohn's disease patient assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1184068Inhibition of IDO1 (unknown origin) using L-tryptophan substrate incubated for 60 mins by HPLC2014European journal of medicinal chemistry, Sep-12, Volume: 84Detailed analysis and follow-up studies of a high-throughput screening for indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
AID425860Antituberculosis activity against Enterococcus faecalis ATCC 29212 isolated from human urine assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID221575Antitumor activity in CF1 mice bearing Ehrlich ascites carcinoma measured as percentage inhibition at 50 mg/kg1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Synthesis and antitumor evaluation of selected 5,6-disubstituted 1(2)H-indazole-4,7-diones.
AID1379655Cytotoxicity against human MCF7 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID1379653Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in log phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID417679Antiproliferative activity against multidrug-resistant human HT-29 cells assessed as [methyl-3H]thymidine incorporation after 16 hrs by XTT assay2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID221264Antitumor activity in CF1 mice bearing Ehrlich ascites carcinoma measured as ascites volume at 50 mg/kg1983Journal of medicinal chemistry, Jun, Volume: 26, Issue:6
Synthesis and antitumor evaluation of selected 5,6-disubstituted 1(2)H-indazole-4,7-diones.
AID425824Antituberculosis activity against Mycobacterium paratuberculosis UCF-7 isolated from Crohn's disease patient assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID335816Cytotoxicity against human KB cells1993Journal of natural products, Oct, Volume: 56, Issue:10
Cytotoxic diterpenoids from the brown alga Dilophus ligulatus.
AID120784Effect of compound on Ehrlich ascites carcinoma growth in CF1 mice at 200 mg/kg per day ip survival at day 9; 6/61981Journal of medicinal chemistry, Jul, Volume: 24, Issue:7
Synthesis and antitumor activity of a series of sulfone analogues of 1,4-naphthoquinone.
AID425652Total body clearance in human2009Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15
Physicochemical determinants of human renal clearance.
AID1216060Cytotoxicity against human DAN-G cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID1520186Inhibition of UGT1A in rat hepatocytes assessed as decrease in bilirubin monoglucuronide level at 75 uM preincubated for 2 mins followed by UDPGA addition measured after 45 mins by HPLC analysis2019MedChemComm, Jan-01, Volume: 10, Issue:1
Efforts in redesigning the antileukemic drug 6-thiopurine: decreasing toxic side effects while maintaining efficacy.
AID118373Compound was tested for the ability to suppress humoral immune response in mice treated for days 0,+1,and +2 at dose of 50 mg/kg (control = 8.9)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis and biological evaluation of certain 2'-deoxy-beta-D-ribo- and -beta-D-arabinofuranosyl nucleosides of purine-6-carboxamide and 4,8-diaminopyrimido[5,4-d]pyrimidine.
AID1575638Inhibition of UDPGDH/UGT-1A in hepatocytes (unknown origin) assessed as reduction in BDG production at 25 uM by HPLC analysis2019MedChemComm, May-01, Volume: 10, Issue:5
New methods to assess 6-thiopurine toxicity and expanding its therapeutic application to pancreatic cancer
AID425849Antituberculosis activity against Mycobacterium avium WSLH1544 isolated from water assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID620843Antiproliferative activity against human SKMES1 cells after 96 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.
AID620841Antiproliferative activity against human HepG2 cells after 96 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.
AID355235Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID96149Cytotoxicity against chronic myelogenous leukemia cell line K-562 was determined by measuring [3H]thymidine incorporation after 5 h2002Bioorganic & medicinal chemistry letters, Feb-25, Volume: 12, Issue:4
Cytotoxic and antibacterial activity of 2-oxopurine derivatives.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID337612Cytotoxicity against mouse P388 cells after 72 hrs by MTT assay1994Journal of natural products, Oct, Volume: 57, Issue:10
Bistramides A, B, C, D, and K: a new class of bioactive cyclic polyethers from Lissoclinum bistratum.
AID405487Antiproliferative activity against mouse WEHI164 cells after 72 hrs by MTT conversion assay2008Journal of natural products, Jun, Volume: 71, Issue:6
Antiproliferative oleanane saponins from Meryta denhamii.
AID181153Compound was tested for dose at which there was no significant weight loss in rat at day 161989Journal of medicinal chemistry, Jul, Volume: 32, Issue:7
Nucleosides of azathioprine and thiamiprine as antiarthritics.
AID471605Cytotoxicity against human A549 cells at exponential phase of growth after 48 hrs by MTT assay2009Journal of natural products, Aug, Volume: 72, Issue:8
Semisynthesis and biological evaluation of abietane-type diterpenes. Revision of the structure of rosmaquinone.
AID471316Antioxidant activity against APPH-induced DNA damage assessed as inhibition time2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Captopril and 6-mercaptopurine: whose SH possesses higher antioxidant ability?
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID118247Compound was tested for the ability to suppress humoral immune response in mice treated for days -2,-1,and 0 at dose of 50 mg/kg (control = 8.1)1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Synthesis and biological evaluation of certain 2'-deoxy-beta-D-ribo- and -beta-D-arabinofuranosyl nucleosides of purine-6-carboxamide and 4,8-diaminopyrimido[5,4-d]pyrimidine.
AID620840Antiproliferative activity against human DU145 cells after 96 hrs by MTT assay2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
3-Aryl-2-[1H-benzotriazol-1-yl]acrylonitriles: a novel class of potent tubulin inhibitors.
AID425825Antituberculosis activity against Mycobacterium paratuberculosis UCF-7 isolated from Crohn's disease patient assessed as minimum drug level required for killing after 56 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID678722Covalent binding affinity to human liver microsomes assessed per mg of protein at 10 uM after 60 mins presence of NADPH2012Chemical research in toxicology, Oct-15, Volume: 25, Issue:10
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
AID425631Antituberculosis activity against Mycobacterium paratuberculosis ATCC 19698 isolated from bovine assessed as lowest drug level producing inhibition at 10'6 CFU of inoculum by agar counting method2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID417678Antiproliferative activity against human B-CLL cells assessed as cell viability after 16 hrs by trypan blue exclusion assay2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID274550Inhibition of Plasmodium falciparum HGXPRT at pH 7.42006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID417664Induction of apoptosis in human B-CLL cells assessed as increase in apoptotic cells at 100 uM after 16 hrs by FACS analysis2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID355231Antiproliferative activity against mouse J774 cells after 48 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID1473739Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay2013Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1636357Drug activation in human Hep3B cells assessed as human CYP3A4-mediated drug metabolism-induced cytotoxicity measured as decrease in cell viability at 300 uM pre-incubated with BSO for 18 hrs followed by incubation with compound for 3 hrs in presence of NA2016Bioorganic & medicinal chemistry letters, 08-15, Volume: 26, Issue:16
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
AID1148049Antitumor activity against mouse P388 cells allografted in DBA/2 mouse assessed as tumor growth inhibition at 20 mg/kg, ip qd relative to control1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 1. N-Protected vinyl, 1,2-dihaloethyl, and cyanomethyl esters of phenylalanine.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID471606Cytotoxicity against human MCF7 cells at lag phase of growth after 48 hrs by MTT assay2009Journal of natural products, Aug, Volume: 72, Issue:8
Semisynthesis and biological evaluation of abietane-type diterpenes. Revision of the structure of rosmaquinone.
AID425857Antituberculosis activity against Escherichia coli ATCC 25922 clinical isolate assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID50749In vitro cytotoxic activity against human colon tumor-8r cells in culture and LD50 was reported at the end of incubation period of 48 hours.1984Journal of medicinal chemistry, Apr, Volume: 27, Issue:4
Synthesis and antitumor activity of some aromatic seleno lactones.
AID290206Antiproliferative activity against human DU145 cells by MTT assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
AID670610Selectivity index, ratio of IC50 for african green monkey Vero cells to IC50 for human MCF7 cells after 48 hrs2012European journal of medicinal chemistry, Aug, Volume: 54Withaferin A-related steroids from Withania aristata exhibit potent antiproliferative activity by inducing apoptosis in human tumor cells.
AID680354TP_TRANSPORTER: efflux in MRP5-expressing MDCKII cells2000Proceedings of the National Academy of Sciences of the United States of America, Jun-20, Volume: 97, Issue:13
Multidrug-resistance protein 5 is a multispecific organic anion transporter able to transport nucleotide analogs.
AID425861Antituberculosis activity against Mycobacterium paratuberculosis UCF-7 isolated from Crohn's disease patient assessed as colony counts at 2 ug after 12 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID425844Antituberculosis activity against Mycobacterium avium JTC48627 isolated from bison fecal sample assessed as minimum drug level required for killing within 15 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID425848Antituberculosis activity against Mycobacterium avium EPA3 isolated from water assessed as minimum drug level required for killing within 15 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID138285Anticarcinoma activity of Diazomethyl Ketone against Ehrlich ascites Carcinoma pharmacological screens were reported; 6/61980Journal of medicinal chemistry, Mar, Volume: 23, Issue:3
Antitumor agents: diazomethyl ketone and chloromethyl ketone analogues prepared from N-tosyl amino acids.
AID274558Inhibition of Plasmodium lophurae 6 oxopurine phosphoribosyl transferase2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID376273Antiproliferative activity against mouse WEHI164 cells after 3 days by MTT conversion assay2006Journal of natural products, Apr, Volume: 69, Issue:4
Pregnane glycosides from Leptadenia pyrotechnica.
AID417663Induction of apoptosis in human B-CLL cells assessed as increase in apoptotic cells at 50 uM after 16 hrs by FACS analysis2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID268021Aqueous solubility of the compound2006Bioorganic & medicinal chemistry letters, Jul-01, Volume: 16, Issue:13
Synthesis, hydrolyses and dermal delivery of N-alkyl-N-alkyloxycarbonylaminomethyl (NANAOCAM) derivatives of phenol, imide and thiol containing drugs.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID290204Antiproliferative activity against human SKMES1 cells by MTT assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
AID1216057Cytotoxicity against human Aspc-1 cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID681386TP_TRANSPORTER: uptake in mOat3-expressing oocytes2004Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 32, Issue:5
Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3.
AID471604Cytotoxicity against human A549 cells at lag phase of growth after 48 hrs by MTT assay2009Journal of natural products, Aug, Volume: 72, Issue:8
Semisynthesis and biological evaluation of abietane-type diterpenes. Revision of the structure of rosmaquinone.
AID355232Antiproliferative activity against mouse J774 cells after 72 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID337614Cytotoxicity against mouse B16 cells after 72 hrs by MTT assay1994Journal of natural products, Oct, Volume: 57, Issue:10
Bistramides A, B, C, D, and K: a new class of bioactive cyclic polyethers from Lissoclinum bistratum.
AID1132829Cytostatic activity against human HeLa cells assessed as growth inhibition after 72 hrs by colorimetric method1978Journal of medicinal chemistry, Jun, Volume: 21, Issue:6
Cytostatic quinones. 3. Synthesis of benzotriazolequinones by a new oxidation with m-chloroperbenzoic acid. Biochemical studies.
AID1216053Cytotoxicity against human T3M4 cells by crystal violet staining2011Drug metabolism and disposition: the biological fate of chemicals, Jan, Volume: 39, Issue:1
Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluorouracil.
AID1379652Cytotoxicity against human A549 cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID425843Antituberculosis activity against Mycobacterium avium JTC48627 isolated from bison fecal sample assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID405485Antiproliferative activity against mouse J774.A1 cells after 72 hrs by MTT conversion assay2008Journal of natural products, Jun, Volume: 71, Issue:6
Antiproliferative oleanane saponins from Meryta denhamii.
AID425826Antituberculosis activity against Mycobacterium paratuberculosis B213 isolated from bovine assessed as minimum drug level required for inhibition by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID290203Antiproliferative activity against human MCF7 cells by MTT assay2007European journal of medicinal chemistry, Mar, Volume: 42, Issue:3
Synthesis and antiproliferative properties of N3/8-disubstituted 3,8-diazabicyclo[3.2.1]octane analogues of 3,8-bis[2-(3,4,5-trimethoxyphenyl)pyridin-4-yl]methyl-piperazine.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID274564Inhibition of Escherichia coli Sphi609 cells expressing Plasmodium falciparum HGXPRT2006Journal of medicinal chemistry, Dec-14, Volume: 49, Issue:25
Lead compounds for antimalarial chemotherapy: purine base analogs discriminate between human and P. falciparum 6-oxopurine phosphoribosyltransferases.
AID101082Inhibitory concentration on multidrug-resistant L1210 leukemia cells.1991Journal of medicinal chemistry, Jul, Volume: 34, Issue:7
Additional nucleotide derivatives of mitosenes. Synthesis and activity against parental and multidrug resistant L1210 leukemia.
AID1148051Antineoplastic activity against mouse EAC allografted in CF1 mouse assessed as animal survival on day 7 measured at 33 mg/kg1977Journal of medicinal chemistry, Dec, Volume: 20, Issue:12
Antineoplastic agents. 2. Structure-activity studies on N-protected vinyl, 1,2-dibromoethyl, and cyanomethyl esters of several amino acids.
AID425846Antituberculosis activity against Mycobacterium avium JTC981 isolated from bongo fecal sample assessed as minimum drug level required for killing within 15 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1124440In vitro cytostatic activity against human HeLa cells assessed as cell growth after 72 hrs by colorimetric method1979Journal of medicinal chemistry, May, Volume: 22, Issue:5
Alkylating nucleosides 1. Synthesis and cytostatic activity of N-glycosyl(halomethyl)-1,2,3-triazoles. A new type of alkylating agent.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID356694Antiproliferative activity against mouse WEHI164 cells assessed as cell viability after 96 hrs by MTT assay2001Journal of natural products, Feb, Volume: 64, Issue:2
New bioactive sulfated metabolites from the Mediterranean tunicate Sidnyum turbinatum.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID477295Octanol-water partition coefficient, log P of the compound2010European journal of medicinal chemistry, Apr, Volume: 45, Issue:4
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1379650Cytotoxicity against human HeLa cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID355237Antiproliferative activity against mouse P388 cells after 48 hrs by MTT assay1997Journal of natural products, Oct, Volume: 60, Issue:10
Porrigenins A and B, novel cytotoxic and antiproliferative sapogenins isolated from Allium porrum.
AID1364978Antiviral activity against Chikungunya virus S-27 assessed as viral titer interferon loading2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID417484Cytotoxicity against human HeLa cells assessed as reduced cell viability at 200 uM by trypan blue exclusion assay relative to control2009European journal of medicinal chemistry, Feb, Volume: 44, Issue:2
Novel derivatives of 6-mercaptopurine: synthesis, characterization and antiproliferative activities of S-allylthio-mercaptopurines.
AID1767040Antibacterial activity against Helicobacter pylori assessed growth inhibition at 50 uM incubated for 3 days2021Journal of medicinal chemistry, 05-13, Volume: 64, Issue:9
AID421866Cytotoxicity against mouse WEHI164 cells by rapid colorimetric assay2009Journal of natural products, Feb-27, Volume: 72, Issue:2
3-Alkylpyridinium alkaloids from the Pacific sponge Haliclona sp.
AID425842Antituberculosis activity against Mycobacterium avium 104 isolated from AIDS patient assessed as minimum drug level required for killing within 15 days by MGIT 960 susceptibility test2008Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2
Thiopurine drugs azathioprine and 6-mercaptopurine inhibit Mycobacterium paratuberculosis growth in vitro.
AID1379656Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability using compound addition to cell culture cells in lag phase of growth and incubated for 48 hrs by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Structure-based design, synthesis, and biological evaluation of withaferin A-analogues as potent apoptotic inducers.
AID471313Antioxidant activity assessed as DPPH radical scavenging activity2009European journal of medicinal chemistry, Dec, Volume: 44, Issue:12
Captopril and 6-mercaptopurine: whose SH possesses higher antioxidant ability?
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347155Optimization screen NINDS Rhodamine qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347167Vero cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347149Furin counterscreen qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347150Optimization screen NINDS AMC qHTS for Zika virus inhibitors: Linked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347168HepG2 cells viability qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347169Tertiary RLuc qRT-PCR qHTS assay for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID686947qHTS for small molecule inhibitors of Yes1 kinase: Primary Screen2013Bioorganic & medicinal chemistry letters, Aug-01, Volume: 23, Issue:15
Identification of potent Yes1 kinase inhibitors using a library screening approach.
AID1745855NCATS anti-infectives library activity on the primary C. elegans qHTS viability assay2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1745854NCATS anti-infectives library activity on HEK293 viability as a counter-qHTS vs the C. elegans viability qHTS2023Disease models & mechanisms, 03-01, Volume: 16, Issue:3
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6,178)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903405 (55.11)18.7374
1990's615 (9.95)18.2507
2000's841 (13.61)29.6817
2010's1043 (16.88)24.3611
2020's274 (4.44)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 80.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index80.08 (24.57)
Research Supply Index8.85 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index147.52 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (80.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials445 (6.79%)5.53%
Reviews0 (0.00%)6.00%
Reviews612 (9.34%)6.00%
Case Studies0 (0.00%)4.05%
Case Studies602 (9.19%)4.05%
Observational0 (0.00%)0.25%
Observational34 (0.52%)0.25%
Other5 (100.00%)84.16%
Other4,861 (74.17%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (195)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase II Study of MOAD (Methotrexate, Vincristine, L-asparaginase and Dexamethasone) With Subcutaneous Campath for Adults With Relapsed or Refractory Acute Leukemia (ALL) [NCT00262925]Phase 212 participants (Actual)Interventional2006-06-30Terminated(stopped due to slow accrual)
"A Phase III Trial Comparing ARA-C/High-Dose Mitoxantrone (ALL-2') to A Standard Vincristine/Prednisone Based Regimen ('L-20') as Induction Therapy For Adult Patients With Acute Lymphoblastic Leukemia (ALL): The ALL-4 Protocol" [NCT00002766]Phase 3170 participants (Actual)Interventional1996-03-31Completed
MultiCTR Randomized Double-Blind Double-Dummy Study to Evaluate Clinical Efficacy/Safety of DR 6MP for Targeted Ileal Delivery vs Purinethol in Patients w/Moderately Active Crohn's Disease [NCT01094613]Phase 1/Phase 270 participants (Actual)Interventional2010-11-30Terminated(stopped due to Sponsor withdrew support of study due to reorganization and project prioritization)
Phase II Study of the Combination of Low-Intensity Chemotherapy and Blinatumomab in Patients With Philadelphia Chromosome Negative Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) [NCT03518112]Phase 26 participants (Actual)Interventional2018-04-18Terminated(stopped due to Due to Competing Studies)
Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil - a Prospective Collaborative Study [NCT05959720]180 participants (Anticipated)Observational [Patient Registry]2023-09-05Recruiting
Prospective Study of Rituximab Combined With Chemotherapy for CD20+ Adult Acute Lymphoblastic Leukemia [NCT01358253]Phase 4100 participants (Actual)Interventional2010-12-31Completed
On the Impact of Therapeutic Tumor Necrosis Factor-alpha Inhibition on Anogenital Human Papillomavirus Infection [NCT02376478]222 participants (Actual)Observational2009-12-31Completed
Total XV - Total Therapy Study XV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00137111]Phase 3501 participants (Actual)Interventional2000-07-08Completed
An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia [NCT03564704]Phase 2/Phase 380 participants (Anticipated)Interventional2016-02-14Recruiting
An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Target Total Therapy for Adult Early T-cell Progenitor Acute Lymphoblastic Leukemia/Lymphoma [NCT03553238]Phase 2/Phase 370 participants (Anticipated)Interventional2016-02-14Recruiting
A Phase 2 Study of Blinatumomab (NSC# 765986) in Combination With Nivolumab (NSC # 748726), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/= 1 to < 31 Years Old With First Relapse [NCT04546399]Phase 2550 participants (Anticipated)Interventional2020-12-04Suspended(stopped due to Other - FDA Partial Clinical Hold)
Treatment of Late Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months) [NCT00096135]168 participants (Actual)Interventional2004-11-30Completed
LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis [NCT02205762]Phase 2/Phase 31,400 participants (Anticipated)Interventional2016-11-02Recruiting
TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II [NCT05848687]Phase 1/Phase 290 participants (Anticipated)Interventional2023-11-01Not yet recruiting
A Phase II Study of Dasatinib (Sprycel®) (NSC #732517) as Primary Therapy Followed by Transplantation for Adults >/= 18 Years With Newly Diagnosed Ph+ Acute Lymphoblastic Leukemia by CALGB, ECOG and SWOG [NCT01256398]Phase 266 participants (Actual)Interventional2010-12-14Completed
A Phase III Randomized Trial of Blinatumomab for Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia in Adults [NCT02003222]Phase 3488 participants (Actual)Interventional2014-05-19Active, not recruiting
A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia [NCT02723994]Phase 2171 participants (Actual)Interventional2016-09-30Active, not recruiting
Phase I Study of MLN 9708 in Addition to Chemotherapy for the Treatment of Acute Lymphoblastic Leukemia in Older Adults [NCT02228772]Phase 119 participants (Actual)Interventional2014-12-31Completed
International Collaborative Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 [NCT03643276]Phase 35,000 participants (Anticipated)Interventional2018-07-15Recruiting
Phase I Trial of Ruxolitinib in Combination With a Pediatric Based-regimen for Adolescents and Young Adults (AYAs) With Ph-like Acute Lymphoblastic Leukemia (ALL) [NCT03571321]Phase 115 participants (Anticipated)Interventional2019-05-28Recruiting
A Randomized Trial for Adults With Newly Diagnosed Acute Lymphoblastic Leukemia [NCT01085617]Phase 31,033 participants (Actual)Interventional2010-12-31Active, not recruiting
S0521, A Randomized Trial of Maintenance Versus Observation for Patients With Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III [NCT00492856]Phase 3105 participants (Actual)Interventional2007-06-01Completed
Phase 1b/2 Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT02303821]Phase 1130 participants (Anticipated)Interventional2015-02-16Recruiting
A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy) [NCT02112916]Phase 3847 participants (Actual)Interventional2014-10-04Active, not recruiting
"A Novel Pediatric-Inspired Regimen With Reduced Myelosuppressive Drugs for Adults (Aged 18-60) With Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia" [NCT01920737]Phase 239 participants (Actual)Interventional2013-08-31Active, not recruiting
International Phase 3 Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones [NCT03007147]Phase 3475 participants (Anticipated)Interventional2017-08-08Recruiting
Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL) [NCT02101853]Phase 3669 participants (Actual)Interventional2014-12-17Active, not recruiting
Intensified Methotrexate, Nelarabine (Compound 506U78) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-cell Acute Lymphoblastic Leukemia (ALL) or T-cell Lymphoblastic Lymphoma [NCT00408005]Phase 31,895 participants (Actual)Interventional2007-01-22Active, not recruiting
High Risk B-Precursor Acute Lymphoblastic Leukemia (ALL) [NCT00075725]Phase 33,154 participants (Actual)Interventional2003-12-29Completed
Intensive Treatment For T-CELL Acute Lymphoblastic Leukemia and Advanced Stage Lymphoblastic Non-Hodgkin's Lymphoma: A Pediatric Oncology Group Phase III Study [NCT01230983]Phase 3573 participants (Actual)Interventional1996-06-30Completed
Determinants of Mercaptopurine Toxicity in Paediatric Acute Lymphoblastic [NCT03920813]Phase 4500 participants (Anticipated)Interventional2015-01-31Enrolling by invitation
Multicenter Trial for Treatment of Acute Lymphoblastic Leukemia in Adults (05/93) [NCT00199069]Phase 4720 participants Interventional1993-04-30Completed
Nordic Society of Paediatric Haematology and Oncology Treatment Protocol for Children (1.0 - 17.9 Years of Age) and Young Adults (18-45 Years of Age) With ALL. Efficacy of Individualised 6MP Dosing During Consolidation Therapy [NCT00816049]Phase 3775 participants (Actual)Interventional2009-01-31Completed
A Prospective, Single Arm, Open Label, Clinical Trial to Evaluate the Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage [NCT04440267]Phase 250 participants (Anticipated)Interventional2020-06-20Not yet recruiting
A Phase II Study of Double Induction Chemotherapy for Newly Diagnosed Non-L3 Adult Acute Lymphoblastic Leukemia With Investigation of Minimal Residual Disease and Risk of Relapse Following Maintenance Chemotherapy [NCT00109837]Phase 279 participants (Actual)Interventional2005-04-30Completed
Pethema LAL-RI/2008: Treatment for Patients With Standard Risk Acute [NCT02036489]Phase 4107 participants (Actual)Interventional2008-01-31Completed
A Randomised Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA Versus Standard ATRA and Anthracycline-Based Chemotherapy (AIDA Regimen) for Newly Diagnosed, Non High-Risk Acute Promyelocytic Leukemia [NCT00482833]Phase 3276 participants (Actual)Interventional2007-08-31Completed
Young Adult Acute Lymphoid Leukemia (ALL): Intensification of Pediatric AIEOP LLA-2000 Treatment [NCT01156883]76 participants (Actual)Interventional2010-04-30Completed
Treatment of Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia in [NCT06099366]Phase 2116 participants (Anticipated)Interventional2024-01-15Not yet recruiting
Standard Risk B-precursor Acute Lymphoblastic Leukemia (ALL) [NCT00103285]Phase 35,377 participants (Actual)Interventional2005-04-11Completed
A Phase 1 Study Combining Venetoclax With a Pediatric-Inspired Regimen for Newly Diagnosed Adults With B Cell Ph-Like Acute Lymphoblastic Leukemia [NCT05157971]Phase 16 participants (Anticipated)Interventional2022-03-17Recruiting
A Phase II Study of Blinatumomab and POMP (Prednisone, Vincristine, Methotrexate, 6-Mercaptopurine) for Patients ≥ 65 Years of Age With Newly Diagnosed Philadelphia-Chromosome Negative (Ph-) Acute Lymphoblastic Leukemia (ALL) and of Dasatinib, Prednisone [NCT02143414]Phase 253 participants (Actual)Interventional2015-06-30Active, not recruiting
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Blinatumomab With or Without Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia [NCT02877303]Phase 280 participants (Anticipated)Interventional2016-11-01Recruiting
Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00549848]Phase 3600 participants (Actual)Interventional2007-10-29Completed
Comparative Pharmacokinetics of a Compounded 6-mercaptopurine Liquid Formulation Preparation and Tablets [NCT01324336]40 participants (Actual)Observational2011-07-31Completed
A Phase I/II Dose Escalation Study of Subcutaneous Campath-1H (NSC #715969, IND #10864) During Intensification Therapy in Adults With Untreated Acute Lymphoblastic Leukemia (ALL) [NCT00061945]Phase 1/Phase 2302 participants (Actual)Interventional2003-06-30Completed
A Phase III Trial of Treatment of Advanced-Stage Anaplastic Large Cell Lymphoma (ALCL) With Standard APO (Doxorubicin, Prednisone, Vincristine) Versus Consolidation With a Regimen Including Vinblastine [NCT00059839]Phase 3129 participants (Actual)Interventional2003-11-30Completed
Randomized Phase III Study for the Treatment of Newly Diagnosed Disseminated Lymphoblastic Lymphoma or Localized Lymphoblastic Lymphoma [NCT00004228]Phase 3393 participants (Actual)Interventional2000-06-30Completed
TEMPLE - Thiopurine Enhanced Mutations for PD-1/Ligand-1 Efficacy [NCT05276284]Phase 1/Phase 239 participants (Anticipated)Interventional2022-09-01Recruiting
Single-Dose Fasting In Vivo Bioequivalence Study of Mercaptopurine (50 mg; Mylan) and Purinethol® Tablets (50 mg; Gate) in Healthy Male Volunteers [NCT00648336]Phase 160 participants (Actual)Interventional2003-11-30Completed
A Prospective Phase II Trial of Modified MRC UKALL Ⅻ/ECOG E2993 Regimen in the Treatment of Low Risk Philadelphia Chromosome Negative Acute Lymphoblastic Leukemia for Young Adults [NCT02660762]Phase 2100 participants (Anticipated)Interventional2016-01-31Recruiting
Ma-Spore ALL 2010 Study [NCT02894645]Phase 4500 participants (Anticipated)Interventional2008-10-31Recruiting
DFCI ALL Adult Consortium Protocol: Adult ALL Trial [NCT01005758]Phase 2180 participants (Anticipated)Interventional2009-01-31Not yet recruiting
A Phase 3 Trial Investigating Blinatumomab (NSC# 765986) in Combination With Chemotherapy in Patients With Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients With Localized B-Lymphoblastic Lymphom [NCT03914625]Phase 36,720 participants (Anticipated)Interventional2019-07-03Recruiting
Phase 2 Clinical Trial for Comprehensive Treatment Program for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Tagraxofusp (SL-401) in Combination With HCVAD/Mini-CVD and VENETOCLAX [NCT04216524]Phase 240 participants (Anticipated)Interventional2020-05-29Recruiting
Risk Adapted Treatment of Newly Diagnosed Childhood Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide (Trisenox® ) During Consolidation [NCT00866918]Phase 3106 participants (Actual)Interventional2009-03-09Completed
Pilot, Randomized, Open-Label, Two-Way Crossover Comparative Bioavailability Study of 40 mg Delayed Release Oral 6Mercaptopurine Versus 100 mg Purinethol in Patients With Crohns Disease [NCT00774982]Phase 112 participants (Actual)Interventional2008-12-31Completed
A Randomized Trial of the I-BFM-SG for the Management of Childhood Non-B Acute Lymphoblastic Leukemia [NCT00764907]Phase 34,000 participants (Anticipated)Interventional2002-11-30Recruiting
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome [NCT02521493]Phase 3312 participants (Anticipated)Interventional2015-12-23Active, not recruiting
A Multicenter and Randomized Prospective Study for Improving the Outcome of Childhood Acute Promyeloid Leukemia [NCT02200978]Phase 4176 participants (Actual)Interventional2011-09-30Completed
Risk-stratified Randomized Controlled Trial in Paediatric Crohn Disease:Methotrexate vs Azathioprine or Adalimumab for Maintaining Remission in Patients at Low or High Risk for Aggressive Disease Course, respectively-a Treatment Strategy [NCT02852694]Phase 4312 participants (Anticipated)Interventional2017-02-28Recruiting
A Pilot Study of Intravenous EZN-2285 (SC-PEG E. Coli L-asparaginase) or Intravenous Oncaspar® in the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (ALL) [NCT00671034]Phase 3166 participants (Actual)Interventional2008-07-21Completed
A Phase III Study, Randomized, to Evaluate the Reduction of Chemotherapy Intensity in Association With Nilotinib (Tasigna®) in Philadelphia Chromosome-positive (Ph+) ALL of Young Adults (18-59 Years Old) (GRAAPH-2014) [NCT02611492]Phase 3265 participants (Anticipated)Interventional2016-04-30Recruiting
An Open-label, Multicenter, Phase 2 Study Evaluating the Efficacy and Safety of Daratumumab in Pediatric and Young Adult Subjects >=1 and <=30 Years of Age With Relapsed/Refractory Precursor B-cell or T-cell Acute Lymphoblastic Leukemia or Lymphoblastic L [NCT03384654]Phase 247 participants (Actual)Interventional2018-05-14Completed
Intensified Tyrosine Kinase Inhibitor Therapy (Dasatinib NSC# 732517) in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (ALL) [NCT00720109]Phase 2/Phase 363 participants (Actual)Interventional2008-07-14Completed
Treatment of High Risk Adult Acute Lymphoblastic Leukemia [NCT00853008]Phase 4100 participants (Anticipated)Interventional2003-01-31Completed
Escalating Dose Intravenous Methotrexate Without Leucovorin Rescue Versus Oral Methotrexate and Single Versus Double Delayed Intensification for Children With Standard Risk Acute Lymphoblastic Leukemia [NCT00005945]Phase 33,054 participants (Actual)Interventional2000-06-30Completed
Pharmacogenetic Testing in the Clinical Setting: is Screening for TPMT Genotype a Cost-effective Treatment Strategy? - The First Prospective Randomized Controlled Trial Within the Dutch Health Care System. [NCT00521950]853 participants (Actual)Interventional2007-09-30Completed
A Collaborative Trial for the Treatment of Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplasia [NCT00136084]Phase 3238 participants (Actual)Interventional2002-08-31Completed
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies [NCT00381680]Phase 3275 participants (Actual)Interventional2007-03-31Completed
Plasma Kinetics of Tablet and Liquid Formulations of 6-mercaptopurine in Childhood Acute Lymphoblastic Leukemia. [NCT01906671]Phase 416 participants (Anticipated)Interventional2013-06-30Recruiting
German Multicenter Trial for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years With Rituximab for Improvement of Prognosis in CD20 Positive Standard Risk ALL (Amend 2) [NCT00199004]Phase 460 participants (Anticipated)Interventional2004-04-30Completed
ICON1: Physician Treatment Decisions and Patient-Reported Outcomes in Pediatric Refractory Immune Thrombocytopenia [NCT01971684]120 participants (Actual)Observational2013-08-31Completed
Phase III Study to Compare Haplo-identical HSCT Versus Chemotherapy in First Remission for Standard-risk Adult Acute Lymphoblastic Leukemia [NCT02042690]Phase 3131 participants (Actual)Interventional2014-07-31Completed
CINJALL: Treatment for Children With Acute Lymphocytic Leukemia [NCT00176462]Phase 260 participants (Actual)Interventional2001-02-28Completed
Treatment of Patients With Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy) [NCT01190930]Phase 39,350 participants (Actual)Interventional2010-08-09Active, not recruiting
Intensified PEG-Asparaginase in High Risk Acute Lymphoblastic Leukemia (ALL): A Pilot Study [NCT00866307]Phase 1104 participants (Actual)Interventional2009-02-23Completed
AIEOP LLA 2000 Multicenter Study for the Diagnosis and Treatment of Childhood Acute Lymphoblastic Leukemia [NCT00613457]Phase 32,039 participants (Actual)Interventional2000-09-30Completed
Modified BFM-95 Regimen for the Treatment of Newly Diagnosed T-lymphoblastic Lymphoma in Adults:a Prospective Phase II Study [NCT02396043]Phase 250 participants (Anticipated)Interventional2015-03-31Recruiting
Phase III Randomized Trial of Autologous and Allogeneic Stem Cell Transplantation Versus Intensive Conventional Chemotherapy in Acute Lymphoblastic Leukemia in First Remission [NCT00002514]Phase 31,929 participants (Actual)Interventional1993-05-07Completed
A Multicenter Study of Treatment Protocol for Childhood Acute Lymphoblastic Leukemia in China, 2008. [NCT00707083]Phase 32,231 participants (Actual)Interventional2008-05-01Completed
Pediatric-inspired Regimen Combined With Venetoclax for Adolescent and Adult Patients With de Novo Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia [NCT05660473]Phase 2100 participants (Anticipated)Interventional2022-10-31Recruiting
The Individualized Treatment of 6-mercaptopurine in Children With Acute Lymphoblastic Leukemia in China [NCT04228393]Phase 2/Phase 382 participants (Anticipated)Interventional2020-02-01Not yet recruiting
Clinical Study of GD-2008 ALL Protocol for Childhood Acute Lymphoblastic Leukemia in Guangdong Province [NCT00846703]Phase 4600 participants (Anticipated)Interventional2008-07-31Recruiting
A Pilot Study of Arsenic Trioxide-Based Consolidation Therapy for the Primary Treatment of Acute Promyelocytic Leukemia [NCT00276601]Phase 20 participants Interventional2004-10-31Completed
Multicenter Trial for Treatment Optimization in T-lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1) [NCT00199017]Phase 475 participants (Anticipated)Interventional2004-04-30Completed
Total Therapy Study XIV for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia [NCT00187005]Phase 353 participants (Actual)Interventional1998-07-31Terminated(stopped due to Toxicity)
A Study of Children With Refractory or Relapsed Acute Lymphoblastic Leukemia (ALLR16) [NCT00187083]Phase 340 participants (Actual)Interventional1997-02-28Completed
Treatment for Newly Diagnosed Patients With Stage III/IV Non-Hodgkin Lymphoma-Study XIII (A Therapeutic Pilot Study) [NCT00187122]42 participants (Actual)Interventional1993-03-31Completed
LAL-BR/2001: Study Treatment to Low Risk ALL [NCT00526175]Phase 4150 participants (Anticipated)Interventional2001-06-30Completed
A Phase 1-2 Study of 6-Thioguanine in Combination With Methotrexate and 6-Mercaptopurine During Maintenance Therapy of Childhood, Adolescent, and Adult Lymphoblastic Non-Hodgkin's Lymphoma and Acute Lymphoblastic Leukemia [NCT02912676]Phase 1/Phase 230 participants (Actual)Interventional2016-10-31Completed
ALL-BFM 2000 Multi-Center Study for the Treatment of Children and Adolescents With Acute Lymphoblastic Leukemia [NCT00430118]Phase 34,559 participants (Actual)Interventional2000-07-31Completed
A Pharmacokinetic Study to Assess the Single-Dose Bioequivalence of a Potential Generic Formulation of a 6-Mercaptopurine 50 mg Tablet Compared to a Marketed 6-Mercaptopurine 50 mg Tablet, Purinethol®, When Administered to Healthy Male Subjects, in the Fa [NCT00602134]54 participants (Actual)Interventional2002-11-30Completed
PETHEMA LAL-RI/96: Treatment for Patients With Standard Risk Acute Lymphoblastic Leukemia [NCT00494897]Phase 4374 participants (Actual)Interventional1996-06-30Completed
A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement [NCT02828358]Phase 278 participants (Actual)Interventional2017-04-01Active, not recruiting
LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive [NCT00526305]Phase 4100 participants (Anticipated)Interventional2000-01-31Completed
An Observational Study of the Immunopathogenesis of and Response to Step-Up Inflammatory Bowel Disease Therapy for Hermansky-Pudlak Syndrome-Associated Colitis [NCT00514982]Phase 20 participants (Actual)Interventional2007-08-07Withdrawn
Modified BFM (Berlin-Frankfurt-Munster)Backbone Therapy for Chinese Children or Adolescents With Newly Diagnosed Lymphoblastic Lymphoma [NCT02845882]Phase 3150 participants (Anticipated)Interventional2016-01-31Active, not recruiting
A Phase III Study of Risk Directed Therapy for Infants With Acute Lymphoblastic Leukemia (ALL): Randomization of Highest Risk Infants to Intensive Chemotherapy +/- FLT3 Inhibition (CEP-701, Lestaurtinib; NSC#617807) [NCT00557193]Phase 3218 participants (Actual)Interventional2008-01-15Active, not recruiting
LBL 2018 - International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma [NCT04043494]Phase 3683 participants (Anticipated)Interventional2019-08-23Recruiting
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic or Biphenotypic Leukemia [NCT00550992]445 participants (Anticipated)Interventional2006-01-31Recruiting
Efficacy of Optimized Thiopurine Therapy in Ulcerative Colitis (OPTIC) [NCT02910245]Phase 3136 participants (Anticipated)Interventional2016-11-30Recruiting
Phase II Study of the Hyper-CVAD Regimen in Sequential Combination With Inotuzumab Ozogamicin as Frontline Therapy for Adults With B-Cell Lineage Acute Lymphocytic Leukemia [NCT03488225]Phase 24 participants (Actual)Interventional2018-03-28Terminated(stopped due to the study was closed early due to competing trials)
A RANDOMIZED PHASE III TRIAL COMPARING DEXAMETHASONE WITH PREDNISONE IN INDUCTION TREATMENT AND BONE MARROW TRANSPLANTATION WITH INTENSIVE MAINTENANCE TREATMENT IN ADOLESCENT AND ADULT ACUTE LYMPHOBLASTIC LEUKEMIA (ALL-4) [NCT00002700]Phase 3392 participants (Anticipated)Interventional1995-08-31Completed
Understanding the Ethnic and Racial Differences in Survival in Children With Acute Lymphoblastic Leukemia [NCT00268528]720 participants (Anticipated)Observational2005-05-30Completed
Pilot, Open-Label, Randomized, Parallel Group Study to Evaluate Clinical/ and Immunological Efficacy/Safety of Locally Delivered 6-MP or Calcitriol vs Purinethol in Non-Steroid Dependent Patients With Active CD [NCT00287170]Phase 1/Phase 215 participants (Actual)Interventional2006-07-31Completed
A Phase II Study of Campath-1H in Children With Acute Lymphoblastic Leukemia in Second or Greater Relapse or Twice Induction Failure [NCT00089349]Phase 225 participants (Actual)Interventional2004-07-31Completed
Multicentric Study for the Treatment of Children With Acute Lymphoblastic Leukemia [NCT00343369]550 participants (Anticipated)Interventional2003-01-31Recruiting
Randomized Controlled Trial to Test Efficacy of High-Dose Methotrexate Consolidation Therapy for BCR-ABL-Negative Acute Lymphoblastic Leukemia in Adults [NCT00131027]Phase 3240 participants (Anticipated)Interventional2002-09-30Recruiting
Phase I/II Study of the Combination of Inotuzumab Ozogamycin (CMC-544) With Low-Intensity Chemotherapy in Patients With Acute Lymphoblastic Leukemia (ALL) [NCT01371630]Phase 1/Phase 2276 participants (Anticipated)Interventional2011-08-26Recruiting
A Phase I/II Trial of ABT-751 Combined With Dexamethasone, PEG-asparaginase, and Doxorubicin in Relapsed Acute Lymphoblastic Leukemia (ALL) [NCT00439296]Phase 1/Phase 29 participants (Actual)Interventional2006-05-22Terminated(stopped due to The study was stopped due to poor accrual and lack of funding.)
Treatment of Older Adults With Acute Lymphoblastic Leukemia [NCT00973752]Phase 230 participants (Actual)Interventional2009-08-31Completed
Phase II Study of Hyper-CVAD Plus Nelarabine in Previously Untreated T-ALL and Lymphoblastic Lymphoma [NCT00501826]Phase 2160 participants (Anticipated)Interventional2007-07-11Recruiting
Treatment Of Newly Diagnosed Adult Acute Lymphoblastic Leukemia With Intensified Post Remission Therapy Containing PEG-Asparaginase. [NCT00184041]Phase 247 participants (Actual)Interventional2004-07-31Completed
A Phase I-II Study of the Combination of Ruxolitinib or Dasatinib With Chemotherapy in Patients With Philadelphia Chromosome (Ph)-Like Acute Lymphoblastic Leukemia (ALL) [NCT02420717]Phase 211 participants (Actual)Interventional2015-07-15Terminated(stopped due to Study was closed early due to low accrual and lack of response.)
Treatment of Acute Lymphoblastic Leukemia in Children [NCT00400946]Phase 3800 participants (Actual)Interventional2005-04-30Completed
A Phase II Study of Bortezomib and Vorinostat in Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies [NCT02419755]Phase 212 participants (Actual)Interventional2015-04-14Terminated(stopped due to Accrual goals were no longer feasible based on restrictions imposed by the DSMB.)
A Phase III Study of Large Cell Lymphomas in Children and Adolescents: Comparison of APO vs APO + IDMTX/HDARA-C and Continuous vs Bolus Infusion of Doxorubicin [NCT00002618]Phase 3242 participants (Anticipated)Interventional1994-12-31Completed
Induction Intensification in Infant ALL: A Children's Oncology Group Study [NCT00002756]Phase 2221 participants (Actual)Interventional1996-06-30Completed
A Study of Modified Augmented BFM Therapy for Infants With Acute Lymphoblastic Leukemia [NCT00022126]Phase 26 participants (Actual)Interventional2002-11-30Completed
International Collaborative Treatment Protocol for Infants Under One Year With Acute Lymphoblastic Leukemia [NCT00015873]Phase 3350 participants (Anticipated)Interventional1999-05-31Completed
The Use of Modified BFM +/- Compound 506U78 (Nelarabine) (NSC# 686673, IND #52611) in an Intensive Chemotherapy Regimen for the Treatment of T-Cell Leukemia [NCT00016302]100 participants (Actual)Interventional2001-04-30Completed
Treatment Protocol for T-Cell and B-Precursor Cell Lymphoblastic Lymphoma of the European Inter-group Co-operation on Childhood Non-Hodgkin-Lymphoma (EICNHL) [NCT00275106]Phase 3600 participants (Anticipated)Interventional2004-09-30Terminated(stopped due to Withdrawn due to an excess of toxic deaths)
PILOT MULTINATIONAL PROTOCOLS IN ACUTE LYMPHOBLASTIC LEUKEMIA AND DIFFUSE NON-HODGKIN'S LYMPHOMA [NCT00018954]Phase 20 participants Interventional1992-10-31Completed
A Children's Oncology Group Pilot Study for the Treatment of Very High Risk Acute Lymphoblastic Leukemia in Children and Adolescents (Imatinib (STI571, GLEEVEC) NSC#716051) [NCT00022737]Phase 3220 participants (Actual)Interventional2002-10-31Completed
A Randomized Study of Two Methods of CNS Prophylaxis in Patients With Acute Lymphoblastic Leukemia [NCT00019409]Phase 30 participants (Actual)Interventional1999-10-31Withdrawn
Phase 2 Study of Applying Pediatric Regimens to Younger Adult Patients With BCR-ABL-Negative Acute Lymphoblastic Leukemia [NCT00131053]Phase 2120 participants (Anticipated)Interventional2002-09-30Recruiting
Pilot Study I for Treatment of Cancer in Children With Ataxia-Telangiectasia [NCT00187057]6 participants (Actual)Interventional2002-09-30Completed
Prospective Study of the Diagnosis and Treatment of Myelodysplastic Syndromes (MDS) in Childhood [NCT00047268]Phase 30 participants Interventional1998-07-31Active, not recruiting
An Intergroup Phase II Clinical Trial for Adolescents and Young Adults With Untreated Acute Lymphoblastic Leukemia (ALL) [NCT00558519]Phase 2318 participants (Actual)Interventional2008-03-12Active, not recruiting
Phase II Study of Individual 6-mercaptopurine(6MP) Dose Increments in Children With Acute Lymphoblastic Leukemia (ALL) Receiving High-dose Methotrexate (HDM) and PEG-asparaginase [NCT00548431]Phase 238 participants (Actual)Interventional2007-12-31Completed
Asia-wide, Multicenter Open-label, Phase II Non-randomised Study Involving Children With Down Syndrome Under 21 Year-old With Newly Diagnosed, Treatment naïve Acute Lymphoblastic Leukemia [NCT03286634]Phase 260 participants (Anticipated)Interventional2017-04-18Recruiting
Augmented Berlin-Frankfurt-Munster Therapy for Adolescents/Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [NCT00866749]Phase 2120 participants (Actual)Interventional2006-09-12Completed
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL [NCT03150693]Phase 3310 participants (Anticipated)Interventional2017-06-01Suspended(stopped due to Unacceptable Toxicity)
A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL [NCT01503632]Phase 3570 participants (Actual)Interventional2012-02-21Active, not recruiting
Phase Ib/II Study of the Combination of Low-Intensity Chemotherapy and Tagraxofusp in Patients With Acute Lymphoblastic Leukemia (ALL) [NCT05032183]Phase 1/Phase 240 participants (Anticipated)Interventional2022-02-17Recruiting
An Investigator Initiated Prospective, Single Center, Randomized, Open Label Study to Assess the Efficacy of Adalimumab for the Maintenance of Remission in Post-operative CD Patients [NCT01629628]Phase 3100 participants (Anticipated)Interventional2012-07-31Not yet recruiting
A SINGLE CENTER, SINGLE-DOSE, OPEN-LABEL, RANDOMIZED, TWO-PERIOD CROSSOVER STUDY TO ASSESS THE BIOEQUIVALENCE OF AN ORAL MERCAPTOPURINE SUSPENSION 100 mg / 5 mL VERSUS AN ORAL MERCAPTOPURINE TABLET 50 mg (PURINETHOL®) IN AT LEAST 62 HEALTHY MALE SUBJECTS [NCT01697020]Phase 170 participants (Actual)Interventional2012-09-30Completed
Treatment Protocol for Newky Diagnosed Adult Ph-Chromosome Positive (BCR::ABL1) Acute Lymphoblastic Leukemia (LALPh2022) [NCT06175702]150 participants (Anticipated)Observational2023-12-25Not yet recruiting
Phase 4, Open Label Multicenter Randomized Controlled Trial. Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Immunomodulator Failure [NCT01802593]Phase 420 participants (Actual)Interventional2013-02-28Terminated(stopped due to lack of budget and failure to reach milestones)
A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma [NCT01700946]Phase 280 participants (Actual)Interventional2013-04-15Completed
A Pilot Study to Evaluate if Response to Infliximab or Adalimumab May be Regained With the Addition of an Immunomodulator [NCT02413047]3 participants (Actual)Interventional2015-05-31Terminated(stopped due to physician decision to stop study early due to low enrollment)
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma [NCT03117751]Phase 2/Phase 3790 participants (Actual)Interventional2017-03-29Active, not recruiting
RAVEN: A Phase I/II Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax [NCT05192889]Phase 1/Phase 290 participants (Anticipated)Interventional2022-08-25Recruiting
ABT-199 (Venetoclax) and Purine Analogues as Novel Oral Drug Combination for Treatment of Relapsed/Refractory Acute Myeloid Leukemia: the ApoAML Trial [NCT05506332]Phase 110 participants (Anticipated)Interventional2022-07-15Recruiting
A Phase II Study Incorporating Panobinostat, Bortezomib and Liposomal Vincristine Into Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma [NCT02518750]Phase 23 participants (Actual)Interventional2016-11-23Terminated(stopped due to Due to slow accrual)
A Randomized Phase III Study to Compare Arsenic Trioxide (ATO) Combined to ATRA and Idarubicin Versus Standard ATRA and Anthracyclines-based Chemotherapy (AIDA Regimen) for Patients With Newly Diagnosed, High-risk Acute Promyelocytic Leukemia [NCT02688140]Phase 3280 participants (Anticipated)Interventional2016-06-30Active, not recruiting
TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY [NCT00002704]Phase 2156 participants (Actual)Interventional1996-01-31Completed
Treatment of Patients With Acute Lymphoblastic Leukemia With Unfavorable Features: A Phase III Group-wide Study [NCT00002812]Phase 32,078 participants (Actual)Interventional1996-09-30Completed
Phase III Randomized Study of Concurrent Tretinoin and Chemotherapy With or Without Arsenic Trioxide (AS2O3) (NSC # 706363) as Initial Consolidation Therapy Followed by Maintenance Therapy With Intermittent Tretinoin Versus Intermittent Tretinoin Plus Mer [NCT00003934]Phase 3420 participants (Actual)Interventional1999-06-30Completed
Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia Testing Increased Doses of Daunorubicin During Induction, and Cytarabine During Consolidation, Followed by High-Dose Methotrexate and Intrathecal Methotrexate in Place of Cranial Irradia [NCT00003700]Phase 2163 participants (Actual)Interventional1999-01-31Completed
Pilot Study for Treatment of Elderly Patients (>65 Years) With Acute Lymphoblastic Leukemia [NCT00199095]Phase 440 participants Interventional1997-02-28Completed
Multicenter Trial for Treatment of Acute Lymphocytic Leukemia in Adults (Pilot Study 06/99) [NCT00199056]Phase 4225 participants Interventional1999-10-31Completed
Multicenter Study To Optimize Treatment in Elderly Patients (> 55 Years, No Upper Age Limit) With Acute Lymphoblastic Leukemia (GMALL Elderly 1/2003)(Amend 2) [NCT00198978]Phase 4377 participants (Actual)Interventional2003-01-31Completed
ALinC 17: Protocol for Patients With Newly Diagnosed Standard Risk Acute Lymphoblastic Leukemia (ALL): A Phase III Study [NCT00005596]Phase 31,076 participants (Actual)Interventional2000-04-30Completed
Evaluation of the Clinical and Immunological Impact of Two Therapeutic Strategies (Increasing the Infliximab Dose or Introduction of Immunosuppressive Therapy) in Patients Chronic Inflammatory Bowel Diseases in Loss of Response to Infliximab [NCT03370601]9 participants (Actual)Interventional2017-01-03Terminated(stopped due to Not enough recruitment Lack of funding CR)
A proSpective Randomized Controlled Trial comParing infliximAb-antimetabolites Combination Therapy to Anti-metabolites monotheRapy and Infliximab monothErapy in Crohn's Disease Patients in Sustained Steroid-free Remission on Combination Therapy [NCT02177071]Phase 4211 participants (Actual)Interventional2015-10-09Completed
German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003) [NCT00198991]Phase 41,883 participants (Actual)Interventional2003-04-30Completed
A Prospective Institutional Study for the Treatment of Children With Newly Diagnosed Langerhans Cell Histiocytosis Using a Cytarabine Contained Protocol [NCT04773366]Phase 3200 participants (Anticipated)Interventional2018-07-01Recruiting
A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia [NCT00186875]Phase 247 participants (Actual)Interventional2003-11-30Completed
S0535, A Phase II Study of ATRA, Arsenic Trioxide and Gemtuzumab Ozogamicin in Patients With Previously Untreated High-Risk Acute Promyelocytic Leukemia [NCT00551460]Phase 278 participants (Actual)Interventional2007-11-15Completed
Phase II Clinical Trial Of 6-Mercaptopurine (6MP) and Low-Dose Methotrexate In Patients With Known BRCA Defective Tumours [NCT01432145]Phase 274 participants (Actual)Interventional2011-05-31Completed
Randomized Comparisons of Oral Mercaptopurine vs Oral Thioguanine and IT Methotrexate vs ITT for Standard Risk Acute Lymphoblastic Leukemia [NCT00002744]Phase 31,970 participants (Actual)Interventional1996-05-31Completed
TREATMENT OF ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: PHASE II TRIALS OF AN INDUCTION REGIMEN INCLUDING PEG-L-ASPARAGINASE, WITH OR WITHOUT PIXY, IN PREVIOUSLY UNTREATED PATIENTS, FOLLOWED BY ALLOGENEIC BONE MARROW TRANSPLANTATION OR FURTHER CHEMOTHERAPY IN FI [NCT00002665]Phase 250 participants (Anticipated)Interventional1995-07-31Completed
INDUCTION WITH ALL-TRANS RETINOIC ACID IN COMBINATION WITH IDARUBICIN AND INTENSIVE CONSOLIDATION FOLLOWED BY BONE MARROW TRANSPLANTATION OR A RANDOMIZED MAINTENANCE TREATMENT DEPENDING UPON THE AMOUNT OF MINIMAL RESIDUAL DISEASE IN ACUTE PROMYELOCYTIC LE [NCT00002701]Phase 3750 participants (Anticipated)Interventional1995-10-31Active, not recruiting
Phase III Study of Combination Chemotherapy in Children With T Cell and Pre-B Cell Non-Hodgkin's Lymphoma [NCT00003650]Phase 3179 participants (Actual)Interventional1997-02-28Completed
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Infants Less Than 1 Year of Age. [NCT00002785]Phase 20 participants Interventional1996-07-31Completed
The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenanc [NCT00003728]Phase 31,500 participants (Anticipated)Interventional1998-12-31Active, not recruiting
[NCT00004688]Phase 235 participants Interventional1996-08-31Completed
MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93) [NCT00002531]Phase 20 participants Interventional1993-01-31Active, not recruiting
Non-Hodgkin's Lymphoma T Cell Protocol [NCT00003423]Phase 3100 participants (Anticipated)Interventional1995-05-31Active, not recruiting
ALinC 17: Continuous Intensification for Very High Risk Acute Lymphocytic Leukemia (A.L.L.): A Pediatric Oncology Group Pilot Study [NCT00003783]Phase 236 participants (Actual)Interventional1999-03-31Completed
Treatment Optimization in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment - a Phase IV-trial With a Phase III-part to Evaluate Safety and Efficacy of Ne [NCT02881086]Phase 31,000 participants (Actual)Interventional2016-08-31Active, not recruiting
NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma [NCT01451515]Phase 223 participants (Actual)Interventional2012-05-25Completed
A Randomized Multi-Center Treatment Study (COALL 08-09) to Improve the Survival of Children With Acute Lymphoblastic Leukemia on Behalf of the German Society of Pediatric Hematology and Oncology [NCT01228331]Phase 2/Phase 3745 participants (Actual)Interventional2010-10-31Active, not recruiting
ALINC #17 Treatment for Patients With Low Risk Acute Lymphoblastic Leukemia: A Pediatric Oncology Group Phase III Study [NCT00005585]Phase 3838 participants (Actual)Interventional2000-04-30Completed
Concurrent Ponatinib With Chemotherapy for Young Adults With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia [NCT02776605]Phase 230 participants (Actual)Interventional2016-06-30Active, not recruiting
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I [NCT02553460]Phase 1/Phase 250 participants (Actual)Interventional2016-01-29Active, not recruiting
Dasatinib Plus Multi-agent Chemotherapy for New Diagnosed Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia [NCT02523976]Phase 230 participants (Actual)Interventional2015-08-01Completed
Phase II Study of Adult Acute Lymphoblastic Leukaemia (ALL): Imatinib in Combination With Chemotherapy in Ph+ Patients, and Post-remissional Treatment Intensification in High-risk Ph- Patients, With Minimal Residual Disease Monitoring. [NCT00458848]Phase 2470 participants (Actual)Interventional2004-10-31Completed
A Multicenter Randomized, Open-label Study to Compare the Efficacy of Subcutaneous Infliximab Monotherapy With Subcutaneous Infliximab and Concomitant Immunosuppression in the Treatment of Moderate to Severe Crohn's Disease [NCT06059989]Phase 3158 participants (Anticipated)Interventional2021-11-25Recruiting
A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) Including a Stratum Evaluating Dasatinib (NSC#732517) in Patients With Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations [NCT02883049]Phase 35,937 participants (Actual)Interventional2012-02-29Active, not recruiting
A Randomized International Phase 3 Trial of Imatinib and Chemotherapy With or Without Blinatumomab in Patients With Newly-Diagnosed Philadelphia Chromosome-Positive or Philadelphia Chromosome-Like ABL-Class B-Cell Acute Lymphoblastic Leukemia [NCT06124157]Phase 3680 participants (Anticipated)Interventional2024-01-22Not yet recruiting
International Collaborative Treatment Protocol For Children And Adolescents With Acute Lymphoblastic Leukemia [NCT01117441]Phase 36,136 participants (Actual)Interventional2010-06-30Completed
A Multicenter Phase II Study in Adults With Untreated Acute Lymphoblastic Leukemia: Testing Pharmacokinetically Individualized Doses of L-Asparaginase Following the DFCI Pediatric Consortium Protocol [NCT00136435]Phase 2100 participants (Anticipated)Interventional2002-06-30Active, not recruiting
Medical Research Council Working Party on Leukaemia in Children UK National Lymphoblastic Leukaemia (ALL) Trial [NCT00003437]Phase 31,800 participants (Anticipated)Interventional1997-01-31Active, not recruiting
ALinC 17: Protocol for Patients With Newly Diagnosed High Risk Acute Lymphoblastic Leukemia (ALL) - Evaluation of the Augmented BFM Regimen: A Phase III Study [NCT00005603]Phase 3276 participants (Actual)Interventional2000-03-31Completed
Protocol for Patients With Newly Diagnosed Better Risk Acute Lymphoblastic Leukemia (ALL): A POG Pilot Study [NCT00003671]Phase 259 participants (Actual)Interventional1998-12-31Completed
A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy [NCT03959085]Phase 34,772 participants (Anticipated)Interventional2019-10-31Recruiting
A Randomized Phase II Study Comparing Inotuzumab Plus Chemotherapy Versus Standard Chemotherapy in Older Adults With Philadelphia-Chromosome-Negative B-Cell Acute Lymphoblastic Leukemia [NCT05303792]Phase 266 participants (Anticipated)Interventional2023-02-27Recruiting
Thiopurine Induced Pancreatitis in IBD Patients [NCT02281799]Phase 40 participants (Actual)Interventional2015-03-31Withdrawn(stopped due to No Participants Enrolled)
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents [NCT03020030]Phase 3560 participants (Actual)Interventional2017-03-03Active, not recruiting
Phase II Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia [NCT05645718]Phase 227 participants (Anticipated)Interventional2023-07-14Recruiting
A Randomized Trial Using a Modified COG ABFM Regimen Backbone to Investigate Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL) [NCT05681260]Phase 3200 participants (Anticipated)Interventional2023-02-06Recruiting
Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma [NCT02419469]Phase 21 participants (Actual)Interventional2015-11-13Terminated(stopped due to Slow Accrual)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00002766 (1) [back to overview]Complete Remission (CR)
NCT00004228 (2) [back to overview]Event-free Survival
NCT00004228 (2) [back to overview]Percentage of Patients With Overall Survival as Assessed by Time to Death
NCT00059839 (1) [back to overview]Event-free Survival (EFS)
NCT00061945 (6) [back to overview]Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)
NCT00061945 (6) [back to overview]Overall Survival
NCT00061945 (6) [back to overview]Number of Participants Achieving Complete Remission
NCT00061945 (6) [back to overview]Disease-free Survival, for Only Complete Response Patients
NCT00061945 (6) [back to overview]Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)
NCT00061945 (6) [back to overview]Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).
NCT00075725 (7) [back to overview]Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)
NCT00075725 (7) [back to overview]Correlation of Early Marrow Response Status With MRD Negative.
NCT00075725 (7) [back to overview]Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions
NCT00075725 (7) [back to overview]Correlation of Early Marrow Response Status With MRD Positive.
NCT00096135 (1) [back to overview]Event-free Survival
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-Average ALL Patients
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-High Patients.
NCT00103285 (10) [back to overview]Event-Free Survival (EFS) for Low MRD (Negative) Subjects by Genetic Subset (TEL/Trisomy Positive vs Negative)
NCT00103285 (10) [back to overview]Early Marrow Status (EMS) by MRD Status End Induction (Day 29)
NCT00103285 (10) [back to overview]Optimal Time Point for Advance Health Related Quality of Life Intervention
NCT00103285 (10) [back to overview]Health-related Quality of Life Relative to Physical, Social and Emotional Impairment
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-Average ALL Patients
NCT00103285 (10) [back to overview]Overall Survival Probability (OS) According to Induction Day 29 MRD Status
NCT00103285 (10) [back to overview]Event-Free Survival Probability According to MRD Status End Induction (Day 29)
NCT00103285 (10) [back to overview]Event-free Survival (EFS) for SR-Low Patients
NCT00109837 (2) [back to overview]Continuous Complete Remission at 1 Year
NCT00109837 (2) [back to overview]Toxicity
NCT00136084 (7) [back to overview]Relationship of Inhibition of DNA Synthesis and Clinical Response
NCT00136084 (7) [back to overview]To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy
NCT00136084 (7) [back to overview]To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy
NCT00136084 (7) [back to overview]Minimal Residual Disease (MRD).
NCT00136084 (7) [back to overview]Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)
NCT00136084 (7) [back to overview]Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO
NCT00136084 (7) [back to overview]Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.
NCT00137111 (7) [back to overview]Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)
NCT00137111 (7) [back to overview]Continuous Complete Remission Since Week 56 Therapy.
NCT00137111 (7) [back to overview]Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells
NCT00137111 (7) [back to overview]Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells
NCT00137111 (7) [back to overview]Overall Event-free Survival (EFS)
NCT00137111 (7) [back to overview]Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).
NCT00137111 (7) [back to overview]Minimal Residual Disease (MRD)
NCT00176462 (1) [back to overview]Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years
NCT00186875 (4) [back to overview]Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)
NCT00186875 (4) [back to overview]Overall Survival (OS)
NCT00186875 (4) [back to overview]Response Rate
NCT00186875 (4) [back to overview]Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)
NCT00262925 (2) [back to overview]Overall Survival
NCT00262925 (2) [back to overview]Complete Response Rate
NCT00381680 (6) [back to overview]Frequency and Severity of Adverse Effects
NCT00381680 (6) [back to overview]Event Free Survival. EFS
NCT00381680 (6) [back to overview]Event Free Survival (EFS)
NCT00381680 (6) [back to overview]Adjusted Event Free Survival
NCT00381680 (6) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3
NCT00381680 (6) [back to overview]Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1
NCT00400946 (10) [back to overview]5-Year Disease-Free Survival
NCT00400946 (10) [back to overview]5-Year Disease-Free Survival by Bone Marrow Day 18 Status
NCT00400946 (10) [back to overview]5-year Disease-Free Survival by CNS Directed Treatment Group
NCT00400946 (10) [back to overview]5-Year Disease-Free Survival by MRD Day 32 Status
NCT00400946 (10) [back to overview]Asparaginase-Related Toxicity Rate
NCT00400946 (10) [back to overview]Induction Infection Toxicity Rate
NCT00400946 (10) [back to overview]Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]Induction Serum Asparaginase Activity Level
NCT00400946 (10) [back to overview]Induction Therapeutic Nadir Serum Asparaginase Activity Rate
NCT00400946 (10) [back to overview]Post-Induction Nadir Serum Asparaginase Activity Level
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)
NCT00408005 (8) [back to overview]Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
NCT00408005 (8) [back to overview]Cumulative Incidence of CNS Relapse for T-ALL by Risk Group
NCT00439296 (3) [back to overview]Number of Patients That Experienced Dose Limiting Toxicity From ABT-751
NCT00439296 (3) [back to overview]Number of Patients That Achieved Complete Response to ABT-751
NCT00439296 (3) [back to overview]Number of Patients With Occurrence of Toxic Death
NCT00458848 (3) [back to overview]Percentage of Participants Reaching Disease Free Survival
NCT00458848 (3) [back to overview]Number of Patients Reaching Complete Hematological Response After Induction Therapy
NCT00458848 (3) [back to overview]Percentage of Participants Reaching Overall Survival
NCT00492856 (2) [back to overview]Number of Patients With Grade 3 Through 5 Adverse Events That Are Related to Study Drug
NCT00492856 (2) [back to overview]3-year Disease-free Survival (DFS) Rate
NCT00548431 (1) [back to overview]Toxicity of Treatment in Terms of Number of Participants With Serious Adverse Events or Adverse Events, Reported
NCT00549848 (6) [back to overview]Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5%
NCT00549848 (6) [back to overview]Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01%
NCT00549848 (6) [back to overview]Probability of Overall Survival
NCT00549848 (6) [back to overview]Probability of Event-free Survival
NCT00549848 (6) [back to overview]Probability of CNS Relapse
NCT00549848 (6) [back to overview]Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase.
NCT00551460 (3) [back to overview]Continuous Complete Remission at 3 Years
NCT00551460 (3) [back to overview]Mortality Rate at 6 Weeks
NCT00551460 (3) [back to overview]Frequency of Toxicities
NCT00557193 (10) [back to overview]Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts
NCT00557193 (10) [back to overview]Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy
NCT00557193 (10) [back to overview]Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm
NCT00557193 (10) [back to overview]Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2
NCT00557193 (10) [back to overview]Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)
NCT00557193 (10) [back to overview]Percent Probability for Event-free Survival (EFS) for Patients on Arm A
NCT00557193 (10) [back to overview]Number of Patients Who Experienced Lestaurtinib-related Dose Limiting Toxicity (DLT)
NCT00558519 (5) [back to overview]Number of Participants Who Experienced at Least One Grade 3 or Higher Adverse Event at Least Possibly Related to Treatment (Toxicity)
NCT00558519 (5) [back to overview]Overall Survival
NCT00558519 (5) [back to overview]Complete Response Rate
NCT00558519 (5) [back to overview]Disease-free Survival
NCT00558519 (5) [back to overview]Event-free Survival
NCT00671034 (9) [back to overview]Pharmacodynamics (PD)
NCT00671034 (9) [back to overview]Immunogenicity
NCT00671034 (9) [back to overview]Percentage of Participants With Complete Remission at the End of Induction
NCT00671034 (9) [back to overview]Percentage of Participants With Event-free Survival (EFS)
NCT00671034 (9) [back to overview]Asparaginase Level
NCT00671034 (9) [back to overview]Toxicities During Post Induction Intensification Therapy (All Grades)
NCT00671034 (9) [back to overview]Plasma and CSF Concentrations of Asparagine in ug/ml
NCT00671034 (9) [back to overview]Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy)
NCT00671034 (9) [back to overview]Percentage of Participants With Minimal Residual Disease (MRD)<0.01% at the End of Induction
NCT00720109 (5) [back to overview]Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events
NCT00720109 (5) [back to overview]Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)
NCT00720109 (5) [back to overview]Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation
NCT00720109 (5) [back to overview]Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy
NCT00720109 (5) [back to overview]Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy
NCT00866307 (2) [back to overview]AALL08P1 Feasibility Outcome
NCT00866307 (2) [back to overview]AALL08P1 Safety Outcome
NCT00866749 (4) [back to overview]3-Year Event-Free Survival (EFS)
NCT00866749 (4) [back to overview]Overall Survival
NCT00866749 (4) [back to overview]Participants With a Complete Response (CR)
NCT00866749 (4) [back to overview]Participants Achieving Negative Minimal Residual Disease (MRD)
NCT00866918 (4) [back to overview]Overall Survival (OS)
NCT00866918 (4) [back to overview]Hematologic Remission Rate
NCT00866918 (4) [back to overview]Hematologic, Molecular, and Cytogenetic Remission Rate
NCT00866918 (4) [back to overview]Event-free Survival (EFS)
NCT00973752 (1) [back to overview]Overall Survival at One Year
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in Boy AR Patients Overall at End of Therapy: Social Functioning
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left
NCT01190930 (41) [back to overview]Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right
NCT01190930 (41) [back to overview]DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care
NCT01190930 (41) [back to overview]DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization
NCT01190930 (41) [back to overview]DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens
NCT01190930 (41) [back to overview]Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization
NCT01190930 (41) [back to overview]Event Free Survival (EFS) for B-LLy Patients
NCT01190930 (41) [back to overview]Overall Survival (OS) for B-LLy Patients
NCT01190930 (41) [back to overview]Sample Collection of Central Path Review Slides in B-LLy Patients
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Emotional
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Physical
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Social Functioning
NCT01190930 (41) [back to overview]Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical
NCT01256398 (6) [back to overview]Response
NCT01256398 (6) [back to overview]Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)
NCT01256398 (6) [back to overview]Overall Survival (OS)
NCT01256398 (6) [back to overview]Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.
NCT01256398 (6) [back to overview]Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause
NCT01256398 (6) [back to overview]Disease Free Survival (DFS)
NCT01432145 (1) [back to overview]Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population.
NCT01451515 (4) [back to overview]Probability of Event-free Survival (EFS)
NCT01451515 (4) [back to overview]Probability of Overall Survival (OS)
NCT01451515 (4) [back to overview]Minimal Disseminated Disease (MDD)
NCT01451515 (4) [back to overview]Minimal Residual Disease (MRD)
NCT01700946 (4) [back to overview]3-year Event-free Survival Rates in Patients With Relapsed ALL
NCT01700946 (4) [back to overview]3-year Overall Survival Rate of Patients With Relapsed ALL
NCT01700946 (4) [back to overview]Mean of CD20 Expression Levels
NCT01700946 (4) [back to overview]Median CD20 Expression Levels
NCT02101853 (4) [back to overview]Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients
NCT02101853 (4) [back to overview]Overall Survival (OS) of LR Relapse Patients
NCT02101853 (4) [back to overview]Overall Survival (OS) of HR and IR Relapse Patients
NCT02101853 (4) [back to overview]Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients
NCT02112916 (6) [back to overview]EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)
NCT02112916 (6) [back to overview]Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)
NCT02112916 (6) [back to overview]Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase
NCT02112916 (6) [back to overview]Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients
NCT02112916 (6) [back to overview]EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond
NCT02112916 (6) [back to overview]EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3
NCT02143414 (6) [back to overview]Overall Survival Rate (Cohort I)
NCT02143414 (6) [back to overview]Incidence of Dose-limiting Toxicity (Cohort II)
NCT02143414 (6) [back to overview]Disease-free Survival (Cohort II)
NCT02143414 (6) [back to overview]Number of Participants With Grade 3 Through 5 Adverse Events That Are Related to Study Drugs
NCT02143414 (6) [back to overview]Minimal Residual Disease Negativity
NCT02143414 (6) [back to overview]Complete Response Rate (Cohort I)
NCT02419469 (1) [back to overview]Event Free Survival (EFS)
NCT02419755 (1) [back to overview]Number of Relevant Toxicities Related to Therapy
NCT02420717 (4) [back to overview]Overall Survival
NCT02420717 (4) [back to overview]Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)
NCT02420717 (4) [back to overview]Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)
NCT02420717 (4) [back to overview]Progression-free Survival
NCT02553460 (1) [back to overview]Percentage of Treatment-related Mortality (TRM)
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine
NCT02828358 (5) [back to overview]Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine
NCT02828358 (5) [back to overview]Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine
NCT03384654 (13) [back to overview]Number of Participants With Anti-daratumumab Antibodies
NCT03384654 (13) [back to overview]Minimum Observed Serum Concentration (Cmin) of Daratumumab
NCT03384654 (13) [back to overview]Minimal Residual Disease (MRD) Negative Rate
NCT03384654 (13) [back to overview]Maximum Observed Serum Concentration (Cmax) of Daratumumab
NCT03384654 (13) [back to overview]Event-free Survival (EFS)
NCT03384654 (13) [back to overview]Cohort 2: Percentage of Participants With Complete Response (CR) for T-cell ALL
NCT03384654 (13) [back to overview]Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL)
NCT03384654 (13) [back to overview]Concentration of Daratumumab in Cerebrospinal Fluid (CSF)
NCT03384654 (13) [back to overview]Relapse-free Survival (RFS)
NCT03384654 (13) [back to overview]Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)
NCT03384654 (13) [back to overview]Overall Survival (OS)
NCT03384654 (13) [back to overview]Concentration of Daratumumab in Cerebrospinal Fluid (CSF)
NCT03384654 (13) [back to overview]Overall Response Rate (ORR)
NCT03488225 (5) [back to overview]Participants to Achieve Complete Remission (CR):
NCT03488225 (5) [back to overview]Overall Survival
NCT03488225 (5) [back to overview]Number of Participants With Minimal Residual Disease (MRD) Negativity
NCT03488225 (5) [back to overview]Event-Free Survival
NCT03488225 (5) [back to overview]Number of Participants With Adverse Events
NCT03518112 (5) [back to overview]Duration of Response
NCT03518112 (5) [back to overview]Participants With a Response
NCT03518112 (5) [back to overview]Overall Survival
NCT03518112 (5) [back to overview]Number of Participants Negative for Minimal Residual Disease (MRD)
NCT03518112 (5) [back to overview]Event Free Survival (EFS) Where Events Defined as no Response, Loss of Response, or Death

Complete Remission (CR)

complete remission (CR) Disappearance of all clinical evidence of leukemia for a minimum of four weeks. The patient should have a neutrophil count > 1,000 x 10^6/1, a platelet count > 100,000 x 10^9/1, no circulating blasts, and < than or = to blasts on bone marrow differential in a qualitatively normal or hypercellular marrow. Progressive disease or failure: Increasing bone marrow infiltrate or development of organ failure or extramedullary infiltrates due to leukemia. (NCT00002766)
Timeframe: 2 years

,
Interventionparticipants (Number)
Complete RemissionComplete Response (CR)FailureFailure-ProgressionRelapse
All-25014581
L-20501114100

[back to top]

Event-free Survival

Assessed by time to treatment failure, occurrence of second malignant neoplasm, or death from any cause. Statistical analysis will be to estimate the difference in the proportion of patients treated with each therapy who are long-term event-free survivors due either to the difference between the backbone therapy regimens (CCG BFM vs NHL/BFM-95), or due to the intensification. (NCT00004228)
Timeframe: 5 years

Interventionpercentage of particpants (Number)
A0 (Localized Disease Stg I/II) Modified CCG BFM88
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens82
A2 (Disseminated, No CNS - CCG Mod BFM w/ Intens80
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy63
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens82
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens84
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment90

[back to top]

Percentage of Patients With Overall Survival as Assessed by Time to Death

Overall survival will be computed by measuring the rate of deaths during induction due primarily to treatment toxicity and cumulative incidence of toxic deaths in induction or deaths in remission overall and separately for treatment groups defined by the two design factors. (NCT00004228)
Timeframe: 5 years

Interventionpercentage of participants (Number)
A0 (Localized Disease Stg I/II) Modified CCG BFM96
A1 (Disseminated, No CNS - CCG Mod BFM w/Out Intens84
A2 (Disseminated, No CNS - CCG Mod BFM w/Intens88
B2 (CNS+) NHL/BFM-95 w/Intens Delayed Radiation Therapy81
B2 (Disseminated,CNS- (< Amend 7B)) NHL/BFM-95 w/Intens85
B1 (Disseminated CNS-) NHL/BFM-95 w/Out Intens85
B1 (NHL/BFM-95 w/Out Intens) Additional Enrollment92

[back to top]

Event-free Survival (EFS)

Percentage of EFS patients. This is measured as the time from study entry until disease progression, disease recurrence, occurrence of a second malignant neoplasm, or death from any cause. To measure Event Free Survival, repeated one-sided logrank tests will be performed The upper critical values are based on the one-sided alpha-spending functions of t2 (alpha=0.05) and the lower critical values are based on testing the alternative hypothesis at 0.005 level. (NCT00059839)
Timeframe: From first enrollment up to 3 years.

Interventionpercentage of participants (Number)
Standard (APO) With Vincristine (Arm I)74
Consolidation (Includes Vinblastine) (Arm II)79

[back to top]

Number of Participants Who Proceed to Course V Within 2-6 Weeks of the Last Dose of Alemtuzumab (Phase II)

The primary endpoint is the number of participants who are able to proceed to course V within two - six weeks of completion of course IV. (NCT00061945)
Timeframe: 8 months

Interventionparticipants (Number)
Phase II - Alemtuzumab and Combination Chemotherapy30

[back to top]

Overall Survival

Overall Survival is defines as the time from registration to death due to any cause. It is estimated using the Kaplan-Meier method with confidence intervals presented. (NCT00061945)
Timeframe: 9 years 4 months

Interventionmonths (Median)
Phase I - Alemtuzumab and Combination Chemotherapy33.6
Phase II - Alemtuzumab and Combination Chemotherapy23.1

[back to top]

Number of Participants Achieving Complete Remission

A complete remission (CR) requires the following: an absolute neutrophil count (segs and bands) > 1500/μl, no circulating blasts, platelets > 100,000/μl; bone marrow cellularity > 20% with trilineage hematopoiesis, and < 5% marrow blast cells, none of which appear neoplastic. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement). (NCT00061945)
Timeframe: 9 years

Interventionparticipants (Number)
Phase I - Alemtuzumab and Combination Chemotherapy92
Phase II - Alemtuzumab and Combination Chemotherapy145

[back to top]

Disease-free Survival, for Only Complete Response Patients

Disease Free Survival (DFS) is defined as the time from a Complete Response (CR) until death or relapse. The date of last clinical assesment will be used as the censor date for patients with no death or relapse. The DFS will be estimated using the Kaplan-Meier method with confidence intervals presented. (NCT00061945)
Timeframe: 9 years 4 months

Interventionmonths (Median)
Phase I - Alemtuzumab and Combination Chemotherapy58.6
Phase II - Alemtuzumab and Combination Chemotherapy19.8

[back to top]

Maximum Tolerated Dose (MTD) of Alemtuzumab (Phase I)

The maximum tolerated dose is defined as the highest alemtuzumab dose at which less than 40% of patients develop the dose limiting toxicity (DLT), where DLT is defined as the inability to proceed (due to medical complications) with the protocol treatment within six weeks of receiving the last dose of alemtuzumab. Groups of six patients will be enrolled into each cohort at the time of re-registration prior to starting Course IV. After a cohort has accrued 6 patients and at least 3 have completed the 2-6 week post alemtuzumab observation period without DLT, the incoming patients will be assigned to the next cohort in the table while the DLT and other toxicities continue to be assessed for the newly closed cohort. If less than 3 out of 6 enrolled patients in a cohort have completed the 2-6 week post alemtuzumab observation period without DLT, additional patients may continue to enroll in that same cohort, i.e., accrual will not be suspended while waiting for patient follow-up data. (NCT00061945)
Timeframe: 6 weeks

Interventionmg (Number)
Phase I - Alemtuzumab and Combination Chemotherapy30

[back to top]

Minimal Residual Disease (MRD) During Treatment With Alemtuzumab (Phase II)

Minimal Residual Disease measures the presence of of circulating leukemia cells in the body. Patients that report a Complete Response (CR) during treatment are further tested to determine the presence of small amounts of circulating leukemia cells. Here we report the number of patients who were MRD negative. (NCT00061945)
Timeframe: 9 years 4 months

InterventionParticipants (Count of Participants)
Phase II - Alemtuzumab and Combination Chemotherapy16

[back to top]

Correlation of Minimal Residual Disease (MRD) Positive With Overall Survival (OS)

Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 Years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years79.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)69.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old65.6
Dexamethasone, High Dose Methotrexate (IM) < 10 Years86.2
Prednisone, Capizzi Methotrexate <10 Years93.8
Prednisone, Capizzi Methotrexate >= 10 Years63.1
Predisone and High Dose Methotrexate < 10 Yrs Old84.2
Prednisone and High Dose Methotrexate >=10 Years73.6
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years74.6

[back to top]

Correlation of Minimal Residual Disease (MRD) Negative With Event Free Survival (EFS).

Bone marrow MRD status is defined as negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years86.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)93.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old80.5
Dexamethasone, High Dose Methotrexate (IM) < 10 Years93.1
Prednisone, Capizzi Methotrexate <10 Years86.5
Prednisone, Capezzi Methotrexate >= 10 Years83.4
Prednisone and High Dose Methotrexate < 10 Yrs Old84.2
Prednisone and High Dose Methotrexate >=10 Years83.9
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years85.3
Prednisone, Capezzi Methotrexate (Down's Syndrome)74.4
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)25

[back to top]

Correlation of Minimal Residual Disease (MRD) Negative With Overall Survival (OS).

Bone marrow MRD status is defined as negative with < .01 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years95.4
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)92.9
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old87.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years98.1
Prednisone, Capizzi Methotrexate <10 Years93.3
Prednisone, Capizzi Methotrexate >= 10 Years90.2
Prednisone and High Dose Methotrexate < 10 Yrs Old94.5
Prednisone and High Dose Methotrexate >=10 Years90.5
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years91.6
Prednisone, Capizzi Methotrexate (Down's Syndrome)78.3
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)25.0

[back to top]

Correlation of Minimal Residual Disease (MRD) Positive With Event Free Survival (EFS)

Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years66.5
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)43.3
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old35.4
Dexamethasone, High Dose Methotrexate (IM) < 10 Years80
Prednisone, Capizzi Methotrexate <10 Years34.7
Prednisone, Capizzi Methotrexate >= 10 Years39
Prednisone and High Dose Methotrexate < 10 Yrs Old55
Prednisone and High Dose Methotrexate >=10 Years47.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years49.4

[back to top]

Correlation of Early Marrow Response Status With MRD Negative.

Bone marrow status is defined as: M1: < 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: > 25% lymphoblasts. Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: Day 29

Interventionparticipants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years182
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)72
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old198
Dexamethasone, High Dose Methotrexate (IM) < 10 Years188
Prednisone, Capizzi Methotrexate <10 Years195
Prednisone, Capezzi Methotrexate >= 10 Years471
Prednisone and High Dose Methotrexate < 10 Yrs Old190
Prednisone and High Dose Methotrexate >=10 Years479
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years208
Prednisone, Capezzi Methotrexate (Down's Syndrome)25
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)3
Prednisone and High Dose Methotrexate (Non Randomly Assigned)18

[back to top]

Comparison of the Increase in Cure Rate of High Risk ALL Without Causing More Serious Side Effects Between Interventions

Event Free Probability. (NCT00075725)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years83.2
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)81.6
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old69.1
Dexamethasone, High Dose Methotrexate (IM) < 10 Years91.2
Prednisone, Capizzi Methotrexate <10 Years82.1
Prednisone, Capezzi Methotrexate >= 10 Years73.5
Predisone and High Dose Methotrexate < 10 Yrs Old80.8
Prenisone and High Dose Methotrexate >=10 Years75.8
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years77.0
Prenisone, Capezzi Methotrexate (Down's Syndrome)61.8
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)44.4

[back to top]

Correlation of Early Marrow Response Status With MRD Positive.

Bone marrow status is defined as: M1: < 5% lymphoblasts; M2: 5-25% lymphoblasts; M3: > 25% lymphoblasts. Bone marrow MRD status is defined as positive with >= 0.1 detectable leukemia cells, and negative with < 0.1 detectable leukemia cells. (NCT00075725)
Timeframe: Day 29

Interventionparticipants (Number)
Dexamethasone and Capizzi Methotrexate Patients < 10 Years26
Dexamethasone, High Dose Methotrexate (Non Randomly Assigned)12
Dexamethasone & Capizzi Methotrexate Patients => 10 Years Old43
Dexamethasone, High Dose Methotrexate (IM) < 10 Years14
Prednisone, Capizzi Methotrexate <10 Years16
Prednisone, Capezzi Methotrexate >= 10 Years95
Prednisone and High Dose Methotrexate < 10 Yrs Old17
Prednisone and High Dose Methotrexate >=10 Years98
Dexamethasone, High Dose Methotrexate (IM) >= 10 Years39
Prednisone, Capezzi Methotrexate (Down's Syndrome)3
Dexamethasone, Capizzi Methotrexate Down Syndrome (Non Random)3
Prednisone and High Dose Methotrexate (Non Randomly Assigned)3

[back to top]

Event-free Survival

Monitoring of efficacy results will be performed in comparison with historical results. (NCT00096135)
Timeframe: 3 years

Interventionpercentage of participants (Number)
CNS Patients - Treatment (Combination Chemotherapy)64.9
Testicular Relapse Patients (Combination Chemotherapy)70

[back to top]

Event-free Survival (EFS) for SR-Average ALL Patients

EFS for SR-Average with standard and Intensified Consolidation. Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

,
Interventionpercent probability (Number)
Standard and Intensified therapyStandard therapy
Group 2-SR-avg ALL, Arm I-combination Chemotherapy83.8287.41
Group 2-SR-avg ALL, Arm II-combination Chemotherapy88.8988.29

[back to top]

Event-free Survival (EFS) for SR-High Patients.

Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

Interventionpercent probability (Number)
Group 3-SR-high ALL, Combination Chemotherapy85.58

[back to top]

Event-Free Survival (EFS) for Low MRD (Negative) Subjects by Genetic Subset (TEL/Trisomy Positive vs Negative)

Event-free probability where EFS is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

InterventionPercent probability (Number)
Group 1-SR-low ALL, Arm I-combination Chemotherapy95.22
Group 2-SR-avg ALL, Arm I-combination Chemotherapy88.52

[back to top]

Early Marrow Status (EMS) by MRD Status End Induction (Day 29)

Early Marrow Status defined as M1 versus M2/M3 marrow is correlated with MRD (Positive vs. Negative) (NCT00103285)
Timeframe: Early Marrow Status at Day 15, MRD Status at Day 29 of therapy.

InterventionParticipants (Count of Participants)
All Patients for Induction, MRD Negative4378
All Patients for Induction, MRD Positive258

[back to top] [back to top] [back to top]

Event-free Survival (EFS) for SR-Average ALL Patients

EFS for SR-Average with standard and Intensified Consolidation. Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

,
Interventionpercent probability (Number)
Standard and Intensified therapy
Group 2-SR-avg ALL, Arm III-combination Chemotherapy88.34
Group 2-SR-avg ALL, Arm IV-combination Chemotherapy90.51

[back to top]

Overall Survival Probability (OS) According to Induction Day 29 MRD Status

Overall survival by Day 29 MRD status (negative vs positive), Overall survival defined as time from study entry to death or date of last contact for patients who are alive. (NCT00103285)
Timeframe: Overall Survival Probability of 6 years

Interventionpercent probability (Number)
Induction Therapy, MRD Negative97.07
Induction Therapy, MRD Positive90.47

[back to top]

Event-Free Survival Probability According to MRD Status End Induction (Day 29)

Event-Free survival by Day 29 MRD status (negative vs positive), Event Free Probability (time from study entry to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: MRD at Day 29 of therapy

InterventionPercent Probability (Number)
Induction Therapy, MRD Negative91.39
Induction Therapy, MRD Positive79.86

[back to top]

Event-free Survival (EFS) for SR-Low Patients

Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00103285)
Timeframe: 6 years

InterventionPercent probability (Number)
SR-low ALL, Arm I-combination Chemotherapy95.22
SR-low ALL, Arm II-combination Chemotherapy93.96

[back to top]

Continuous Complete Remission at 1 Year

A patient has a continuous complete remission at 1 year if they achieve a CR and are alive 365 days after registering to the study. (NCT00109837)
Timeframe: After induction, after consolidation, every 3 months during maintenance, and every three months after off treatment for up to a year

Interventionparticipants (Number)
Treatment21

[back to top]

Toxicity

Number of patients with Grade 3-5 adverse events that are related to study drug by given type of adverse event (NCT00109837)
Timeframe: Patients were assessed for adverse events after the induction cycle

InterventionParticipants with a given type of AE (Number)
ALT, SGPT (serum glutamic pyruvic transaminase)AST, SGOT (serum glut oxaloacetic transaminase)Albumin, serum-low (hypoalbuminemia)Alkaline phosphataseAnorexiaAscites (non-malignant)Bilirubin (hyperbilirubinemia)Calcium, serum-low (hypocalcemia)CholecystitisCholesterol, serum-high (hypercholesterolemia)Coagulation-Other (Specify)Colitis, infectious (e.g., Clostridium difficile)ConstipationDIC (disseminated intravascular coagulation)Death not assoc with CTCAE term-Multi-organ failEdema: limbFatigue (asthenia, lethargy, malaise)Febrile neutropeniaFever (in the abs of neutropenia)FibrinogenGlucose, serum-high (hyperglycemia)Glucose, serum-low (hypoglycemia)HemoglobinHypertensionHypotensionHypoxiaIleus, GI (functional obstruction of bowel)Infec(doc clin or mibio) w/ Gr 3/4 neut-AnalInfec(doc clin or mibio) w/ Gr 3/4 neut-BladderInfec(doc clin or mibio) w/ Gr 3/4 neut-BloodInfec(doc clin or mibio) w/ Gr 3/4 neut-BronchusIInfec(doc clin or mibio) w/ Gr 3/4 neut-CatheterInfec(doc clin or mibio) w/ Gr 3/4 neut-Eye NOSInfec(doc clin or mibio) w/ Gr 3/4 neut-LungInfec(doc clin or mibio) w/ Gr 3/4 neut-NoseInfec(doc clin or mibio) w/ Gr 3/4 neut-PharynxInfec(doc clin or mibio) w/ Gr 3/4 neut-Ur tractInfec with nor ANC or Gr 1/2 neut-Lung (pneumonia)Infection-Other (Specify)Leukocytes (total WBC)LipaseLiver dysfunction/failure (clinical)LymphopeniaMagnesium, serum-high (hypermagnesemia)Mucositis/stomatitis (clinical exam) - Oral cavityMucositis/stomatitis (funct/symp) - Oral cavityMucositis/stomatitis (func/symp) - PharynxMuscle weak,gen spec area-Whole bodyNauseaNeuropathy: motorNeutrophils/granulocytes (ANC/AGC)Pain - Abdomen NOSPain - BonePain - NeckPancreatic endocrine: glucose intolerancePancreatitisPhosphate, serum-low (hypophosphatemia)PlateletsPotassium, serum-high (hyperkalemia)Potassium, serum-low (hypokalemia)Rash/desquamationRenal failureSodium, serum-low (hyponatremia)Thrombosis/thrombus/embolismThrombotic microangiopathyTriglyceride, serum-high (hypertriglyceridemia)Tumor lysis syndromeTyphlitis (cecal inflammation)Uric acid, serum-high (hyperuricemia)Vomiting
Induction171332216712111211318111161332321111111111122143121912112314711111144171261215111

[back to top]

Relationship of Inhibition of DNA Synthesis and Clinical Response

Clinical response is defined as MRD (minimal residual disease) measured by flow cytometry at day 22. The MRD at day 22 is classified as positive (with MRD) or negative (no detectable MRD). The relation between inhibition of DNA synthesis and MRD was performed by logistic regression. In the model, logit of probability of MRD positive was regressed on inhibition of DNA synthesis. (NCT00136084)
Timeframe: Measurements were assessed in Induction I chemotherapy

InterventionPercent inhibition of DNA Synthesis (Mean)
Overall66.7

[back to top]

To Assess Whether Inhibition of DNA Synthesis is Greater After High-dose Ara-C (HDAC) Than After Low-dose Ara-C (LDAC) Therapy

Inhibition of DNA synthesis is defined as the percentage of DNA synthesis rate at 24-hour post-araC treatment over DNA synthesis rate pre-araC treatment. (NCT00136084)
Timeframe: Measurements were assessed in Induction I chemotherapy

InterventionPercent Inhibition of DNA Synthesis (Mean)
Arm 1: (HDAC)60.6
Arm 2:(LDAC)72.8

[back to top]

To Estimate the Overall Event-free Survival (EFS) of AML Patients Who Undergo Risk-adapted and Genotype-directed Therapy

Overall event-free survival (EFS) was defined as the time from study enrollment to induction failure, relapse, secondary malignancy, death, or study withdrawal for any reason, with event-free patients censored on the date of the last follow-up (NCT00136084)
Timeframe: Five Year

InterventionPercentage of Participants (Number)
Overall62.4

[back to top]

Minimal Residual Disease (MRD).

Detection of Minimal Residual Disease following one course of chemotherapy where positive MRD was defined as one or more leukemic cell per 1000 mononuclear bone-marrow cells (>=0.1%). (NCT00136084)
Timeframe: Day 22 MRD measurement

,
Interventionparticipants (Number)
MRD PositiveMRD Negative
Arm 1: (HDAC)3168
Arm 2:(LDAC)4363

[back to top]

Proportion of Minimal Residual Disease (MRD)+ Patients Who Become MRD- After One Course of Gemtuzumab Ozogamicin (GO)

To estimate the proportion of minimal residual disease (MRD)+ patients who become MRD- after one course of gemtuzumab ozogamicin (GO) (NCT00136084)
Timeframe: Consolidation I

InterventionParticipants (Number)
NegativePositive
Overall114

[back to top]

Proportion of MRD Reduction After One Course of Cytarabine + Daunomycin + Etoposide (ADE) + GO

To estimate proportion of patients with MRD reduction after one course of Induction II (cytarabine + daunomycin + etoposide (ADE) + GO), who had no response to first course of induction therapy. (NCT00136084)
Timeframe: Induction II

InterventionParticipants (Number)
DecreaseIncrease or no change
Overall272

[back to top]

Proportion of Patients Experienced Toxicity of Cytarabine + Daunomycin + Etoposide (ADE) + GO.

To estimate proportion of patients experiencing CTC Grade 3 or 4 toxicity during Induction II (Cytarabine + Daunomycin + Etoposide (ADE) + GO), who had no response to first course of induction therapy (NCT00136084)
Timeframe: Induction II

InterventionParticipants (Number)
Experienced Grade 3 or 4 toxicitiesDid not experience Grade 3 or 4 toxicities
Overall273

[back to top]

Circulating Leukemia Cells in Peripheral Blood Change From Prior to the Methotrexate Infusion to Three Days After Between Two Arms (4 Hours vs. 24 Hours)

"White blood cell (leukocytes) counts in peripheral blood by Complete Blood Count~Measurement: Percentage change of leukemia cells from baseline" (NCT00137111)
Timeframe: Immediately before the methotrexate infusion and three days after subsequent infusion

InterventionPercent change (Mean)
4 hr-44
24 hr-50

[back to top]

Continuous Complete Remission Since Week 56 Therapy.

CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow up time (range) 4.5 (1 to 7.8) years

InterventionPercentage of participants (Number)
Patients With High Risk of CNS Relapse92.2

[back to top]

Median Difference in NLRP3 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs. Glucocorticoid-sensitive Cells

Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of NLRP3 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment

Interventionarbitrary units (Median)
Prednisolone-sensitive cellsPrednisolone-resistant cells
Total Therapy41.2110.7

[back to top]

Median Difference in CASP1 Gene Expression in Primary Leukemia Cells of Patients in Glucocorticoid-resistant Cells vs Glucocorticoid-sensitive Cells

Prednisolone sensitivity was measured in primary leukemia cells from bone marrow collected at diagnosis. Expression of CASP1 was determined by HG-U133A microarray. Values given are gene expression values, and the unit is arbitrary units (AU) defined as scaled fluorescence measured on microarray. (NCT00137111)
Timeframe: Pre-treatment

Interventionarbitrary units (Median)
Prednisolone-sensitive cellsPrednisolone-resistant cells
Total Therapy341.3447.9

[back to top]

Overall Event-free Survival (EFS)

EFS was measured from the start of on-study to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Failure to enter remission was considered an event at time zero. Measurement was determined by Kaplan-Meyer estimate. (NCT00137111)
Timeframe: Median follow-up time (range) 5.6 (1.3 to 8.9) years

InterventionPercentage of Participants (Number)
Total Therapy87.3

[back to top]

Mean Difference of Active Methotrexate Polyglutamates (MTXPG) in Leukemia Cells Between Two Arms (4 Hours vs. 24 Hours).

Children were randomly assigned to receive initial single-agent treatment with HDMTX (1g/m^2) as either a 24-hour infusion or a 4-hour infusion and the outcome measure was the accumulation of MTXPG in leukemia cells. (NCT00137111)
Timeframe: 42 hours after start of high dose methotrexate infusion (HDMTX)

Interventionpmol/1,000,000,000 cells (Mean)
4 hr1688
24 hr2521

[back to top]

Minimal Residual Disease (MRD)

Detection of MRD at end of induction where positive MRD was defined as one or more leukemic cell per 10,000 mononuclear bone-marrow cells (>=0.01%). (NCT00137111)
Timeframe: End of Induction (Day 46 MRD measurement)

Interventionparticipants (Number)
Negative <0.01%Positive >= 0.01%
Total Therapy390102

[back to top]

Percentage of Patients With ALL at High Risk of Relapse (Arm 2) Who Were Relapse-free at 5 Years

This measure looks at the percentage of patients on Arm 2 who did not experience a relapse at 5 years, where relapse is defined as the presence of progressive disease after the achievement of a complete remission. (NCT00176462)
Timeframe: 5 years

Interventionpercentage of participants (Number)
Arm 2 High Risk64.9

[back to top]

Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)

The prevalence of MRD in children undergoing treatment for relapsed ALL and to compare the results to those obtained in children with newly diagnosed ALL. MRD is considered as positive (i.e., prevalent) if its level is >=0.01%. The prevalence of MRD after Block B is defined as the proportion of MRD positives. (NCT00186875)
Timeframe: End of Block B therapy (Day 19)

,,
InterventionParticipants (Count of Participants)
Negative <0.01%Positive ≥0.01%
High Risk210
Standard Risk1111
TOTXV Participants191297

[back to top]

Overall Survival (OS)

OS is measured from the start of on-study to the date of death or to the last date of follow-up. Measurement is determined by Kaplan-Meyer estimate. The probability of survival at 5 years after diagnosis is given. (NCT00186875)
Timeframe: 2 years after last patient completes therapy (approximately 4 years after enrollment)

Interventionprobability (Mean)
Standard Risk0.654
High Risk0.357

[back to top]

Response Rate

"The response rate is defined as the proportion of participants who attain morphological complete remission after the re-induction Block C, inclusive of all patients who begin re-induction. Morphological complete remission was defined as <5% blasts in bone marrow by morphology." (NCT00186875)
Timeframe: End of re-induction Block C (approximately 1 month after the start of therapy)

,
Interventionproportion of participants (Number)
Complete remissionFailure to reach complete remission
High Risk0.7860.214
Standard Risk0.8460.154

[back to top]

Minimal Residual Disease (MRD) Compared With Historical Data From TOTXV Protocol (NCT00137111)

The prevalence of MRD in children undergoing treatment for relapsed ALL and to compare the results to those obtained in children with newly diagnosed ALL. MRD is considered as positive (i.e., prevalent) if its level is >=0.01%. The prevalence of MRD after Block C is defined as the proportion of MRD positives. (NCT00186875)
Timeframe: End of Block Block C therapy (Day 46)

,,
InterventionParticipants (Count of Participants)
Negative <0.01%Positive ≥0.01%
High Risk18
Standard Risk119
TOTXV Participants390102

[back to top]

Overall Survival

Time from registration to death from any cause. Patients alive were censored at follow up. (NCT00262925)
Timeframe: assessed every 3 months if patient is < 2 years from study entry and every 6 months if patient is 2-5 years from study entry

Interventionmonths (Median)
Treatment (Chemotherapy, Enzyme Inhibitor Therapy)5.2

[back to top]

Complete Response Rate

"Complete response requires that all of the following be present for at least four weeks.~1. Peripheral Blood Counts: Neutrophil count >= 1.0 x 109/L, Platelet count >= 100 x 109/L, Reduced hemoglobin concentration or hematocrit has no bearing on remission status, Leukemic blasts must not be present in the peripheral blood.~2 .Bone Marrow Aspirate and Biopsy: Cellularity of bone marrow biopsy must be > 20% with maturation of all cell lines, <= 5% blasts.~3. Extramedullary leukemia, such as CNS or soft tissue involvement, must not be present." (NCT00262925)
Timeframe: assessed before the first consolidation cycle and first cytoreduction cycle, before the first and after the last maintenance cycle; after discontinuing treatment, assessed every 3 months if < 2 years and every 6 months if 2-5 years from study entry

Interventionpercentage of participants (Number)
Treatment (Chemotherapy, Enzyme Inhibitor Therapy)33

[back to top]

Frequency and Severity of Adverse Effects

Percentage of patients who developed at least 1 episode of grade 2 to 4 neuropathy. (NCT00381680)
Timeframe: Up to 107 weeks

Interventionpercentage of participants (Number)
CC or CT genotypeHigh-risk CEP72 genotype (TT at rs924607)
All Patients17.344.4

[back to top]

Event Free Survival. EFS

Percentage of patients who were event free at 3 years among those on Standard VCR dosing who did not undergo Hematopoietic Stem Cell Transplant (SCT). (NCT00381680)
Timeframe: 3 years after enrollment

Interventionpercentage of participants EFS at 3 yrs3 (Number)
Regimen A: Standard Vincristine Dosing66.0

[back to top]

Event Free Survival (EFS)

Percentage of patients who were event free at 3 years among those with isolated BM or combined BM relapse >= 36 months. (NCT00381680)
Timeframe: 3 years

,
Interventionpercentage of participants (Number)
MRD < 0.01% BL1MRD >= 0.01% BL1MRD < 0.01% BL3MRD >= 0.01% BL3
Regimen A88.560.083.861.5
Regimen B77.346.283.333.3

[back to top]

Adjusted Event Free Survival

Adjusted percentage of patients who were event free at 3 years. For patients who received matched donor SCT, EFS was adjusted to start from the actual SCT date. For patients who did not undergo SCT, EFS was adjusted to start from median time to SCT based on patients who received matched related SCT (where patients who had events prior to SCT date were excluded from the calculation of median time to SCT). (NCT00381680)
Timeframe: 3 years

Interventionadjusted percentage of participants (Number)
Received SCTDid not receive SCT
Regimen A: Standard Vincristine Dosing82.264.2

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 3

Percentage of patients who had minimal residual disease (MRD) < 0.01% among those with isolated BM or combined BM relapse >= 36 months and had successful MRD determinations at End Block 3. (NCT00381680)
Timeframe: End of Block 3 (105 days) of Induction therapy

Interventionpercentage of participants (Number)
Regimen A81.4
Regimen B88.9

[back to top]

Rate of Minimal Residual Disease (MRD) < 0.01% at End Block 1

Percentage of patients who had minimal residual disease (MRD) < 0.01% among those with isolated BM or combined BM relapse >= 36 months and had successful MRD determinations at End Block 1 (NCT00381680)
Timeframe: End of Block 1 (35 days) of Induction therapy

Interventionpercentage of participants (Number)
Regimen A50.8
Regimen B41.5

[back to top]

5-Year Disease-Free Survival

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
Intramuscular Native E Coli L-asparaginase (IM-EC).89
Intravenous PEG-asparaginase (IV-PEG).90

[back to top]

5-Year Disease-Free Survival by Bone Marrow Day 18 Status

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
M1 Day 18 Bone Marrow Status.89
M2/M3 Day 18 Bone Marrow Status.78
Hypocellular Day 18 Bone Marrow Status.88

[back to top]

5-year Disease-Free Survival by CNS Directed Treatment Group

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
CNS-1.89
CNS-2.89
CNS-31.00
Traumatic Tap With Blasts.84
Traumatic Tap Without Blasts.87

[back to top]

5-Year Disease-Free Survival by MRD Day 32 Status

Disease-free survival (DFS) in a landmark analysis is defined as the duration of time from asparaginase randomization (which occurred after patients achieved complete remission and were assigned to a final risk group) to documented relapse, death during remission or second malignant neoplasm. DFS is estimated based on the Kaplan-Meier method and 5-year DFS is the probability of patients remaining alive, relapse-free and without occurrence of second malignant neoplasm 5 years from asparaginase randomization. Disease relapse is defined as >25% lymphoblasts identified morphologically in bone marrow aspirate/biopsy, or identification of lymphoblasts in marrow (any percentage) identified to be leukemic by flow cytometry, cytogenetics, FISH, immunohistochemistry, or other tests. Appearance of leukemic cells at any extramedullary site (a single, unequivocal lymphoblast in the CSF may qualify as CNS leukemia) also qualifies if confirmed by the PI. (NCT00400946)
Timeframe: Disease evaluations occurred continuously on treatment. Suggested long-term follow-up was monthly for 6m, bi-monthly for 6m, every 4 months for 1y, semi-annually for 1y, then annually. Median follow-up in this study cohort is 6 yrs, up to 10y.

Interventionprobability (Number)
Low Day 32 MRD Level.79
High Day 32 MRD Level.90

[back to top] [back to top]

Induction Infection Toxicity Rate

Infection toxicity rate is defined as the percentage of patients who experience bacterial or fungal infection of grade 3 or higher with treatment attribution of possibly, probably or definite based on CTCAEv3 during remission induction phase of combination chemotherapy. (NCT00400946)
Timeframe: Assessed daily during remission induction days 4-32.

Interventionpercentage of participants (Number)
Overall26

[back to top]

Post-Induction Therapeutic Nadir Serum Asparaginase Activity Rate

Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Post-Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL ever during post-induction therapy. (NCT00400946)
Timeframe: Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.

Interventionpercentage of participants (Number)
Intramuscular Native E Coli L-asparaginase (IM-EC)71
Intravenous PEG-asparaginase (IV-PEG)99

[back to top]

Induction Serum Asparaginase Activity Level

Serum asparaginase activity (NSAA) levels were estimated based on established methods. (NCT00400946)
Timeframe: Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.

InterventionIU/mL (Median)
Day 4 NSAA LevelDay 11 NSAA LevelDay 18 NSAA LevelDay 25 NSAA Level
Overall.694.505.211.048

[back to top]

Induction Therapeutic Nadir Serum Asparaginase Activity Rate

Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. Induction therapeutic NSAA rate is defined as the percentage of patients achieving a NSAA level above 0.1 IU/mL at a given timepoint. (NCT00400946)
Timeframe: Samples for serum asparaginase activity analyses were obtained days 4, 11, 18 and 25 post one-dose of IV-PEG on day 7 of the induction phase.

Interventionpercentage of participants (Number)
Day 4 NSAA RateDay 11 NSAA RateDay 18 NSAA RateDay 25 NSAA Rate
Overall97968712

[back to top]

Post-Induction Nadir Serum Asparaginase Activity Level

Nadir serum asparaginase activity (NSAA) levels were estimated based on established methods. (NCT00400946)
Timeframe: Samples for nadir serum asparaginase activity analyses were obtained before doses administered at weeks 5, 11, 17, 23 and 29 of post-induction asparaginase treatment.

,
InterventionIU/mL (Mean)
Week 5 NSAA LevelWeek 11 NSAA LevelWeek 17 NSAA LevelWeek 23 NSAA LevelWeek 29 NSAA Level
Intramuscular Native E Coli L-asparaginase (IM-EC)0.1290.1430.1590.1800.123
Intravenous PEG-asparaginase (IV-PEG)0.7260.7730.7870.7570.806

[back to top]

Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I (Combination Chemotherapy)89.01
ARM II (Combination Chemotherapy)90.53
ARM III (Combination Chemotherapy)78.07
ARM IV (Combination Chemotherapy)86.46

[back to top]

Disease-free Survival (DFS) for Randomized Nelarabine T-ALL Cohort (Arm I + Arm III vs. Arm II + Arm IV)

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I and ARM III (Combination Chemotherapy)82.96
ARM II and ARM IV (Combination Chemotherapy)88.30

[back to top]

Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I vs. Arm II vs. Arm III vs. Arm IV)

Disease-free survival defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, remission death) or date of last contact for those who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I (Combination Chemotherapy)91.76
ARM II (Combination Chemotherapy)90.53
ARM III (Combination Chemotherapy)86.06
ARM IV (Combination Chemotherapy)84.89

[back to top]

Disease-free Survival (DFS) for Randomized Methotrexate T-ALL Cohort (Arm I + Arm II vs. Arm III + Arm IV)

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

Interventionpercent probability (Number)
ARM I and ARM II (Combination Chemotherapy)91.45
ARM III and ARM IV (Combination Chemotherapy)85.78

[back to top]

Cumulative Incidence of CNS Relapse for T-ALL by Risk Group

Cumulative incidence of CNS relapse adjusting for DFS events, was calculated using the method Gray et. al. High risk patients receive cranial radiation and low risk patients receive no cranial radiation. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

,
Interventionpercent probability (Number)
Low RiskIntermediate RiskHigh Risk
ARM I (Combination Chemotherapy)1.851.163.64
ARM III (Combination Chemotherapy)1.929.16.52

[back to top]

Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from end of induction

Interventionpercent probability (Number)
Standard RiskHigh Risk
ARM I (Combination Chemotherapy)87.485.1

[back to top]

Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. (NCT00408005)
Timeframe: 4 years from end of induction

Interventionpercent probability (Number)
High RiskInduction Failure
ARM II (Combination Chemotherapy)85.0100

[back to top]

Cumulative Incidence of CNS Relapse for T-ALL by Risk Group

Cumulative incidence of CNS relapse adjusting for DFS events, was calculated using the method Gray et. al. High risk patients receive cranial radiation and low risk patients receive no cranial radiation. (NCT00408005)
Timeframe: 4 years from randomization at the end of induction

,
Interventionpercent probability (Number)
Intermediate RiskHigh Risk
ARM II (Combination Chemotherapy)1.080
ARM IV (Combination Chemotherapy)0.853.45

[back to top]

Number of Patients That Experienced Dose Limiting Toxicity From ABT-751

"ABT-751 was given daily for 21 days for a period of 28 day course in combination with dexamethasone, PEG-asparaginase, and doxorubicin. The occurrence of a dose limiting toxicity (DLT) was evaluated at the end of the 28 day course.~DLT will be defined as any of the following events that are deemed by the investigator as probably or definitely attributable to ABT-751. Toxicity grade follows the CTCAE criteria, version 3.0. A copy of the CTCAE can be downloaded from the CTEP home page (http://ctep.cancer.gov).~Grade 3 or 4 Ileus~Grade 3 or 4 Constipation~Grade 3 or 4 Gastrointestinal obstruction, any location~Grade 3 or 4 Sensory Neuropathy~Grade 3 or 4 Motor Neuropathy~Grade 3 or 4 Neuropathic pain lasting longer than 24 hours despite medical intervention~Grade 3 or 4 Hypoxia in the absence of anemia or infection~Grade 4 Alanine aminotransferase (ALT) which does not return to" (NCT00439296)
Timeframe: Each dose level is evaluated

,
InterventionParticipants (Count of Participants)
# of patients with DLT# of patients without DLT
Dose Level 004
Dose Level 123

[back to top]

Number of Patients That Achieved Complete Response to ABT-751

Complete response (CR) is the occurrence of all of the following on approximately Day 29: less than 5% leukemic blasts in the bone marrow aspirate with no evidence of leukemic blasts in the CSF or peripheral blood and recovery of peripheral blood counts of an Absolute neutrophil count (ANC) > 750/μL and Platelet count > 75,000 μL. (NCT00439296)
Timeframe: Day 29 of Course 1

,
InterventionParticipants (Count of Participants)
# of patients not achieving complete response# of patients who achieved complete response
Dose Level 013
Dose Level 141

[back to top]

Number of Patients With Occurrence of Toxic Death

The occurrence of toxic death at anytime that is definitely, probably or possibly related to the treatment. (NCT00439296)
Timeframe: From the first dose of study therapy until 30 days after last therapy dose. Last dose protocol therapy is on day 21.

,
InterventionParticipants (Count of Participants)
# of patients that experienced toxic death# of patients that did not experience toxic death
Dose Level 004
Dose Level 105

[back to top]

Percentage of Participants Reaching Disease Free Survival

(NCT00458848)
Timeframe: At 60 months

Interventionpercentage of participants (Number)
Philadelphia Positive, Imatinib Only in Induction Therapy45.8

[back to top]

Number of Patients Reaching Complete Hematological Response After Induction Therapy

(NCT00458848)
Timeframe: At the end of induction, day +50

Interventionparticipants (Number)
Philadelphia Positive, Imatinib Only in Induction Therapy49

[back to top]

Percentage of Participants Reaching Overall Survival

Overall survival from diagnosis (NCT00458848)
Timeframe: At 60 months

Interventionpercentage of patients (Number)
Philadelphia Positive, Imatinib Only in Induction Therapy48.8

[back to top] [back to top]

3-year Disease-free Survival (DFS) Rate

DFS measured from date of post-consolidation randomization until relapse of any kind or death from any cause. Observation censored at date of last follow-up for patients last known to be alive without report of relapse. Relapse from CR/CRi is occurrence of marrow blasts ≥ 5% or presence of Auer rods or presence of neoplastic promyelocytes; (re)appearance of leukemic blasts or neoplastic promyelocytes in the peripheral blood; or (re)appearance of extramedullary disease. Relapse from PR is sum of marrow blasts and promyelocytes ≥ 20%, or sum of marrow blasts and promyelocytes 6-19% with Auer rods and/or neoplastic promyelocytes; or (re)appearance of leukemic blasts or neoplastic promyelocytes in the peripheral blood; or (re)appearance of extramedullary disease. Relapse from CRc is reappearance of t(15;17) in cytogenetic analysis. Relapse from CRm/PRm is reappearance of PML-RARα by RT-PCR as defined by a normalized quotient > 10^-5 based on RT-PCR performed at appropriate central lab. (NCT00492856)
Timeframe: Up to 3 years

Interventionpercentage of patients (Number)
Post-consolidation Therapy Arm I96
Post-consolidation Therapy Arm II100

[back to top]

Toxicity of Treatment in Terms of Number of Participants With Serious Adverse Events or Adverse Events, Reported

Number of participants following the protocol treatment for the full consolidation therapy with toxicity in this pilot study trying to individually titrate 6-mercaptopurine to the highest tolerable level during Consolidation. (NCT00548431)
Timeframe: 3 months ( 79 days )

InterventionParticipants (Number)
6-mercaptopurine26

[back to top]

Proportion of Participants With Minimal Residual Disease (MRD) on the 15th Day of Remission Induction ≥ 5%

To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol. (NCT00549848)
Timeframe: Middle of remission induction, Day 15 in Total XVI and Day 19 in Total XV

InterventionParticipants (Count of Participants)
TOTXVI PEG 350022
TOTXVI PEG 250026
TOTXVI Not Randomized31
All Eligible Patients in TOTXV55

[back to top]

Proportion of Participants With Minimal Residual Disease (MRD) at End of Remission Induction ≥ 0.01%

To study whether intensifying induction, including fractionated cyclophosphamide and thioguanine, in patients with day 15 MRD ≥ 5% will result in improved leukemia cytoreduction in this subgroup compared to therapy followed in the TOTXV protocol. (NCT00549848)
Timeframe: End of remission induction; day 42 in Total XVI and day 46 in Total XV

InterventionParticipants (Count of Participants)
TOTXVI PEG 35007
TOTXVI PEG 250012
TOTXVI Not Randomized20
All Eligible Patients in TOTXV44

[back to top]

Probability of Overall Survival

To estimate the overall survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV. (NCT00549848)
Timeframe: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years

InterventionPercentage of participants (Number)
TOTXVI PEG 350097.5
TOTXVI PEG 250095.6
TOTVI Not Randomized90.8
All Eligible Patients in TOTXV93.5

[back to top]

Probability of Event-free Survival

"To estimate the event-free survival of children with ALL who are treated with risk-directed therapy and to compare the EFS results of TOTXVI with that of TOTXV (NCT00137111).~EFS will be measured from the date of complete response to the date of initial failure for patients who fail. Failure includes the traditional endpoints of failure to achieve a complete remission, relapse in any site, secondary malignancy, and death during induction or remission. EFS time will be measured to the date of last contact for patients who are failure free at the time of analysis. The EFS time is defined to be zero (0) for patients who die during induction therapy or fail to achieve a complete remission." (NCT00549848)
Timeframe: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years

InterventionPercentage of participants (Number)
TOTXVI PEG 350092.4
TOTXVI PEG 250091.1
TOTXVI Not Randomized86.3
All Eligible Patients in TOTXV87.1

[back to top]

Probability of CNS Relapse

To assess whether intensification of CNS-directed intrathecal and systemic chemotherapy will improve outcome in patients at high-risk of CNS relapse. (NCT00549848)
Timeframe: For Total XVI: 3.5 years after the last enrollment, up to approximately 13.5 years For Total XV: patients are followed continuously, up to 20.5 years

InterventionPercentage of participants (Number)
TOTXVI PEG 35000.8
TOTXVI PEG 25001.8
TOTXVI Not Randomized2.7
All Eligible Patients in TOTXV5.7

[back to top]

Percentage of Participants With Continuous Complete Remission of Patients Receiving High-dose and Conventional Dose PEG-asparaginase.

"The primary objective of this study is to compare the distributions of continuous complete remission of patients randomized on the first day of the continuation phase to receive a higher dose of PEG-asparaginase or to receive the conventional dose (2,500 units/m2).~The randomization will occur on the starting day of the continuation phase, at which time all information necessary for performing the randomization should be available. In the rare case that immunophenotype and/or Day-15 MRD is not available, we will make the following assumptions: If immunophenotype is unknown at the time the randomization is to be executed, then it will be assumed B-lineage. If Day-15 MRD is unknown at the time of randomization, then it will be assumed negative (<0.01%). Past experience indicate that few patients will fall into these unknown categories." (NCT00549848)
Timeframe: 3.5 years after the last enrollment up to 12.5 years

InterventionPercentage of participants (Number)
PEG 3500 Units/m^291.6
PEG 2500 Units/m^290.7

[back to top]

Continuous Complete Remission at 3 Years

Binary variable: yes if the patient achieves complete remission and remains in continuous complete remission until at least 3 years after entering the study; otherwise no. (NCT00551460)
Timeframe: 3 years

Interventionpercentage of participants (Number)
ATRA + GO + Arsenic74

[back to top]

Mortality Rate at 6 Weeks

(NCT00551460)
Timeframe: 6 weeks

Interventionpercentage of participants (Number)
ATRA + GO + Arsenic11

[back to top]

Frequency of Toxicities

Adverse events that were possibly, probably or definitely related to study drug are reported. (NCT00551460)
Timeframe: Up to 3 years

InterventionParticipants (Number)
ALT, SGPT (serum glutamic pyruvic transaminase)AST, SGOTAcidosis (metabolic or respiratory)Acute vascular leak syndromeAdult respiratory distress syndrome (ARDS)Albumin, serum-low (hypoalbuminemia)Alkaline phosphataseAlkalosis (metabolic or respiratory)Allergic reaction/hypersensitivityAllergic rhinitisAllergy/Immunology-OtherAnorexiaArthritis (non-septic)Ascites (non-malignant)AtelectasisAtrioventricular block - 2nd degree Mobitz Type IIAtrioventricular block - first degreeAuditory/Ear-OtherBicarbonate, serum-lowBilirubin (hyperbilirubinemia)Blood/Bone Marrow-OtherBronchospasm, wheezingBruising (in absence of Gr 3-4 thrombocytopenia)CNS cerebrovascular ischemiaCalcium, serum-high (hypercalcemia)Calcium, serum-low (hypocalcemia)Carbon monoxide diffusion capacity (DL(co))Cardiac Arrhythmia-OtherCardiac General-OtherCardiac troponin I (cTnI)Cardiac troponin T (cTnT)Cardiac-ischemia/infarctionChelitisCholesterol, serum-high (hypercholesterolemia)ConfusionConstipationCoughCreatinineCytokine release syndrome/acute infusion reactionDIC (disseminated intravascular coagulation)Dental: periodontal diseaseDermal change lymphedema, phlebolymphedemaDermatology/Skin-OtherDiarrheaDistention/bloating, abdominalDizzinessDry mouth/salivary gland (xerostomia)Dry skinDysphagia (difficulty swallowing)Dyspnea (shortness of breath)Edema, larynxEdema: head and neckEdema: limbEdema: visceraEncephalopathyEsophagitisEyelid dysfunctionFatigue (asthenia, lethargy, malaise)Febrile neutropeniaFever in absence of neutropenia, ANC lt1.0x10e9/LFibrinogenFlatulenceFlushingGGT (gamma-glutamyl transpeptidase)Gastrointestinal-OtherGlomerular filtration rateGlucose, serum-high (hyperglycemia)Glucose, serum-low (hypoglycemia)Hair loss/Alopecia (scalp or body)Hearing: pts w/o audiogram not enroll monitor prgmHeartburn/dyspepsiaHematomaHemoglobinHemorrhage, Respiratory tract NOSHemorrhage, CNSHemorrhage, GI - Lower GI NOSHemorrhage, GI - Oral cavityHemorrhage, GI - RectumHemorrhage, GI - Upper GI NOSHemorrhage, GU - BladderHemorrhage, GU - Urinary NOSHemorrhage, GU - VaginaHemorrhage, pulmo/upper resp- Bronchopulmonary NOSHemorrhage, pulmonary/upper respiratory - LungHemorrhage, pulmonary/upper respiratory - NoseHemorrhage/Bleeding-OtherHemorrhoidsHepatobiliary/Pancreas-OtherHiccoughs (hiccups, singultus)Hot flashes/flushesHypertensionHypotensionHypoxiaINR (of prothrombin time)Ileus, GI (functional obstruction of bowel)Incontinence, analInduration/fibrosis (skin and subcutaneous tissue)Inf (clin/microbio) w/Gr 3-4 neuts - BloodInf (clin/microbio) w/Gr 3-4 neuts - ColonInf (clin/microbio) w/Gr 3-4 neuts - Dental-toothInf (clin/microbio) w/Gr 3-4 neuts - LungInf (clin/microbio) w/Gr 3-4 neuts - Oral cav-gumsInf (clin/microbio) w/Gr 3-4 neuts - SkinInf (clin/microbio) w/Gr 3-4 neuts - StomachInf w/normal ANC or Gr 1-2 neutrophils - BloodInf w/normal ANC or Gr 1-2 neutrophils - LungInf w/normal ANC or Gr 1-2 neutrophils - UTIInf w/normal ANC or Gr 1-2 neutrophils - Up airwayInf w/normal ANC or Gr 1-2 neutrophils - VaginaInf w/unknown ANC - Oral cavity-gums (gingivitis)Infection (documented clinically or microbiologicaInfection with unknown ANC - BloodInfection with unknown ANC - Lung (pneumonia)Infection-OtherInjection site reaction/extravasation changesInsomniaLeak (including anastomotic), GU - BladderLeft ventricular systolic dysfunctionLeukocytes (total WBC)Liver dysfunction/failure (clinical)LymphopeniaMagnesium, serum-high (hypermagnesemia)Magnesium, serum-low (hypomagnesemia)Mental statusMetabolic/Laboratory-OtherMood alteration - agitationMood alteration - anxietyMood alteration - depressionMucositis/stomatitis (clinical exam) - Oral cavityMucositis/stomatitis (functional/symp) - Oral cavMuscle weakness, not d/t neuropathy - Extrem-lowerMuscle weakness, not d/t neuropathy - body/generalMusculoskeletal/Soft Tissue-OtherNasal cavity/paranasal sinus reactionsNauseaNeurology-OtherNeuropathy: cranial - CN II VisionNeuropathy: motorNeuropathy: sensoryNeutrophils/granulocytes (ANC/AGC)Obstruction, GU - BladderOcular/Visual-OtherOptic disc edemaPTT (Partial thromboplastin time)Pain - Abdomen NOSPain - BackPain - BonePain - ButtockPain - Cardiac/heartPain - Chest/thorax NOSPain - Dental/teeth/peridontalPain - EsophagusPain - Extremity-limbPain - EyePain - FacePain - Head/headachePain - JointPain - MusclePain - NeckPain - Oral cavityPain - PleuraPain - SinusPain - StomachPain - Throat/pharynx/larynxPain - UrethraPain-OtherPetechiae/purpura (hemorrhage into skin or mucosa)Phosphate, serum-low (hypophosphatemia)PlateletsPleural effusion (non-malignant)Pneumonitis/pulmonary infiltratesPotassium, serum-high (hyperkalemia)Potassium, serum-low (hypokalemia)Prolonged QTc intervalProteinuriaPruritus/itchingPsychosis (hallucinations/delusions)Pulmonary/Upper Respiratory-OtherRash/desquamationRenal failureRenal/Genitourinary-OtherRetinoic acid syndromeRigors/chillsSVT and nodal arrhythmia - Atrial fibrillationSVT and nodal arrhythmia - SVT arrhythmia NOSSVT and nodal arrhythmia - Sinus arrhythmiaSVT and nodal arrhythmia - Sinus bradycardiaSVT and nodal arrhythmia - Sinus tachycardiaSeizureSodium, serum-high (hypernatremia)Sodium, serum-low (hyponatremia)Soft tissue necrosis - Extremity-lowerSomnolence/depressed level of consciousnessSpeech impairment (e.g., dysphasia or aphasia)Stricture/stenosis (incl anastomotic) GI - PharynxSweating (diaphoresis)Syncope (fainting)Syndromes-OtherTaste alteration (dysgeusia)Thrombosis/embolism (vascular access-related)Thrombosis/thrombus/embolismThyroid function, low (hypothyroidism)Triglyceride, serum-high (hypertriglyceridemia)UlcerationUric acid, serum-high (hyperuricemia)Urinary frequency/urgencyUrinary retention (including neurogenic bladder)Urine color changeVaginal discharge (non-infectious)Ventricular arrhythmia - PVCsVentricular arrhythmia - Ventricular tachycardiaVision-blurred visionVision-flashing lights/floatersVision-photophobiaVitreous hemorrhageVoice changes/dysarthriaVomitingWatery eye (epiphora, tearing)Weight gainWeight loss
ATRA + GO + Arsenic3746413242348611812211272341841221121131462617511911323104111327153321213429221322112391612341382412110431982221254148111111431122312112513191326119168183141026193340214338152131482119125214477321118261574093928216121526426711352015191611924212111221411117243133239

[back to top]

Describe in Vitro Sensitivity as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts

Described via means and standard deviations in samples which have primary resistance to lestaurtinib (NCT00557193)
Timeframe: Sampled at the start of induction

InterventionProportion of cells that are viable (Median)
Arm A (Standard Risk MLL-G)0.75
Arm B (IR/HR MLL-R Chemotherapy)0.48
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)0.47

[back to top]

Describe FLT3 Protein Expression as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts

Described via means and standard deviations in available Arm C relapse samples (NCT00557193)
Timeframe: At relapse (up to 3 years)

InterventionqPCR fold expression ratio (Mean)
Arm C (Safety/Efficacy Dose Level 2)5.73

[back to top]

Describe FLT3 Protein Expression as a Molecular Mechanism of Primary Resistance to Lestaurtinib in Leukemic Blasts

Described via mean and standard deviation by group. (NCT00557193)
Timeframe: Sampled at the start of induction

InterventionqPCR fold expression ratio (Mean)
Arm A (Standard Risk MLL-G)1.25
Arm B (IR/HR MLL-R Chemotherapy)7.85
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)5.83

[back to top]

Describe in Vitro Sensitivity as a Molecular Mechanism of Acquired Resistance to Lestaurtinib in Leukemic Blasts

Described via means and standard deviations in samples which have acquired resistance to lestaurtinib (NCT00557193)
Timeframe: At relapse (up to 3 years)

InterventionProportion of cells that are viable (Mean)
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)0.69

[back to top]

Pharmacodynamics PIA Levels in Infants Given Lestaurtinib at DL2 in Combination With Chemotherapy

Summarized with mean and standard deviation for those with available data in Arm C (NCT00557193)
Timeframe: Sampled between weeks 6-12 from start of induction

InterventionActivity percentage (Mean)
Arm C (Safety/Efficacy Dose Level 2)69.00

[back to top]

Percent Probability of Event Free Survival (EFS) by MRD Status and Treatment Arm

Three-year EFS estimates and 90% CI will be reported by treatment arm and end-induction MRD status. (NCT00557193)
Timeframe: 3 Years from end of Induction)

Interventionpercent probability (Number)
Arm A (MRD Negative)86.05
Arm A (MRD Positive)87.5
Arm B (MRD Negative)47.37
Arm B (MRD Positive)22.73
Arm C (MRD Negative)51.85
Arm C (MRD Positive)27.03

[back to top]

Percent Probability for Event-free Survival (EFS) of MLL-R Infants Treated With Combination Chemotherapy With or Without Lestaurtinib at DL2

Event Free Probability where EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. EFS will be compared between patients on treatment Arm C at DL2 to those on Arm B. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years.

Interventionpercent probability (Number)
Arm B (IR/HR MLL-R Chemotherapy)38.89
Arm C (IR/HR MLL-R Chemotherapy and Lestaurtinib)35.82

[back to top]

Percent Probability for Event-free Survival (EFS) for Patients on Arm C at Dose Level 2 (DL2)

EFS time is defined as time from randomization to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years

Interventionpercentage probability (Number)
Arm C (Safety/Efficacy Dose Level 2)35.82

[back to top]

Percent Probability for Event-free Survival (EFS) for Patients on Arm A

EFS time is defined as time from treatment assignment to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free. EFS is constructed using the Kaplan-Meier life table method with confidence interval based on standard errors computed using the method of Peto and Peto. (NCT00557193)
Timeframe: From start of post-induction therapy for up to 10 years

Interventionpercentage probability (Number)
Arm A (Standard Risk MLL-G)86.67

[back to top] [back to top] [back to top]

Overall Survival

OS was defined from registration to death resulting from any cause. (NCT00558519)
Timeframe: Up to 8 years post-registration

Interventionmonths (Median)
Treatment (Pediatric Regimen)NA

[back to top]

Complete Response Rate

Complete response rate is defined as the percentage of patients who achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) at the end of induction therapy. (NCT00558519)
Timeframe: Up to 8 years post-registration

Interventionpercentage of patients (Number)
Treatment (Pediatric Regimen)89

[back to top]

Disease-free Survival

DFS was defined as time from bone marrow response in this study to the earliest occurrence of any of the following: failure to achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) by day 60, death, relapse at any site, or development of second malignant disease. (NCT00558519)
Timeframe: Up to 8 years post-registration

Interventionmonths (Median)
Treatment (Pediatric Regimen)81.7

[back to top]

Event-free Survival

EFS was defined as time from registration in this study to the earliest occurrence of any of the following: failure to achieve bone marrow response (defined using the M bone marrow criteria for acute lymphoblastic leukemia (ALL); if M0 to M1 status (blast cells ,5%) was achieved by the end of induction or extended induction, the patient was considered a responder) by day 60, death, relapse at any site, or development of second malignant disease. (NCT00558519)
Timeframe: Up to 8 years post-registration

Interventionmonths (Median)
Treatment (Pediatric Regimen)78.1

[back to top]

Pharmacodynamics (PD)

Plasma Asparaginase Concentration During consolidation and induction. (NCT00671034)
Timeframe: Day 29 of consolidation and induction

,,
InterventionmIU/mL (Median)
Plasma Asparaginase Concentration- ConsolidationPlasma Asparaginase Concentration- Induction
Arm I (Calaspargase Pegol 2100)575.9271.6
Arm II (Calaspargase Pegol 2500)617.2339.6
Arm III (Pegaspargase 2500)562.172.8

[back to top]

Immunogenicity

Number of Patients with Positive Immunogenicity tests (NCT00671034)
Timeframe: 25 Days Post-dose (Day 29)

InterventionParticipants (Count of Participants)
Arm I (Calaspargase Pegol 2100)2
Arm II (Calaspargase Pegol 2500)2
Arm III (Pegaspargase 2500)4

[back to top]

Percentage of Participants With Complete Remission at the End of Induction

Complete Remission (CR) rate; where CR is defined as M1 marrow (< 5% lymphoblasts in the bone marrow) (NCT00671034)
Timeframe: End of induction (Day 29)

InterventionPercentage of participants (Number)
Arm I (Calaspargase Pegol 2100)92.4
Arm II (Calaspargase Pegol 2500)97.6
Arm III (Pegaspargase 2500)94.1

[back to top]

Percentage of Participants With Event-free Survival (EFS)

Percentage of participants who were event free. Event Free Probability defined as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignant neoplasm, remission death) or date of last contact for subjects who are event-free. (NCT00671034)
Timeframe: 5 Years

InterventionPercentage of participants (Number)
Arm I (Calaspargase Pegol 2100)72.35
Arm II (Calaspargase Pegol 2500)80.8
Arm III (Pegaspargase 2500)79.34

[back to top]

Asparaginase Level

The proportion of patients with an asparaginase level of at least 0.1 IU/mL and the proportion with at least 0.4 IU/mL on Days 4, 15, 22 and 29 of Induction compared to Oncaspar (NCT00671034)
Timeframe: Days 4, 15, 22 and 29 of Induction

,,
Interventionpercentage of patients (Number)
Level at least 0.1 IU/mL day 4Level at least 0.1 IU/mL day 15Level at least 0.1 IU/mL day 22Level at least 0.1 IU/mL day 29Level at least 0.4 IU/mL day 4Level at least 0.4 IU/mL day 15Level at least 0.4 IU/mL day 22Level at least 0.4 IU/mL day 29
Arm I (Calaspargase Pegol 2100)098.498.294.9075.837.513.6
Arm II (Calaspargase Pegol 2500)010010095.0095.062.527.5
Arm III (Pegaspargase 2500)010095.128.6093.014.60

[back to top]

Toxicities During Post Induction Intensification Therapy (All Grades)

The calculation of AE incidence will be based on the number of patients per AE category. For each patient who has multiple AEs classified to the same category, that patient will be tabulated under the worst toxicity grade for that AE category. The incidence of AEs will be tabulated by treatment arm and by organ class. Special attention will be paid to hypersensitivity, pancreatitis, coagulopathy, infection, neurologic dysfunction and thromboembolic events. (NCT00671034)
Timeframe: Up to 5 years

,,
InterventionPercentage of participants (Number)
Alergic Reaction - ConsolidationAlergic Reaction - Delayed Intensification IAlergic Reaction - Interim Maintenance ICNS - ConsolidationCNS - Delayed Intensification ICNS - Interim Maintenance IHyperbilirubinemia - ConsolidationHyperbilirubinemia - Delayed Intensification IHyperbilirubinemia - Interim Maintenance IHyperglycemia - ConsolidationHyperglycemia - Delayed Intensification IHyperglycemia - Interim Maintenance IHyperlipidemia - ConsolidationHyperlipidemia - Delayed Intensification IHyperlipidemia - Interim Maintenance I% patients w/INR increase - Consolidation% pts w/INR increase - Delayed Intensification I% patients w/INR increase - Interim Maintenance IPancreatitis - ConsolidationPancreatitis -Delayed Intensification IPancreatitis - Interim Maintenance I% pts w/prolongation of APT time - Consolidation% pts w/prolongation APT time -Delayed Intension I%pts w/prolongation APT time-Interim maintenance IThrombosis - ConsolidationThrombosis - Delayed Intensification IThrombosis - Interim Maintenance I
Arm I (Calaspargase Pegol 2100)20.44.40.00.00.00.053.128.941.344.944.434.82.02.22.26.16.72.210.22.22.28.28.96.50.02.20.0
Arm II (Calaspargase Pegol 2500)27.30.00.00.03.80.045.538.527.642.461.544.83.00.03.43.03.80.06.17.73.49.126.96.90.00.00.0
Arm III (Pegaspargase 2500)23.30.02.10.02.60.030.210.533.346.536.833.37.00.02.67.00.02.67.00.02.67.018.47.72.30.00.0

[back to top]

Plasma and CSF Concentrations of Asparagine in ug/ml

The plasma and CSF concentrations of asparagine in ug/ml after administration of EZN-2285 compared to Oncaspar. (NCT00671034)
Timeframe: 25 Days Post-dose (Day 29)

,,
Interventionug/mL (Mean)
CSF asparagine concentration (ug/mL)Plasma asparagine concentration (ug/mL)
Arm I (Calaspargase Pegol 2100)0.20.2
Arm II (Calaspargase Pegol 2500)0.190.25
Arm III (Pegaspargase 2500)0.260.83

[back to top]

Pharmacokinetics (PK) (Half-life of SC-PEG E. Coli L-asparaginase (EZN-2285) Compared to Pegaspargase During Induction and Consolidation Therapy)

Mean half-life of plasma asparaginase during consolidation and Induction; half-life is defined as the time taken for drug concentration to decrease by half. (NCT00671034)
Timeframe: Post Day 29 of Induction and Post Day 22 of Consolidation

,,
Interventionhours (Mean)
Asparaginase half-life during ConsolidationAsparaginase half-life during Induction
Arm I (Calaspargase Pegol 2100)415.8305.1
Arm II ( Calaspargase Pegol 2500)355.9321.5
Arm III (Pegaspargase 2500)117.2126.9

[back to top]

Percentage of Participants With Minimal Residual Disease (MRD)<0.01% at the End of Induction

Percentage of participants with Negative MRD (MRD<0.01%). (NCT00671034)
Timeframe: End of induction (Day 29)

InterventionPercentage of participants (Number)
Arm I (Calaspargase Pegol 2100)65.2
Arm II (Calaspargase Pegol 2500)81
Arm III (Pegaspargase 2500)72.5

[back to top]

Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events

Number of patients in safety cohort with dose limiting toxicity (DLT)(including treatment delay) (NCT00720109)
Timeframe: Weeks 3 through 23 of treatment (From week 3 Induction through Intensification Block 1)

InterventionPts with DLTs (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)1

[back to top]

Overall EFS Rate for the Combined Cohort of Standard- and High-Risk Patients (Who Receive the Final Chosen Dose of Dasatinib)

An event is defined as: Induction failure, relapse at any site, secondary malignancy, or death. (NCT00720109)
Timeframe: From the time entry on study to first event or date of last follow-up, assessed up to 7 years

Interventionpercentage of patients (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)79.8
Standard-risk83.2
High-risk66.7

[back to top]

Percent of Patients MRD Positive (MRD > 0.01%) at End of Consolidation

A 1-sample Z-test of proportions (alpha=5%, 1-sided test) will be used. (NCT00720109)
Timeframe: At end of consolidation (at 11 weeks)

InterventionPercentage of participants (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)10.5
Standard-risk0
High-risk66.7

[back to top]

Contribution of Dasatinib on Minimal Residual Disease (MRD) After Induction Therapy

Percent of patients MRD Positive (MRD > 0.01%) at End of Induction. (NCT00720109)
Timeframe: At the end of induction therapy (at 5 weeks)

InterventionPercentage of participants (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)40.7
Standard-risk29.2
High-risk100.0

[back to top]

Event-Free Survival (EFS) of Patients With Standard-risk Disease Treated With Dasatinib in Combination With Intensified Chemotherapy

Event-Free Survival (EFS) curves will be constructed using the Kaplan-Meier life table method with standard errors computed using the method of Peto and Peto. A 1-sided 95% confidence interval for EFS will be constructed. (NCT00720109)
Timeframe: At 3 years

InterventionPercent probability (Number)
Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)79.8
Standard-risk83.2
High-risk66.7

[back to top]

AALL08P1 Feasibility Outcome

Percentage of Group B (High Risk-High) patients that tolerate at least 8 of the 12-14 total doses of pegaspargase during Consolidation, Interim Maintenance, and Delayed Intensification periods. Only Grp B analyzed since this is prespecified in protocol. (NCT00866307)
Timeframe: Consolidation through Delayed Intensification

Interventionpercentage of participants (Number)
Group B (High Risk-High)53.3

[back to top]

AALL08P1 Safety Outcome

Percentage of Group B (High Risk-High) patients taking less than 49 weeks from day 1 of consolidation to day 1 of maintenance therapy. Only Group B analyzed since this is prespecified in protocol. (NCT00866307)
Timeframe: Consolidation through Delayed Intensification

Interventionpercentage of participants (Number)
Group B (High Risk-High)50.0

[back to top]

3-Year Event-Free Survival (EFS)

3-year EFS was calculated based on the participants with a complete response (CR). Study regimen considered successful if it exhibits a 3-year EFS rate greater than 60% and response rate no less than 90% with Grade III-IV infectious toxicity rate in induction no more than 33%. (NCT00866749)
Timeframe: 3 Years

InterventionParticipants (Count of Participants)
Augmented BFM Therapy68

[back to top]

Overall Survival

Overall Survival defined: Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT00866749)
Timeframe: Up to 12 years

InterventionMonths (Median)
Augmented BFM Therapy121

[back to top]

Participants With a Complete Response (CR)

Complete Response defined as: Bone Marrow blasts /= 100 and an Absolute Neutrophil Count (ANC) >/= 1000 (NCT00866749)
Timeframe: Up to 1 year

Interventionparticipants (Number)
Augmented BFM Therapy108

[back to top]

Participants Achieving Negative Minimal Residual Disease (MRD)

To evaluate the prognostic significance of minimal residual disease (MRD) in bone marrow samples of participants who achieved a complete response (CR) at the end of induction (day 29) and at the end of consolidation (day 84) in this group of patients. (NCT00866749)
Timeframe: up to 3 months

Interventionparticipants (Number)
Participants with CR and MRD negative on Day 29Participants with CR and MRD negative on day 84
Augmented BFM Therapy6087

[back to top]

Overall Survival (OS)

OS - time from study entry to death. (NCT00866918)
Timeframe: At 3 years from study entry

InterventionPercentage of participants (Number)
Standard Risk98.4
High Risk85.7

[back to top]

Hematologic Remission Rate

Proportion of patients in hematologic remission at end of consolidation, course 1 are reported. (NCT00866918)
Timeframe: End of consolidation, course 1: up to 5 months

InterventionProportion of participants (Number)
Standard Risk1.0000
High Risk0.8824

[back to top]

Hematologic, Molecular, and Cytogenetic Remission Rate

Proportion of patients in hematologic, molecular, and cytogenetic remission at end of consolidation, course 3 and 4 are reported. Patients were determined to be in remission by all three criteria. (NCT00866918)
Timeframe: End of consolidation, course 3; up to 7 months (for Standard Risk) or end of consolidation, course 4; up to 9 months (for High Risk)

InterventionProportion of participants (Number)
Standard Risk0.8095
High Risk0.5882

[back to top]

Event-free Survival (EFS)

EFS - time from study entry until failure to achieve complete remission during consolidation, relapse, or death. For further clarification see definitions provided in the protocol. (NCT00866918)
Timeframe: At 3 years from study entry

InterventionPercentage of participants (Number)
Standard Risk95.4
High Risk82.9

[back to top]

Overall Survival at One Year

The number of participants alive one year after baseline. (NCT00973752)
Timeframe: 1 years

InterventionParticipants (Count of Participants)
Experimental19

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.27
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.34

[back to top]

Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-1.21

[back to top]

Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Physical

Age and gender standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-1.44

[back to top]

Burden of Therapy in AR Patients Overall at End of Consolidation Therapy: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-0.42

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1 year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.86

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.59

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 1: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.19

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1.7 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.84

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1.7 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.20

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.5 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.74

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.66

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.30

[back to top]

Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.71
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.51

[back to top]

Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.85
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.47

[back to top]

Burden of Therapy in Boy AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Therapy: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.46
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.33

[back to top]

Burden of Therapy in Boy AR Patients Overall at End of Therapy: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Genetic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.62

[back to top]

Burden of Therapy in Boy AR Patients Overall at End of Therapy: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.67

[back to top]

Burden of Therapy in Boy AR Patients Overall at End of Therapy: Social Functioning

Age standardized Quality of life, measured by the Social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 3.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.40

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 4.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-1.19

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL 12 Months Post Therapy: Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 4.2 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-1.12

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-0.84

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Consolidation Therapy-Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2 Months

InterventionZ-Score (Mean)
B-ALL Average Risk-0.87

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.36

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 1: Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 1 Year

InterventionZ-Score (Mean)
B-ALL Average Risk-0.39

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.28

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for the cohort will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.27

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Left

Strength in the left ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for each randomization group will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-1.19
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks0.21

[back to top]

Characterize Vincristine-associated Neuropathy in Children Undergoing Therapy for Average Risk (AR) ALL by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Right

Strength in the right ankle dorsiflexors averaged over two measurements. Age and gender standardized mean and standard deviation for each randomization group will be reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-1.12
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.02

[back to top]

DFS for SR Down Syndrome Patients With Standardized Treatment and Enhanced Supportive Care

DFS is calculated as the time from end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. The 5-year DFS and 95% confidence interval for these patients will be estimated. (NCT01190930)
Timeframe: 5.1 years

Interventionpercent probability (Number)
Standard Risk With Down Syndrome89.77

[back to top]

DFS in Average Risk (AR) Patients Based on the Pulse Frequency Randomization

DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated. (NCT01190930)
Timeframe: 5.7 years

Interventionpercent probability (Number)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks94.10
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks95.13

[back to top]

DFS in Low Risk (LR) Patients Based on Randomization to 1 of 2 Low-intensity Regimens

DFS is calculated as the time from randomization at the end of Induction to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated. (NCT01190930)
Timeframe: 5.1 years

Interventionpercent probability (Number)
B-ALL Low Risk Arm I (LR-M)98.75
B-ALL Low Risk Arm II (LR-C)98.50

[back to top]

Disease Free Survival (DFS) in Average Risk (AR) Patients Based on the Methotrexate Dose Randomization

DFS is calculated as the time from randomization at the end of interim maintenance II to first event (relapse, second malignancy, remission death) or date of last contact. Five year DFS estimates will be calculated from the point of randomization for both groups. Two-sided 95% confidence intervals will be calculated. (NCT01190930)
Timeframe: 5.7 years

Interventionpercent probability (Number)
B-ALL Average Risk: MTX 20 mg/m^2/Week Starting Dose95.05
B-ALL Average Risk: MTX 40 mg/m^2/Week Starting Dose94.17

[back to top]

Event Free Survival (EFS) for B-LLy Patients

EFS is calculated as the Time from study enrollment to first event (induction failure, relapse, second malignancy, remission death) or date of last contact. The 5-year EFS and 95% confidence interval for these patients will be estimated. (NCT01190930)
Timeframe: 5 years

Interventionpercent probability (Number)
B-LLy94.54

[back to top]

Overall Survival (OS) for B-LLy Patients

OS is calculated as the time from study enrollment to death or date of last contact. The 5-year OS and 95% confidence interval for these patients will be estimated. (NCT01190930)
Timeframe: 5 years

Interventionpercent probability (Number)
B-LLy93.97

[back to top]

Sample Collection of Central Path Review Slides in B-LLy Patients

Percent of B-LLy patients who had adequate/usable samples of samples collected will be reported. (NCT01190930)
Timeframe: Up to 1 month

Interventionpercentage of patients (Number)
B-LLy89.7

[back to top]

Burden of Therapy in AR Patients Overall at End of Maintenance Cycle 4: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated with mean and standard deviation reported. (NCT01190930)
Timeframe: 1.7 years

InterventionZ-Score (Mean)
B-ALL Average Risk-0.63

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.72
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.77

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Emotional

Age standardized Quality of life, measured by the emotional subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported. (NCT01190930)
Timeframe: 1.7 years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.80
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.89

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported. (NCT01190930)
Timeframe: 1.7 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.62
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.64

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 4: Social Functioning

Age standardized Quality of life, measured by the social functioning subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with means and standard deviation reported. (NCT01190930)
Timeframe: 1.7 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.16
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.25

[back to top]

Burden of Therapy in AR Patients by Vincristine Pulse Frequency Randomization Groups (4 Week vs. 12 Week) at End of Maintenance Cycle 7 (Boys)/End of Therapy (Girls): Physical

Age standardized Quality of life, measured by the physical subscale of Pediatric Quality of Life Inventory 4.0 Generic Core Scales (PedsQL), will be calculated for each group with mean and standard deviation reported. (NCT01190930)
Timeframe: 2.4 Years

InterventionZ-Score (Mean)
B-ALL Average Risk: VCR/DEX Pulse Every 4 Weeks-0.64
B-ALL Average Risk: VCR/DEX Pulse Every 12 Weeks-0.67

[back to top]

Response

Proportion of patients reaching a CR. A CR requires the following: an absolute neutrophil count (segs and bands) >1000/μL, no circulating blasts, platelets >100,000/μL; adequate bone marrow cellularity with trilineage hematopoiesis, and <5% marrow leukemia blast cells. All previous extramedullary manifestations of disease must be absent (e.g., lymphadenopathy, splenomegaly, skin or gum infiltration, testicular masses, or CNS involvement). (NCT01256398)
Timeframe: 10 years

Interventionproportion of participants (Number)
Treatment (Chemotherapy, Transplant).9846

[back to top]

Probability of Being BCR-ABL Negative in the Bone Marrow and Peripheral Blood at the Completion of the CNS Prophylaxis Course (Restricted to Those Patients Achieving a CR)

Proportions will be estimated based on the combined and individual cohorts. (NCT01256398)
Timeframe: 10 years

Interventionproportion of participants (Number)
Treatment (Chemotherapy, Transplant)0.667

[back to top]

Overall Survival (OS)

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: 10 years

InterventionMonths (Median)
Treatment (Chemotherapy, Transplant)55.9

[back to top]

Feasibility of Maintenance Therapy in This Patient Population (Restricted to Those Patients Achieving a CR). Feasibility Will be Defined as the Number of Deaths Ocuring.

Proportions will be estimated based on the combined and individual cohorts. (NCT01256398)
Timeframe: 10 years

InterventionParticipants (Count of Participants)
Treatment (Chemotherapy, Transplant)5

[back to top]

Disease Free Survival Defined From the Date of First Induction Complete Response (CR) to Relapse or Death Due to Any Cause

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: At 3 years after CR

Interventionpercentage of patients (Number)
Treatment (Chemotherapy, Transplant)52.6

[back to top]

Disease Free Survival (DFS)

Estimated using the Kaplan-Meier estimator. Proportions will be estimated using point as well as interval estimators. All interval estimators will be constructed using the finite sample size sampling distribution at the unadjusted two-sided level of 0.05. (NCT01256398)
Timeframe: 10 years

InterventionMonths (Median)
Treatment (Chemotherapy, Transplant)29.7

[back to top]

Objective Response Rate to 6-mercaptopurine and Methotrexate (6MP/MTX) in This Patient Population.

"1st stage: If less than 3/30 evaluable patients respond at 8 weeks the trial will be stopped for futility. If 3 or more out of 30 evaluable patients respond then a further 35 patients will be recruited (2nd stage) - this was met.~The proportion of patients responding to treatment (complete response, partial response or stable disease) at the second stage will be presented per Response Evaluation Criteria In Solid Tumours (RECIST) criteria version 1.1 measured radiologically with computerised tomography (CT) and/or magnetic resonance imaging (MRI); the same method is used at baseline and at follow-up: Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions. Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD. Patients who yield progressive disease (PD) are classed as non-responders." (NCT01432145)
Timeframe: 8 weeks after start of treatment

InterventionParticipants (Count of Participants)
6-Mercaptopurine and Methotrexate (6MP/MTX)22

[back to top]

Probability of Event-free Survival (EFS)

"For EFS, relapse and second malignancies are considered as failures in addition to death in complete remission. The time to EFS will be set to 0 for patients who fail to achieve complete remission. Kaplan-Meier estimates of the OS and EFS curves are computed, along with estimates of standard errors by Peto's method.~Please note the unit of measurement of probabilities are percentages." (NCT01451515)
Timeframe: Two years post therapy.

Interventionpercentage of event-free patients (Number)
Stratum 191.7
Stratum 271.4
Stratum 3100
All Enrollments86.96

[back to top]

Probability of Overall Survival (OS)

"For OS, only deaths are considered failures for OS. Kaplan-Meier estimates of the OS curves are computed along with estimates of standard errors by Peto's method.~Please note the unit of measurement of probabilities are percentages." (NCT01451515)
Timeframe: Two years post therapy.

Interventionpercentage of patients alive (Number)
Stratum 191.7
Stratum 271.4
Stratum 3100
All Enrollments86.96

[back to top]

Minimal Disseminated Disease (MDD)

Detectable disease in bone marrow or blood: A binary measure, positive (detectable), negative (non-detectable) (NCT01451515)
Timeframe: At Diagnosis

,,
Interventionparticipants (Number)
NegativePositive
Stratum 141
Stratum 223
Stratum 304

[back to top]

Minimal Residual Disease (MRD)

Detectable disease in bone marrow or blood: A binary measure, positive (detectable), negative (non-detectable) (NCT01451515)
Timeframe: Day 8

,,
Interventionparticipants (Number)
NegativePositive
Stratum 180
Stratum 241
Stratum 304

[back to top]

3-year Event-free Survival Rates in Patients With Relapsed ALL

Estimate the 3-year event-free survival rate of participants with first relapse or primary refractory precursor B-cell ALL treated with risk-directed therapy. (NCT01700946)
Timeframe: 3 years of follow-up since the on-study date

Interventionpercentage of participants (Number)
STANDARD RISK83.3
HIGH RISK55.7
All Patients Enrolled on the Study67.83

[back to top]

3-year Overall Survival Rate of Patients With Relapsed ALL

Estimate the 3-year survival rate of participants with first relapse or primary refractory precursor B-cell ALL treated with risk-directed therapy. (NCT01700946)
Timeframe: 3 years of follow-up since the on-study date

Interventionpercentage of participants (Number)
STANDARD RISK94.4
HIGH RISK55.5
All Patients Enrolled on the Study72.63

[back to top]

Mean of CD20 Expression Levels

To estimate mean levels of CD20 expression at baseline, during treatment with dexamethasone-containing chemotherapy and following rituximab treatment in Block I of remission induction therapy for relapsed precursor B-cell ALL. (NCT01700946)
Timeframe: Baseline and at the end of Block I (approximately 5 weeks after the on-study date)

,,
Interventionpercentage of CD20 Antigen (Mean)
At BaselineAt Block I
All Patients Enrolled on the Study36.2319.43
HIGH RISK39.8220.10
STANDARD RISK31.1018.54

[back to top]

Median CD20 Expression Levels

To estimate median levels of CD20 expression at baseline, during treatment with dexamethasone-containing chemotherapy and following rituximab treatment in Block I of remission induction therapy for relapsed precursor B-cell ALL. (NCT01700946)
Timeframe: Baseline and at the end of Block I (approximately 5 weeks after the on-study date)

,,
Interventionpercentage of CD20 Antigen (Median)
At BaselineAt Block 1
All Patients Enrolled on the Study22.015.58
HIGH RISK23.1319.58
STANDARD RISK16.4011.83

[back to top]

Disease Free Survival (DFS) of High-risk (HR) and Intermediate-risk (IR) Relapse Patients

DFS rates of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). DFS is calculated as the time from randomization to date of first event (treatment failure, relapse, second malignancy, remission death) or date of last contact. Two-year DFS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 2 years from date of randomization

Interventionpercentage of participants (Number)
Arm A (HR and IR Control)39.04
Arm B (HR and IR Blinatumomab)54.44

[back to top]

Overall Survival (OS) of LR Relapse Patients

OS rates of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). OS is calculated as the time from randomization to date of death or date of last contact. Three-year OS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 3 years from date of randomization

Interventionpercentage of participants (Number)
Arm C (LR Control)88.29
Arm D (LR Blinatumomab)90.37

[back to top]

Overall Survival (OS) of HR and IR Relapse Patients

OS rates of HR and IR relapse B-ALL patients who are randomized following Induction Block 1 chemotherapy to receive either two intensive chemotherapy blocks or two 5-week blocks of blinatumomab (HR/IR Randomization). OS is calculated as the time from randomization to date of death or date of last contact. Two-year OS estimates will be calculated from date of randomization for both Arm A and Arm B. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 2 years from date of randomization

Interventionpercentage of participants (Number)
Arm A (HR and IR Control)58.40
Arm B (HR and IR Blinatumomab)71.33

[back to top]

Disease Free Survival (DFS) of Low Risk (LR) Relapse Patients

DFS rates of LR relapse B-ALL patients who are randomized following Block 1 chemotherapy to receive either chemotherapy alone or chemotherapy plus blinatumomab (LR Randomization). DFS is calculated as the time from randomization to date of first event (relapse, second malignancy, remission death) or date of last contact. Three-year DFS estimates will be calculated from date of randomization for both Arm C and Arm D. Two-sided 95% confidence intervals will be calculated. (NCT02101853)
Timeframe: Up to 3 years from date of randomization

Interventionpercentage of participants (Number)
Arm C (LR Control)58.94
Arm D (LR Blinatumomab)67.00

[back to top]

EFS for Standard (SR) and Intermediate Risk (IR) T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no Cranial Radiation Therapy [CRT]) and Similar Patients on AALL0434 (Received CRT)

EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact. (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
AALL1231 T-ALL Patients88.3
AALL0434 T-ALL Patients88.8

[back to top]

Cumulative Incidence Rates of Isolated Central Nervous System (CNS) Relapse for SR and IR T-ALL Patients on the Non-bortezomib Containing Arm on This Study (no CRT) and Similar Patients on AALL0434 (Receive CRT)

Cumulative incidence of isolated CNS relapse adjusting for competing risks using the method of: Gray R, A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1141:1154, 1988 (NCT02112916)
Timeframe: 3 years

,
InterventionPercentage of participants (Number)
Isolated CNS RelapseIsolated Bone Marrow RelapseCombined Bone Marrow Relapse
AALL0434 T-ALL Patients2.23.01.8
AALL1231 T-ALL Patients3.61.41.3

[back to top]

Toxicity Rates Associated With Modified Standard Therapy, Including Dexamethasone and Additional Pegaspargase

Percentage of patients who experienced Grade 3 or higher Toxicity Assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 4.0 (NCT02112916)
Timeframe: 3 years from start of therapy by patient

InterventionPercentage of participants (Number)
Total Patients78.0

[back to top]

Event-free Survival (EFS) for Modified Augmented Berlin-Frankfurt-Munster Backbone With or Without Bortezomib in All Randomized Patients

EFS is calculated as time from randomization at study entry to first event (induction failure, induction death, relapse, second malignancy, remission death) or date of last contact. Three-year EFS rates will be calculated for both groups. (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
Arm A (Combination Chemotherapy)81.7
Arm B (Combination Chemotherapy, Bortezomib)85.1

[back to top]

EFS for Very High Risk (VHR) T-LLy Patients Treated With HR Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Have Complete or Partial Remission and Those Who do Not Respond

EFS for very high risk (VHR) T-LLy patients treated with HR Berlin-Frankfurt-Munster (BFM) intensification blocks who have complete or partial remission and those who do not respond (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
VHR T-LLy (CR/PR)0

[back to top]

EFS for Very High Risk (VHR) T-ALL Patients Treated With High Risk (HR) Berlin-Frankfurt-Munster (BFM) Intensification Blocks Who Become Minimal Residual Disease (MRD) Negative and Those Who Remain MRD Positive at the End of HR Block 3

EFS will be calculated as time from the end of the three high-risk blocks of therapy to first event (relapse, second malignancy, remission death) or date of last contact. (NCT02112916)
Timeframe: 3 years

InterventionPercentage of participants (Number)
VHR T-ALL MRD Undetectable25.0
VHR T-ALL MRD Detectable88.9

[back to top]

Overall Survival Rate (Cohort I)

To evaluate the 3-year overall survival rate in elderly participants with newly diagnosed Ph-negative ALL treated with blinatumomab followed by POMP maintenance. Overall (NCT02143414)
Timeframe: From the day of registration on study until death from any cause, assessed at 3 years

Interventionpercentage of participants (Number)
Cohort I (Ph-)34

[back to top]

Incidence of Dose-limiting Toxicity (Cohort II)

Defined as any grade 4 or higher treatment-related, non-hematologic toxicity in the first cycle of post-remission therapy (blinatumomab/dasatinib) graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. Only participants with Ph-positive ALL or Ph-like DSMKF ALL were evaluated. (NCT02143414)
Timeframe: Up to day 42 of post-remission therapy

InterventionParticipants (Count of Participants)
Cohort II (Ph+/Ph-like)0

[back to top]

Disease-free Survival (Cohort II)

An estimate of disease free survival in Ph-positive ALL and Ph-like DSMKF ALL (Cohort II). Disease free survival is measured by the number of years between the date the patient first achieves complete remission (CR) or complete remission with incomplete platelet recovery (CRi) until relapse from CR/CRi or death from any cause. CR is defined as having <5% marrow aspirate blasts, ANC >1,000/mcL, platelets > 100,000/mcL, no blasts in peripheral blood, and C1 extramedullary disease status. CRi is the same as CR but platelet count may be <= 100,000/mcL and/or ANC <=1,000/mcL. (NCT02143414)
Timeframe: Duration of treatment and follow up until death or date of primary analysis (about 7.5 years)

Interventionyears (Median)
Cohort II (Ph+/Ph-like)5.3

[back to top] [back to top]

Minimal Residual Disease Negativity

To estimate in each cohort the rate of minimal residual disease (MRD) negativity. (NCT02143414)
Timeframe: Participants are assessed after induction treatment and again after re-induction treatment, if re-induction treatment is received (i.e. up to 85 days after registration)

,
InterventionParticipants (Count of Participants)
MRD-MRD+
Cohort I (Ph-)121
Cohort II (Ph+/Ph-like)79

[back to top]

Complete Response Rate (Cohort I)

Complete response rate is measured by the number of participants achieving complete remission (CR) or complete remission with incomplete platelet recovery (CRi) rate. CR is defined as having <5% marrow aspirate blasts, ANC >1,000/mcL, platelets > 100,000/mcL, no blasts in peripheral blood, and C1 extramedullary disease status. CRi is the same as CR but platelet count may be <= 100,000/mcL and/or ANC <=1,000/mcL. (NCT02143414)
Timeframe: Participants are assessed after induction treatment and again after re-induction treatment, if re-induction treatment is received (i.e. up to 85 days after registration)

InterventionParticipants (Count of Participants)
CR or CRiNo CR or CRi
Cohort I (Ph-)1910

[back to top]

Event Free Survival (EFS)

Event free survival defined as the time from treatment to relapse of leukemia or death for any reason or lost to follow-up. Study regimen considered successful if it exhibits a 3-year EFS rate greater than 65% and response rate no less than 90% with Grade III-IV infectious toxicity rate in induction no more than 33%. (NCT02419469)
Timeframe: 3 years

InterventionParticipants (Count of Participants)
Ofatumumab Plus ChemotherapyNA

[back to top] [back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT02420717)
Timeframe: Up to 4 years 7 months

InterventionMonths (Median)
Phase I Ruxolitinib 15mg4.8
Phase I Ruxolitinib 20mg5.4
Phase I Ruxolitinib 25mg38.5

[back to top]

Maximal Tolerated Dose (MTD) of Ruxolitinib in Combination With Chemotherapy Defined as the Highest Dose Level at Which no More Than 1 Out of 6 Patients Experience a Dose Limiting Toxicity (Phase I)

The method of Thall, Simon and Estey will be used for toxicity monitoring for this study. The severity of the toxicities will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 whenever possible. Safety data will be summarized by category, severity and frequency. (NCT02420717)
Timeframe: 42 days

InterventionMilligrams (mg) (Number)
Phase I Ruxolitinib 15mg25

[back to top]

Participants With Complete Response (Complete Response [CR]/CR With Incomplete Marrow Recovery [CRi]) (Phase II)

Complete Response (CR) is disappearance of all clinical and/or radiologic evidence of disease, Neutrophil count ≥ 1.0 x 10^9/L, Platelet count ≥ 100 x 10^9/L, Normal bone marrow differential (≤ 5% blasts), No extra-medullary leukemia. Complete Remission with Incomplete Blood Count Recovery (CRi) is CR except for ANC < 1.0 x 10^9/L and/or platelets < 100 x 10^9/L. (NCT02420717)
Timeframe: 42 days

InterventionParticipants (Count of Participants)
Phase I Ruxolitinib 15mg0
Phase I Ruxolitinib 20mg1
Phase I Ruxolitinib 25mg0

[back to top]

Progression-free Survival

Time from date of treatment start until the date of first objective documentation of disease-relapse. (NCT02420717)
Timeframe: Up to 4 years 7 months

InterventionMonths (Median)
Phase I Ruxolitinib 15mg2.3
Phase I Ruxolitinib 20mg1.8
Phase I Ruxolitinib 25mg1.9

[back to top] [back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of First Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients after the first course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 6, Day 5 (Following the induction phase (35 days), the first course of Azacitidine began around Week 6 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged75.54

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 5 of Second Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients after the second course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 13, Day 5 (Following induction phase (5 weeks), the first course of Azacitidine (1 week), and consolidation (6 weeks), the second course of Azacitidine began around Week 13 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged74.52

[back to top]

Tolerability of Azacitidine in Combination With Interfant-06 Standard Chemotherapy in Evaluable Infant Patients With Newly Diagnosed ALL With KMT2A Gene Rearrangement (KMT2A-R). KMT2A Gene Rearrangement (KMT2A-R)

Proportion of KMT2A-Rearranged patients treated with azacitidine with Dose Limiting Toxicities (DLTs) from the first course of azacitidine administration up to fourth course of azacitidine administration. (NCT02828358)
Timeframe: 6 months

Interventionpercentage of participants (Number)
KMT2A-Rearranged6.45

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to Second Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients before the second course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 13, Day 1 (Following induction phase (5 weeks), the first course of Azacitidine (1 week), and consolidation (6 weeks), the second course of Azacitidine began around Week 13 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged76.5

[back to top]

Biologic Activity, Defined as Global Deoxyribonucleic Acid (DNA) Methylation Change in Peripheral Blood Mononuclear Cells (PBMC)s; Day 1 Prior to First Course of Azacitidine

Will calculate the percentage of CpG site methylation for all patients before the first course of azacitidine. Mean and standard deviation will be reported. (NCT02828358)
Timeframe: Week 6, Day 1 (Following the induction phase (35 days), the first course of Azacitidine began around Week 6 of therapy)

InterventionPercentage of CpG methylation (Mean)
KMT2A-Rearranged78.17

[back to top]

Number of Participants With Anti-daratumumab Antibodies

Number of participants with anti-daratumumab antibodies was reported. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionParticipants (Count of Participants)
Cohort 1: B-cell ALL (1-17 Years)0
Cohort 2: T-Cell ALL (1-17 Years)0
Cohort 2: T-Cell ALL (18-30 Years)0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)0

[back to top]

Minimum Observed Serum Concentration (Cmin) of Daratumumab

Cmin was defined as minimum observed serum concentration of daratumumab. (NCT03384654)
Timeframe: Cohort 1: B-cell ALL: Predose on Day 1 of Cycle 2; Cohort 2: T-cell ALL (1-17 years): Predose on Day 22 of Cycle 2; Cohort 2: T-cell ALL (18-30 years): Predose on Day 1 of Cycle 2; Cohort 2: T-cell LL (1-30 years): Predose on Day 22 of Cycle 2

Interventionmcg/mL (Mean)
Cohort 1: B-cell ALL (1-17 Years)172
Cohort 2: T-Cell ALL (1-17 Years)369
Cohort 2: T-Cell ALL (18-30 Years)172
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)365

[back to top]

Minimal Residual Disease (MRD) Negative Rate

MRD negative rate was defined as the percentage of participants who were considered MRD negative after MRD testing by bone marrow aspirate at any timepoint after first study treatment administration and before disease progression or starting subsequent anti-cancer therapy or allogeneic hematopoietic stem cell transplant (HSCT). MRD negative was defined as less than (<) 0.01% abnormal population counts to nucleated mononuclear cells when measured by flow cytometry. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionPercentage of participants (Number)
Cohort 1: B-cell ALL (1-17 Years)0
Cohort 2: T-Cell ALL (1-17 Years)45.8
Cohort 2: T-Cell ALL (18-30 Years)20.0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)50.0

[back to top]

Maximum Observed Serum Concentration (Cmax) of Daratumumab

Cmax was defined as maximum observed serum concentration of daratumumab. (NCT03384654)
Timeframe: Cohort 1: B-cell ALL: End of infusion (EOI) on Day 1 of Cycle 2; Cohort 2: T-cell ALL (1-17 years): EOI on Day 22 of Cycle 2; Cohort 2: T-cell ALL (18-30 years): EOI on Day 1 of Cycle 2; Cohort 2: T-cell LL (1-30 years): EOI on Day 22 of Cycle 2

InterventionMicrograms per milliliter (mcg/mL) (Mean)
Cohort 1: B-cell ALL (1-17 Years)494
Cohort 2: T-Cell ALL (1-17 Years)763
Cohort 2: T-Cell ALL (18-30 Years)501
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)758

[back to top]

Event-free Survival (EFS)

EFS was defined as the time (in months) from the date of first treatment to the first documented treatment failure (that is [ie], disease progression) or date of relapse from CR or death due to any cause, whichever occurred first. Per NCCN criteria, relapse from CR is defined as: reappearance of leukemia blasts in the peripheral blood or >5% blasts in the bone marrow; reappearance of extramedullary disease or new extramedullary disease. Progressive disease: increase of at least 25% in the absolute number of circulating peripheral or bone marrow blasts, or development of new extramedullary disease. Kaplan-Meier method was used for the analysis. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionMonths (Median)
Cohort 1: B-cell ALL (1-17 Years)1.1
Cohort 2: T-Cell ALL (1-17 Years)8.9
Cohort 2: T-Cell ALL (18-30 Years)10.3
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)2.9

[back to top]

Cohort 2: Percentage of Participants With Complete Response (CR) for T-cell ALL

Complete response based on the modified NCCN criteria was defined as: less than 5% blasts in the bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets >100*10^9 cells/L and ANC >1.0*10^9 cells/L. This outcome measure was planned to be analyzed for specified arms only. (NCT03384654)
Timeframe: End of Cycle 1 (that is, up to 28 days)

InterventionPercentage of participants (Number)
Cohort 2: T-Cell ALL (1-17 Years)41.7
Cohort 2: T-Cell ALL (18-30 Years)60.0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)30.0

[back to top]

Cohort 1: Percentage of Participants With Complete Response (CR) for B-cell Acute Lymphoblastic Leukemia (ALL)

Complete response based on the modified National Comprehensive Cancer Network (NCCN) criteria was defined as: less than 5 percent (%) blasts in the bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets greater than (>)100*10^9 cells/liter (L) and absolute neutrophil count (ANC) >1.0*10^9 cells/L. This outcome measure was planned to be analyzed for specified arm only. (NCT03384654)
Timeframe: Up to 2 cycles, that is, up to 56 days (each cycle of 28-days)

InterventionPercentage of participants (Number)
Cohort 1: B-cell ALL (1-17 Years)0

[back to top]

Concentration of Daratumumab in Cerebrospinal Fluid (CSF)

Concentration of daratumumab in CSF was reported. '0' in the number analyzed field signifies that none of the participants were available for the analysis at the specified time points. (NCT03384654)
Timeframe: Pre-dose on Cohort 1: Cycles 1 and 2: Day 1; Cohort 2: Cycle 1 Day 1 and Day 15 and Cycle 2 Day 2 and Day 15

Interventionmcg/mL (Mean)
Cycle 1 Day 1 predoseCycle 2 Day 1 predose
Cohort 1: B-cell ALL (1-17 Years)NA0.573

[back to top]

Relapse-free Survival (RFS)

RFS was defined as the time (in months) from CR to relapse from CR, or disease progression or death due to any cause, whichever occurred first. For ALL, as per NCCN criteria, relapse from CR is defined as: reappearance of leukemia blasts in the peripheral blood or >5% blasts in the bone marrow, or reappearance of extramedullary disease or new extramedullary disease. Progressive disease: increase of at least 25% in absolute number of circulating peripheral or bone marrow blasts, or development of new extramedullary disease. Kaplan-Meier method was used for analysis. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionMonths (Median)
Cohort 2: T-Cell ALL (1-17 Years)19.4
Cohort 2: T-Cell ALL (18-30 Years)9.4
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)NA

[back to top]

Percentage of Participants Who Received an Allogeneic Hematopoietic Stem Cell Transplant (HSCT)

Percentage of participants who received an allogeneic HSCT after treatment with daratumumab were reported. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionPercentage of participants (Number)
Cohort 1: B-cell ALL (1-17 Years)14.3
Cohort 2: T-Cell ALL (1-17 Years)75.0
Cohort 2: T-Cell ALL (18-30 Years)60.0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)30.0

[back to top]

Overall Survival (OS)

OS was defined as the time (in months) from the date of first study drug administration to the date of death due to any cause. Kaplan-Meier method was used for the analysis. Participants who died after consent withdrawal were considered as having an OS event. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionMonths (Median)
Cohort 1: B-cell ALL (1-17 Years)3.2
Cohort 2: T-Cell ALL (1-17 Years)10.9
Cohort 2: T-Cell ALL (18-30 Years)12.0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)4.2

[back to top]

Concentration of Daratumumab in Cerebrospinal Fluid (CSF)

Concentration of daratumumab in CSF was reported. '0' in the number analyzed field signifies that none of the participants were available for the analysis at the specified time points. (NCT03384654)
Timeframe: Pre-dose on Cohort 1: Cycles 1 and 2: Day 1; Cohort 2: Cycle 1 Day 1 and Day 15 and Cycle 2 Day 2 and Day 15

,,
Interventionmcg/mL (Mean)
Cycle 1 Day 1 predoseCycle 1 Day 15 predoseCycle 2 Day 2 predoseCycle 2 Day 15 predose
Cohort 2: T-Cell ALL (1-17 Years)NA0.9070.9150.934
Cohort 2: T-Cell ALL (18-30 Years)NA0.3190.2960.163
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)NA0.4561.231.06

[back to top]

Overall Response Rate (ORR)

For ALL participants, ORR was defined as percentage of participants who achieved CR or CR with only partial hematological recovery(CRi) as per NCCN criteria. CR for ALL: less than 5% blasts in bone marrow; no evidence of circulating blasts or extramedullary disease; full recovery of peripheral blood counts: platelets >100*10^9 cells/L and ANC >1.0*10^9 cells/L. CRi for ALL: less than 5% blasts in bone marrow; no evidence of circulating blasts or extramedullary disease; partial recovery of peripheral blood counts not meeting criteria for CR. For LL participants, ORR was defined as percentage of participants who had CR or PR during or after treatment administration but prior to start of subsequent anti-cancer therapy or allogeneic hematopoietic stem cell transplant(HSCT). CR for LL: disappearance of all evidence of disease from all sites. PR for LL: decrease of >=50% in sum of products of diameter of lesions of up to 6 of largest dominant nodes or nodal masses with no new lesions. (NCT03384654)
Timeframe: Up to 4 years 4 months

InterventionPercentage of participants (Number)
Cohort 1: B-cell ALL (1-17 Years)14.3
Cohort 2: T-Cell ALL (1-17 Years)83.3
Cohort 2: T-Cell ALL (18-30 Years)80.0
Cohort 2: T-Cell Lymphoblastic Leukemia (LL) (1-30 Years)50.0

[back to top]

Participants to Achieve Complete Remission (CR):

Complete Remission (CR) is defined as - Normalization of the peripheral blood and bone marrow blasts /= 100X10^9/L and complete resolution of all sites of extramedullary disease. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionParticipants (Count of Participants)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)4

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionMonths (Median)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)24

[back to top]

Number of Participants With Minimal Residual Disease (MRD) Negativity

MRD levels continuously assessed during induction and consolidation therapy by 6-color multiparameter flow. MRD negativity defined by a value of at least 10-4 and confirmed on a second bone marrow aspiration/biopsy performed after a subsequent cycle. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionParticipants (Count of Participants)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)4

[back to top]

Event-Free Survival

Event-free survival defined as the time interval from date of treatment start until the date of death, disease progression or relapse. (NCT03488225)
Timeframe: Start of treatment up to 2 years

InterventionMonths (Median)
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)24

[back to top]

Number of Participants With Adverse Events

For the purpose of toxicity monitoring, toxicities are defined as any treatment -related grade 3 or 4 non-hematologic AEs occurred any time during the trial.NCI Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 utilized for adverse event reporting. (NCT03488225)
Timeframe: Start of treatment up to 30 days after last dose received.

InterventionParticipants (Count of Participants)
Neutropenic FeverPeripheral Sensory NeuropathyAllergic ReactionMuscle Weakness
Treatment (Hyper-CVAD, Inotuzumab Ozogamicin)2111

[back to top]

Duration of Response

"Response date to loss of response or last follow up. Complete Remission (CR): Normalization of the peripheral blood and bone marrow with 5% or less blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 10^9/L or above, and platelet count of 100 x 10^9/L. Complete resolution of all sites of extramedullary disease is required for CR.~Complete remission without recovery of counts (CRi): Peripheral blood and marrow results as for CR, but with incomplete recover of counts (platelets < 100 x 10^9/L; neutrophils < 1 x 10^9/L).~Partial Response (PR): As above for CR except for the presence of 6-25% marrow blasts." (NCT03518112)
Timeframe: Time from the first day of treatment assessed up to 3 years, 1 month

InterventionMonths (Median)
Treatment (Blinatumomab, Combination Chemotherapy)4.4

[back to top]

Participants With a Response

"defined as the percentage of patients achieving complete response (CR) or CR with inadequate count recovery (CRi). Complete Remission (CR): Normalization of the peripheral blood and bone marrow with 5% or less blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 10^9/L or above, and platelet count of 100 x 10^9/L. Complete resolution of all sites of extramedullary disease is required for CR.~Complete remission without recovery of counts (CRi): Peripheral blood and marrow results as for CR, but with incomplete recover of counts (platelets < 100 x 10^9/L; neutrophils < 1 x 10^9/L)." (NCT03518112)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Treatment (Blinatumomab, Combination Chemotherapy)4

[back to top]

Overall Survival

Time from date of treatment start until date of death due to any cause or last Follow-up. (NCT03518112)
Timeframe: Time from the first day of treatment assessed up to 3 years, 1 month

InterventionMonths (Median)
Treatment (Blinatumomab, Combination Chemotherapy)16.7

[back to top]

Number of Participants Negative for Minimal Residual Disease (MRD)

Minimal Residual Disease (MRD) was assessed by flow cytometry. MRD negativity: Absence of detectable leukemia using multiparameter flow cytometry with a sensitivity of NCT03518112)
Timeframe: Up to 3 years

InterventionParticipants (Count of Participants)
Treatment (Blinatumomab, Combination Chemotherapy)4

[back to top]

Event Free Survival (EFS) Where Events Defined as no Response, Loss of Response, or Death

"Time from date of treatment start until the date of first objective documentation of disease-relapse. Relapse and resistant disease will be defined based on morphological assessment of bone marrow and peripheral blood.~Complete Remission (CR): Normalization of the peripheral blood and bone marrow with 5% or less blasts in normocellular or hypercellular marrow with a granulocyte count of 1 x 10^9/L or above, and platelet count of 100 x 10^9/L. Complete resolution of all sites of extramedullary disease is required for CR.~Complete remission without recovery of counts (CRi): Peripheral blood and marrow results as for CR, but with incomplete recover of counts (platelets < 100 x 10^9/L; neutrophils < 1 x 10^9/L).~Partial Response (PR): As above for CR except for the presence of 6-25% marrow blasts." (NCT03518112)
Timeframe: Time from the first day of treatment assessed up to 3 years, 1 month

InterventionMonths (Median)
Treatment (Blinatumomab, Combination Chemotherapy)5.7

[back to top]